JP4304364B2 - Angiogenesis inhibitor - Google Patents
Angiogenesis inhibitor Download PDFInfo
- Publication number
- JP4304364B2 JP4304364B2 JP2002346601A JP2002346601A JP4304364B2 JP 4304364 B2 JP4304364 B2 JP 4304364B2 JP 2002346601 A JP2002346601 A JP 2002346601A JP 2002346601 A JP2002346601 A JP 2002346601A JP 4304364 B2 JP4304364 B2 JP 4304364B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- ethyl
- adamantyl
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 title claims description 5
- 229940121369 angiogenesis inhibitor Drugs 0.000 title claims description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 361
- -1 imidazolylcarbonyl group Chemical group 0.000 claims description 77
- 229920006395 saturated elastomer Polymers 0.000 claims description 74
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 230000033115 angiogenesis Effects 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000003277 amino group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 201000002154 Pterygium Diseases 0.000 claims description 7
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 7
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 7
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 7
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- AIUJHENHBJHHMY-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCCC1=CC=NC=C1 AIUJHENHBJHHMY-UHFFFAOYSA-N 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 179
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 177
- 239000000543 intermediate Substances 0.000 description 150
- 230000002829 reductive effect Effects 0.000 description 110
- 239000000203 mixture Substances 0.000 description 103
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 78
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 76
- 238000004519 manufacturing process Methods 0.000 description 75
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 57
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 56
- 235000002639 sodium chloride Nutrition 0.000 description 54
- 238000010898 silica gel chromatography Methods 0.000 description 51
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 238000001816 cooling Methods 0.000 description 44
- 239000012044 organic layer Substances 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 38
- 239000011780 sodium chloride Substances 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000002904 solvent Substances 0.000 description 35
- 239000003921 oil Substances 0.000 description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 33
- 239000013078 crystal Substances 0.000 description 27
- 238000001914 filtration Methods 0.000 description 27
- 235000017557 sodium bicarbonate Nutrition 0.000 description 25
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000012299 nitrogen atmosphere Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 238000010992 reflux Methods 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- QDYISHPTUNJPHS-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(2-methyl-3-pyridin-4-ylpropyl)-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCC(C)CC1=CC=NC=C1 QDYISHPTUNJPHS-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 9
- 239000012280 lithium aluminium hydride Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- DFTPIBFPPYDWEC-UHFFFAOYSA-N 5-pyridin-4-ylpentanoic acid Chemical compound OC(=O)CCCCC1=CC=NC=C1 DFTPIBFPPYDWEC-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 0 CCC(*(C)(C)C)*(CC)(CN)*C Chemical compound CCC(*(C)(C)C)*(CC)(CN)*C 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000003889 eye drop Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000002198 insoluble material Substances 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 7
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 229960004106 citric acid Drugs 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- UOOOCYFGAHYTSG-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]pentan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCCCCC)C3 UOOOCYFGAHYTSG-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- YWJSTJKZGMYFRH-WAYWQWQTSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[(z)-3-pyridin-4-ylprop-2-enyl]urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC\C=C/C1=CC=NC=C1 YWJSTJKZGMYFRH-WAYWQWQTSA-N 0.000 description 5
- JURFPUSNTWSSPJ-UHFFFAOYSA-N 3-pyridin-4-ylpropan-1-amine Chemical compound NCCCC1=CC=NC=C1 JURFPUSNTWSSPJ-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 229940012356 eye drops Drugs 0.000 description 5
- 201000011066 hemangioma Diseases 0.000 description 5
- AKQZDJIZNCKJSP-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-3-(pyridin-4-ylmethylideneamino)propanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CCN=CC1=CC=NC=C1 AKQZDJIZNCKJSP-UHFFFAOYSA-N 0.000 description 5
- OTOGOOXMAOJQSH-UHFFFAOYSA-N n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCNC(=O)C)C(=O)NCCCC1=CC=NC=C1 OTOGOOXMAOJQSH-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 150000003335 secondary amines Chemical class 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- RBNPERAXQUZNCT-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-amino-3-(3-pyridin-4-ylpropyl)urea;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC(C3)CC2CC13CCN(N)C(=O)NCCCC1=CC=NC=C1 RBNPERAXQUZNCT-UHFFFAOYSA-N 0.000 description 4
- HPQYWBQXGAYWHZ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-[3-(1-oxidopyridin-1-ium-4-yl)propyl]-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCCC1=CC=[N+]([O-])C=C1 HPQYWBQXGAYWHZ-UHFFFAOYSA-N 0.000 description 4
- RMSYNXSUUXWVSE-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-[3-[tert-butyl(dimethyl)silyl]oxy-3-pyridin-4-ylpropyl]-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC(O[Si](C)(C)C(C)(C)C)C1=CC=NC=C1 RMSYNXSUUXWVSE-UHFFFAOYSA-N 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- ZZJZBKSKQRRPFJ-UHFFFAOYSA-N OCCC(C)(C1=CC=CC=C1)NC(=S)NCCCC1=CC=NC=C1 Chemical compound OCCC(C)(C1=CC=CC=C1)NC(=S)NCCCC1=CC=NC=C1 ZZJZBKSKQRRPFJ-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- HNLXNPWUWRIZRM-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-propyl-5-pyridin-4-ylpentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC)C(=O)CCCCC1=CC=NC=C1 HNLXNPWUWRIZRM-UHFFFAOYSA-N 0.000 description 4
- QVHCDIXOASJMAN-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]pentan-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCCCCC)C3 QVHCDIXOASJMAN-UHFFFAOYSA-N 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- IXDOAUBHQRTRJG-UHFFFAOYSA-N tert-butyl 3-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]propanoate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC(=O)OC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 IXDOAUBHQRTRJG-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- FKSPXXPCOQSCFO-UHFFFAOYSA-N 1-(2-cyclohexylethyl)-3-(2-methyl-3-pyridin-4-ylpropyl)-1-pentylurea Chemical compound C=1C=NC=CC=1CC(C)CNC(=O)N(CCCCC)CCC1CCCCC1 FKSPXXPCOQSCFO-UHFFFAOYSA-N 0.000 description 3
- AAISVFYGRJWKFD-UHFFFAOYSA-N 1-(2-methyl-3-pyridin-4-ylpropyl)-3-(2-phenylheptan-2-yl)urea Chemical compound CCCCCC(C)(NC(=O)NCC(C)CC1=CC=NC=C1)C1=CC=CC=C1 AAISVFYGRJWKFD-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- VKFSIUPRLSDNKD-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-(methylamino)ethyl]-3-(3-pyridin-4-ylpropyl)urea;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC(C3)CC2CC13CCN(CCNC)C(=O)NCCCC1=CC=NC=C1 VKFSIUPRLSDNKD-UHFFFAOYSA-N 0.000 description 3
- MHBZVASHZYXXNB-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(4-pyridin-4-ylbutan-2-yl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC(C)CCC1=CC=NC=C1 MHBZVASHZYXXNB-UHFFFAOYSA-N 0.000 description 3
- YWJSTJKZGMYFRH-AATRIKPKSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[(e)-3-pyridin-4-ylprop-2-enyl]urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC\C=C\C1=CC=NC=C1 YWJSTJKZGMYFRH-AATRIKPKSA-N 0.000 description 3
- KLVNJZLUOJMGAR-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)-1-(3,3,3-trifluoropropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 KLVNJZLUOJMGAR-UHFFFAOYSA-N 0.000 description 3
- DOHBWNHTMAUNTK-UHFFFAOYSA-N 2-methyl-3-pyridin-4-ylpropan-1-amine Chemical compound NCC(C)CC1=CC=NC=C1 DOHBWNHTMAUNTK-UHFFFAOYSA-N 0.000 description 3
- YGULNNXYUJYOSY-UHFFFAOYSA-N 2-methyl-3-pyridin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=C1 YGULNNXYUJYOSY-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000007135 Retinal Neovascularization Diseases 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000000159 corneal neovascularization Diseases 0.000 description 3
- ZYIGUOOKJHOVAE-UHFFFAOYSA-N diethyl 2-methyl-2-(pyridin-4-ylmethyl)propanedioate Chemical compound CCOC(=O)C(C)(C(=O)OCC)CC1=CC=NC=C1 ZYIGUOOKJHOVAE-UHFFFAOYSA-N 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 238000013210 evaluation model Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
- BXUVXRODAMZIAZ-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-2-(2-pyridin-4-ylethylsulfanyl)acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CSCCC1=CC=NC=C1 BXUVXRODAMZIAZ-UHFFFAOYSA-N 0.000 description 3
- HVPRNDSHZDOEKF-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-3-(pyridin-4-ylmethylsulfanyl)propanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CCSCC1=CC=NC=C1 HVPRNDSHZDOEKF-UHFFFAOYSA-N 0.000 description 3
- RAPHLBWFMHYIDV-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-5-pyridin-4-ylpentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CCCCC1=CC=NC=C1 RAPHLBWFMHYIDV-UHFFFAOYSA-N 0.000 description 3
- JEUZRAOJTMEPSJ-UHFFFAOYSA-N n-pentyl-n-(2-phenylethyl)-5-pyridin-4-ylpentanamide Chemical compound C=1C=NC=CC=1CCCCC(=O)N(CCCCC)CCC1=CC=CC=C1 JEUZRAOJTMEPSJ-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- VOPFBQTUENFBFS-UHFFFAOYSA-N tert-butyl n-[2-[2-(1-adamantyl)ethyl-[(2-methyl-3-pyridin-4-ylpropyl)carbamoyl]amino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)OC(C)(C)C)C(=O)NCC(C)CC1=CC=NC=C1 VOPFBQTUENFBFS-UHFFFAOYSA-N 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- XQHREIIQNLOULY-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl) n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)OC(C)(C)C(Cl)(Cl)Cl)C(=O)NCCCC1=CC=NC=C1 XQHREIIQNLOULY-UHFFFAOYSA-N 0.000 description 2
- JXFIEFVSEXCXIX-UHFFFAOYSA-N (2-cyano-2-methyl-1-pyridin-4-ylpropyl) 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC(C(C)(C)C#N)C1=CC=NC=C1 JXFIEFVSEXCXIX-UHFFFAOYSA-N 0.000 description 2
- UMYUZTAXTBQHDS-CUHAHZSFSA-N (2r)-n-[2-(1-adamantyl)ethyl]-2-amino-n-pentyl-3-(2-pyridin-4-ylethylsulfanyl)propanamide;dihydrochloride Chemical compound Cl.Cl.C([C@H](N)C(=O)N(CCC12CC3CC(CC(C3)C1)C2)CCCCC)SCCC1=CC=NC=C1 UMYUZTAXTBQHDS-CUHAHZSFSA-N 0.000 description 2
- VDZNQMWUZPJQOB-SPOFAMFQSA-N (2r)-n-[2-(1-adamantyl)ethyl]-n-pentyl-1-(2-pyridin-4-ylethyl)pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C([C@@H]1C(=O)N(CCC23CC4CC(CC(C4)C2)C3)CCCCC)CCN1CCC1=CC=NC=C1 VDZNQMWUZPJQOB-SPOFAMFQSA-N 0.000 description 2
- JEDNDJXRXYASRQ-OJLCJRGFSA-N (2r)-n-[2-(1-adamantyl)ethyl]-n-pentylpyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)[C@H]1CCCN1 JEDNDJXRXYASRQ-OJLCJRGFSA-N 0.000 description 2
- VDZNQMWUZPJQOB-FUEWETBOSA-N (2s)-n-[2-(1-adamantyl)ethyl]-n-pentyl-1-(2-pyridin-4-ylethyl)pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C([C@H]1C(=O)N(CCC23CC4CC(CC(C4)C2)C3)CCCCC)CCN1CCC1=CC=NC=C1 VDZNQMWUZPJQOB-FUEWETBOSA-N 0.000 description 2
- ITIFVJFWLMXNAK-UHFFFAOYSA-N (5-methyl-2-propan-2-ylcyclohexyl) n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound CC(C)C1CCC(C)CC1OC(=O)N(C)CCN(C(=O)NCCCC=1C=CN=CC=1)CCC1(C2)CC(C3)CC2CC3C1 ITIFVJFWLMXNAK-UHFFFAOYSA-N 0.000 description 2
- MIBXVCOCMAKCKU-UHFFFAOYSA-N 1,1-bis(3-methylbutyl)-3-(3-pyridin-4-ylpropyl)urea;hydrochloride Chemical compound Cl.CC(C)CCN(CCC(C)C)C(=O)NCCCC1=CC=NC=C1 MIBXVCOCMAKCKU-UHFFFAOYSA-N 0.000 description 2
- LGUFVTOOMRDIPB-UHFFFAOYSA-N 1,1-bis(hex-5-enyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=CCCCCN(CCCCC=C)C(=O)NCCCC1=CC=NC=C1 LGUFVTOOMRDIPB-UHFFFAOYSA-N 0.000 description 2
- FBQOEUIFEUUDFT-UHFFFAOYSA-N 1,1-bis(oct-7-enyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=CCCCCCCN(CCCCCCC=C)C(=O)NCCCC1=CC=NC=C1 FBQOEUIFEUUDFT-UHFFFAOYSA-N 0.000 description 2
- BMTWOOCWDSWVSZ-UHFFFAOYSA-N 1,1-bis[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)urea;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC1=CC=NC=C1 BMTWOOCWDSWVSZ-UHFFFAOYSA-N 0.000 description 2
- AZNLPOUUCAHROJ-UHFFFAOYSA-N 1,1-dibutyl-3-(2-methyl-3-pyridin-4-ylpropyl)urea Chemical compound CCCCN(CCCC)C(=O)NCC(C)CC1=CC=NC=C1 AZNLPOUUCAHROJ-UHFFFAOYSA-N 0.000 description 2
- XHJWKMSGVGNLCT-UHFFFAOYSA-N 1,1-dibutyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound CCCCN(CCCC)C(=O)NCCCC1=CC=NC=C1 XHJWKMSGVGNLCT-UHFFFAOYSA-N 0.000 description 2
- KEUQCJWAQMLWLO-UHFFFAOYSA-N 1,1-dicyclohexyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1CCCCC1N(C1CCCCC1)C(=O)NCCCC1=CC=NC=C1 KEUQCJWAQMLWLO-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- MYKHOEVLMCOTCP-UHFFFAOYSA-N 1-(2-cyclohexylethyl)-1-(2-methoxyethyl)-3-methyl-3-pyridin-4-ylurea Chemical compound C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)C)CCOC MYKHOEVLMCOTCP-UHFFFAOYSA-N 0.000 description 2
- WXCZWWCXVBLABU-UHFFFAOYSA-N 1-(2-cyclohexylethyl)-1-pentyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CCCCC)CCC1CCCCC1 WXCZWWCXVBLABU-UHFFFAOYSA-N 0.000 description 2
- KTBOITVENXPMIH-UHFFFAOYSA-N 1-(2-phenylethyl)-3-(3-pyridin-4-ylpropyl)imidazolidine-2-thione Chemical compound C1CN(CCC=2C=CC=CC=2)C(=S)N1CCCC1=CC=NC=C1 KTBOITVENXPMIH-UHFFFAOYSA-N 0.000 description 2
- CYTUMDALFQUHMR-UHFFFAOYSA-N 1-(3-cyclohexylpropyl)-1-propyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CCC)CCCC1CCCCC1 CYTUMDALFQUHMR-UHFFFAOYSA-N 0.000 description 2
- GVXNOKDKDYFDHR-UHFFFAOYSA-N 1-(3-methylbutyl)-3-(3-pyridin-4-ylpropyl)-1-(3,3,3-trifluoropropyl)urea Chemical compound CC(C)CCN(CCC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 GVXNOKDKDYFDHR-UHFFFAOYSA-N 0.000 description 2
- PSCGXRWYXVOHEU-UHFFFAOYSA-N 1-[1-(1-adamantyl)-5-imidazol-1-ylpentan-3-yl]-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCC(N(CCCCC)C(N)=O)CCN1C=CN=C1 PSCGXRWYXVOHEU-UHFFFAOYSA-N 0.000 description 2
- KMNVSLFYJJTVQN-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(2-aminoethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN)C(=O)NCCCC1=CC=NC=C1 KMNVSLFYJJTVQN-UHFFFAOYSA-N 0.000 description 2
- JSDJCLVATFSYJA-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(2-aminoethyl)-3-(3-pyridin-4-ylpropyl)urea;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC(C3)CC2CC13CCN(CCN)C(=O)NCCCC1=CC=NC=C1 JSDJCLVATFSYJA-UHFFFAOYSA-N 0.000 description 2
- GTQBIMUEJSSDGH-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(cyanomethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC#N)C(=O)NCCCC1=CC=NC=C1 GTQBIMUEJSSDGH-UHFFFAOYSA-N 0.000 description 2
- BNSXIIFKYDXNNF-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(cyclopentylmethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC1CCCC1)C(=O)NCCCC1=CC=NC=C1 BNSXIIFKYDXNNF-UHFFFAOYSA-N 0.000 description 2
- VCYAGNFUBGGUCE-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-(ethylamino)ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCNCC)C(=O)NCCCC1=CC=NC=C1 VCYAGNFUBGGUCE-UHFFFAOYSA-N 0.000 description 2
- SJQXDAKDFVCBSX-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-[2-methoxyethyl(methyl)amino]ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)CCOC)C(=O)NCCCC1=CC=NC=C1 SJQXDAKDFVCBSX-UHFFFAOYSA-N 0.000 description 2
- BLAKNPNOJHFMIQ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-but-2-enyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC=CC)C(=O)NCCCC1=CC=NC=C1 BLAKNPNOJHFMIQ-UHFFFAOYSA-N 0.000 description 2
- OLOWYXPGZLBJAK-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-but-2-ynyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC#CC)C(=O)NCCCC1=CC=NC=C1 OLOWYXPGZLBJAK-UHFFFAOYSA-N 0.000 description 2
- CNFZITUWCODTON-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-butyl-3-(3-pyridin-4-ylpropyl)urea;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13CCN(CCCC)C(=O)NCCCC1=CC=NC=C1 CNFZITUWCODTON-UHFFFAOYSA-N 0.000 description 2
- VFDHNBJNZFPGJM-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-cyclopentyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(C1CCCC1)C(=O)NCCCC1=CC=NC=C1 VFDHNBJNZFPGJM-UHFFFAOYSA-N 0.000 description 2
- ZEKVWDVJDDGZOJ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-cyclopropyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(C1CC1)C(=O)NCCCC1=CC=NC=C1 ZEKVWDVJDDGZOJ-UHFFFAOYSA-N 0.000 description 2
- NHGFADHKXWYRQW-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-hydroxy-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(O)C(=O)NCCCC1=CC=NC=C1 NHGFADHKXWYRQW-UHFFFAOYSA-N 0.000 description 2
- UCMPHCOWKKXRDY-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(1-pyridin-4-ylpentan-3-yl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC(CC)CCC1=CC=NC=C1 UCMPHCOWKKXRDY-UHFFFAOYSA-N 0.000 description 2
- FDVJNGCMRQTHAX-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(2-pyridin-2-ylethyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC1=CC=CC=N1 FDVJNGCMRQTHAX-UHFFFAOYSA-N 0.000 description 2
- PGIDKWMUCNFRSK-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(2-pyridin-3-ylethyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC1=CC=CN=C1 PGIDKWMUCNFRSK-UHFFFAOYSA-N 0.000 description 2
- RJJHTLGHVLEACN-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(2-pyridin-4-ylethyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC1=CC=NC=C1 RJJHTLGHVLEACN-UHFFFAOYSA-N 0.000 description 2
- NYNRYUXSFHNCPV-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(2-pyridin-4-yloxyethyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCOC1=CC=NC=C1 NYNRYUXSFHNCPV-UHFFFAOYSA-N 0.000 description 2
- MODHSIFIAYQOOT-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-2-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCCC1=CC=CC=N1 MODHSIFIAYQOOT-UHFFFAOYSA-N 0.000 description 2
- NBBOYCRWJJZODZ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-3-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCCC1=CC=CN=C1 NBBOYCRWJJZODZ-UHFFFAOYSA-N 0.000 description 2
- OXRCFCGQBGYGHN-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-4-ylbutyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC(C)C1=CC=NC=C1 OXRCFCGQBGYGHN-UHFFFAOYSA-N 0.000 description 2
- SZGFOIAXDAKILH-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-4-ylpropyl)thiourea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=S)NCCCC1=CC=NC=C1 SZGFOIAXDAKILH-UHFFFAOYSA-N 0.000 description 2
- NCEKYFRVJFAVFP-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-4-ylpropyl)urea;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCCC1=CC=NC=C1 NCEKYFRVJFAVFP-UHFFFAOYSA-N 0.000 description 2
- WFEUVKPMGSRJQG-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-quinolin-4-ylpropyl)urea Chemical compound C1=CC=C2C(CCCNC(=O)N(CCC34CC5CC(CC(C5)C3)C4)CCCCC)=CC=NC2=C1 WFEUVKPMGSRJQG-UHFFFAOYSA-N 0.000 description 2
- XNSDCMVIDSSQAD-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(4-pyridin-4-ylbutyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCCCC1=CC=NC=C1 XNSDCMVIDSSQAD-UHFFFAOYSA-N 0.000 description 2
- AGADHCZBIPMEDT-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[2-(pyridin-4-ylamino)ethyl]urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCNC1=CC=NC=C1 AGADHCZBIPMEDT-UHFFFAOYSA-N 0.000 description 2
- IICALQDKSLYQPB-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[2-(pyridin-4-ylmethyl)butyl]urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCC(CC)CC1=CC=NC=C1 IICALQDKSLYQPB-UHFFFAOYSA-N 0.000 description 2
- KCZBZMCSXZGPGG-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-pyridin-4-yl-2-(pyridin-4-ylmethyl)propyl]urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCC(CC=1C=CN=CC=1)CC1=CC=NC=C1 KCZBZMCSXZGPGG-UHFFFAOYSA-N 0.000 description 2
- JWANDFFWYHSESF-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-phenylmethoxy-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(OCC=1C=CC=CC=1)C(=O)NCCCC1=CC=NC=C1 JWANDFFWYHSESF-UHFFFAOYSA-N 0.000 description 2
- KMOWQZKBUXAFHW-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-propyl-3-(3-pyridin-4-ylpropyl)urea;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13CCN(CCC)C(=O)NCCCC1=CC=NC=C1 KMOWQZKBUXAFHW-UHFFFAOYSA-N 0.000 description 2
- KKBGTMTYHMPNJW-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(2,2-dimethyl-3-pyridin-4-ylpropyl)-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCC(C)(C)CC1=CC=NC=C1 KKBGTMTYHMPNJW-UHFFFAOYSA-N 0.000 description 2
- LUROGFBBQSGHMU-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(2-benzyl-3-pyridin-4-ylpropyl)-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCC(CC=1C=CN=CC=1)CC1=CC=CC=C1 LUROGFBBQSGHMU-UHFFFAOYSA-N 0.000 description 2
- QHFXZIXZTWWRIZ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(2-methyl-3-pyridin-4-ylpropyl)-1-(3,3,3-trifluoropropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC(F)(F)F)C(=O)NCC(C)CC1=CC=NC=C1 QHFXZIXZTWWRIZ-UHFFFAOYSA-N 0.000 description 2
- XFOLXQRCHOAHDJ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-hydroxy-3-pyridin-4-ylpropyl)-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC(O)C1=CC=NC=C1 XFOLXQRCHOAHDJ-UHFFFAOYSA-N 0.000 description 2
- SUHDHKNJGVFLHH-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-methyl-4-pyridin-4-ylbutan-2-yl)-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NC(C)C(C)CC1=CC=NC=C1 SUHDHKNJGVFLHH-UHFFFAOYSA-N 0.000 description 2
- LMUVUICLNRONOP-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-oxo-3-pyridin-4-ylpropyl)-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC(=O)C1=CC=NC=C1 LMUVUICLNRONOP-UHFFFAOYSA-N 0.000 description 2
- HDHIKKKNGZRFJC-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)-1,3-diazinan-2-one Chemical compound C1CCN(CCC23CC4CC(CC(C4)C2)C3)C(=O)N1CCCC1=CC=NC=C1 HDHIKKKNGZRFJC-UHFFFAOYSA-N 0.000 description 2
- IKUKPMSNEPRQTI-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)-1,3-diazinane-2,4-dione;hydrochloride Chemical compound Cl.O=C1CCN(CCC23CC4CC(CC(C4)C2)C3)C(=O)N1CCCC1=CC=NC=C1 IKUKPMSNEPRQTI-UHFFFAOYSA-N 0.000 description 2
- WTILGXNOSJNESO-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)-1-(2,2,2-trifluoroethyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 WTILGXNOSJNESO-UHFFFAOYSA-N 0.000 description 2
- XTWCMKKGJURZRR-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-[2-(4-hydroxyphenyl)ethyl]-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC1=CC=C(O)C=C1 XTWCMKKGJURZRR-UHFFFAOYSA-N 0.000 description 2
- YMIRPWICFKXBPG-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-[3-[tert-butyl(diphenyl)silyl]oxy-3-pyridin-4-ylpropyl]-1-pentylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCC(C=1C=CN=CC=1)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 YMIRPWICFKXBPG-UHFFFAOYSA-N 0.000 description 2
- XUYIUKZMFQYULG-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-methyl-1-pentyl-3-pyridin-2-ylurea Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C(=O)N(C1=NC=CC=C1)C)CCCCC XUYIUKZMFQYULG-UHFFFAOYSA-N 0.000 description 2
- DVQVTOOGEYGREH-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-methyl-1-pentyl-3-pyridin-3-ylurea Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C(=O)N(C=1C=NC=CC=1)C)CCCCC DVQVTOOGEYGREH-UHFFFAOYSA-N 0.000 description 2
- WOBUODGBXDMNNF-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-methyl-1-pentyl-3-pyridin-4-ylurea Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C(=O)N(C1=CC=NC=C1)C)CCCCC WOBUODGBXDMNNF-UHFFFAOYSA-N 0.000 description 2
- OTHSYRMKUCUJCX-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-pentyl-1-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(C(=O)NCCCCC)CCCC1=CC=NC=C1 OTHSYRMKUCUJCX-UHFFFAOYSA-N 0.000 description 2
- FHFJBMYKZZLUDM-UHFFFAOYSA-N 1-[2-(1-adamantylamino)ethyl]-1-propyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13NCCN(CCC)C(=O)NCCCC1=CC=NC=C1 FHFJBMYKZZLUDM-UHFFFAOYSA-N 0.000 description 2
- TWNOOBXJGFPCBU-UHFFFAOYSA-N 1-[2-(1h-imidazol-5-yl)ethyl]-1-(3-methylbutyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CCC(C)C)CCC1=CN=CN1 TWNOOBXJGFPCBU-UHFFFAOYSA-N 0.000 description 2
- XMVZRTFVQHNRCK-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-butyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCCC)C(=O)NCCCC1=CC=NC=C1 XMVZRTFVQHNRCK-UHFFFAOYSA-N 0.000 description 2
- XRSXFCZNUGUTGK-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-ethyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CC)C(=O)NCCCC1=CC=NC=C1 XRSXFCZNUGUTGK-UHFFFAOYSA-N 0.000 description 2
- BCYBRUUEFIFYKO-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-pentyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCCCC)C(=O)NCCCC1=CC=NC=C1 BCYBRUUEFIFYKO-UHFFFAOYSA-N 0.000 description 2
- WOPNUKSECXHTJU-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-propyl-3-(2-pyridin-4-ylethyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCC)C(=O)NCCC1=CC=NC=C1 WOPNUKSECXHTJU-UHFFFAOYSA-N 0.000 description 2
- MGONZICZEFZNQG-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-propyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCC)C(=O)NCCCC1=CC=NC=C1 MGONZICZEFZNQG-UHFFFAOYSA-N 0.000 description 2
- KMKODHZJUCVXJS-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-propyl-3-(3-pyridin-4-ylpropyl)urea;phosphoric acid Chemical compound OP(O)(O)=O.C1C(C2)CC(C3)CC2CC13CCCN(CCC)C(=O)NCCCC1=CC=NC=C1 KMKODHZJUCVXJS-UHFFFAOYSA-N 0.000 description 2
- YFUYKLUURFSKJV-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-1-propyl-3-(4-pyridin-4-ylbutyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCC)C(=O)NCCCCC1=CC=NC=C1 YFUYKLUURFSKJV-UHFFFAOYSA-N 0.000 description 2
- MKWKBPSNQMQIHA-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-3-(2-methyl-3-pyridin-4-ylpropyl)-1-propylurea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCC)C(=O)NCC(C)CC1=CC=NC=C1 MKWKBPSNQMQIHA-UHFFFAOYSA-N 0.000 description 2
- UHSKANWUIRPTNQ-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-3-(3-pyridin-4-ylpropyl)-1-(2,2,2-trifluoroethyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 UHSKANWUIRPTNQ-UHFFFAOYSA-N 0.000 description 2
- MGWWYOVZSIQGKY-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-3-(3-pyridin-4-ylpropyl)-1-(3,3,3-trifluoropropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 MGWWYOVZSIQGKY-UHFFFAOYSA-N 0.000 description 2
- OBOGYCHSQBDCEM-UHFFFAOYSA-N 1-[3-(1-adamantyl)propyl]-3-methyl-1-propyl-3-pyridin-4-ylurea Chemical compound C12(CC3CC(CC(C1)C3)C2)CCCN(C(=O)N(C1=CC=NC=C1)C)CCC OBOGYCHSQBDCEM-UHFFFAOYSA-N 0.000 description 2
- IYQUBVCAELSGLT-UHFFFAOYSA-N 1-[4-(1-adamantyl)butyl]-1-ethyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCCN(CC)C(=O)NCCCC1=CC=NC=C1 IYQUBVCAELSGLT-UHFFFAOYSA-N 0.000 description 2
- XMZRUZYLNWDUKH-UHFFFAOYSA-N 1-[4-(1-adamantyl)butyl]-1-propyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCCCN(CCC)C(=O)NCCCC1=CC=NC=C1 XMZRUZYLNWDUKH-UHFFFAOYSA-N 0.000 description 2
- HODYTILLMVHIRI-UHFFFAOYSA-N 1-benzhydryl-1-(3-phenylpropyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=CC=CC=1CCCN(C(C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)NCCCC1=CC=NC=C1 HODYTILLMVHIRI-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- JJEFTDURTWFUNX-UHFFFAOYSA-N 1-cyclohexyl-1-[2-(3,4-dimethoxyphenyl)ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C(=O)NCCCC=1C=CN=CC=1)C1CCCCC1 JJEFTDURTWFUNX-UHFFFAOYSA-N 0.000 description 2
- XTVDQILTHMZCET-UHFFFAOYSA-N 1-cyclopropyl-3-(3-pyridin-4-ylpropyl)-1-[2-(3,4,5-trimethoxyphenyl)ethyl]urea Chemical compound COC1=C(OC)C(OC)=CC(CCN(C2CC2)C(=O)NCCCC=2C=CN=CC=2)=C1 XTVDQILTHMZCET-UHFFFAOYSA-N 0.000 description 2
- LBWNYLKVTMQJHU-UHFFFAOYSA-N 1-ethyl-3-(3-pyridin-4-ylpropyl)-1-[2-(3,4,5-trimethoxyphenyl)ethyl]urea Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CC)CCC1=CC(OC)=C(OC)C(OC)=C1 LBWNYLKVTMQJHU-UHFFFAOYSA-N 0.000 description 2
- XVZHCZGNKAWZSC-UHFFFAOYSA-N 1-pentyl-1-(3-phenylpropyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CCCCC)CCCC1=CC=CC=C1 XVZHCZGNKAWZSC-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QPHKFMOPPHRCKW-UHFFFAOYSA-N 2-(1-adamantyl)-n-methylethanamine Chemical compound C1C(C2)CC3CC2CC1(CCNC)C3 QPHKFMOPPHRCKW-UHFFFAOYSA-N 0.000 description 2
- GKRPMKRIQVEDAE-UHFFFAOYSA-N 2-(1-adamantyl)ethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCN)C3 GKRPMKRIQVEDAE-UHFFFAOYSA-N 0.000 description 2
- RYAKVKATDZQYAM-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonyl-propylamino]acetic acid Chemical compound CCCN(CC(O)=O)C(=O)OC(C)(C)C RYAKVKATDZQYAM-UHFFFAOYSA-N 0.000 description 2
- CPVUTQCPLUFWOC-UHFFFAOYSA-N 2-[[1-adamantyl(propyl)carbamoyl]-(3-pyridin-4-ylpropyl)amino]acetamide Chemical compound C12(CC3CC(CC(C1)C3)C2)N(C(=O)N(CCCC1=CC=NC=C1)CC(=O)N)CCC CPVUTQCPLUFWOC-UHFFFAOYSA-N 0.000 description 2
- ZZZQLDFHIZXCAA-UHFFFAOYSA-N 2-methyl-3-pyridin-4-ylpropanamide Chemical compound NC(=O)C(C)CC1=CC=NC=C1 ZZZQLDFHIZXCAA-UHFFFAOYSA-N 0.000 description 2
- UHDWRCXAXSFLOJ-UHFFFAOYSA-N 2-methylbutan-2-yl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)OC(C)(C)CC)C(=O)NCCCC1=CC=NC=C1 UHDWRCXAXSFLOJ-UHFFFAOYSA-N 0.000 description 2
- JMQRTIDYFMJAFA-UHFFFAOYSA-N 3-[2-(1-adamantyl)ethyl]-1-(3-pyridin-4-ylpropyl)-1,3-diazinane-2,4-dione;hydrochloride Chemical compound Cl.O=C1N(CCC23CC4CC(CC(C4)C2)C3)C(=O)CCN1CCCC1=CC=NC=C1 JMQRTIDYFMJAFA-UHFFFAOYSA-N 0.000 description 2
- HCPYTVPYSHNTLF-UHFFFAOYSA-N 3-[2-cyclohexylethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound CC(C)(C)OC(=O)N(CCC(O)=O)CCC1CCCCC1 HCPYTVPYSHNTLF-UHFFFAOYSA-N 0.000 description 2
- FVQKGQNSCKJPIJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN2C(OCC2)=O)C=CC=1 FVQKGQNSCKJPIJ-UHFFFAOYSA-N 0.000 description 2
- GTIPSKSJGWIIDK-UHFFFAOYSA-N 3-[bis(hex-5-enyl)amino]propanenitrile Chemical compound C=CCCCCN(CCC#N)CCCCC=C GTIPSKSJGWIIDK-UHFFFAOYSA-N 0.000 description 2
- DSIPHFDYAHGJKY-UHFFFAOYSA-N 3-hydroxy-2,2-dimethyl-3-pyridin-4-ylpropanenitrile Chemical compound N#CC(C)(C)C(O)C1=CC=NC=C1 DSIPHFDYAHGJKY-UHFFFAOYSA-N 0.000 description 2
- BURCZJNCKSLVSZ-UHFFFAOYSA-N 3-hydroxy-3-pyridin-4-ylpropanenitrile Chemical compound N#CCC(O)C1=CC=NC=C1 BURCZJNCKSLVSZ-UHFFFAOYSA-N 0.000 description 2
- NMNFWLIHFSRPKT-UHFFFAOYSA-N 3-pyridin-4-ylbutanamide Chemical compound NC(=O)CC(C)C1=CC=NC=C1 NMNFWLIHFSRPKT-UHFFFAOYSA-N 0.000 description 2
- KYSQGRVBIOODEO-UHFFFAOYSA-N 3-pyridin-4-ylbutanoic acid Chemical compound OC(=O)CC(C)C1=CC=NC=C1 KYSQGRVBIOODEO-UHFFFAOYSA-N 0.000 description 2
- UAJOHTPJVGVBJV-UHFFFAOYSA-N 3-quinolin-4-ylprop-2-en-1-amine Chemical compound C1=CC=C2C(C=CCN)=CC=NC2=C1 UAJOHTPJVGVBJV-UHFFFAOYSA-N 0.000 description 2
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 2
- FTFBFLRZEAZBAU-UHFFFAOYSA-N 4-pyridin-4-ylbutan-2-one Chemical compound CC(=O)CCC1=CC=NC=C1 FTFBFLRZEAZBAU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 102000007347 Apyrase Human genes 0.000 description 2
- 108010007730 Apyrase Proteins 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- NMHBAYVSPWXWKU-UHFFFAOYSA-N CCC(C)NC1(CC(C2)C3)CC3CC2C1.OC(CCCCC1=CC=NC=C1)=O Chemical compound CCC(C)NC1(CC(C2)C3)CC3CC2C1.OC(CCCCC1=CC=NC=C1)=O NMHBAYVSPWXWKU-UHFFFAOYSA-N 0.000 description 2
- XKIUWDBAPRUNQD-UHFFFAOYSA-N CCCCC(C)NC1(CC(C2)C3)CC3CC2C1.OC(CCCCC1=CC=NC=C1)=O Chemical compound CCCCC(C)NC1(CC(C2)C3)CC3CC2C1.OC(CCCCC1=CC=NC=C1)=O XKIUWDBAPRUNQD-UHFFFAOYSA-N 0.000 description 2
- FYENDBVHNGZMGR-UHFFFAOYSA-N Cl.C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)CC)C=1SC=CC1 Chemical compound Cl.C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)CC)C=1SC=CC1 FYENDBVHNGZMGR-UHFFFAOYSA-N 0.000 description 2
- CXVFWRLPGSYXGZ-UHFFFAOYSA-N Cl.C1(CCCCC1)CCN1C(N(C(C(C1)C)=O)C1=CC=NC=C1)=O Chemical compound Cl.C1(CCCCC1)CCN1C(N(C(C(C1)C)=O)C1=CC=NC=C1)=O CXVFWRLPGSYXGZ-UHFFFAOYSA-N 0.000 description 2
- ONHDSOVNHIGQMU-UHFFFAOYSA-N Cl.Cl.C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)C)CCNC Chemical compound Cl.Cl.C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)C)CCNC ONHDSOVNHIGQMU-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010058490 Hyperoxia Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SHOSHLJBVHRJRE-UHFFFAOYSA-N N-[2-(1-adamantyl)ethyl]-2-amino-N-pentylpropanamide Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C(C(C)N)=O)CCCCC SHOSHLJBVHRJRE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- YWSGPQBZMYYZQU-UHFFFAOYSA-N benzyl 3-pyridin-4-ylbut-2-enoate Chemical compound C=1C=NC=CC=1C(C)=CC(=O)OCC1=CC=CC=C1 YWSGPQBZMYYZQU-UHFFFAOYSA-N 0.000 description 2
- QXQXPYRDKUVFID-UHFFFAOYSA-N benzyl N-methyl-N-[3-phenyl-3-(3-pyridin-4-ylpropylcarbamoylamino)butyl]carbamate Chemical compound C(C1=CC=CC=C1)OC(=O)N(C)CCC(C)(C1=CC=CC=C1)NC(=O)NCCCC1=CC=NC=C1 QXQXPYRDKUVFID-UHFFFAOYSA-N 0.000 description 2
- NYQFILVYNCCFEP-UHFFFAOYSA-N benzyl n-methyl-n-[2-[pentyl(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]carbamate Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CCCCC)CCN(C)C(=O)OCC1=CC=CC=C1 NYQFILVYNCCFEP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- REJPDMLLCDXIOV-UHFFFAOYSA-N but-2-ynal Chemical compound CC#CC=O REJPDMLLCDXIOV-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- NISLLLKCAMZRRG-UHFFFAOYSA-N ethyl 3-oxo-2-(pyridin-4-ylmethyl)butanoate Chemical compound CCOC(=O)C(C(C)=O)CC1=CC=NC=C1 NISLLLKCAMZRRG-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000000222 hyperoxic effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- XHKIICJRFHUVGG-UHFFFAOYSA-N n'-[2-(1-adamantyl)ethyl]-n-(3-pyridin-4-ylpropyl)propane-1,3-diamine Chemical compound C1C(C2)CC(C3)CC2CC13CCNCCCNCCCC1=CC=NC=C1 XHKIICJRFHUVGG-UHFFFAOYSA-N 0.000 description 2
- AUFSXFBECUTVGL-UHFFFAOYSA-N n,n-bis(3-methylbutyl)-5-pyridin-4-ylpentanamide Chemical compound CC(C)CCN(CCC(C)C)C(=O)CCCCC1=CC=NC=C1 AUFSXFBECUTVGL-UHFFFAOYSA-N 0.000 description 2
- NXCWGWUZJSURMG-UHFFFAOYSA-N n,n-bis[2-(1-adamantyl)ethyl]-5-pyridin-4-ylpentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)CCCCC1=CC=NC=C1 NXCWGWUZJSURMG-UHFFFAOYSA-N 0.000 description 2
- KTDAXSVRVRUIPP-UHFFFAOYSA-N n-(2-cyclohexylethyl)-n-pentyl-5-pyridin-4-ylpentanamide Chemical compound C=1C=NC=CC=1CCCCC(=O)N(CCCCC)CCC1CCCCC1 KTDAXSVRVRUIPP-UHFFFAOYSA-N 0.000 description 2
- LLLWSLXHBBPYOR-UHFFFAOYSA-N n-(3-pyridin-4-ylpropyl)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)NCCCC1=CC=NC=C1 LLLWSLXHBBPYOR-UHFFFAOYSA-N 0.000 description 2
- WZLFSVMIRVBIDX-UHFFFAOYSA-N n-(4-pyridin-4-ylbutan-2-ylidene)hydroxylamine Chemical compound ON=C(C)CCC1=CC=NC=C1 WZLFSVMIRVBIDX-UHFFFAOYSA-N 0.000 description 2
- XMNNSBCJPMDGBS-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-2-(2-hydroxyethoxy)-n-pentylacetamide Chemical compound C1C(C2)CC3CC2CC1(CCN(CCCCC)C(=O)COCCO)C3 XMNNSBCJPMDGBS-UHFFFAOYSA-N 0.000 description 2
- AMFXTKKXASBHGW-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-2-amino-n-pentyl-3-(pyridin-4-ylmethylsulfanyl)propanamide;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)C(N)CSCC1=CC=NC=C1 AMFXTKKXASBHGW-UHFFFAOYSA-N 0.000 description 2
- VFAAOGWVAACBND-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-2-bromo-n-pentylacetamide Chemical compound C1C(C2)CC3CC2CC1(CCN(CCCCC)C(=O)CBr)C3 VFAAOGWVAACBND-UHFFFAOYSA-N 0.000 description 2
- PDGWLEJUYAIDPV-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-2-methyl-n-pentyl-3-(pyridin-4-ylmethylsulfanyl)propanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)C(C)CSCC1=CC=NC=C1 PDGWLEJUYAIDPV-UHFFFAOYSA-N 0.000 description 2
- AYNARYHEVASKMX-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-3-[methyl(pyridin-4-ylmethyl)amino]-n-pentylpropanamide;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CCN(C)CC1=CC=NC=C1 AYNARYHEVASKMX-UHFFFAOYSA-N 0.000 description 2
- UGXKQXOLXLGORP-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-3-amino-n-pentylpropanamide Chemical compound C1C(C2)CC3CC2CC1(CCN(CCCCC)C(=O)CCN)C3 UGXKQXOLXLGORP-UHFFFAOYSA-N 0.000 description 2
- KADVVNXCDSHAFC-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-5-pyridin-4-yl-n-(3,3,3-trifluoropropyl)pentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC(F)(F)F)C(=O)CCCCC1=CC=NC=C1 KADVVNXCDSHAFC-UHFFFAOYSA-N 0.000 description 2
- RTBIMWJLTSEQBM-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-[2-(dimethylamino)ethyl]-5-pyridin-4-ylpentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C)C(=O)CCCCC1=CC=NC=C1 RTBIMWJLTSEQBM-UHFFFAOYSA-N 0.000 description 2
- MYWRCXGZHORWCH-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-[2-(methylamino)ethyl]-5-pyridin-4-ylpentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCNC)C(=O)CCCCC1=CC=NC=C1 MYWRCXGZHORWCH-UHFFFAOYSA-N 0.000 description 2
- UHQPYQUKVSQVNH-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-but-2-enyl-5-pyridin-4-ylpentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC=CC)C(=O)CCCCC1=CC=NC=C1 UHQPYQUKVSQVNH-UHFFFAOYSA-N 0.000 description 2
- VPVISCNKMGXIOK-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-2-(2-pyridin-4-ylethoxy)acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)COCCC1=CC=NC=C1 VPVISCNKMGXIOK-UHFFFAOYSA-N 0.000 description 2
- XAIPESVYEUSTGK-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-2-(2-pyridin-4-ylethylamino)acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CNCCC1=CC=NC=C1 XAIPESVYEUSTGK-UHFFFAOYSA-N 0.000 description 2
- YVSCDTVUCBAGSP-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-2-(2-pyridin-4-ylethylamino)acetamide;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CNCCC1=CC=NC=C1 YVSCDTVUCBAGSP-UHFFFAOYSA-N 0.000 description 2
- LZEOMSCOZADZHX-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-2-(2-pyridin-4-yloxyethoxy)acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)COCCOC1=CC=NC=C1 LZEOMSCOZADZHX-UHFFFAOYSA-N 0.000 description 2
- QAPNOSDRZZPVHP-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-3-(pyridin-4-ylmethylamino)propanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CCNCC1=CC=NC=C1 QAPNOSDRZZPVHP-UHFFFAOYSA-N 0.000 description 2
- BPBXABUBDPKVNY-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n-pentyl-4-pyridin-4-ylbutanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)CCCC1=CC=NC=C1 BPBXABUBDPKVNY-UHFFFAOYSA-N 0.000 description 2
- UEPYNCNDMALIHK-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]propan-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCCC)C3 UEPYNCNDMALIHK-UHFFFAOYSA-N 0.000 description 2
- ZXPKBPNUWWLQQW-UHFFFAOYSA-N n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylimidazole-1-carboxamide Chemical compound C1=CN=CN1C(=O)N(C)CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC1=CC=NC=C1 ZXPKBPNUWWLQQW-UHFFFAOYSA-N 0.000 description 2
- QHLHPUHTBLPHLA-UHFFFAOYSA-N n-[2-[2-(1-adamantyl)ethyl-[(2-methyl-3-pyridin-4-ylpropyl)carbamoyl]amino]ethyl]-n,3,3-trimethylbutanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)CC(C)(C)C)C(=O)NCC(C)CC1=CC=NC=C1 QHLHPUHTBLPHLA-UHFFFAOYSA-N 0.000 description 2
- VQTZMJJESVFVRU-UHFFFAOYSA-N n-[3-(1-adamantyl)propyl]-n-propyl-5-pyridin-4-ylpentanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCC)C(=O)CCCCC1=CC=NC=C1 VQTZMJJESVFVRU-UHFFFAOYSA-N 0.000 description 2
- BUCBPAXMXLVROO-UHFFFAOYSA-N n-methyl-3-pyridin-4-ylpropan-1-amine Chemical compound CNCCCC1=CC=NC=C1 BUCBPAXMXLVROO-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004263 retinal angiogenesis Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 2
- NTNRCELGODQRKX-UHFFFAOYSA-N tert-butyl 3-[2-(1-adamantyl)ethyl-pentylamino]-2-amino-3-oxo-2-(pyridin-4-ylmethylsulfanylmethyl)propanoate Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C(C(CSCC2=CC=NC=C2)(N)C(=O)OC(C)(C)C)=O)CCCCC NTNRCELGODQRKX-UHFFFAOYSA-N 0.000 description 2
- CBMBSAWCELAEFR-UHFFFAOYSA-N tert-butyl 3-[2-(1-adamantyl)ethylcarbamoyl-(3-pyridin-4-ylpropyl)amino]propanoate Chemical compound C1C(C2)CC(C3)CC2CC13CCNC(=O)N(CCC(=O)OC(C)(C)C)CCCC1=CC=NC=C1 CBMBSAWCELAEFR-UHFFFAOYSA-N 0.000 description 2
- IXHBUBNGCHLSKI-UHFFFAOYSA-N tert-butyl N-methyl-N-[3-phenyl-3-(3-pyridin-4-ylpropylcarbamoylamino)butyl]carbamate Chemical compound C(C)(C)(C)OC(=O)N(C)CCC(C)(C1=CC=CC=C1)NC(=O)NCCCC1=CC=NC=C1 IXHBUBNGCHLSKI-UHFFFAOYSA-N 0.000 description 2
- QKRKMOWZDWMYTB-UHFFFAOYSA-N tert-butyl n-(3-amino-3-oxopropyl)-n-(2-cyclohexylethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCC(N)=O)CCC1CCCCC1 QKRKMOWZDWMYTB-UHFFFAOYSA-N 0.000 description 2
- APFBOXBUGOGTNE-UHFFFAOYSA-N tert-butyl n-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]carbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(NC(=O)OC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 APFBOXBUGOGTNE-UHFFFAOYSA-N 0.000 description 2
- PLZNEQILFLBHON-UHFFFAOYSA-N tert-butyl n-[2-(1-adamantyl)ethyl-pentylcarbamoyl]-n-(2-pyridin-4-yloxyethyl)carbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)N(C(=O)OC(C)(C)C)CCOC1=CC=NC=C1 PLZNEQILFLBHON-UHFFFAOYSA-N 0.000 description 2
- ULSYNIZSFKLVIU-UHFFFAOYSA-N tert-butyl n-[2-(1-adamantylamino)-2-oxoethyl]-n-propylcarbamate Chemical compound C1C(C2)CC3CC2CC1(NC(=O)CN(CCC)C(=O)OC(C)(C)C)C3 ULSYNIZSFKLVIU-UHFFFAOYSA-N 0.000 description 2
- RWMRTGBPXPWRIZ-UHFFFAOYSA-N tert-butyl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)OC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 RWMRTGBPXPWRIZ-UHFFFAOYSA-N 0.000 description 2
- OXNAJYREGSQDPD-UHFFFAOYSA-N tert-butyl n-[2-[3-(1-adamantyl)propyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCCN(CCN(C)C(=O)OC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 OXNAJYREGSQDPD-UHFFFAOYSA-N 0.000 description 2
- GKPWVPGDWPHZJH-UHFFFAOYSA-N tert-butyl n-[3-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]propyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCN(C)C(=O)OC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 GKPWVPGDWPHZJH-UHFFFAOYSA-N 0.000 description 2
- DTCXEAIRKNDNID-UHFFFAOYSA-N tert-butyl n-[3-[2-(1-adamantyl)ethyl-pentylamino]-3-oxopropyl]carbamate Chemical compound C1C(C2)CC3CC2CC1(CCN(CCCCC)C(=O)CCNC(=O)OC(C)(C)C)C3 DTCXEAIRKNDNID-UHFFFAOYSA-N 0.000 description 2
- HCWRJOQMTQTHJI-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-[pentyl(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCN(CCCCC)C(=O)NCCCC1=CC=NC=C1 HCWRJOQMTQTHJI-UHFFFAOYSA-N 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- AVQABZVTPWROCF-UHFFFAOYSA-M (2-oxo-2-phenylmethoxyethyl)-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1COC(=O)C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 AVQABZVTPWROCF-UHFFFAOYSA-M 0.000 description 1
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 1
- ZXAQFYZQHPGMMN-BZSJEYESSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylcyclohexane-1-carboxamide Chemical compound C1C[C@H](CC(C1)C(=O)NC2=CC=CC=C2)OC3=CC(=CC(=N3)C(F)(F)F)CN ZXAQFYZQHPGMMN-BZSJEYESSA-N 0.000 description 1
- ZWHOTPNCEFWATE-CQSZACIVSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-CQSZACIVSA-N 0.000 description 1
- ZWHOTPNCEFWATE-AWEZNQCLSA-N (3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-AWEZNQCLSA-N 0.000 description 1
- SNAKUPLQASYKTC-AWEZNQCLSA-N (3S)-3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC[C@@H]1CN(CCC1)C(=O)NC1=CC=CC=C1 SNAKUPLQASYKTC-AWEZNQCLSA-N 0.000 description 1
- RDAFNSMYPSHCBK-QPJJXVBHSA-N (e)-3-phenylprop-2-en-1-amine Chemical compound NC\C=C\C1=CC=CC=C1 RDAFNSMYPSHCBK-QPJJXVBHSA-N 0.000 description 1
- GFESBPOYRDVLGG-UHFFFAOYSA-N 1,1-bis(2-hydroxypropyl)-3-(3-pyridin-4-ylpropyl)urea;hydrochloride Chemical compound Cl.CC(O)CN(CC(C)O)C(=O)NCCCC1=CC=NC=C1 GFESBPOYRDVLGG-UHFFFAOYSA-N 0.000 description 1
- PLRKAMJYPUSLRR-UHFFFAOYSA-N 1,1-bis(3-methylbutyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound CC(C)CCN(CCC(C)C)C(=O)NCCCC1=CC=NC=C1 PLRKAMJYPUSLRR-UHFFFAOYSA-N 0.000 description 1
- ZXIIZQHITDHONW-UHFFFAOYSA-N 1,1-bis[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC1=CC=NC=C1 ZXIIZQHITDHONW-UHFFFAOYSA-N 0.000 description 1
- AHYXPRUWCSKIQI-UHFFFAOYSA-N 1,1-didecyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound CCCCCCCCCCN(CCCCCCCCCC)C(=O)NCCCC1=CC=NC=C1 AHYXPRUWCSKIQI-UHFFFAOYSA-N 0.000 description 1
- GTOMSSDKPZTYEC-UHFFFAOYSA-N 1,1-dihexyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound CCCCCCN(CCCCCC)C(=O)NCCCC1=CC=NC=C1 GTOMSSDKPZTYEC-UHFFFAOYSA-N 0.000 description 1
- PVFAXWLZKIIKNN-UHFFFAOYSA-N 1,1-dipentyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound CCCCCN(CCCCC)C(=O)NCCCC1=CC=NC=C1 PVFAXWLZKIIKNN-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- VORNNDDNHFRMAW-UHFFFAOYSA-N 1-(1-adamantyl)-3-methyl-1-pentyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C12(CC3CC(CC(C1)C3)C2)N(C(=O)N(CCCC1=CC=NC=C1)C)CCCCC VORNNDDNHFRMAW-UHFFFAOYSA-N 0.000 description 1
- RMMYPNPDVWMVMB-UHFFFAOYSA-N 1-(1-adamantyl)-3-methyl-1-propyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C12(CC3CC(CC(C1)C3)C2)N(C(=O)N(CCCC1=CC=NC=C1)C)CCC RMMYPNPDVWMVMB-UHFFFAOYSA-N 0.000 description 1
- JDOJNQPGCWEBSL-UHFFFAOYSA-N 1-(2-cyclohexylethyl)-1,3-bis(pyridin-4-ylmethyl)urea Chemical compound C1CCCCC1CCN(CC=1C=CN=CC=1)C(=O)NCC1=CC=NC=C1 JDOJNQPGCWEBSL-UHFFFAOYSA-N 0.000 description 1
- LDMHOAPGYQKRCB-UHFFFAOYSA-N 1-(2-cyclohexylethyl)-1-[2-(dimethylamino)ethyl]-3-methyl-3-pyridin-4-ylurea Chemical compound C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)C)CCN(C)C LDMHOAPGYQKRCB-UHFFFAOYSA-N 0.000 description 1
- MVDNWXSJDMXLOR-UHFFFAOYSA-N 1-(2-cyclohexylethyl)-3-ethyl-3-pyridin-4-yl-1-thiophen-2-ylurea Chemical compound C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)CC)C=1SC=CC=1 MVDNWXSJDMXLOR-UHFFFAOYSA-N 0.000 description 1
- PAESDHMDFCJGCL-UHFFFAOYSA-N 1-(2-cyclohexylethyl)-3-methyl-1-pentyl-3-pyridin-4-ylurea Chemical compound C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)C)CCCCC PAESDHMDFCJGCL-UHFFFAOYSA-N 0.000 description 1
- QSNUJGDZNLROBF-UHFFFAOYSA-N 1-(2-phenylheptan-2-yl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C(CCCC)C(C)(C1=CC=CC=C1)NC(=O)NCCCC1=CC=NC=C1 QSNUJGDZNLROBF-UHFFFAOYSA-N 0.000 description 1
- RAVIQFQJZMTUBX-AWEZNQCLSA-N 1-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-2-(3,4-dichlorophenyl)ethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(CC1=CC(=C(C=C1)Cl)Cl)=O RAVIQFQJZMTUBX-AWEZNQCLSA-N 0.000 description 1
- XAOMFUPJQYNDEG-LBPRGKRZSA-N 1-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-2-methylpropan-1-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(C(C)C)=O XAOMFUPJQYNDEG-LBPRGKRZSA-N 0.000 description 1
- BGKFVDMZCOJBLE-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(2-methoxyethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCOC)C(=O)NCCCC1=CC=NC=C1 BGKFVDMZCOJBLE-UHFFFAOYSA-N 0.000 description 1
- ANTJUWIEFLVHFU-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(2-methylprop-2-enyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC(=C)C)C(=O)NCCCC1=CC=NC=C1 ANTJUWIEFLVHFU-UHFFFAOYSA-N 0.000 description 1
- VIDCMVDGSLULNG-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(3-methylbut-2-enyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC=C(C)C)C(=O)NCCCC1=CC=NC=C1 VIDCMVDGSLULNG-UHFFFAOYSA-N 0.000 description 1
- GVIRDQTWBQOHJM-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(3-phenylprop-2-enyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC=CC=1C=CC=CC=1)C(=O)NCCCC1=CC=NC=C1 GVIRDQTWBQOHJM-UHFFFAOYSA-N 0.000 description 1
- FNYXDJWCKXYMDI-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(cyclopropylmethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC1CC1)C(=O)NCCCC1=CC=NC=C1 FNYXDJWCKXYMDI-UHFFFAOYSA-N 0.000 description 1
- YNRZTLBSDNQMDK-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-(furan-2-ylmethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC=1OC=CC=1)C(=O)NCCCC1=CC=NC=C1 YNRZTLBSDNQMDK-UHFFFAOYSA-N 0.000 description 1
- YBUPJTCFBSTDKU-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-(dimethylamino)ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C)C(=O)NCCCC1=CC=NC=C1 YBUPJTCFBSTDKU-UHFFFAOYSA-N 0.000 description 1
- XSUJGDRWSWYDTQ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-[methyl(methylsulfonyl)amino]ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)S(C)(=O)=O)C(=O)NCCCC1=CC=NC=C1 XSUJGDRWSWYDTQ-UHFFFAOYSA-N 0.000 description 1
- KAPBBLNPJDGQCA-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-[methyl(propylcarbamoyl)amino]ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)NCCC)C(=O)NCCCC1=CC=NC=C1 KAPBBLNPJDGQCA-UHFFFAOYSA-N 0.000 description 1
- LELWOWMBDQJZHC-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-[methyl-(4-methylphenyl)sulfonylamino]ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=C(C)C=CC=1S(=O)(=O)N(C)CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC1=CC=NC=C1 LELWOWMBDQJZHC-UHFFFAOYSA-N 0.000 description 1
- MXAZSXSHWGMYDI-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-[2-[tert-butylcarbamoyl(methyl)amino]ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)NC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 MXAZSXSHWGMYDI-UHFFFAOYSA-N 0.000 description 1
- SENGPHOAQNXJGF-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-benzyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC=1C=CC=CC=1)C(=O)NCCCC1=CC=NC=C1 SENGPHOAQNXJGF-UHFFFAOYSA-N 0.000 description 1
- JEBIKHKUBDWGHE-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-butyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCC)C(=O)NCCCC1=CC=NC=C1 JEBIKHKUBDWGHE-UHFFFAOYSA-N 0.000 description 1
- YAFJYGCIZUIDDP-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-decyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCCCCCCC)C(=O)NCCCC1=CC=NC=C1 YAFJYGCIZUIDDP-UHFFFAOYSA-N 0.000 description 1
- OFEDIZBNIJIQJJ-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-ethyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC)C(=O)NCCCC1=CC=NC=C1 OFEDIZBNIJIQJJ-UHFFFAOYSA-N 0.000 description 1
- ZWCGFEQBOOYLHO-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-hexyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCCC)C(=O)NCCCC1=CC=NC=C1 ZWCGFEQBOOYLHO-UHFFFAOYSA-N 0.000 description 1
- VIVRTIYHHOJJQX-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-methyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(C)C(=O)NCCCC1=CC=NC=C1 VIVRTIYHHOJJQX-UHFFFAOYSA-N 0.000 description 1
- YWJSTJKZGMYFRH-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-4-ylprop-2-enyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCC=CC1=CC=NC=C1 YWJSTJKZGMYFRH-UHFFFAOYSA-N 0.000 description 1
- XGWUENJZCVWYOR-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-prop-2-ynyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CC#C)C(=O)NCCCC1=CC=NC=C1 XGWUENJZCVWYOR-UHFFFAOYSA-N 0.000 description 1
- SUBRNFJHNYPWQK-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-propan-2-yl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(C(C)C)C(=O)NCCCC1=CC=NC=C1 SUBRNFJHNYPWQK-UHFFFAOYSA-N 0.000 description 1
- QAJQCKPWVRFOJH-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-propyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCC)C(=O)NCCCC1=CC=NC=C1 QAJQCKPWVRFOJH-UHFFFAOYSA-N 0.000 description 1
- JCWKYZRSOCOZPX-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)-1-(4,4,4-trifluorobutyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 JCWKYZRSOCOZPX-UHFFFAOYSA-N 0.000 description 1
- NZTIVMKRTCNQFV-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)-1-(5,5,5-trifluoropentyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC(F)(F)F)C(=O)NCCCC1=CC=NC=C1 NZTIVMKRTCNQFV-UHFFFAOYSA-N 0.000 description 1
- KUNUTSLQJCVZCM-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-3-methyl-3-(3-pyridin-4-ylpropyl)-1-thiophen-2-ylurea Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C(=O)N(CCCC1=CC=NC=C1)C)C=1SC=CC=1 KUNUTSLQJCVZCM-UHFFFAOYSA-N 0.000 description 1
- CKDNEGDSDCJZGC-UHFFFAOYSA-N 1-acetamido-1-[2-(1-adamantyl)ethyl]-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(NC(=O)C)C(=O)NCCCC1=CC=NC=C1 CKDNEGDSDCJZGC-UHFFFAOYSA-N 0.000 description 1
- HTNCOFXUXVKNNZ-UHFFFAOYSA-N 1-benzyl-3-cyclohexyl-3-(3-phenylpropyl)-1-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=CC=CC=1CCCN(C1CCCCC1)C(=O)N(CC=1C=CC=CC=1)CCCC1=CC=NC=C1 HTNCOFXUXVKNNZ-UHFFFAOYSA-N 0.000 description 1
- VQHPRVYDKRESCL-UHFFFAOYSA-N 1-bromoadamantane Chemical compound C1C(C2)CC3CC2CC1(Br)C3 VQHPRVYDKRESCL-UHFFFAOYSA-N 0.000 description 1
- YDTDIWODTJABHQ-UHFFFAOYSA-N 1-butyl-1-(2-cyclohexylethyl)-3-methyl-3-pyridin-4-ylurea Chemical compound C(CCC)N(C(=O)N(C1=CC=NC=C1)C)CCC1CCCCC1 YDTDIWODTJABHQ-UHFFFAOYSA-N 0.000 description 1
- XTIGGAHUZJWQMD-UHFFFAOYSA-N 1-chloro-2-methoxyethane Chemical compound COCCCl XTIGGAHUZJWQMD-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- XNANJUVQYIVGOG-UHFFFAOYSA-N 1-pentyl-1-(2-piperidin-1-ylethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CCCCC)CCN1CCCCC1 XNANJUVQYIVGOG-UHFFFAOYSA-N 0.000 description 1
- JVIAODYKVANINC-UHFFFAOYSA-N 1-pentyl-1-(2-pyridin-2-ylethyl)-3-(3-pyridin-4-ylpropyl)urea Chemical compound C=1C=NC=CC=1CCCNC(=O)N(CCCCC)CCC1=CC=CC=N1 JVIAODYKVANINC-UHFFFAOYSA-N 0.000 description 1
- WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
- DALCKCLRBMBYEB-UHFFFAOYSA-N 1-pyridin-4-ylpentan-3-amine Chemical compound CCC(N)CCC1=CC=NC=C1 DALCKCLRBMBYEB-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- FCWKTYAKHOSQHZ-UHFFFAOYSA-N 2,2-dimethyl-3-pyridin-4-ylpropan-1-amine Chemical compound NCC(C)(C)CC1=CC=NC=C1 FCWKTYAKHOSQHZ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- OGMPCYLBWOMIRO-UHFFFAOYSA-N 2-(1-adamantyl)-2-cyclopentylethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13C(CN)C1CCCC1 OGMPCYLBWOMIRO-UHFFFAOYSA-N 0.000 description 1
- CEVRDXQYFYJBOR-UHFFFAOYSA-N 2-(1-adamantyl)-2-cyclopropylethanamine Chemical compound C1C(C2)CC(C3)CC2CC13C(CN)C1CC1 CEVRDXQYFYJBOR-UHFFFAOYSA-N 0.000 description 1
- AFEWTVAATUXQHG-UHFFFAOYSA-N 2-(1-adamantyl)-3-(furan-2-yl)propan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13C(CN)CC1=CC=CO1 AFEWTVAATUXQHG-UHFFFAOYSA-N 0.000 description 1
- XLFVZHZGMQKQCR-UHFFFAOYSA-N 2-(1-adamantyl)-3-phenylpropan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13C(CN)CC1=CC=CC=C1 XLFVZHZGMQKQCR-UHFFFAOYSA-N 0.000 description 1
- HDYOQAAFGJNYGF-UHFFFAOYSA-N 2-(1-adamantyl)-n-(2-methoxyethyl)ethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCCOC)C3 HDYOQAAFGJNYGF-UHFFFAOYSA-N 0.000 description 1
- YCDYBBMGDLNZGL-UHFFFAOYSA-N 2-(1-adamantyl)-n-(cyclopentylmethyl)ethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13CCNCC1CCCC1 YCDYBBMGDLNZGL-UHFFFAOYSA-N 0.000 description 1
- IXXZYVLVZRCNMB-UHFFFAOYSA-N 2-(1-adamantyl)-n-(cyclopropylmethyl)ethanamine Chemical compound C1C(C2)CC(C3)CC2CC13CCNCC1CC1 IXXZYVLVZRCNMB-UHFFFAOYSA-N 0.000 description 1
- XCKXWSFNJOQMIH-UHFFFAOYSA-N 2-(1-adamantyl)-n-(thiophen-2-ylmethyl)ethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13CCNCC1=CC=CS1 XCKXWSFNJOQMIH-UHFFFAOYSA-N 0.000 description 1
- UOCRBSIVRRPPSC-UHFFFAOYSA-N 2-(1-adamantyl)-n-[(2-methyl-1,3-thiazol-4-yl)methyl]ethanamine Chemical compound S1C(C)=NC(CNCCC23CC4CC(CC(C4)C2)C3)=C1 UOCRBSIVRRPPSC-UHFFFAOYSA-N 0.000 description 1
- NUUUXJAVFDBNRA-UHFFFAOYSA-N 2-(1-adamantyl)-n-ethylethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCC)C3 NUUUXJAVFDBNRA-UHFFFAOYSA-N 0.000 description 1
- TWMKVKIJGLSCJT-UHFFFAOYSA-N 2-(1-adamantyl)-n-methylacetamide Chemical compound C1C(C2)CC3CC2CC1(CC(=O)NC)C3 TWMKVKIJGLSCJT-UHFFFAOYSA-N 0.000 description 1
- PVMRHHYSMYVGQV-UHFFFAOYSA-N 2-(1-adamantyl)-n-methylethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNC)C3 PVMRHHYSMYVGQV-UHFFFAOYSA-N 0.000 description 1
- KBWMAUGKQSNALP-UHFFFAOYSA-N 2-(1-adamantyl)-n-phenylmethoxyethanamine Chemical compound C1C(C2)CC(C3)CC2CC13CCNOCC1=CC=CC=C1 KBWMAUGKQSNALP-UHFFFAOYSA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- SNJMEUDNDRSJAS-UHFFFAOYSA-N 2-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(CCN)C3 SNJMEUDNDRSJAS-UHFFFAOYSA-N 0.000 description 1
- GTZXSBQCNBNWPK-UHFFFAOYSA-N 2-(2-chloro-2-oxoethoxy)acetyl chloride Chemical compound ClC(=O)COCC(Cl)=O GTZXSBQCNBNWPK-UHFFFAOYSA-N 0.000 description 1
- NORKQDMUHKNJNN-UHFFFAOYSA-N 2-(3-pyridin-4-ylpropyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCC1=CC=NC=C1 NORKQDMUHKNJNN-UHFFFAOYSA-N 0.000 description 1
- BCLSJHWBDUYDTR-UHFFFAOYSA-N 2-(propylamino)ethanol Chemical compound CCCNCCO BCLSJHWBDUYDTR-UHFFFAOYSA-N 0.000 description 1
- XZBAGOKDTBEUAK-UHFFFAOYSA-N 2-(pyridin-4-ylmethyl)butan-1-amine Chemical compound CCC(CN)CC1=CC=NC=C1 XZBAGOKDTBEUAK-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- RNIUHIHTGPHJEN-AWEZNQCLSA-N 2-[(3S)-1-[2-(3,4-dichlorophenyl)acetyl]piperidin-3-yl]oxy-6-(trifluoromethyl)pyridine-4-carbonitrile Chemical compound ClC=1C=C(C=CC=1Cl)CC(=O)N1C[C@H](CCC1)OC=1C=C(C#N)C=C(N=1)C(F)(F)F RNIUHIHTGPHJEN-AWEZNQCLSA-N 0.000 description 1
- DCGQVDFBDSTUML-AWEZNQCLSA-N 2-[(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidine-1-carbonyl]chromen-4-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1OC2=CC=CC=C2C(C=1)=O DCGQVDFBDSTUML-AWEZNQCLSA-N 0.000 description 1
- APDYPEOKIUKUQV-UHFFFAOYSA-N 2-[1-(2-oxo-2-piperidin-1-ylethyl)indol-4-yl]oxy-6-(trifluoromethyl)pyridine-4-carbonitrile Chemical compound O=C(CN1C=CC2=C(C=CC=C12)OC=1C=C(C#N)C=C(N=1)C(F)(F)F)N1CCCCC1 APDYPEOKIUKUQV-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BVKRPQCDGACLPX-UHFFFAOYSA-N 2-[4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyindol-1-yl]-N-methyl-N-phenylacetamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2C=CN(C2=CC=C1)CC(=O)N(C1=CC=CC=C1)C BVKRPQCDGACLPX-UHFFFAOYSA-N 0.000 description 1
- CWSUDZBRNKKURY-UHFFFAOYSA-N 2-benzyl-3-pyridin-4-ylpropan-1-amine Chemical compound C=1C=NC=CC=1CC(CN)CC1=CC=CC=C1 CWSUDZBRNKKURY-UHFFFAOYSA-N 0.000 description 1
- KWNVSNXIXBJJHG-UHFFFAOYSA-N 2-cyclohexyl-n-(2-methoxyethyl)ethanamine;hydrochloride Chemical compound Cl.COCCNCCC1CCCCC1 KWNVSNXIXBJJHG-UHFFFAOYSA-N 0.000 description 1
- WIKBVKJZIZSPLL-UHFFFAOYSA-N 2-methyl-3-pyridin-4-ylpropan-1-ol Chemical compound OCC(C)CC1=CC=NC=C1 WIKBVKJZIZSPLL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- IDLHTECVNDEOIY-UHFFFAOYSA-N 2-pyridin-4-ylethanamine Chemical compound NCCC1=CC=NC=C1 IDLHTECVNDEOIY-UHFFFAOYSA-N 0.000 description 1
- YSUKTUWMBAKSSV-UHFFFAOYSA-N 2-pyridin-4-yloxyethanamine Chemical compound NCCOC1=CC=NC=C1 YSUKTUWMBAKSSV-UHFFFAOYSA-N 0.000 description 1
- BKSZDIVRPCPIDA-UHFFFAOYSA-N 3-(1-adamantyl)-n-(2,2,2-trifluoroethyl)propan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCCNCC(F)(F)F)C3 BKSZDIVRPCPIDA-UHFFFAOYSA-N 0.000 description 1
- VWKLMPOKKGNEFO-UHFFFAOYSA-N 3-(1-adamantyl)-n-propylpropan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCCNCCC)C3 VWKLMPOKKGNEFO-UHFFFAOYSA-N 0.000 description 1
- LCVMHCVYIXLDOD-UHFFFAOYSA-N 3-(2-cyclohexylethylamino)propanamide;hydrochloride Chemical compound Cl.NC(=O)CCNCCC1CCCCC1 LCVMHCVYIXLDOD-UHFFFAOYSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- OVLKVEZDRRUWKT-UHFFFAOYSA-N 3-[2-cyclohexylethyl-[methyl(pyridin-4-yl)carbamoyl]amino]propanamide Chemical compound C(N)(=O)CCN(C(=O)N(C1=CC=NC=C1)C)CCC1CCCCC1 OVLKVEZDRRUWKT-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- CJYDQTAWSHWBIT-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxy-2-methylpropyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC(C)(C)O)C=CC=1 CJYDQTAWSHWBIT-UHFFFAOYSA-N 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 description 1
- LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- SONNQRNOTIAJDS-GFCCVEGCSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(2R)-2,3-dihydroxypropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC[C@H](CO)O)C=CC=1 SONNQRNOTIAJDS-GFCCVEGCSA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- ISXSUKUXUPLGTD-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(5-oxopyrrolidin-2-yl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2NC(CC2)=O)C=CC=1 ISXSUKUXUPLGTD-UHFFFAOYSA-N 0.000 description 1
- FJPUKTJEFOXMJX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[1-(hydroxymethyl)cyclopropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2(CC2)CO)C=CC=1 FJPUKTJEFOXMJX-UHFFFAOYSA-N 0.000 description 1
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 1
- ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 description 1
- AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- VVPGEFWZAXBZHR-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]sulfanyl-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)SC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 VVPGEFWZAXBZHR-UHFFFAOYSA-N 0.000 description 1
- OIBZMMPOWDEASK-UHFFFAOYSA-N 3-[[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]amino]methyl]-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)NCC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 OIBZMMPOWDEASK-UHFFFAOYSA-N 0.000 description 1
- XXAFCSLVTWGVEY-UHFFFAOYSA-N 3-[[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]amino]methyl]-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)NCC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 XXAFCSLVTWGVEY-UHFFFAOYSA-N 0.000 description 1
- CVJPFWWVXHIYEL-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxy-3-pyridin-4-ylpropan-1-amine Chemical compound CC(C)(C)[Si](C)(C)OC(CCN)C1=CC=NC=C1 CVJPFWWVXHIYEL-UHFFFAOYSA-N 0.000 description 1
- ZEUUECKRCFPQMQ-UHFFFAOYSA-N 3-[tert-butyl(diphenyl)silyl]oxy-3-pyridin-4-ylpropan-1-amine Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OC(CCN)C1=CC=NC=C1 ZEUUECKRCFPQMQ-UHFFFAOYSA-N 0.000 description 1
- UBKBYANALPCHED-UHFFFAOYSA-N 3-[tert-butyl(diphenyl)silyl]oxy-3-pyridin-4-ylpropanenitrile Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OC(CC#N)C1=CC=NC=C1 UBKBYANALPCHED-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- OHQFZFQTVFOYGV-UHFFFAOYSA-N 3-cyclohexyl-n-propylpropan-1-amine;hydrochloride Chemical compound Cl.CCCNCCCC1CCCCC1 OHQFZFQTVFOYGV-UHFFFAOYSA-N 0.000 description 1
- OOOKFECOOJGDKJ-UHFFFAOYSA-N 3-methyl-4-pyridin-4-ylbutan-2-amine Chemical compound CC(N)C(C)CC1=CC=NC=C1 OOOKFECOOJGDKJ-UHFFFAOYSA-N 0.000 description 1
- FPXGMRHKHOBEBA-UHFFFAOYSA-N 3-methyl-n-(3,3,3-trifluoropropyl)butan-1-amine;hydrochloride Chemical compound Cl.CC(C)CCNCCC(F)(F)F FPXGMRHKHOBEBA-UHFFFAOYSA-N 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical group C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 1
- QLLGCGSTKZOIGY-UHFFFAOYSA-N 3-pyridin-4-yl-2-(pyridin-4-ylmethyl)propan-1-amine Chemical compound C=1C=NC=CC=1CC(CN)CC1=CC=NC=C1 QLLGCGSTKZOIGY-UHFFFAOYSA-N 0.000 description 1
- QXDRXJVROBDWIJ-UHFFFAOYSA-N 3-pyridin-4-ylbutan-1-amine Chemical compound NCCC(C)C1=CC=NC=C1 QXDRXJVROBDWIJ-UHFFFAOYSA-N 0.000 description 1
- KOZMKKDQRHAAIG-UHFFFAOYSA-N 3-pyridin-4-ylprop-2-en-1-amine Chemical compound NCC=CC1=CC=NC=C1 KOZMKKDQRHAAIG-UHFFFAOYSA-N 0.000 description 1
- PZVZGDBCMQBRMA-UHFFFAOYSA-N 3-pyridin-4-ylpropan-1-ol Chemical compound OCCCC1=CC=NC=C1 PZVZGDBCMQBRMA-UHFFFAOYSA-N 0.000 description 1
- VEONADHCZDIKEW-UHFFFAOYSA-N 3-quinolin-4-ylpropan-1-amine Chemical compound C1=CC=C2C(CCCN)=CC=NC2=C1 VEONADHCZDIKEW-UHFFFAOYSA-N 0.000 description 1
- LEYGNTFSUFPATN-UHFFFAOYSA-N 4-(1-adamantyl)-n-ethylbutan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCCCNCC)C3 LEYGNTFSUFPATN-UHFFFAOYSA-N 0.000 description 1
- FLXLSRTTYNIDLM-UHFFFAOYSA-N 4-(1-adamantyl)-n-propylbutan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCCCNCCC)C3 FLXLSRTTYNIDLM-UHFFFAOYSA-N 0.000 description 1
- DWCBGHNGQBPOOR-UHFFFAOYSA-N 4-(2-chloroethyl)pyridine;hydrochloride Chemical compound Cl.ClCCC1=CC=NC=C1 DWCBGHNGQBPOOR-UHFFFAOYSA-N 0.000 description 1
- QEIVWSRXBYOTAZ-UHFFFAOYSA-N 4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1CCN(CC1)C(=O)NC1=CC=CC=C1 QEIVWSRXBYOTAZ-UHFFFAOYSA-N 0.000 description 1
- HOWFLZVASJDZRZ-UHFFFAOYSA-N 4-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OCC1CCN(CC1)C(=O)NC1=CC=CC=C1 HOWFLZVASJDZRZ-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
- RXKNNAKAVAHBNK-UHFFFAOYSA-N 4-nitropyridine-n-oxide Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C=C1 RXKNNAKAVAHBNK-UHFFFAOYSA-N 0.000 description 1
- KLMKQKKMDYLMOF-UHFFFAOYSA-N 4-pyridin-4-ylbutan-2-amine Chemical compound CC(N)CCC1=CC=NC=C1 KLMKQKKMDYLMOF-UHFFFAOYSA-N 0.000 description 1
- FOFSNCRMWLKAIM-UHFFFAOYSA-N 5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-3,4-dihydro-1H-quinolin-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2CCC(NC2=CC=C1)=O FOFSNCRMWLKAIM-UHFFFAOYSA-N 0.000 description 1
- ZFYXJIYPIORSQE-UHFFFAOYSA-N 5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)pyridine-3-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=NC=C(C(=O)NCCS(=O)(=O)C)C=1 ZFYXJIYPIORSQE-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- RIMXEJYJXDBLIE-UHFFFAOYSA-N 6-bromohex-1-ene Chemical compound BrCCCCC=C RIMXEJYJXDBLIE-UHFFFAOYSA-N 0.000 description 1
- NRLQBVLOUUPAMI-UHFFFAOYSA-N 8-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2CCC3(CNC(O3)=O)CC2)C=CC=1 NRLQBVLOUUPAMI-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VFWCVFXSJJESEC-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N(C)CCN(C(=O)N(C1=CC=NC=C1)C)CCC1CCCCC1 Chemical compound C(C)(C)(C)OC(=O)N(C)CCN(C(=O)N(C1=CC=NC=C1)C)CCC1CCCCC1 VFWCVFXSJJESEC-UHFFFAOYSA-N 0.000 description 1
- PZGXZDLIBKDCTG-UHFFFAOYSA-N C12(CC3CC(CC(C1)C3)C2)CCN(C(=O)N(CCCC2=CC=NC=C2)C)C=2N=C(SC2)C Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C(=O)N(CCCC2=CC=NC=C2)C)C=2N=C(SC2)C PZGXZDLIBKDCTG-UHFFFAOYSA-N 0.000 description 1
- XMKQLIPOJDSLFJ-UHFFFAOYSA-N CCC(O)=O.NCCCC1=CC=NC=C1 Chemical compound CCC(O)=O.NCCCC1=CC=NC=C1 XMKQLIPOJDSLFJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- SMRSHVSLJBCRGB-UHFFFAOYSA-N Cl.C1(CCCCC1)CCN(C=1SC=CC1)C Chemical compound Cl.C1(CCCCC1)CCN(C=1SC=CC1)C SMRSHVSLJBCRGB-UHFFFAOYSA-N 0.000 description 1
- NPKSPVBVQWDMPI-UHFFFAOYSA-N Cl.C1(CCCCC1)N(CCC(C1=CC=C(C=C1)OC)C1=CC=CC=C1)C Chemical compound Cl.C1(CCCCC1)N(CCC(C1=CC=C(C=C1)OC)C1=CC=CC=C1)C NPKSPVBVQWDMPI-UHFFFAOYSA-N 0.000 description 1
- ADOSYLSZSYXXQB-UHFFFAOYSA-N Cl.C12(CC3CC(CC(C1)C3)C2)N(CC)CC Chemical compound Cl.C12(CC3CC(CC(C1)C3)C2)N(CC)CC ADOSYLSZSYXXQB-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- JDCLUYDBENDDSR-NSHDSACASA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-(5-methyl-1,3,4-oxadiazol-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1OC(=NN=1)C JDCLUYDBENDDSR-NSHDSACASA-N 0.000 description 1
- RWQJLIWMOBYOTI-AWEZNQCLSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyridin-3-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=CC=1 RWQJLIWMOBYOTI-AWEZNQCLSA-N 0.000 description 1
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- PKZVFOVXYKCBCJ-UHFFFAOYSA-N [2-(1H-indol-4-yloxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1C=CC2=C(C=CC=C12)OC1=NC(=CC(=C1)CN)C(F)(F)F PKZVFOVXYKCBCJ-UHFFFAOYSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- GXFIJNNOECYQOJ-UHFFFAOYSA-N [2-[1-(1-methylpyrazol-4-yl)indol-4-yl]oxy-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound CN1N=CC(=C1)N1C=CC2=C(C=CC=C12)OC1=NC(=CC(=C1)CN)C(F)(F)F GXFIJNNOECYQOJ-UHFFFAOYSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- BYWBCSRCPLBDFU-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)N BYWBCSRCPLBDFU-CYBMUJFWSA-N 0.000 description 1
- LJHFUFVRZNYVMK-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)O LJHFUFVRZNYVMK-CYBMUJFWSA-N 0.000 description 1
- LJHFUFVRZNYVMK-ZDUSSCGKSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3S)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H](CC1)O LJHFUFVRZNYVMK-ZDUSSCGKSA-N 0.000 description 1
- JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 description 1
- KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 description 1
- UGKIKJFPXNOHHA-UHFFFAOYSA-N [5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypyridin-3-yl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=NC=1)C(=O)N1CC(C(C1)O)F UGKIKJFPXNOHHA-UHFFFAOYSA-N 0.000 description 1
- IQUWAPNUQVLWGG-GFCCVEGCSA-N [5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypyridin-3-yl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=NC=1)C(=O)N1C[C@@H](CC1)N IQUWAPNUQVLWGG-GFCCVEGCSA-N 0.000 description 1
- OMDGZMWCRQKQGN-UHFFFAOYSA-O [Br+].C12(CC3CC(CC(C1)C3)C2)CCN(C(NCCCC2=CC=[N+](C=C2)CC2=CC=CC=C2)=O)CCNC(=O)OC(C)(C)C Chemical compound [Br+].C12(CC3CC(CC(C1)C3)C2)CCN(C(NCCCC2=CC=[N+](C=C2)CC2=CC=CC=C2)=O)CCNC(=O)OC(C)(C)C OMDGZMWCRQKQGN-UHFFFAOYSA-O 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- USWKATPWLBLYML-UHFFFAOYSA-N benzyl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)N(C)CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC1=CC=NC=C1 USWKATPWLBLYML-UHFFFAOYSA-N 0.000 description 1
- OMRHPKIWSOCTCB-UHFFFAOYSA-N benzyl n-[2-[2-(1-adamantyl)ethylamino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCNCCN(C)C(=O)OCC1=CC=CC=C1 OMRHPKIWSOCTCB-UHFFFAOYSA-N 0.000 description 1
- CZZDSAPKXPNKCE-UHFFFAOYSA-N benzyl n-methyl-n-[2-(2-phenylethylamino)ethyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N(C)CCNCCC1=CC=CC=C1 CZZDSAPKXPNKCE-UHFFFAOYSA-N 0.000 description 1
- YUHPYUXNKOLXCD-UHFFFAOYSA-N benzyl n-methyl-n-[2-(pentylamino)ethyl]carbamate Chemical compound CCCCCNCCN(C)C(=O)OCC1=CC=CC=C1 YUHPYUXNKOLXCD-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- NEEDEQSZOUAJMU-UHFFFAOYSA-N but-2-yn-1-ol Chemical compound CC#CCO NEEDEQSZOUAJMU-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- PJGJQVRXEUVAFT-UHFFFAOYSA-N chloroiodomethane Chemical compound ClCI PJGJQVRXEUVAFT-UHFFFAOYSA-N 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- GLBPQTCZGNDFFR-UHFFFAOYSA-N cyclohexyl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C1CCCCC1OC(=O)N(C)CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC1=CC=NC=C1 GLBPQTCZGNDFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UPQZOUHVTJNGFK-UHFFFAOYSA-N diethyl 2-methylpropanedioate Chemical compound CCOC(=O)C(C)C(=O)OCC UPQZOUHVTJNGFK-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- ZVHRTJHLSYKEAK-UHFFFAOYSA-N ethyl 2-[5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-2-oxo-3,4-dihydroquinolin-1-yl]acetate Chemical compound CCOC(=O)CN1C(=O)CCC2=C1C=CC=C2OC1=NC(=CC(CN)=C1)C(F)(F)F ZVHRTJHLSYKEAK-UHFFFAOYSA-N 0.000 description 1
- RJCGNNHKSNIUAT-UHFFFAOYSA-N ethyl 3-aminopropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCN RJCGNNHKSNIUAT-UHFFFAOYSA-N 0.000 description 1
- NRGYMGGQHJZHAU-UHFFFAOYSA-N ethyl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)OCC)C(=O)NCCCC1=CC=NC=C1 NRGYMGGQHJZHAU-UHFFFAOYSA-N 0.000 description 1
- CBJGDRDAVRKEIF-UHFFFAOYSA-N ethyl(pentyl)azanium;chloride Chemical compound Cl.CCCCCNCC CBJGDRDAVRKEIF-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GUBWPRKLOSREGY-UHFFFAOYSA-N methyl 2-[2-[2-(1-adamantyl)ethyl-pentylamino]-2-oxoethoxy]acetate Chemical compound C1C(C2)CC3CC2CC1(CCN(CCCCC)C(=O)COCC(=O)OC)C3 GUBWPRKLOSREGY-UHFFFAOYSA-N 0.000 description 1
- HSTKBCPHMFVYQK-UHFFFAOYSA-N methyl 3-(2-cyclohexylethylamino)propanoate;hydrochloride Chemical compound Cl.COC(=O)CCNCCC1CCCCC1 HSTKBCPHMFVYQK-UHFFFAOYSA-N 0.000 description 1
- FEIQEWJEXNBGIS-UHFFFAOYSA-N methyl 3-[2-cyclohexylethyl-[methyl(pyridin-4-yl)carbamoyl]amino]propanoate Chemical compound C1(CCCCC1)CCN(C(=O)N(C1=CC=NC=C1)C)CCC(=O)OC FEIQEWJEXNBGIS-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- RIEABXYBQSLTFR-UHFFFAOYSA-N monobutyrin Chemical compound CCCC(=O)OCC(O)CO RIEABXYBQSLTFR-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- QSAUUWRICILVIS-UHFFFAOYSA-N n'-(1-adamantyl)-n-propylethane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC3CC2CC1(NCCNCCC)C3 QSAUUWRICILVIS-UHFFFAOYSA-N 0.000 description 1
- HWVWEGOXLGPYDB-UHFFFAOYSA-N n'-pyridin-4-ylethane-1,2-diamine Chemical compound NCCNC1=CC=NC=C1 HWVWEGOXLGPYDB-UHFFFAOYSA-N 0.000 description 1
- LQWSJMQZDQMETG-UHFFFAOYSA-N n-(1-adamantyl)-2-(propylamino)acetamide Chemical compound C1C(C2)CC3CC2CC1(NC(=O)CNCCC)C3 LQWSJMQZDQMETG-UHFFFAOYSA-N 0.000 description 1
- RVAYVIPSSSQCDR-UHFFFAOYSA-N n-(2-cyclohexylethyl)-n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCNCCC1CCCCC1 RVAYVIPSSSQCDR-UHFFFAOYSA-N 0.000 description 1
- SIGIIXYMDHGVLA-UHFFFAOYSA-N n-(2-cyclohexylethyl)butan-1-amine;hydrochloride Chemical compound Cl.CCCCNCCC1CCCCC1 SIGIIXYMDHGVLA-UHFFFAOYSA-N 0.000 description 1
- GBJFFWZLTCKJAH-UHFFFAOYSA-N n-(2-cyclohexylethyl)pentan-1-amine;hydrochloride Chemical compound Cl.CCCCCNCCC1CCCCC1 GBJFFWZLTCKJAH-UHFFFAOYSA-N 0.000 description 1
- OSRHKMRCHOAGPY-UHFFFAOYSA-N n-(2-phenylethyl)pentan-1-amine;hydrochloride Chemical compound Cl.CCCCCNCCC1=CC=CC=C1 OSRHKMRCHOAGPY-UHFFFAOYSA-N 0.000 description 1
- ZDWHCOOBFAEJCB-UHFFFAOYSA-N n-(2-piperidin-1-ylethyl)pentan-1-amine Chemical compound CCCCCNCCN1CCCCC1 ZDWHCOOBFAEJCB-UHFFFAOYSA-N 0.000 description 1
- JIDSUZBXAPTDQT-UHFFFAOYSA-N n-(2-pyridin-2-ylethyl)pentan-1-amine Chemical compound CCCCCNCCC1=CC=CC=N1 JIDSUZBXAPTDQT-UHFFFAOYSA-N 0.000 description 1
- VAYQORMOEJCAQC-UHFFFAOYSA-N n-(3-phenylpropyl)pentan-1-amine;hydrochloride Chemical compound Cl.CCCCCNCCCC1=CC=CC=C1 VAYQORMOEJCAQC-UHFFFAOYSA-N 0.000 description 1
- FYRQQNZIWJPRRB-UHFFFAOYSA-N n-(3-pyridin-4-ylpropyl)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-2-carboxamide Chemical compound C1CC2CCCCC2CN1C(=O)NCCCC1=CC=NC=C1 FYRQQNZIWJPRRB-UHFFFAOYSA-N 0.000 description 1
- NXFMCSKACFCCGP-UHFFFAOYSA-N n-(3-pyridin-4-ylpropyl)-3,4-dihydro-1h-isoquinoline-2-carboxamide Chemical compound C1CC2=CC=CC=C2CN1C(=O)NCCCC1=CC=NC=C1 NXFMCSKACFCCGP-UHFFFAOYSA-N 0.000 description 1
- DQNIIZVZJLIDBK-UHFFFAOYSA-N n-(3-pyridin-4-ylpropyl)-3,6-dihydro-2h-pyridine-1-carboxamide Chemical compound C1CC=CCN1C(=O)NCCCC1=CC=NC=C1 DQNIIZVZJLIDBK-UHFFFAOYSA-N 0.000 description 1
- NQGPLLJEZQXPBC-UHFFFAOYSA-N n-(3-pyridin-4-ylpropyl)azepane-1-carboxamide Chemical compound C1CCCCCN1C(=O)NCCCC1=CC=NC=C1 NQGPLLJEZQXPBC-UHFFFAOYSA-N 0.000 description 1
- BWGSWRCQRACKBR-UHFFFAOYSA-N n-(3-pyridin-4-ylpropyl)morpholine-4-carboxamide Chemical compound C1COCCN1C(=O)NCCCC1=CC=NC=C1 BWGSWRCQRACKBR-UHFFFAOYSA-N 0.000 description 1
- UETJZLOJRIGDCO-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-2,2,2-trifluoroethanamine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCC(F)(F)F)C3 UETJZLOJRIGDCO-UHFFFAOYSA-N 0.000 description 1
- HNOPLXIJOMYWLP-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-2-methylprop-2-en-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCC(=C)C)C3 HNOPLXIJOMYWLP-UHFFFAOYSA-N 0.000 description 1
- WGBGZUMUKVCCSN-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-3,3,3-trifluoropropan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCCC(F)(F)F)C3 WGBGZUMUKVCCSN-UHFFFAOYSA-N 0.000 description 1
- AEGKZRYAVYNRQF-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-3-pyridin-4-ylpropan-1-amine Chemical compound C1C(C2)CC(C3)CC2CC13CCNCCCC1=CC=NC=C1 AEGKZRYAVYNRQF-UHFFFAOYSA-N 0.000 description 1
- RMGFRMIDJCTQML-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-4,4,4-trifluorobutan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCCCC(F)(F)F)C3 RMGFRMIDJCTQML-UHFFFAOYSA-N 0.000 description 1
- CWVCBWZEFZBYHM-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-5,5,5-trifluoropentan-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCCCCC(F)(F)F)C3 CWVCBWZEFZBYHM-UHFFFAOYSA-N 0.000 description 1
- WXGVVOZOHQDFAW-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-n',n'-dimethylethane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.C1C(C2)CC3CC2CC1(CCNCCN(C)C)C3 WXGVVOZOHQDFAW-UHFFFAOYSA-N 0.000 description 1
- ZFVUGGZMZILACZ-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]but-2-en-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCC=CC)C3 ZFVUGGZMZILACZ-UHFFFAOYSA-N 0.000 description 1
- KQIFBQUFGQCAHW-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]but-2-yn-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCC#CC)C3 KQIFBQUFGQCAHW-UHFFFAOYSA-N 0.000 description 1
- XJYFQILKUNRYRE-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]butan-1-amine Chemical compound C1C(C2)CC3CC2CC1(CCNCCCC)C3 XJYFQILKUNRYRE-UHFFFAOYSA-N 0.000 description 1
- SSSDOCRIAAEWAA-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]decan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCCCCCCCCCC)C3 SSSDOCRIAAEWAA-UHFFFAOYSA-N 0.000 description 1
- UNTIWBXRPBRLJC-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]hexan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCCCCCC)C3 UNTIWBXRPBRLJC-UHFFFAOYSA-N 0.000 description 1
- LDJQCFQDVKXAEJ-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]propan-2-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNC(C)C)C3 LDJQCFQDVKXAEJ-UHFFFAOYSA-N 0.000 description 1
- OMBFJXPQSCSBGM-UHFFFAOYSA-N n-[2-(1-adamantyloxy)ethyl]propan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(OCCNCCC)C3 OMBFJXPQSCSBGM-UHFFFAOYSA-N 0.000 description 1
- AAIFNJQLLMRNDS-UHFFFAOYSA-N n-[2-(1h-imidazol-5-yl)ethyl]-3-methylbutan-1-amine;dihydrochloride Chemical compound Cl.Cl.CC(C)CCNCCC1=CN=CN1 AAIFNJQLLMRNDS-UHFFFAOYSA-N 0.000 description 1
- CDEMNRGJMIWVIH-UHFFFAOYSA-N n-[2-(3,4,5-trimethoxyphenyl)ethyl]cyclopropanamine Chemical compound COC1=C(OC)C(OC)=CC(CCNC2CC2)=C1 CDEMNRGJMIWVIH-UHFFFAOYSA-N 0.000 description 1
- QYUUWFKPJWELGD-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]cyclohexanamine Chemical compound C1=C(OC)C(OC)=CC=C1CCNC1CCCCC1 QYUUWFKPJWELGD-UHFFFAOYSA-N 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- CLCGLDBXZNIGSN-UHFFFAOYSA-N n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n,3,3-trimethylbutanamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)CC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 CLCGLDBXZNIGSN-UHFFFAOYSA-N 0.000 description 1
- BIWPVAVPOFRFHM-UHFFFAOYSA-N n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylacetamide Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(C)=O)C(=O)NCCCC1=CC=NC=C1 BIWPVAVPOFRFHM-UHFFFAOYSA-N 0.000 description 1
- DORFVAAVSNFDLL-UHFFFAOYSA-N n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylpyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)N(C)CCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC1=CC=NC=C1 DORFVAAVSNFDLL-UHFFFAOYSA-N 0.000 description 1
- RSIJQHRUXHKITN-UHFFFAOYSA-N n-[2-[2-(1-adamantyl)ethylamino]ethyl]acetamide;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCNCCNC(=O)C)C3 RSIJQHRUXHKITN-UHFFFAOYSA-N 0.000 description 1
- QRGMHLNCNMTOOO-UHFFFAOYSA-N n-[3-(1-adamantyl)propyl]butan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCCNCCCC)C3 QRGMHLNCNMTOOO-UHFFFAOYSA-N 0.000 description 1
- FZAADKUAINUUOF-UHFFFAOYSA-N n-[3-(1-adamantyl)propyl]pentan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(CCCNCCCCC)C3 FZAADKUAINUUOF-UHFFFAOYSA-N 0.000 description 1
- LILMKEPBJGENKO-UHFFFAOYSA-N n-benzhydryl-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1CCCNC(C=1C=CC=CC=1)C1=CC=CC=C1 LILMKEPBJGENKO-UHFFFAOYSA-N 0.000 description 1
- LIBBCZOPAZDNJW-UHFFFAOYSA-N n-ethyl-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound CCNCCC1=CC(OC)=C(OC)C(OC)=C1 LIBBCZOPAZDNJW-UHFFFAOYSA-N 0.000 description 1
- VOQWUDQCRSPLKH-UHFFFAOYSA-N n-ethyl-n-prop-2-ynyladamantan-1-amine Chemical compound C1C(C2)CC3CC2CC1(N(CC#C)CC)C3 VOQWUDQCRSPLKH-UHFFFAOYSA-N 0.000 description 1
- RFDSGAGBPXOEEY-UHFFFAOYSA-N n-hex-5-enylhex-5-en-1-amine Chemical compound C=CCCCCNCCCCC=C RFDSGAGBPXOEEY-UHFFFAOYSA-N 0.000 description 1
- ZHIAZZWWYFQHPQ-UHFFFAOYSA-N n-methyl-n-pentyladamantan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(N(C)CCCCC)C3 ZHIAZZWWYFQHPQ-UHFFFAOYSA-N 0.000 description 1
- NBUOVUWCFITPSC-UHFFFAOYSA-N n-methyl-n-propyladamantan-1-amine;hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(N(C)CCC)C3 NBUOVUWCFITPSC-UHFFFAOYSA-N 0.000 description 1
- JMPVLYWTCOEOAE-UHFFFAOYSA-N n-oct-7-enyloct-7-en-1-amine Chemical compound C=CCCCCCCNCCCCCCC=C JMPVLYWTCOEOAE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- NSTHNVMITOXEJZ-TYYBGVCCSA-N oxalic acid;(e)-3-pyridin-4-ylprop-2-enal Chemical compound OC(=O)C(O)=O.O=C\C=C\C1=CC=NC=C1 NSTHNVMITOXEJZ-TYYBGVCCSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- TZIVSUDXCZJINE-UHFFFAOYSA-N propan-2-yl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(C)C(=O)OC(C)C)C(=O)NCCCC1=CC=NC=C1 TZIVSUDXCZJINE-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- UXNNIWVXHVNJGO-DARVDTQBSA-N tert-butyl (2R)-3-[2-(1-adamantyl)ethyl-pentylamino]-2-amino-3-oxo-2-(2-pyridin-4-ylethylsulfanylmethyl)propanoate Chemical compound C12(CC3CC(CC(C1)C3)C2)CCN(C([C@](CSCCC1=CC=NC=C1)(C(=O)OC(C)(C)C)N)=O)CCCCC UXNNIWVXHVNJGO-DARVDTQBSA-N 0.000 description 1
- LEXHPTPLTHJCKK-SQGNYKRJSA-N tert-butyl (2r)-2-[2-(1-adamantyl)ethyl-pentylcarbamoyl]pyrrolidine-1-carboxylate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)[C@H]1CCCN1C(=O)OC(C)(C)C LEXHPTPLTHJCKK-SQGNYKRJSA-N 0.000 description 1
- TYILMRSTAZBPAI-UHFFFAOYSA-N tert-butyl 3-[2-cyclohexylethyl-[methyl(pyridin-4-yl)carbamoyl]amino]propanoate Chemical compound C(C)(C)(C)OC(=O)CCN(C(=O)N(C1=CC=NC=C1)C)CCC1CCCCC1 TYILMRSTAZBPAI-UHFFFAOYSA-N 0.000 description 1
- HONNWTDYWUAZJF-UHFFFAOYSA-N tert-butyl 4-[2-[4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyindol-1-yl]acetyl]piperazine-1-carboxylate Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2C=CN(C2=CC=C1)CC(=O)N1CCN(CC1)C(=O)OC(C)(C)C HONNWTDYWUAZJF-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UIXHGPFDWNFBOG-UHFFFAOYSA-N tert-butyl n-(2-pyridin-4-yloxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCOC1=CC=NC=C1 UIXHGPFDWNFBOG-UHFFFAOYSA-N 0.000 description 1
- HFSAXDLSTDMFTC-UHFFFAOYSA-N tert-butyl n-[2-(1-adamantyl)ethylamino]carbamate Chemical compound C1C(C2)CC3CC2CC1(CCNNC(=O)OC(C)(C)C)C3 HFSAXDLSTDMFTC-UHFFFAOYSA-N 0.000 description 1
- GOCKANRSHLSOEC-UHFFFAOYSA-N tert-butyl n-[2-(2-cyclohexylethylamino)ethyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CCNCCC1CCCCC1 GOCKANRSHLSOEC-UHFFFAOYSA-N 0.000 description 1
- HETDGCBMZOYWJO-UHFFFAOYSA-N tert-butyl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]-n-ethylcarbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCN(CC)C(=O)OC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 HETDGCBMZOYWJO-UHFFFAOYSA-N 0.000 description 1
- JSJROSBIFNFPRJ-UHFFFAOYSA-N tert-butyl n-[2-[2-(1-adamantyl)ethyl-(3-pyridin-4-ylpropylcarbamoyl)amino]ethyl]carbamate Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCNC(=O)OC(C)(C)C)C(=O)NCCCC1=CC=NC=C1 JSJROSBIFNFPRJ-UHFFFAOYSA-N 0.000 description 1
- NIPDQJPBXRAJPW-UHFFFAOYSA-N tert-butyl n-[2-[2-(1-adamantyl)ethylamino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC3CC2CC1(CCNCCN(C)C(=O)OC(C)(C)C)C3 NIPDQJPBXRAJPW-UHFFFAOYSA-N 0.000 description 1
- QPYBUGNGRZGZAH-UHFFFAOYSA-N tert-butyl n-[2-[3-(1-adamantyl)propylamino]ethyl]-n-methylcarbamate Chemical compound C1C(C2)CC3CC2CC1(CCCNCCN(C)C(=O)OC(C)(C)C)C3 QPYBUGNGRZGZAH-UHFFFAOYSA-N 0.000 description 1
- MEHBFBZIYWSMDC-UHFFFAOYSA-N tert-butyl n-[3-[2-(1-adamantyl)ethylamino]propyl]-n-methylcarbamate Chemical compound C1C(C2)CC3CC2CC1(CCNCCCN(C)C(=O)OC(C)(C)C)C3 MEHBFBZIYWSMDC-UHFFFAOYSA-N 0.000 description 1
- BQPYGOQXOSDHQG-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(2-phenylethylamino)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CCNCCC1=CC=CC=C1 BQPYGOQXOSDHQG-UHFFFAOYSA-N 0.000 description 1
- NMTCQKYDRKUAIR-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(pentylamino)ethyl]carbamate Chemical compound CCCCCNCCN(C)C(=O)OC(C)(C)C NMTCQKYDRKUAIR-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical group C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- 125000005389 trialkylsiloxy group Chemical group 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- FYNLSLAIBHJATR-UHFFFAOYSA-M triphenyl(phenylmethoxycarbonyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 FYNLSLAIBHJATR-UHFFFAOYSA-M 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Description
【0001】
【発明の属する技術分野】
本発明は、新規なウレア化合物を有効成分として含む血管新生阻害剤に関し、特に眼疾患および癌疾患に有用な薬物に関するものである。
【0002】
【従来の技術】
血管の恒常性は内皮細胞の有する多様な機能によって保たれている。血管内皮細胞は、1)血液中の栄養物などの必要な成分を組織へ輸送する仲介をし、不必要に多量の成分が通過することを防ぐ作用、2)血液が凝固しないで円滑に循環させる作用、3)血管が離断したときに出血を阻止する作用、および4)血管の緊張を一定に保つ調節作用を有している。
【0003】
血管内皮細胞によって産生されたプロテアーゼによる基底膜の分解、血管内皮細胞の遊走・増殖、血管内皮細胞の管腔形成、基底膜の形成と周皮細胞の取り囲みという段階で血管新生が生じる。血管新生は種々の疾患、特に糖尿病性網膜症、未熟児網膜症、黄斑変性症、血管新生緑内障、網膜静脈閉塞症、網膜動脈閉塞症、翼状片、ルベオーシス、角膜新生血管症、固形腫瘍、血管腫、腫瘍の増殖・転移などと密接なつながりがある。血管新生はさまざまな増殖因子やサイトカイン、アラキドン酸代謝物、モノブチリンなどによって引き起こされると考えられている。これらの中でも増殖因子はもっとも重要な血管新生因子と考えられている(非特許文献1参照)。
【0004】
【非特許文献1】
医学のあゆみ,170, 536-539 (1994)。
【0005】
【発明が解決しようとする課題】
このように、糖尿病性網膜症、未熟児網膜症、黄斑変性症、血管新生緑内障、網膜静脈閉塞症、網膜動脈閉塞症、翼状片、ルベオーシス、角膜新生血管症、固形腫瘍、血管腫、腫瘍の増殖・転移などの治療剤として有用な血管新生阻害作用を有する化合物を探索することは意義深い。
【0006】
【課題を解決するための手段】
本発明者等は、種々の化学構造を有する化合物を創製して、ヒト血管内皮細胞を用いた血管新生阻害試験および高酸素負荷誘発網膜血管新生法による血管新生阻害試験を実施した結果、下記一般式[1]で表される構造を有する新規なウレア化合物は、上記in vitroおよびin vivoのいずれの試験においても優れた血管新生阻害作用を有し、血管新生が関与する疾患、特に糖尿病性網膜症、未熟児網膜症、黄斑変性症、血管新生緑内障、網膜静脈閉塞症、網膜動脈閉塞症、翼状片、ルベオーシス、角膜新生血管症等の眼疾患および固形腫瘍、血管腫、腫瘍の増殖・転移等の癌疾患の治療剤として有用であることを見出し、本発明を完成するに至った。
【0007】
本発明は、下記一般式[1]で示される化合物またはその塩類(以下特記なき限り「本化合物」とする)を有効成分として含む血管新生阻害剤に関するものである。
【0008】
【化6】
[式中、Aは−(NR4)−または−(CR5R6)−を示し;
Bは鎖中に、−O−または−S−を含有してもよいアルキレン基を示し;
R1 はアルキル基を示し、該アルキル基は、ハロゲン原子、ヒドロキシ基、アミノ基、シクロアルキル基、アダマンチル基、アリール基、カルボキシル基、アルコキシカルボニル基、アリールオキシカルボニル基、アミノカルボニル基、シアノ基または飽和若しくは不飽和の複素環で置換されていてもよく;上記された各アミノ基、ヒドロキシ基およびアミノカルボニル基の水素原子はアルキル基、シクロアルキル基、アリール基、アリールアルキル基、アシル基、アルコキシカルボニル基、シクロアルキルオキシカルボニル基、アリールアルコキシカルボニル基、ハロゲノアルキルオキシカルボニル基、イミダゾリルカルボニル基、不飽和の複素環または不飽和の複素環が置換したアルキル基で置換されていてもよく;
R 2 は、アダマンチルアルキル基またはシクロアルキルアルキル基を示し;
R3はピリジン環を示し;
R 4 、R 5 およびR 6 は、同一または異なって水素原子またはアルキル基を示し;
XはOを示す。以下同じ。]
【0009】
本化合物は、優れた血管新生阻害作用を有するので、糖尿病性網膜症、未熟児網膜症、黄斑変性症、血管新生緑内障、網膜静脈閉塞症、網膜動脈閉塞症、翼状片、ルベオーシス、角膜新生血管症、固形腫瘍、血管腫、腫瘍の増殖・転移などの血管新生を伴う疾患の治療剤の有効成分として作用する。
【0010】
【発明の実施の形態】
一般式[1]で規定された各基について詳しく説明する。
【0011】
アルキレン基とはメチレン基、エチレン基、トリメチレン基、プロピレン基、テトラメチレン基、ペンタメチレン基、ヘキサメチレン基、オクタメチレン基、デカメチレン基、ドデカメチレン基、メチルメチレン基、エチルエチレン基、ジメチルエチレン基、プロピルエチレン基、イソプロピルエチレン基、メチルトリメチレン基等の1〜12個の炭素原子を有する直鎖または分枝のアルキレン基を示す。
【0012】
アルケニレン基とは、ビニレン基、プロペニレン基、ブテニレン基、ペンテニレン基、ヘキセニレン基、オクテニレン基、ブタンジイリデン基、メチルプロペニレン基等の1個以上の二重結合を有し、2〜12個の炭素原子を有する直鎖または分枝のアルケニレン基を示す。
【0013】
アルキル基とはメチル基、エチル基、プロピル基、ブチル基、ヘキシル基、オクチル基、デシル基、ドデシル基、イソプロピル基、イソブチル基、イソペンチル基、イソヘキシル基、イソオクチル基、t-ブチル基、3,3−ジメチルブチル基等の1〜12個の炭素原子を有する直鎖または分枝のアルキル基を示す。
【0014】
アルコキシ基とはメトキシ基、エトキシ基、プロポキシ基、ブトキシ基、ヘキシルオキシ基、オクチルオキシ基、デシルオキシ基、ドデシルオキシ基、イソプロポキシ基、t-ブトキシ基等の1〜12個の炭素原子を有する直鎖または分枝のアルコキシ基を示す。
【0015】
アルケニル基とはビニル基、アリル基、3−ブテニル基、5−ヘキセニル基、イソプロペニル基等の2〜12個の炭素原子を有する直鎖または分枝のアルケニル基を示す。
【0016】
アルキニル基とは、エチニル基、プロピニル基、ブチニル基等の2〜12個の炭素原子を有する直鎖または分枝のアルキニル基を示す。
【0017】
シクロアルキル基とはシクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基、シクロヘプチル基、シクロオクチル基、シクロデシル基、シクロドデシル基等の3〜20個の炭素原子を有するシクロアルキル基を示す。
【0018】
シクロアルケニル基とはシクロペンテニル基、シクロヘキセニル基、シクロヘプテニル基等の5〜20個の炭素原子を有するシクロアルケニル基を示す。
【0019】
アリール基とはフェニル基、ナフチル基等の芳香族炭化水素環を示し、それらは1個以上の置換基を有してもよく、置換基としては、例えばアルキル基、シクロアルキル基、カルボキシ基、アミノ基、ヒドロキシ基、アミノアルキル基、ヒドロキシアルキル基、ニトロ基、シアノ基、ハロゲン原子、アルキルオキシ基などが挙げられる。
【0020】
シロキシ基とは、トリアルキルシリルオキシ基、ジアルキル(アリール)シリルオキシ基、アルキル(ジアリール)オキシ基、トリアリールシリルオキシ基などの珪素含有有機基を示す。
【0021】
ハロゲン原子とはフッ素、塩素、臭素、ヨウ素を示す。
【0022】
複素環とは、例えば窒素原子、酸素原子、硫黄原子を1〜4個を含む5〜20員環の飽和若しくは不飽和の単環式複素環または2環式複素環を示し、これらの複素環は、1個以上の置換基を有してもよく、その置換基としては、例えばアルキル基、シクロアルキル基、カルボキシ基、アミノ基、ヒドロキシ基、アミノアルキル基、ヒドロキシアルキル基、ニトロ基、シアノ基、ハロゲン原子、アルキルオキシ基、アリール基、アリールアルキル基、飽和若しくは不飽和の複素環などが挙げられる。また上記の複素環が環内に窒素原子または硫黄原子を有するとき、それらの原子が酸化され、N−オキシド、S−オキシドなどの形になっていてもよい。
【0023】
飽和の複素環の具体例としては、窒素原子を環内に有するピロリジン、ピペリジン、ホモピペリジン、ピペラジン、窒素原子と酸素原子を環内に有するモルホリン、窒素原子と硫黄原子を環内に有するチオモルホリンなどの単環式複素環が挙げられ、それらはベンゼン環等と縮合してテトラヒドロキノリン、テトラヒドロイソキノリンなどの2環式複素環を形成してもよい。
【0024】
不飽和の複素環の具体例としては、窒素原子を環内に有するピロール、ピリジン、ピラゾール、イミダゾール、ピラジン、ピリダジン、ピリミジンなどの単環式複素環またはインドール、キノリン、イソキノリン、ベンズイミダゾール、ナフチリジン、ピロロピリジン、イミダゾピリジンなどの2環式複素環、酸素原子を環内に有するフランなどの単環式複素環またはベンゾフランなどの2環式複素環、硫黄原子を環内に有するチオフェンなどの単環式複素環またはベンゾチオフェンなどの2環式複素環、窒素原子と酸素原子若しくは硫黄原子を環内に有するオキサゾール、イソオキサゾール、チアゾール、イソチアゾールなどの単環式複素環またはベンゾオキサゾール、ベンゾチアゾール、チエノピリジン、オキサゾロピリジン、チアゾロピリジン、フロピリジンなどの2環式複素環などが挙げられる。さらに、上記の不飽和複素環は部分的に飽和結合を含む形であってもよい。
【0025】
本発明における塩類とは医薬として許容される塩であれば特に制限はなく、塩酸、硝酸、硫酸、リン酸等の無機酸との塩、酢酸、フマル酸、マレイン酸、コハク酸、酒石酸等の有機酸との塩、また、ナトリウム、カリウム、カルシウム等のアルカリ金属またはアルカリ土類金属との塩などが挙げられる。また、本化合物の第四級アンモニウム塩も本発明における塩類に包含される。さらに、本化合物に幾何異性体または光学異性体が存在する場合には、それらの異性体も本発明の範囲に含まれる。なお、本化合物は水和物および溶媒和物の形態をとっていてもよい。
【0026】
本発明の好ましい例としては、下記(1)〜(3)のものが挙げられる。
【0027】
(1)一般式[1]で規定された各基が以下の基から選択され、またはそれらの組み合わせからなる化合物またはその塩類
1) R3:ピリジン環。
【0028】
2) R1、R2、R4、R5およびR6のうちの少なくとも1つ:アダマンチルアルキル基、アダマンチルオキシアルキル基、アダマンチルアミノアルキル基またはアダマンチルアミノカルボニルアルキル基。
【0029】
3) R1およびR2のうちの少なくとも1つ:アダマンチルアルキル基、アダマンチルオキシアルキル基、アダマンチルアミノアルキル基またはアダマンチルアミノカルボニルアルキル基。
【0030】
4) R1およびR2のうちの少なくとも1つ:アダマンチルアルキル基。
【0031】
(2)一般式[1]で規定された各基が以下の基からなる化合物またはその塩類A:−(NR4)−、−(CR5R6)−または−O−、
B:鎖中に、−O−、−S−、−(NR7)−、−CO−、−N=
若しくは
【化8】
を含有してもよいアルキレン基またはアルケニレン基であって、該アルキレン基はヒドロキシ基、アルコキシ基、アリール基、シロキシ基または飽和若しくは不飽和の複素環で置換されていてもよく、Aと結合して飽和の複素環を形成してもよい、
R1:水素原子、アルキル基、アルケニル基、アルキニル基、シクロアルキル基、シクロアルケニル基、ヒドロキシ基またはアミノ基であって、該アルキル基、アルケニル基、アルキニル基、シクロアルキル基またはシクロアルケニル基は、ハロゲン原子、ヒドロキシ基、アミノ基、シクロアルキル基、アリール基、カルボキシル基、アルコキシカルボニル基、アルキルアミノカルボニル基、アダマンチル基、アリールオキシカルボニル基、シアノ基または飽和若しくは不飽和の複素環で置換されていてもよく、R1中の各アミノ基、ヒドロキシ基およびアミノカルボニル基の水素原子はアルキル基、シクロアルキル基、アリール基、アリールアルキル基、アシル基、アルコキシカルボニル基、シクロアルキルオキシカルボニル基、アリールアルコキシカルボニル基、ハロゲノアルキルオキシカルボニル基、イミダゾリルカルボニル基、不飽和の複素環または不飽和の複素環で置換されたアルキル基で置換されていてもよい、
R2:アダマンチルアルキル基、アダマンチルオキシアルキル基、アダマンチルアミノアルキル基またはアダマンチルアミノカルボニルアルキル基、
R3:不飽和の複素環、
R4:水素原子、アルキル基、アダマンチルアルキル基、カルボキシアルキル基、アルコキシカルボニル基、アルコキシカルボニルアルキル基、アミノ基、アルキルアミノ基、アシルアミノ基またはアルコキシカルボニルアミノ基、
R5およびR6:同一または異なって水素原子、アルキル基、アミノ基またはアルコキシカルボニルアミノ基、
R7:水素原子またはアルキル基、
X:=Oまたは=S、
n:1〜5の整数。
【0032】
これらのうち、R2がアダマンチルアルキル基であって、R3がピリジン環であるものがより好ましい。
【0033】
さらに、一般式[1]で規定された各基が以下の基からなる化合物またはその塩類が特に好ましい。
【0034】
A:−(NR4)−、−(CR5R6)−または−O−、
B:鎖中に−S−若しくは
【化9】
を含有してもよいアルキレン基またはアルケニレン基、
R1:アルキル基またはアルケニル基であって、該アルキル基はハロゲン原子またはアミノ基で置換されていてもよく、さらに該アミノ基はアルキル基、アシル基、アリールアルキルオキシカルボニル基、シクロアルキルオキシカルボニル基またはアルコキシカルボニル基で置換されていてもよい、
R2:アダマンチルアルキル基、
R3:ピリジン環、
R4:水素原子、
R5およびR6:水素原子、
X:=O、
n:1〜5の整数。
【0035】
(3)一般式[1]で規定された各基が以下の基からなる化合物またはその塩類A:−(NR4)−、−(CR5R6)−または−O−、
B:鎖中に、−O−、−S−、−(NR7)−、−N=若しくは
【化10】
を含有してもよいアルキレン基またはアルケニレン基であって、該アルキレン基はヒドロキシ基、アルコキシ基、アリール基または飽和若しくは不飽和の複素環で置換されていてもよく、Aと結合して飽和の複素環を形成してもよい、
R1:水素原子、アルキル基、アルケニル基、アルキニル基、シクロアルキル基、シクロアルケニル基、ヒドロキシ基またはアミノ基であって、該アルキル基、アルケニル基、アルキニル基、シクロアルキル基またはシクロアルケニル基は、ハロゲン原子、ヒドロキシ基、アミノ基、シクロアルキル基、アリール基、カルボキシル基、アルコキシカルボニル基、アリールオキシカルボニル基、アミノカルボニル基、シアノ基または飽和若しくは不飽和の複素環で置換されていてもよく、R1の各アミノ基、ヒドロキシ基およびアミノカルボニル基の水素原子はアルキル基、シクロアルキル基、アリール基、アリールアルキル基、アシル基、アルコキシカルボニル基、シクロアルキルオキシカルボニル基、アリールアルコキシカルボニル基、不飽和の複素環または不飽和の複素環で置換されたアルキル基で置換されていてもよい、
R2:アルキル基、アルケニル基、シクロアルキル基、シクロアルキルアルキル基またはアリールアルキル基、
R3:ピリジン環、
R4:水素原子、アルキル基、アダマンチルアルキル基、カルボキシアルキル基、アルコキシカルボニルアルキル基、アミノ基、アルキルアミノ基、アシルアミノ基またはアルコキシカルボニルアミノ基、
R5およびR6:同一または異なって水素原子またはアルキル基、
R7:水素原子またはアルキル基、
X:=Oまたは=S、
n:1〜5の整数。
【0036】
これらのうち、一般式[1]で規定された各基が以下の基からなる化合物またはその塩類がより好ましい。
【0037】
A:−(NR4)−または−(CR5R6)−、
B:アルキレン基またはアルケニレン基、
R1:アルキル基、アルケニル基であって、該アルキル基はハロゲン原子、アミノ基、シクロアルキル基、アリール基、イミダゾール基またはピリジン環で置換されていてもよく、さらに該アミノ基はアルキル基、アシル基、アルコキシカルボニル基、シクロアルキルオキシカルボニル基またはアリールアルコキシカルボニル基で置換されていてもよい、
R2:アルキル基、アルケニル基またはアリールアルキル基、
R3:ピリジン環、
R4:水素原子、
R5およびR6:水素原子、
X:=O。
【0038】
さらに、これらのうち、R1が炭素数3以上のアルキル基であって、R2がアルキル基またはアリールアルキル基であるものが特に好ましい。
【0039】
また、一般式[1]で規定された各基が以下の基からなる化合物またはその塩類がより好ましい。
【0040】
A:−(NR4)−または−(CR5R6)−、
B:アルキレン基またはアルケニレン基、
R1:アルキル基、アルケニル基またはシクロアルキル基であって、該アルキル基はハロゲン原子、ヒドロキシ基、アミノ基、シクロアルキル基、アリール基、カルボキシル基、アルコキシカルボニル基、アリールオキシカルボニル基、アミノカルボニル基、ピリジン環またはチオフェン環で置換されていてもよく、さらにR1中の各アミノ基、ヒドロキシ基およびアミノカルボニル基の水素原子はアルキル基、アリール基、アリールアルキル基、アシル基、アルコキシカルボニル基、シクロアルキルオキシカルボニル基、アリールアルコキシカルボニル基で置換されていてもよい、
R2:シクロアルキル基またはシクロアルキルアルキル基、
R3:ピリジン環、
R4:水素原子、
R5およびR6:水素原子、
X:=O。
【0041】
本化合物の最も好ましい具体例として、下記化合物およびその塩類が挙げられる。
【0042】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア
【化11】
【0043】
○、1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(3,3,3−トリフルオロプロピル)ウレア
【化12】
【0044】
○1−[2−(1−アダマンチル)エチル]−1−(2−ブテニル)−3−[3−(4−ピリジル)プロピル]ウレア
【化13】
【0045】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア
【化14】
【0046】
○1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア
【化15】
【0047】
○(Z)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア
【化16】
【0048】
○(−)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア
【化17】
【0049】
○1−[2−(1−アダマンチル)エチル]−3−[1−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア
【化18】
【0050】
○(+)−1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア
【化19】
【0051】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド
【化20】
【0052】
○3−(4−ピリジルメチルチオ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド
【化21】
【0053】
○2−[2−(4−ピリジル)エチルチオ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド
【化22】
【0054】
○6−(4−ピリジル)カプロン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド
【化23】
【0055】
○cis−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジル)シクロプロピルメチル]ウレア
【化24】
【0056】
○1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア
【化25】
【0057】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア
【化26】
【0058】
○(E)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア
【化27】
【0059】
○(+)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア
【化28】
【0060】
○1,1−ジブチル−3−[3−(4−ピリジル)プロピル]ウレア
【化29】
【0061】
○3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチル−1−フェネチルウレア
【化30】
【0062】
○5−(4−ピリジル)吉草酸 N−ペンチル−N−フェネチルアミド
【化31】
【0063】
○1−(2−シクロヘキシルエチル)−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア
【化32】
【0064】
つぎに、本化合物は例えば下記反応経路1〜3に従って製造できるが、これらの反応経路に限らず種々の反応経路によっても製造できる。なお、詳細な合成方法は後述の実施例で説明する。
【0065】
反応経路1
【化33】
【0066】
アミド体(A)を還元することにより、また第1アミン(B)と脱離基を有する化合物(C)を反応させることにより、第2アミン(D)を得ることができる(なお、上記化学反応式においてR1とR2を入れ替えて合成することができる。)。同様に脱離基を有する化合物(E)と第1アミン(F)を反応させることにより第2アミン(G)を得ることができる。第1アミン(B)あるいは第2アミン(D)と、第1アミン(F)あるいは第2アミン(G)を縮合剤(H)[例えば1,1’−カルボニルジイミダゾール]の存在下で反応させれば、本化合物[2]が得られる。
【0067】
反応経路2
【化34】
【0068】
第1アミン(B)あるいは反応経路1で合成した第2アミン(D)とカルボン酸(I)を縮合剤[例えば1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩]の存在下で反応させれば、本化合物[3]が得られる。
【0069】
反応経路3
【化35】
【0070】
第1アミン(B)あるいは反応経路1で合成した第2アミン(D)とアルコール体(J)を縮合剤(K)[例えば炭酸N,N’−ジスクシンイミジルエステル]の存在下で反応させれば、本化合物[4]が得られる。
【0071】
上記合成方法において、反応物質が分子内にチオール基、ヒドロキシ基またはアミノ基を有する場合、それらの基は必要に応じて適当な保護基で保護しておいてもよく、またそれらの保護基は反応後常法により除去することもできる。また、反応物質が分子内にカルボキシル基を有する場合、カルボキシル基は必要に応じてエステル化してもよく、またエステルは加水分解その他の一般的な方法でカルボン酸にすることもできる。
【0072】
上記の合成方法によって得られた化合物は、常法により前述の様な塩類とすることができる。
【0073】
上記合成方法によって得られた本化合物の有用性を調べるべく、血管新生阻害試験を実施した。詳細については後述の薬理試験の項で示すが、本化合物は、血管新生評価モデルであるin vitroのヒト血管内皮細胞を用いた血管新生およびin vivo の高酸素負荷誘発の網膜血管新生のいずれに対しても強い阻害作用を示すことを見出した。本化合物は、血管新生阻害剤および血管新生が関与する疾患、特に、糖尿病性網膜症、未熟児網膜症、黄斑変性症、血管新生緑内障、網膜静脈閉塞症、網膜動脈閉塞症、翼状片、ルベオーシス、角膜新生血管症、固形腫瘍、血管腫、腫瘍の増殖・転移などの予防剤、治療剤および抑制剤として有用である。
【0074】
本化合物の投与は非経口でも経口でも行うことができる。投与剤型としては、点眼剤、眼軟膏、結膜下注射剤等の眼組織注射剤、結膜デポ型製剤、埋め込み型製剤、結膜嚢内挿入剤、静脈注射剤、錠剤、カプセル剤、散剤、顆粒剤、経皮吸収剤等が挙げられ、これらはDDS製剤を含めて公知の技術を用いて調製することができる。例えば、点眼剤は、添加物として、等張化剤、緩衝剤、pH調節剤、可溶化剤、増粘剤、安定化剤、保存剤、無痛化剤等を適宜配合することにより調製することができる。また、pH調節剤、増粘剤、分散剤などを添加し、薬物を懸濁化させることによって、安定な点眼液を得ることもできる。点眼剤のpHは4.0〜8.0に設定することが望ましく、また、浸透圧比は1.0付近に設定することが望ましい。
【0075】
等張化剤としては、例えばグリセリン、プロピレングリコール、塩化ナトリウム、塩化カリウム、ソルビトール、マンニトール等を挙げることができる。
【0076】
緩衝剤としては例えば、リン酸、リン酸塩、クエン酸、酢酸、ε-アミノカプロン酸、トロメタモール等を挙げることができる。
【0077】
pH調節剤としては、例えば塩酸、クエン酸、リン酸、酢酸、水酸化ナトリウム、水酸化カリウム、炭酸ナトリウム、炭酸水素ナトリウム等を挙げることができる。
【0078】
可溶化剤、分散剤としては、例えばポリソルベート80、ポリオキシエチレン硬化ヒマシ油60、マクロゴール4000、精製大豆レシチン、ポリオキシエチレン(160)ポリオキシプロピレン(30)グリコール等を挙げることができる。
【0079】
増粘剤としては、例えばヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロースなどのセルロース系高分子、ポリビニルアルコール、ポリビニルピロリドン等を、また、安定化剤としては、例えばエデト酸、エデト酸ナトリウム等を挙げることができる。
【0080】
保存剤(防腐剤)としては、汎用のソルビン酸、ソルビン酸カリウム、塩化ベンザルコニウム、塩化ベンゼトニウム、パラオキシ安息香酸メチル、パラオキシ安息香酸プロピル、クロロブタノール等が挙げられ、これらの保存剤を組み合わせて使用することもできる。
【0081】
無痛化剤としてはクロロブタノール、ベンジルアルコール、リドカインなどを挙げることができる。
【0082】
本化合物の投与量は症状、年齢、剤型等によって適宜選択できるが、例えば点眼剤であれば通常0.001%〜10%(w/v)、好ましくは0.01〜5%(w/v)の濃度のものを1日1回乃至数回投与すればよい。
【0083】
以下に、中間体の製造例、本化合物の製造例、製剤例および薬理試験の結果を示すが、これらの例は本発明をよりよく理解するためのものであり、本発明の範囲を限定するものではない。
【0084】
【実施例】
[A]中間体の製造例
中間体製造例1
○2−(1−アダマンチル)−N−ペンチルエチルアミン 塩酸塩(中間体1−1)
メタンスルホン酸 2−(1−アダマンチル)エチルエステル(2.07g,8.01mmol)のエタノール(45.8ml)溶液に、ペンチルアミン(2.69ml,23.2mmol)、炭酸カリウム(2.14g,15.5mmol)、よう化ナトリウム(2.30g,15.3mmol)を加え、17時間加熱還流した。反応溶液を減圧濃縮し、クロロホルム(100ml)で希釈した。これを1N水酸化ナトリウム水溶液(100ml)、飽和塩化ナトリウム水溶液(100ml)で洗浄し、有機層を硫酸マグネシウムで乾燥した。溶媒を減圧留去し、シリカゲルカラムクロマトグラフィーで精製した。得られた標的化合物のフリー体(1.52g,6.10mmol)の酢酸エチル(0.50ml)溶液に、4N塩化水素酢酸エチル溶液(3.1ml)を加えた。析出した固体を酢酸エチルで洗浄し、濾取すると、標的化合物1.33g(60%)が得られた。
【0085】
IR(KBr):2924,2850,2519,1456cm-1
mp:263.0−264.5℃
【0086】
中間体製造例1と同様の操作を行うことにより、以下の化合物が得られた。なお、標的化合物を塩酸塩として単離しないこともある。
【0087】
○N’−[2−(1−アダマンチル)エチル]−N−(ベンジルオキシカルボニル)−N−メチルエチレンジアミン(中間体1−2)
IR(neat):2901,2844,1704cm-1
【0088】
○2−(1−アダマンチル)−N−(シクロペンチルメチル)エチルアミン 塩酸塩(中間体1−3)
IR(KBr):2907,2847,1452cm-1
mp:300.0−310.0℃
【0089】
○N’−[2−(1−アダマンチル)エチル]−N−(t−ブトキシカルボニル)−N−メチルエチレンジアミン(中間体1−4)
IR(neat):3307,2902,2846,1698cm-1
【0090】
○2,2’−ジ(1−アダマンチル)ジエチルアミン 塩酸塩(中間体1−5)
IR(KBr):2900,2845,2735,2453cm-1
mp:325℃
【0091】
○2−(1−アダマンチル)−N−プロピルエチルアミン(中間体1−6)
IR(neat):3276,2903,2846,1450cm-1
【0092】
○N’−[2−(1−アダマンチル)エチル]−N,N−ジメチルエチレンジアミン 二塩酸塩(中間体1−7)
IR(KBr):3424,2901,2846,2445cm-1
mp:254.5−259.0℃
【0093】
○2−(1−アダマンチル)−N−シクロペンチルエチルアミン 塩酸塩(中間体1−8)
IR(KBr):2910,2846,2771,2450cm-1
mp:300−312℃
【0094】
○2−(1−アダマンチル)−N−シクロプロピルエチルアミン(中間体1−9)
IR(neat):3272,2901,2845cm-1
【0095】
○2−(1−アダマンチル)−N−(2−メトキシエチル)エチルアミン 塩酸塩(中間体1−10)
IR(KBr):2909,2846,2792,1451cm-1
mp:278.5−281.5℃
【0096】
○(1−アダマンチル)−N−(2−プロピニル)エチルアミン(中間体1−11)
IR(neat):2900,2845,1450cm-1
【0097】
○N−ペンチル−2−(2−ピリジル)エチルアミン(中間体1−12)
IR(neat):3305,2927,2857,1591cm-1
【0098】
○2−(1−アダマンチル)−N−ベンジルエチルアミン 塩酸塩(中間体1−13)
IR(KBr):2900,2846,2750,2528,2468,2372,1585cm-1
mp:264.0−265.0℃
【0099】
○2−(1−アダマンチル)−N−フルフリルエチルアミン 塩酸塩(中間体1−14)
IR(KBr):3456,2903,2846,2741,2426cm-1
mp:225.0−233.0℃
【0100】
○2−(1−アダマンチル)−N−ブチルエチルアミン(中間体1−15)
IR(neat):2903,1683,1450cm-1
【0101】
○2−シクロヘキシル−N−(2−チエニル)メチルエチルアミン 塩酸塩(中間体1−16)
【0102】
○N−ペンチルフェネチルアミン 塩酸塩(中間体1−17)
IR(KBr):3028,2957,2786,1456cm-1
mp:260.0−285.0℃
【0103】
○2−シクロヘキシル−N−ブチルエチルアミン 塩酸塩(中間体1−18)
IR(KBr):2921,2853,2794,2739,2442,1590,1484,1451cm-1
mp:250℃以上
【0104】
○2−シクロヘキシル−N−ペンチルエチルアミン 塩酸塩(中間体1−19)
IR(KBr):2924,2793,1451cm-1
mp:250℃以上
【0105】
○N−(t−ブトキシカルボニル)−N’−(2−シクロヘキシルエチル)−N−メチルエチレンジアミン(中間体1−20)
IR(neat):3350,2923,2850,1697,1481,1449cm-1
【0106】
○N’−(2−シクロヘキシルエチル)−N,N−ジメチルエチレンジアミン(中間体1−21)
IR(neat):3310,2921,2850,2815,1448cm-1
【0107】
○N−[2−(1−アダマンチル)エチル]−3−(4−ピリジル)プロピルアミン(中間体1−22)
IR(neat):3291,2902,2845,1602,1450cm-1
【0108】
○2−(1−アダマンチル)−N−イソプロピルエチルアミン 塩酸塩(中間体1−23)
IR(KBr):2909,2846,2754,2464,1588,1476,1451cm-1
mp:266.0−269.5℃
【0109】
○N−(2−ピペリジノエチル)ペンチルアミン(中間体1−24)
IR(neat):2932,2854,1466cm-1
【0110】
○2−(1−アダマンチル)−N−[(2−メチルチアゾール−4−イル)メチル]エチルアミン(中間体1−25)
IR(neat):2901,2844,1449cm-1
【0111】
○N−[2−(1−アダマンチル)エチル]シンナミルアミン(中間体1−26)
IR(neat):2901,2845,1449cm-1
【0112】
○N−[2−(1−アダマンチル)エチル]−2−メチル−2−プロペニルアミン(中間体1−27)
IR(neat):2902,2845,1450cm-1
【0113】
○N−[2−(1−アダマンチル)エチル]−3−メチル−2−ブテニルアミン(中間体1−28)
IR(neat):2903,2846,1450cm-1
【0114】
○N−[2−(1−アダマンチル)エチル]デシルアミン 塩酸塩(中間体1−29)
IR(KBr):2926,2849,2778,2469cm-1
mp:204.0−208.5℃
【0115】
○N−[2−(1−アダマンチル)エチル]ヘキシルアミン 塩酸塩(中間体1−30)
IR(KBr):2909,2848,2766,2446cm-1
mp:230.0−243.0℃
【0116】
○2−(1−アダマンチル)−N−(ベンジルオキシ)エチルアミン(中間体1−31)
IR(neat):2901,2846,1452cm-1
【0117】
○2−(1−アダマンチル)−N−[(2−チエニル)メチル]エチルアミン 塩酸塩(中間体1−32)
IR(KBr):2908,2846,2757,2426cm-1
mp:257.0−260.0℃
【0118】
○N−[2−(1−アダマンチル)エチル]−2−ブテニルアミン(中間体1−33)
IR(neat):2901,1450cm-1
【0119】
○N−[2−(1−アダマンチル)エチル]アリルアミン(中間体1−34)
IR(neat):2902,1450cm-1
【0120】
○N−[2−(1−アダマンチル)エチル]シクロプロピルメチルアミン(中間体1−35)
IR(neat):2901,1450cm-1
【0121】
○N−[2−(1−アダマンチル)エチル]−3,3,3−トリフルオロプロピルアミン 塩酸塩(中間体1−36)
IR(KBr):2910,2849,2767,2598,2457cm-1
mp:300.0−310.0℃
【0122】
○1−[2−(1−アダマンチル)エチル]−2−(t−ブトキシカルボニル)ヒドラジン(中間体1−37)
IR(KBr): 3288,2899,1705cm-1
mp:73.5−81.0℃
【0123】
○N−(t−ブトキシカルボニル)−N−メチル−N’−フェネチルエチレンジアミン(中間体1−38)
IR(neat): 3326,3025,2975,2930,1694,1454cm-1
【0124】
○N−(t−ブトキシカルボニル)−N−メチル−N’−ペンチルエチレンジアミン(中間体1−39)
IR(neat):2958,2929,1694,1457cm-1
【0125】
○N−(ベンジルオキシカルボニル)−N−メチル−N’−フェネチルエチレンジアミン(中間体1−40)
IR(neat):3309,3027,2936,2824,1698,1454cm-1
【0126】
○N−(ベンジルオキシカルボニル)−N−メチル−N’−ペンチルエチレンジアミン(中間体1−41)
IR(neat):2928,2858,1703,1455cm-1
【0127】
○2−シクロヘキシル−N−(2−メトキシエチル)エチルアミン 塩酸塩(中間体1−42)
IR(KBr):2923,2855,2784,2478,2444cm-1
mp:205.0−208.0℃
【0128】
○N−エチル−3,4,5−トリメトキシフェネチルアミン(中間体1−43)
IR(neat):3300,2936,2828,1588,1508,1457,1419,1331,1236,1126,1008cm-1
【0129】
○5−[2−(イソペンチルアミノ)エチル]イミダゾール 二塩酸塩(中間体1−44)
IR(KBr):2806,2467,1619,1604,1446,1347,1089,914,827,735,627,622cm-1
mp:235.2−238.0℃
【0130】
○N−シクロヘキシル−3,4−ジメトキシフェネチルアミン(中間体1−45)
IR(neat):2928,2852,1591,1515,1463,1449,1416,1261,1236,1155,1139,1029,802,761cm-1
bp:170℃/210Pa
【0131】
○N−シクロプロピル−3,4,5−トリメトキシフェネチルアミン(中間体1−46)
IR(neat):3304,2932,2832,1588,1505,1459,1418,1332,1236,1126,1009cm-1
【0132】
○N’−[2−(1−アダマンチル)エチル]−N−(t−ブトキシカルボニル)−N−メチル−1,3−プロパンジアミン(中間体1−47)
IR(neat):3308,2902,2845,1698,1480cm-1
【0133】
○N−シクロヘキシル(フェニル)メチル−3−(4−メトキシフェニル)プロピルアミン 塩酸塩(中間体1−48)
IR(KBr):2928,2857,2765,1592,1510,1455,1230,1064,1033,817cm-1
mp:187.5−189.5℃
【0134】
○N−ジフェニルメチル−3−フェニルプロピルアミン(中間体1−49)
IR(neat):3024,2931,1601,1493,1452cm-1
【0135】
○N−ペンチル−3−フェニルプロピルアミン 塩酸塩(中間体1−50)
IR(KBr):3027,2955,2870,2780,2492,2413cm-1
mp:230.0−238.0℃
【0136】
○N−アセチル−N’−[2−(1−アダマンチル)エチル]エチレンジアミン
塩酸塩(中間体1−51)
IR(neat):2897,2845,2361,1826,1707,1567m-1
mp:245.0−247.0℃
【0137】
○N−イソペンチル−3,3,3−トリフルオロプロピルアミン 塩酸塩(中間体1−52)
IR(KBr):2961,2800,1253,1173m-1
mp:288℃以上
【0138】
○N−[2−(1−アダマンチル)エチル]−2,2,2−トリフルオロエチルアミン 塩酸塩(中間体1−53)
IR(KBr):2904,2849,1273,1233,1176,1145m-1
mp:263.0−265.0℃
【0139】
○3−シクロヘキシル−N− プロピルプロピルアミン 塩酸塩(中間体1−54)
IR(KBr):2924,2854,2779m-1
mp:234.6−235.4℃
【0140】
○N’−[3−(1−アダマンチル)プロピル]−N−(t−ブトキシカルボニル)−N−メチルエチレンジアミン(中間体1−55)
1H-NMR (400MHz, CDCl3) δ 0.99-1.10 (m, 2H), 1.32-1.52 (m, 17H), 1.55-1.65 (m, 4H), 1.70 (d, J = 11.8 Hz, 3H), 1.93 (s, 3H), 2.58 (t, J = 7.2 Hz, 2H), 2.77 (br, 2H), 2.91 (s, 3H), 3.33 (br, 2H)
【0141】
中間体製造例2
○4−(3−アミノプロピル)ピリジン(中間体2−1)
N−[3−(4−ピリジル)プロピル]フタルイミド(67.1g、252mmol)とメタノール(504ml)とヒドラジン一水和物(18.3ml、378mmol)を混ぜ、3時間加熱環流した。放冷後不溶物を濾別し、濾液を減圧濃縮した。残留物にクロロホルム(1L)と4N水酸化ナトリウム水溶液(500ml)を加え、分液後、有機層を硫酸ナトリウムで乾燥した。減圧濃縮後減圧蒸留すると、標的化合物20.5g(60%)が無色油状物として得られた。
【0142】
IR(neat):3362,2933,1603cm-1
bp:76.0−79.0℃/40Pa
【0143】
中間体製造例2と同様の操作を行うことにより、以下の化合物が得られた。
【0144】
○3−(4−ピリジル)−2−プロペニルアミン(中間体2−2)
IR(neat):3280,3024,1599cm-1
【0145】
○2−(4−ピリジルオキシ)エチルアミン(中間体2−3)
IR(KBr):3298,3102,1610,1216,1049cm-1
mp:108.0−111.5℃
【0146】
○3−(4−キノリル)−2−プロペニルアミン(中間体2−4)
IR(neat):3270,2944,1585,1568,1508cm-1
【0147】
中間体製造例3
○2−(1−アダマンチル)−N−メチルエチルアミン(中間体3−1)
水素化リチウムアルミニウム(569mg,15.0mmol)のジエチルエーテル(34.0ml)溶液に、氷冷下、1−アダマンタン酢酸N−メチルアミド(1.54g,7.45mmol)のテトラヒドロフラン(15.0ml)溶液を5分間で滴下した。6時間加熱還流した後、再び氷冷下で撹拌し、酢酸エチルを加えて過剰の水素化リチウムアルミニウムを処理した後、反応溶液を1N塩酸(50ml)で2回抽出した。抽出液を4N水酸化ナトリウム水溶液の添加で塩基性にし、ジエチルエーテル(80ml)で抽出した。有機層を飽和塩化ナトリウム水溶液(60ml)で洗浄後、硫酸マグネシウムで乾燥した。溶媒を減圧留去して、標的化合物890mg(66%)を得た。
【0148】
IR(neat):2902,2845,1449cm-1
【0149】
中間体製造例3と同様の操作を行うことにより、以下の化合物が得られた。
【0150】
なお、4N塩化水素酢酸エチル溶液により、該化合物を塩酸塩にすることもできた。
【0151】
○2−(1−アダマンチル)−N−エチルエチルアミン 塩酸塩(中間体3−2)
IR(KBr):2896,2847,2753,2468,1610cm-1
mp:230−245℃
【0152】
○N−メチル−3−(4−ピリジル)プロピルアミン(中間体3−3)
IR(neat):3292,2934,1602cm-1
【0153】
○1−アダマンチル−N−プロピルメチルアミン 塩酸塩(中間体3−4)
IR(KBr):2905,1584,1451cm-1
mp:340℃
【0154】
○2−(1−アダマンチル)−N−メチルエチルアミン 塩酸塩(中間体3−5)
IR(KBr):3422,2900,2846,2676,2450,1630cm-1
mp:200−220℃
【0155】
○3−(1−アダマンチル)−N−プロピルプロピルアミン 塩酸塩(中間体3−6)
IR(KBr):2899,2467,1449cm-1
mp:159.5−162.0℃
【0156】
○1−アダマンチル−N−ペンチルメチルアミン 塩酸塩(中間体3−7)
IR(KBr):2916,2603,2509,2418,1477cm-1
mp:170−235℃
【0157】
○N−[3−(1−アダマンチル)プロピル]ペンチルアミン 塩酸塩(中間体3−8)
IR(KBr):2901,2847,1466,1453cm-1
mp:199−224℃
【0158】
○N−[2−(1−アダマンチル)エチル]−4,4,4−トリフルオロブチルアミン 塩酸塩(中間体3−9)
IR(KBr):3422,2908,2852,2770,2518,1452,1255,1148cm-1
mp:243−274℃
【0159】
○N−[2−(1−アダマンチル)エチル]−5,5,5−トリフルオロペンチルアミン(中間体3−10)
IR(neat):2903,2846,1450,1255,1142cm-1
【0160】
○N−[3−(1−アダマンチル)プロピル]ブチルアミン 塩酸塩(中間体3−11)
IR(KBr):2904,2847,2756,1453cm-1
mp:275.0−276.8℃
【0161】
○3−(1−アダマンチル)−N−(2,2,2−トリフルオロエチル)プロピルアミン 塩酸塩(中間体3−12)
IR(KBr):2902,2850,2739,1274,1258,1176,1139cm-1
mp:262.0−268.0℃
【0162】
○4−(1−アダマンチル)−N−エチルブチルアミン 塩酸塩(中間体3−13)
IR(KBr):2901,2847,2457,1451cm-1
mp:224−230℃
【0163】
○4−(1−アダマンチル)−N−プロピルブチルアミン 塩酸塩(中間体3−14)
IR(KBr):2899,2848,2751,2410,1451cm-1
mp:234−249℃
【0164】
○N−(1−アダマンチル)−N’−プロピルエチレンジアミン 二塩酸塩(中間体3−15)
IR(KBr):2927,2719,2508,2429,1471cm-1
mp:288.5−289.5℃
【0165】
中間体製造例4
○3−[N−[2−(1−アダマンチル)エチル]アミノ]プロピオン酸t−ブチルエステル 塩酸塩(中間体4−1)
2−(1−アダマンチル)エチルアミン塩酸塩(1.0g,4.6mmol)をエタノール(10ml)に溶解し、氷冷下トリエチルアミン(0.65ml,4.6mmol)及びアクリル酸t−ブチルエステル(0.75ml,5.1mmol)を加えた後、混合物を室温に戻し一晩攪拌した。反応溶液を減圧濃縮し、残留物に1N水酸化ナトリウム水溶液(30ml)と酢酸エチル(50ml)を加え、分液した。酢酸エチル層を水(50ml)、飽和塩化ナトリウム水溶液(50ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧濃縮後、シリカゲルカラムクロマトグラフィーにて精製を行った。得られた油状物(0.50g,1.6mmol)をジエチルエーテル(20ml)に溶解し、氷冷下4N塩化水素酢酸エチル溶液(1.0ml,4.0mmol)を加えると固体が析出した。これをジエチルエーテルで濾取すると標的化合物0.33g(23%)が得られた。
【0166】
IR(KBr):2902,2846,1733,1166cm-1
mp:210℃
【0167】
中間体製造例4と同様の操作を行うことにより、以下の化合物が得られた。なお、標的化合物を塩酸塩として単離しないこともある。
【0168】
○3−[N−(2−シクロヘキシルエチル)アミノ]プロピオン酸メチルエステル 塩酸塩(中間体4−2)
IR(KBr):2924,2853,2792,1736,1455,1439cm-1
mp:185.0−187.5℃
【0169】
○3−[N−(2−シクロヘキシルエチル)アミノ]プロピオン酸t−ブチルエステル(中間体4−3)
IR(neat):2977,2922,2850,1728,1449cm-1
【0170】
○3−[N−[3−(4−ピリジル)プロピル]アミノ]プロピオン酸t−ブチルエステル塩酸塩(中間体4−4)
IR(neat):3322,2977,2933,1724,1602,1367,1153cm-1
【0171】
中間体製造例5
○5−(4−ピリジル)吉草酸(中間体5−1)
臭化(ベンジルオキシカルボニルメチル)トリフェニルホスホニウム(4.60g、9.36mmol)、β−(4−ピリジル)アクロレインしゅう酸塩(1.90g、8.51mmol)にN,N−ジメチルホルムアミド(17ml)を加え、氷冷下攪拌した。炭酸カリウム(4.70g、34.0mmol)を加え、反応溶液を室温とした。これを一夜攪拌後酢酸エチル(100ml)で希釈し、水(100ml)2回、飽和食塩水(50ml)の順で洗浄した。硫酸ナトリウムで乾燥後酢酸エチルを減圧留去した。残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、5−(4−ピリジル)吉草酸−2,4−ジエンベンジルエステル2.29g(定量的)が淡黄色油状物として得られた。
【0172】
つぎに、5−(4−ピリジル)吉草酸−2,4−ジエンベンジルエステル(2.25g、8.48mmol)にメタノール(42ml)、酢酸(1.0ml、18mmol)を加え、窒素ガスを10分間通気した。触媒量の水酸化パラジウムオンカーボンを加え、水素雰囲気下室温で一夜攪拌した。セライト濾過により不溶物を濾去した後、濾液を減圧濃縮した。固化した残留物に酢酸エチル(50ml)を加え、室温で3時間攪拌した。結晶を濾取すると、標的化合物1.00g(66%)が淡黄色結晶として得られた。
【0173】
IR(KBr):2943,1719,1636,1605cm-1
mp:155.0−180.0℃
【0174】
中間体製造例6
○3−[ N−(2−シクロヘキシルエチル)アミノ]プロピオン酸アミド 塩酸塩(中間体6−1)
氷冷下、中間体4−3の3−[N−(2−シクロヘキシルエチル)アミノ]プロピオン酸t−ブチルエステル(2.0g、7.8mmol)にトリフルオロ酢酸(6ml)を加えた。一夜攪拌後、減圧濃縮した。残留物に4N塩化水素酢酸エチル溶液を加え、減圧濃縮後、生じた結晶をジエチルエーテルで濾取すると、3−[N−(2−シクロヘキシルエチル)アミノ]プロピオン酸塩酸塩1.5g(96%)が得られた。
【0175】
つぎに、3−[N−(2−シクロヘキシルエチル)アミノ]プロピオン酸塩酸塩(1.0g、4.2mmol)にテトラヒドロフラン(8ml)を加え、室温で攪拌した。炭酸ジ−t−ブチルエステル(1.1g、5.1mmol)及びトリエチルアミン(1.3ml、9.3mmol)を加え一夜攪拌後、5%クエン酸水溶液(10ml)を加えた。クロロホルム(60ml)で抽出後、有機層を飽和食塩水(20ml)で洗浄した。硫酸マグネシウムで乾燥後、減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで精製すると、3−[N−(t−ブトキシカルボニル)−N−(2−シクロヘキシルエチル)アミノ]プロピオン酸0.79g(62%)が無色油状物として得られた。
【0176】
つぎに、3−[N−(t−ブトキシカルボニル)−N−(2−シクロヘキシルエチル)アミノ]プロピオン酸(0.59g、2.0mmol)に無水テトラヒドロフラン(7ml)を加え、−78℃で攪拌した。N−メチルモルホリン(0.22ml、2.0mmol)次いでクロロ蟻酸イソブチルエステル(0.38ml、2.9mmol)のテトラヒドロフラン(3ml)溶液を加えた。1時間後28%アンモニア水溶液(6.0ml、9.8mmol)を加え、1.5時間攪拌した。クロロホルム(50ml)を加え室温とし、飽和重曹水(20ml)、飽和食塩水(20ml)の順で洗浄した。硫酸マグネシウムで乾燥後減圧濃縮し、残留物をシリカゲルカラムクロマトグラフィーで精製すると、3−[N−(t−ブトキシカルボニル)−N−(2−シクロヘキシルエチル)アミノ]プロピオン酸アミド0.34g(58%)が無色結晶として得られた。
【0177】
つぎに、3−[N−(t−ブトキシカルボニル)−N−(2−シクロヘキシルエチル)アミノ]プロピオン酸アミド(0.37g、1.2mmol)に4N塩化水素1,4−ジオキサン溶液(3.1ml)を加え室温で一夜攪拌した。減圧濃縮後、生じた固体にジイソプロピルエーテルを加え濾取すると、標的化合物0.30g(定量的)が無色結晶として得られた。
【0178】
IR(KBr):3386,3196,2921,2852,2808,1705,1656,1452cm-1
mp:165.0℃
【0179】
中間体製造例7
○ジ−5−ヘキセニルアミン(中間体7−1)
3−アミノプロピオニトリル(0.98g、14mmol)にN,N−ジメチルホルムアミド(28ml)を加え、室温で攪拌した。6−ブロモ−1−ヘキセン(5.0g、31mmol)、ヨウ化ナトリウム(11g、73mmol)、炭酸カリウム(5.8g、42mmol)を加え、一夜攪拌した。ジエチルエーテル(100ml)で希釈し、水(100ml、2回)、飽和食塩水(50ml)の順で洗浄した。硫酸ナトリウムで乾燥後、有機層を減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、3−(ジ−5−ヘキセニル)アミノプロピオニトリル2.2g(66%)が無色油状物として得られた。
【0180】
つぎに、3−(ジ−5−ヘキセニル)アミノプロピオニトリル(2.0g、8.6mmol)にエタノール(8.6ml)と水酸化カリウム(0.85g、13mmol)を加え7.5時間加熱環流した。放冷後水(150ml)、クロロホルム(150ml)を加え分配し、有機層を硫酸ナトリウムで乾燥した。減圧濃縮後残留物を塩基性シリカゲルカラムクロマトグラフィーで分離精製すると、標的化合物0.32g(21%)が淡黄色油状物として得られた。
【0181】
IR(neat):3076,2976,2928,2856,1679,1640cm-1
【0182】
中間体製造例7と同様の操作を行うことにより、以下の化合物が得られた。
【0183】
○ジ−7−オクテニルアミン(中間体7−2)
IR(neat):3075,2976,2926,2854,1640cm-1
【0184】
中間体製造例8
○N−[2−(1−アダマンチルオキシ)エチル]プロピルアミン 塩酸塩(中間体8−1)
2−(プロピルアミノ)エタノール(2.4g、23mmol)、1−ブロモアダマンタン(0.50g、2.3mmol)、トリエチルアミン(0.32ml、2.3mmol)を混ぜ、外温100℃で2時間、130℃で5時間、150℃で3時間撹拌した。放冷後酢酸エチル(50ml)を加え、水(50ml)2回、飽和食塩水(30ml)の順で洗浄した。有機層を硫酸ナトリウムで乾燥後減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで分離後、4N塩化水素酢酸エチル溶液(2ml)を加え減圧濃縮し、生じた結晶を酢酸エチルで濾取すると、標的化合物0.16g(25%)が無色結晶として得られた。
【0185】
IR(KBr):3544,2907,2502,1584cm-1
mp:232.0−232.7℃
【0186】
中間体製造例9
○2−プロピルアミノ酢酸 N−(1−アダマンチル)アミド(中間体9−1)ブロモ酢酸(5.00g、36.0mmol)にエタノール(36ml)を加え、氷水冷下撹拌した。プロピルアミン(14.8ml、180mmol)を1分間で加えた後、外温80℃で2.5時間撹拌した。4N水酸化ナトリウム水溶液(27ml)を加え減圧濃縮後、水(27ml)とテトラヒドロフラン(30ml)を加え室温で撹拌した。炭酸ジ−t−ブチルエステル(9.43g、43.2mmol)のテトラヒドロフラン(6ml)溶液を加え、15分後クエン酸一水和物を加え弱酸性にした。酢酸エチル(150ml)で抽出後、水(100ml)、飽和食塩水(50ml)の順で洗浄した。有機層を硫酸ナトリウムで乾燥後減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで分離すると、2−[N−(t−ブトキシカルボニル)−N−プロピルアミノ]酢酸5.06g(65%)が無色固体として得られた。
【0187】
つぎに、2−[N−(t−ブトキシカルボニル)−N−プロピルアミノ]酢酸(4.52g、20.8mmol)、1−アダマンタンアミン(3.46g、22.9mmol)に塩化メチレン(208ml)を加え、室温で撹拌した。N、N−ジイソプロピルエチルアミン(7.25ml、41.6mmol)次いでO−(7−アザベンゾトリアゾール−1−イル)−N,N,N’,N’−テトラメチルウロニウム六フッ化燐酸塩(8.71g、22.9mmol)を加え、一夜撹拌した。反応溶液を減圧濃縮後、残留物をシリカゲルカラムクロマトグラフィーで分離すると、2−[N’−(t−ブトキシカルボニル)−N’−プロピルアミノ]酢酸 N−(1−アダマンチル)アミド7.88g(定量的)が無色油状物として得られた。得られた油状物は室温で固化した。
【0188】
つぎに、2−[N’−(t−ブトキシカルボニル)−N’−プロピルアミノ]酢酸 N−(1−アダマンチル)アミド(7.68g、21.9mmol)に4N塩化水素酢酸エチル溶液(55ml、0.22mol)を加え、室温で1時間撹拌した。生じた結晶に酢酸エチルを濾取後酢酸エチルで洗浄すると、標的化合物5.97g(95%)が無色結晶として得られた。
【0189】
IR(KBr):3272,2906,2848,2589,1676,1562cm-1
mp:278.0−279.2℃
【0190】
中間体製造例10
○N−(t−ブトキシカルボニル)−2−(4−ピリジルオキシ)エチルアミン(中間体10−1)
氷冷下、中間体2−4(200g,1.45mmol)のテトラヒドロフラン(5ml)溶液にジ−t−ブチルジカルボナート(380mg,1.74mmol)とトリエチルアミン(240μl,1.74mmol)を加え、室温にして25分攪拌した。反応液を減圧下溶媒留去した後、酢酸エチル(50ml)と飽和炭酸水素ナトリウム水溶液(50ml)で分配した。水層をさらにクロロホルム(50ml)で抽出し、あわせた有機層を無水硫酸マグネシウムで乾燥した。減圧下溶媒留去して得た残留物をシリカゲルカラムクロマトグラフィーで精製すると標的化合物70mg(20.2%)が得られた。
【0191】
IR(neat):3230,2976,1706,1596cm-1
【0192】
中間体製造例11
○(RS)−2−メチル−3−(4−ピリジル)プロピルアミン(中間体11-1)
窒素雰囲気下、水素化ナトリウム(5.36g、134mmol)にN,N−ジメチルホルムアミド(143ml)を加え、氷冷下攪拌した。メチルマロン酸ジエチルエステル(11.7g、67.1mmol)のN,N−ジメチルホルムアミド(40ml)溶液を5分間で滴下し、10分後4−塩化ピコリル塩酸塩(10.0g、61.0mmol)を少しずつ5分間かけて加え室温とした。1時間後飽和重曹水(500ml)を加え、ジエチルエーテル(400ml)で抽出した。有機層を水(100ml)飽和食塩水(50ml)で洗浄し、硫酸マグネシウムで乾燥した。減圧濃縮すると、2−メチル−2−(4−ピリジルメチル)マロン酸ジエチルエステル17.2g(定量的、水素化ナトリウムオイルを含む)が茶色油状物として得られた。
【0193】
つぎに、2−メチル−2−(4−ピリジルメチル)マロン酸ジエチルエステル(17.2g、64.6mmol)に6N塩酸(96.8ml、581mmol)を加え一夜加熱環流した。放冷後ヘキサン(100ml)で洗浄することにより2−メチル−2−(4−ピリジルメチル)マロン酸ジエチルエステルに含まれていた水素化ナトリウムオイルを除去し減圧濃縮した。生じた結晶を酢酸エチルで濾取すると、2−メチル−3−(4−ピリジル)プロピオン酸10.7g(82%)が薄ピンク色結晶として得られた。
【0194】
つぎに、2−メチル−3−(4−ピリジル)プロピオン酸(1.69g、10.2mmol)にクロロホルム(8ml)、塩化チオニル(2.2ml、30.6mmol)、N,N−ジメチルホルムアミド(1滴)を加え、攪拌しながら1時間加熱環流した。減圧濃縮後クロロホルム(8ml)を加え、氷冷下攪拌している28%アンモニア水溶液にゆっくり加えた。10分後室温とし、一夜攪拌した。減圧濃縮後酢酸エチル(100ml)を加え、生じた不溶物を濾去した。濾液を減圧濃縮し、残留物をシリカゲルカラムクロマトグラフィーで分離精製し、生じた結晶をジエチルエーテルで濾取すると、2−メチル−3−(4−ピリジル)プロピオン酸アミド0.72g(43%)が淡黄色結晶として得られた。
【0195】
つぎに、窒素雰囲気下、水素化リチウムアルミニウム(0.45g、12mmol)に無水ジエチルエーテル(20ml)を加え氷冷下攪拌した。2−メチル−3−(4−ピリジル)プロピオン酸アミド(0.68g、4.1mmol)の無水塩化メチレン(20ml)溶液を5分間で滴下し、室温として一夜攪拌した。再び氷冷下とし、酢酸エチル(5ml)をゆっくり加え、次いで1N水酸化ナトリウム水溶液を初めはゆっくり加え、全量100ml加えた。クロロホルム(100ml)で抽出後、有機層を硫酸ナトリウムで乾燥し減圧濃縮すると、標的化合物0.56g(90%)が淡黄色油状物として得られた。
【0196】
IR(neat):3293,2957,2925,1602cm-1
【0197】
中間体製造例11と同様の操作を行うことにより、以下の化合物が得られた。また、光学活性な酸を用いて光学分割することにより、光学活性体を得ることができた。
【0198】
○ 2−(4−ピリジルメチル)ブチルアミン(中間体11−2)
IR(neat):3296,3025,2960,2874,1602cm-1
【0199】
○ 2−ベンジル−3−(4−ピリジル)プロピルアミン(中間体11−3)
IR(neat):3296,3062,3025,1602cm-1
【0200】
○2,2−ビス(4−ピリジルメチル)エチルアミン(中間体11−4)
IR(neat):3290,3026,2924,1602,1557cm-1
【0201】
○(−)−2−メチル−3−(4−ピリジル)プロピルアミン(中間体11−5)
IR(neat):3362,3301,2958,1603cm-1
[α]20 D:−10.6°(MeOH,C1.0)
【0202】
○(+)−2−メチル−3−(4−ピリジル)プロピルアミン(中間体11−6)
IR(neat):3362,3294,2958,1603cm-1
[α]20 D:+9.9°(MeOH,C1.0)
【0203】
中間体製造例12
○3−(4−キノリル)プロピルアミン(中間体12−1)
室温窒素雰囲気下、 中間体製造例2で得られた3−(4−キノリル)−2−プロペニルアミン(中間体2−4)(188mg,1.02mmol)のメタノール(3ml)溶液に触媒量の10%パラジウムオンカーボンを加え、水素雰囲気下一晩撹拌した。反応液をセライト濾過した後、減圧下溶媒留去して得られた残留物を酢酸エチル(30ml)と飽和塩化アンモニウム水溶液(30ml)で分配した。水層に4N水酸化ナトリウム水溶液(30ml)を加え、クロロホルム(100ml)で抽出し、得られた有機層を無水硫酸マグネシウムで乾燥した。減圧下溶媒留去することにより、標的化合物145mg(76.3%)が得られた。
【0204】
IR(neat):3350,2938,1591,1510cm-1
【0205】
中間体製造例13
○3−(4−ピリジル)ブチルアミン(中間体13−1)
4−アセチルピリジン(2.00g、16.5mmol)、臭化(ベンジルオキシカルボニル)トリフェニルホスホニウム(8.94g、18.2mmol)にN,N−ジメチルホルムアミド(33ml)を加え、氷冷下攪拌した。炭酸カリウム(9.12g、66.0mmol)を加え外温70℃とし、一夜攪拌した。ジエチルエーテル(100ml)で希釈後、水(100ml、2回)、飽和食塩水(50ml)の順で洗浄した。硫酸マグネシウムで乾燥後減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、3−(4−ピリジル)−2−ブテン酸ベンジルエステル1.77g(42%:E体とZ体の混合物)が淡黄色油状物として得られた。
【0206】
つぎに3−(4−ピリジル)−2−ブテン酸ベンジルエステル(1.75g、6.20mmol)にメタノール(31ml)、酢酸(0.71ml、12.4mmol)を加え、室温で10分間窒素ガスを通気した。触媒量の10%−パラジウムオンカーボンを加え、水素雰囲気下室温で一夜攪拌した。不溶物を濾去後、濾液を減圧濃縮した。生じた結晶をアセトンで濾取すると、3−(4−ピリジル)酪酸0.61g(60%)が淡黄色結晶として得られた。
【0207】
つぎに、3−(4−ピリジル)酪酸(0.60g、3.6mmol)にクロロホルム(5ml)、塩化チオニル(0.80ml、11mmol)、N,N−ジメチルホルムアミド(1滴)を加え、攪拌しながら1時間加熱環流した。減圧濃縮後クロロホルム(5ml)を加え、氷冷下攪拌している飽和アンモニア/テトラヒドロフラン(5ml)溶液にゆっくり加えた。2.5時間後不溶物を濾去し、濾液を減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、3−(4−ピリジル)酪酸アミドとその酸化オレフィン体の混合物0.34gが淡黄色結晶として得られた。
【0208】
つぎに、窒素雰囲気下、水素化リチウムアルミニウム(0.16g、4.2mmol)に無水エーテル(8ml)を加え、氷冷下攪拌した。3−(4−ピリジル)酪酸アミド(0.22g、1.4mmol)の無水塩化メチレン(8ml)溶液を2分間で滴下後室温とし、一夜攪拌した。酢酸エチル(1ml)、1N水酸化ナトリウム水溶液(20ml)を加えた後クロロホルム(50ml)で抽出した。有機層を無水硫酸ナトリウムで乾燥後減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、標的化合物0.15g(75%)が淡黄色油状物として得られた。
【0209】
IR(neat):3350,2963,2873,1601cm-1
【0210】
中間体製造例14
○N−(4−ピリジル)エチレンジアミン(中間体14−1)
窒素雰囲気下、4−ブロモピリジン塩酸塩(3.00g、15.5mmol)にエチレンジアミン(10.4ml、155mmol)を加え1.5時間加熱還流した。室温とし、炭酸カリウム(8.57g、62.0mmol)を加えて10分間撹拌後固体を濾別し、固体をトルエン、2−プロパノールで洗浄した。濾液を減圧濃縮後、残留物を塩基性シリカゲルカラムクロマトグラフィーで分離精製後、生じた固体をジイソプロピルエーテルで濾取すると、標的化合物1.63g(77%)が淡黄色固体として得られた。
【0211】
IR(KBr):3320,3240,3028,2930,1615cm-1
mp:114.0−116.5℃
【0212】
中間体製造例15
○4−(3−アミノブチル)ピリジン(中間体15−1)
窒素雰囲気下、水素化ナトリウム(2.81g、70.3mmol)に無水N,N−ジメチルホルムアミド(41ml)を加え、氷水冷下撹拌した。アセト酢酸t−ブチルエステル(6.33g、40.0mmol)のN,N−ジメチルホルムアミド(20ml)溶液を10分間で滴下し、更に10分後窒素気流下として4−(クロロメチル)ピリジン塩酸塩(5.00g、30.5mmol)を少しずつ3分間で加えて室温とした。2時間後飽和重曹水(150ml)を加え、酢酸エチル(100ml)で抽出した。有機層を水(100ml)、飽和食塩水(50ml)で洗浄後、無水硫酸ナトリウムで乾燥した。減圧濃縮後、残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、2−アセチル−3−(4−ピリジル)プロピオン酸エチルエステル1.34g(18%)が淡黄色油状物として得られた。
【0213】
つぎに、2−アセチル−3−(4−ピリジル)プロピオン酸エチルエステル(1.20g、4.81mmol)に6N塩酸(8ml)を加え、1.5時間加熱還流した。減圧濃縮後2−プロパノール(10ml)を加え、再度減圧濃縮した。生じた固体に酢酸エチルを加え濾取すると、4−(4−ピリジル)−2−ブタノン0.79g(89%)が淡黄色固体として得られた。
【0214】
つぎに、4−(4−ピリジル)−2−ブタノン(736mg、3.96mmol)に水(12ml)、テトラヒドロフラン(1.2ml)を加え、室温で撹拌した。炭酸ナトリウム(483mg、4.56mmol)とヒドロキシルアミン塩酸塩(358mg、5.15mmol)を加え、1.5時間攪拌後酢酸エチル(50ml)を加えて希釈した。炭酸水素ナトリウムを加え分液後飽和食塩水(10ml)で洗浄した。有機層を無水硫酸ナトリウムで乾燥後減圧濃縮した。生じた結晶にシクロヘキサンを加え濾取すると、4−(4−ピリジル)−2−ブタノンオキシム584mg(90%)が淡黄色結晶として得られた。
【0215】
つぎに、窒素雰囲気下、水素化リチウムアルミニウム(257mg、6.77mmol)に無水エーテル(19ml)を加え、氷冷下撹拌した。4−(4−ピリジル)−2−ブタノンオキシム(556mg、3.38mmol)のエーテル(15ml)溶液を7分間で滴下後室温とし一夜撹拌した。更に二日間加熱還流後氷冷下撹拌した。酢酸エチルをゆっくり加えた後1N水酸化ナトリウム水溶液(最初はゆっくり、全20ml)を加えた。クロロホルム(80ml)を加え不溶物をセライトで濾去し、分液後クロロホルムを減圧濃縮した。残留物と水層を合わせ、テトラヒドロフラン(20ml)を加え、室温で撹拌した。炭酸ジ−t−ブチルエステル(1.48g、6.78mmol)を加え一夜撹拌した。クロロホルム(50ml)を加え抽出後無水硫酸マグネシウムで乾燥し減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで分離精製した。残留物に4N塩化水素酢酸エチル溶液(3ml)とエタノール(1ml)を加え室温で撹拌した。3時間後減圧濃縮し、残留物にクロロホルム(5ml)、メタノール(5ml)、トリエチルアミン(1ml)を加え減圧濃縮後、残留物を塩基性シリカゲルカラムクロマトグラフィーで分離精製すると、標的化合物161mg(32%)が茶色油状物として得られた。
【0216】
IR(neat):3354,3280,2958,2925,2866,1602cm-1
【0217】
中間体製造例15と同様の操作を行うことにより、以下の化合物が得られた。
【0218】
○1,2−ジメチル−3−(4−ピリジル)プロピルアミン(中間体15−2)
IR(neat):3360,3287,2963,2930,2876,1602cm-1
【0219】
○1−エチル−3−(4−ピリジル)プロピルアミン(中間体15−3)
IR(neat):3357,2963,2934,2875,1605cm-1
【0220】
中間体製造例16
○2,2−ジメチル−3−(4−ピリジル)プロピルアミン(中間体16−1)窒素雰囲気下、ジイソプロピルアミン(10.0ml、71.5mmol)のテトラヒドロフラン(150ml)溶液を−78℃に冷却し、ブチルリチウムのヘキサン溶液(1.6N)を10分間かけて滴下した。氷冷水で20分間冷却後、再度−78℃に冷却し、イソブチロニトリル(3.03ml,33.3mmol)を5分間かけて滴下した。更に4−ピリジンカルボキシアルデヒド(3.18ml,33.3mmol)を5分間かけて滴下し、1時間20分攪拌した。水(100ml)を加え、反応混合物を3日間連続抽出装置にかけ、酢酸エチル(200ml)で抽出した。得られた有機層を無水硫酸マグネシウムで乾燥後減圧下濃縮し、得られた固体をジエチルエーテルで濾取することにより3−ヒドロキシ−2,2−ジメチル−3−(4−ピリジル)プロピオニトリル4.20g(71.6%)が無色固体として得られた。
【0221】
室温下、3−ヒドロキシ−2,2−ジメチル−3−(4−ピリジル)プロピオニトリル(1.00g、5.67mmol)のジクロロメタン(20ml)溶液にトリエチルアミン(1.57ml、11.3mmol)を加えた。更に塩化p−トルエンスルホニル(1.30g、6.80mmol)を加え、50℃で3日間過熱攪拌した。放冷後、反応混合物を減圧濃縮し、シリカゲルカラムクロマトグラフィーで精製すると2,2−ジメチル−3−(4−ピリジル)−3−(p−トリルスルホニルオキシ)プロピオニトリル699mg(37.4%)が淡黄色固体として得られた。
【0222】
窒素雰囲気下、水素化リチウムアルミニウム(345mg,9.10mmol)を加え、氷水冷下、無水ジエチルエーテル(10ml)を滴下した。続いて2,2−ジメチル−3−(4−ピリジル)−3−(p−トリルスルホニルオキシ)プロピオニトリル(600mg,1.82mmol)のテトラヒドロフラン(10ml)溶液を滴下した。室温下、一夜攪拌し、氷水冷下、反応混合物を激しく攪拌しながら、水(324μl)、15%水酸化ナトリウム水溶液(324μl)、水(972μl)を順次加えた。無水硫酸マグネシウムで乾燥後、減圧濃縮し、シリカゲルカラムクロマトグラフィーで精製すると標的化合物(83.0mg,0.505mmol,28%)が淡黄色油状物として得られた。
【0223】
IR(neat):3290,3074,2960,1652,1602,1417cm-1
【0224】
中間体製造例17
○(RS)−2−メチル−3−(4−ピリジル)プロパノール(中間体17−1)
中間体製造例11の合成過程で得られた2−メチル−3−(4−ピリジル)プロピオン酸(136g,0.676mol)をテトラヒドロフラン(1500ml)に溶解し、氷水冷下、水素化ホウ素ナトリウム(56.2g,1.49mol)を加えた。30分後、ヨウ素(85.8g,0.338mol)、テトラヒドロフラン(500ml)の混合液を氷水冷却下滴下し、室温とした。2時間後氷水冷下とし、飽和炭酸水素ナトリウム水溶液(100ml)を滴下した。飽和塩化ナトリウム水溶液(900ml)、水(400ml)を加え、クロロホルム(1L×2)で抽出した。有機層を0.01%チオ硫酸ナトリウム水溶液(1L)、飽和塩化ナトリウム水溶液(500ml)の順で洗浄後、無水硫酸マグネシウムで乾燥し、減圧濃縮すると、標的化合物127.1g(定量的)が黄色油状物として得られた。
【0225】
IR(neat):3292,2928,1606,1558,1419cm-1
【0226】
中間体製造例18
○3−(t−ブチルジフェニルシリルオキシ)−3−(4−ピリジル)プロピルアミン(中間体18−1)
−80℃下,ブチルリチウムヘキサン溶液(10.5ml,16.8mmol)の無水テトラヒドロフラン(20ml)溶液にジイソプロピルアミン(1.98g,19.6mmol)を5分かけて滴下し,0℃に昇温して30分間攪拌した。再び−80℃に冷却後,アセトニトリル(573mg,14.0mmol)を7分かけて滴下し,さらに20分後,4-ピリジンカルボキシアルデヒド(758mg,7.08mmol)を10分かけて滴下した。50分後,飽和塩化アンモニウム水溶液(20ml)を加えて室温に戻した。反応液を4日間連続抽出(酢酸エチル,水)した。有機層を無水硫酸マグネシウムで乾燥後,溶媒を減圧留去してシリカゲルカラムクロマトグラフィーで精製すると,3−ヒドロキシ−3−(4−ピリジル)プロピオニトリル(666mg,無色結晶,63.5%)が得られた。
【0227】
つぎに、得られた3−ヒドロキシ−3−(4−ピリジル)プロピオニトリル(1.00g、6.75mmol)にイミダゾール(4.60g、67.5mmol)、N,N−ジメチルホルムアミド(30ml)を加え、室温で撹拌した。t−ブチルジフェニルクロロシラン(2.23g、8.10mmol)を加え一日撹拌後、外温50℃で更に3時間撹拌した。酢酸エチル(50ml)エーテル(50ml)を加え、水(20ml)3回、飽和食塩水(30ml)の順で洗浄後、有機層を無水硫酸マグネシウムで乾燥した。減圧濃縮後、残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、3−(t−ブチルジフェニルシロキシ)−3−(4−ピリジル)プロピオニトリル2.58g(98.9%)が無色油状物として得られた。
【0228】
窒素雰囲気下,水素化リチウムアルミニウム(299mg,7.87mmol)を無水ジエチルエーテル(10ml)に懸濁させ、氷冷下攪拌しながら、得られた3−(t−ブチルジフェニルシロキシ)−3−(4−ピリジル)プロピオニトリル(1.00g,2.59mmol)の無水ジエチルエーテル(15ml)溶液を8分かけて滴下し,室温に戻して75分間攪拌した。氷冷にして酢酸エチル(15ml)を加えてから,水(0.28ml),15%水酸化ナトリウム水溶液(0.28ml),水(0.85ml)を順番に加え,室温に戻して10分間攪拌した。反応液に無水硫酸マグネシウムを加えて乾燥後,溶媒を減圧留去してシリカゲルカラムクロマトグラフィーで精製すると,標的化合物(180.0mg,黄色油状物,17.8%)が得られた。
【0229】
IR(neat):3286,3071,2932,2858,1601,1428cm-1
【0230】
中間体製造例18と同様の操作を行うことにより、以下の化合物が得られた。
【0231】
○3−(t−ブチルジメチルシリルオキシ)−3−(4−ピリジル)プロピルアミン(中間体18−2)
【0232】
中間体製造例19
○N−[2−(1−アダマンチル)エチル]−2−ブチニルアミン(中間体19−1)
2−ブチン−1−オール(3.0ml、40mmol)にジメチルスルホキシド(60ml)とトリエチルアミン(8.4ml、60mmol)を加え、氷水冷下撹拌した。三酸化硫黄ピリジン錯体(4.2g、26mmol)を加え15分後、更に三酸化硫黄ピリジン錯体(5.1g、32mmol)を加えて1.5時間撹拌した。反応溶液に水(40ml)を加え、塩化メチレン(40ml)で2回抽出し、1N塩酸(30ml)2回、水(40ml)2回の順で洗浄後、有機層を無水硫酸マグネシウムで乾燥した。溶媒を減圧留去すると、2−ブチナール1.0g(37%)が褐色油状物として得られた。
【0233】
ついで、2−(1−アダマンチル)エチルアミン塩酸塩(2.0g、9.3mmol)をクロロホルム(30ml)と1N水酸化ナトリウム水溶液(40ml)で分配し、有機層を無水硫酸マグネシウムで乾燥、減圧濃縮することにより得られた2−(1−アダマンチル)エチルアミンにメタノール(15ml)、トリエチルアミン(2.6ml、19mmol)を加え、室温で撹拌した。次に前反応で得られた2−ブチナール(0.80g、12mmol)のメタノール(10ml)溶液を加え、3時間後氷水冷下水素化ホウ素ナトリウム(1.9g、50mmol)を加えた。1時間後水(40ml)を加え、クロロホルム(60ml)で抽出後飽和食塩水(40ml)で洗浄し、有機層を無水硫酸マグネシウムで乾燥した。減圧濃縮後、残留物をシリカゲルカラムクロマトグラフィーで分離精製すると、標的化合物0.48g(22%)が褐色油状物として得られた。
【0234】
IR(neat):3302,2902,2846,2279,2244cm-1
【0235】
[B]本化合物の製造例
本化合物製造例1
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−1)
中間体2−1の4−(3−アミノプロピル)ピリジン(285mg,2.09mmol)のテトラヒドロフラン(10ml)溶液に1,1’−カルボニルジイミダゾール(427mg,2.63mmol)を加え、室温で20分間攪拌した。中間体1−1の2−(1−アダマンチル)−N−ペンチルエチルアミン塩酸塩(571mg,2.00mmol)を加え、1時間加熱還流した。酢酸エチル(50ml)で希釈し、飽和炭酸水素ナトリウム水溶液(50ml)、飽和塩化ナトリウム水溶液(50ml)で洗浄後、硫酸マグネシウムを加え乾燥した。溶媒を減圧留去し、析出した固体をジイソプロピルエーテルで洗浄後濾取すると、標的化合物606mg(73%)が得られた。
【0236】
IR(KBr):2900,2845,1618,1534cm-1
mp:124.0−124.7℃
【0237】
本化合物製造例1と同様の操作を行うことにより、以下の化合物が得られた。
【0238】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア(化合物1−2)
IR(neat):3339,2902,2846,1626,1530cm-1
【0239】
○N−[3−(4−ピリジル)プロピル]−1−ピペリジンカルボキサミド(化合物1−3)
IR(neat):3339,2934,2854,1621,1538cm-1
【0240】
○N−[3−(4−ピリジル)プロピル]−1,2,3,6−テトラヒドロピリジン−1−カルボキサミド(化合物1−4)
IR(neat):3337,2922,2858,1624,1537,1414cm-1
【0241】
○N−[3−(4−ピリジル)プロピル]−1,2,3,4−テトラヒドロイソキノリン−2−カルボキサミド(化合物1−5)
IR(KBr):3342,2925,1614,1543,1489cm-1
mp:76.0−79.0℃
【0242】
○N−[3−(4−ピリジル)プロピル]−4−モルホリンカルボキサミド(化合物1−6)
IR(KBr):3347,2968,1626,1546,1115cm-1
mp:94.0−98.0℃
【0243】
○N−[3−(4−ピリジル)プロピル]−1−ホモピペリジンカルボキサミド(化合物1−7)
IR(neat):3343,2927,1625,1537cm-1
【0244】
○1,1−ジアリル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−8)
IR(neat):3350,2928,1628,1603,1535cm-1
【0245】
○N−[3−(4−ピリジル)プロピル]−2−デカヒドロイソキノリンカルボキサミド(化合物1−9)
IR(neat):3343,2855,2622,1621,1539cm-1
【0246】
○1,1−ジブチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−10)
IR(neat):3347,2957,2872,1626,1537cm-1
【0247】
○1,1−ジヘキシル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−11)
IR(neat):3348,2928,2857,1626,1532cm-1
【0248】
○1,1−ジイソペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−12)
IR(neat):3344,2955,2869,1626,1533cm-1
【0249】
○1,1−ジデシル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−13)
IR(neat):3346,2925,2854,1626,1537cm-1
【0250】
○1−[2−(1−アダマンチル)エチル]−1−[2−(N−ベンジルオキシカルボニル−N−メチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−14)
IR(neat):3360,2902,2846,1772,1699,1634,1532cm-1
【0251】
○1−[2−(1−アダマンチル)エチル]−1−[2−(ジメチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−15)
IR(KBr):3322,2900,2845,1621,1526cm-1
mp:104.0−106.5℃
【0252】
○1−[2−(1−アダマンチル)エチル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−16)
IR(KBr):3331,2901,2846,1622,1602,1534cm-1
mp:99.0−103.0℃
【0253】
○1−[2−(1−アダマンチル)エチル]−1−(2−プロピニル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−17)
IR(KBr):3322,3204,2899,2845,2112,1626,1605,1543,1444cm-1
mp:152.0−154.0℃
【0254】
○1−[2−(1−アダマンチル)エチル]−1−(2−メトキシエチル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−18)
IR(KBr):3321,2900,2846,1625,1602,1534,1451cm-1
mp:101.5−104.5℃
【0255】
○1−[2−(1−アダマンチル)エチル]−1−シクロプロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−19)
IR(KBr):3365,2900,1633cm-1
mp:108.0−115.5℃
【0256】
○1−[2−(1−アダマンチル)エチル]−1−シアノメチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−20)
IR(neat):3350,2903,2247,1644cm-1
【0257】
○1−[2−(1−アダマンチル)エチル]−1−シクロペンチルメチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−21)
IR(KBr):3328,2906,2845,1615,1450cm-1
mp:155.0−158.0℃
【0258】
○1−[2−(1−アダマンチル)エチル]−1−シクロプロピルメチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−22)
IR(KBr):3328,2900,2845,1618,1534cm-1
mp:123.0−125.0℃
【0259】
○1−[2−(1−アダマンチル)エチル]−1−アリル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−23)
IR(KBr):3329,2900,1625,1538cm-1
mp:99.0−102.0℃
【0260】
○1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(3,3,3−トリフルオロプロピル)ウレア(化合物1−24)
IR(KBr):3310,2900,2847,1622,1543cm-1
mp:107.5−109.0℃
【0261】
○1−[2−(1−アダマンチル)エチル]−1−(2−ブテニル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−25)
IR(KBr):3328,2900,1619cm-1
mp:89.5−93.5℃
【0262】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−26)
IR(neat):3350,2903,2846,1694,1633,1537cm-1
【0263】
○1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(2−チエニル)メチルウレア(化合物1−27)
IR(KBr):3328,2900,2845,1626,1544cm-1
mp:142.5−144.5℃
【0264】
○1−[2−(1−アダマンチル)エチル]−1−ベンジルオキシ−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−28)
IR(neat):3444,3350,2902,2846,1666,1517cm-1
【0265】
○1−[2−(1−アダマンチル)エチル]−1−ヘキシル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−29)
IR(KBr):3354,2901,2845,1619,1538cm-1
mp:119.5−121.5℃
【0266】
○1−(1−アダマンチル)メチル−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−30)
IR(neat):3350,2902,1626cm-1
【0267】
○1−[2−(1−アダマンチル)エチル]−1−(3−メチル−2−ブテニル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−31)
IR(KBr):3358,2900,2845,1622,1526cm-1
mp:93.0−96.0℃
【0268】
○1−[2−(1−アダマンチル)エチル]−1−デシル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−32)
IR(KBr):3340,2924,2846,1626,1602,1534cm-1
mp:75.0−76.0℃
【0269】
○1−[2−(1−アダマンチル)エチル]−1−(2−メチル−2−プロペニル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−33)
IR(KBr):3336,2905,2846,1624,1544cm-1
mp:108.0−109.0℃
【0270】
○1−[2−(1−アダマンチル)エチル]−1−シンナミル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−34)
IR(KBr):3374,2899,2844,1619,1534cm-1
mp:130.0−134.5℃
【0271】
○1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−35)
IR(neat):3349,2901,1626,1536cm-1
【0272】
○1−(1−アダマンチル)メチル−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−36)
IR(neat):3349,2903,1625,1531cm-1
【0273】
○1−[2−(1−アダマンチル)エチル]−1−(2−メチルチアゾール−4−イル)メチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−37)
IR(neat):3337,2901,1632,1536cm-1
【0274】
○1,1−ジペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−38)
IR(neat):3347,2929,2859,1626,1537cm-1
【0275】
○1−ペンチル−1−(2−ピペリジノエチル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−39)
IR(neat):3350,2933,2856,1640,1533cm-1
【0276】
○1−[2−(1−アダマンチル)エチル]−1−メチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−40)
IR(KBr):3334,2901,2846,1626,1604,1534cm-1
mp:99.0−109.0℃
【0277】
○1−[2−(1−アダマンチル)エチル]−1−エチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−41)
IR(KBr):3324,2901,2845,1622,1540cm-1
mp:106.0−115.0℃
【0278】
○1−[2−(1−アダマンチル)エチル]−1−フルフリル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−42)
IR(KBr):3331,2900,2846,1618,1538cm-1
mp:128.0−130.0℃
【0279】
○1−[2−(1−アダマンチル)エチル]−1−ベンジル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−43)
IR(KBr):3335,2901,2847,1619,1538cm-1
mp:130.5−135.0℃
【0280】
○1−(2−シクロヘキシルエチル)−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−44)
IR(neat):3345,2923,1625,1603,1531cm-1
【0281】
○1−ペンチル−1−フェネチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−45)
IR(neat):3345,3063,2929,1625,1533cm-1
【0282】
○1−ブチル−1−(2−シクロヘキシルエチル)−3−(4−ピリジル)メチルウレア(化合物1−46)
IR(neat):3342,2922,2851,1629,1602,1563,1530,1448cm-1
【0283】
○1−(2−シクロヘキシルエチル)−1,3−ビス[(4−ピリジル)メチル]ウレア(化合物1−47)
IR(neat):3337,3029,2922,2850,1633,1602,1534,1445cm-1
【0284】
○1−(2−シクロヘキシルエチル)−3−(4−ピリジル)メチル−1−(2−チエニル)メチルウレア(化合物1−48)
IR(neat):3342,2921,2850,1631,1602,1562,1536,1415,1267,1227cm-1
【0285】
○1−[2−(t−ブトキシカルボニル)エチル]−1−(2−シクロヘキシルエチル)−3−(4−ピリジル)メチルウレア(化合物1−49)
IR(neat):3347,2977,2923,2851,1727,1633,1602,1563,1531,1449cm-1
【0286】
○1−(2−シクロヘキシルエチル)−1−[2−(メトキシカルボニル)エチル]−3−(4−ピリジル)メチルウレア(化合物1−50)
IR(neat):3348,2923,2850,1737,1633,1603,1563,1532,1437cm-1
【0287】
○1−(2−カルバモイルエチル)−1−(2−シクロヘキシルエチル)−3−(4−ピリジル)メチルウレア(化合物1−51)
IR(neat):3324,2922,2850,1673,1632,1606,1563,1530,1448cm-1
【0288】
○1−(2−シクロヘキシルエチル)−1−ペンチル−3−(4−ピリジル)メチルウレア(化合物1−52)
IR(KBr):3313,2925,1627,1602,1527,1410cm-1
mp:64.7−65.8℃
【0289】
○1−(2−シクロヘキシルエチル)−1−(2−ジメチルアミノエチル)−3−(4−ピリジル)メチルウレア(化合物1−53)
IR(KBr):3346,2922,2850,2778,1635,1562,1533,1448cm-1
【0290】
○1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−1−(2−シクロヘキシルエチル)−3−(4−ピリジル)メチルウレア(化合物1−54)
IR(neat):3338,2976,2924,2851,1694,1633,1602,1563,1531,1484,1450cm-1
【0291】
○1−ペンチル−1−[2−(2−ピリジル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−55)
IR(neat):3350,2929,2859,1633,1602,1537cm-1
【0292】
○1,1−ビス[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−56)
IR(neat):3358,2901,2845,1625,1530cm-1mp:80℃
【0293】
○1−[2−(1−アダマンチル)エチル]−1−ブチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−57)
IR(KBr):3315,2901,1618,1534cm-1
mp:109.5−118.0℃
【0294】
○1,1−ビス(2−ヒドロキシプロピル)−3−[3−(4−ピリジル)プロピル]ウレア 塩酸塩(化合物1−58)
IR(neat):3350,1688,1638,1538cm-1
【0295】
○1−[ビス(t−ブトキシカルボニルアミノメチル)]メチル−1−イソペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−59)
IR(neat):3326,2960,1698,1631,1525cm-1
【0296】
○1−シクロヘキシル(フェニル)メチル−1−(3−フェニルプロピル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−60)
IR(KBr):3352,2931,1619,1522cm-1
mp:107.0−112.0℃
【0297】
○1,1−ジシクロヘキシル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−61)
IR(KBr):3304,2930,2848,1638,1602,1533cm-1
mp:143.0−145.5℃
【0298】
○1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−1−フェネチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−62)
IR(neat):3350,1694,1633,1532,1166cm-1
【0299】
○1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−63)
IR(neat):3350,1694,1632,1537,1167cm-1
【0300】
○1−[2−(N−ベンジルオキシカルボニル−N−メチルアミノ)エチル]−1−フェネチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−64)
IR(neat):3350,1698,1632,1531cm-1
【0301】
○1−[3−(1−アダマンチル)プロピル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−65)
IR(KBr):3333,2901,2844,1623,1602,1543cm-1
【0302】
○1−[2−(1−アダマンチル)エチル]−3−ペンチル−1−[3−(4−ピリジル)プロピル]ウレア(化合物1−66)
IR(KBr):3370,3322,2903,2846,1618,1534cm-1
mp:47.0−50.0℃
【0303】
○3−[2−(1−アダマンチル)エチル]−1−[2−(t−ブトキシカルボニル)エチル]−1−[3−(4−ピリジル)プロピル]ウレア(化合物1−67)
IR(neat):3348,2902,2846,1726,1627,1538,1367,1152cm-1
【0304】
○1−[2−(1−アダマンチル)エチル]−1−イソプロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−68)
IR(KBr):3330,2903,2845,1614,1533cm-1
mp:132.0−134.0℃
【0305】
○1−[2−(1−アダマンチル)エチル]−1−[2−(t−ブトキシカルボニル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−69)
IR(KBr):3356,2903,1720,1622,1538,1156cm-1
mp:124.5−127.0℃
【0306】
○1−[2−(1−アダマンチル)エチル]−1−シクロペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−70)
IR(KBr):3297,2906,2844,1618,1544cm-1
mp:135.5−137.5℃
【0307】
○1−[2−(1−アダマンチル)エチル]−1−(t−ブトキシカルボニルアミノ)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−71)
IR(neat):3231,2903,1732,1650cm-1
【0308】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−(2−ピリジル)メチルウレア(化合物1−72)
IR(KBr):3333,2900,2844,1625,1535cm-1
mp:87.5−92.0℃
【0309】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−(3−ピリジル)メチルウレア(化合物1−73)
IR(KBr):3328,2901,2846,1622,1530cm-1
mp:88.5−101.5℃
【0310】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−(4−ピリジル)メチルウレア(化合物1−74)
IR(KBr):3331,2900,2845,1626,1538cm-1
mp:96.5−108.0℃
【0311】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(2−ピリジル)エチル]ウレア(化合物1−75)
IR(KBr):3346,2904,2845,1622,1539cm-1
mp:80.0−100.0℃
【0312】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(3−ピリジル)エチル]ウレア(化合物1−76)
IR(KBr):3334,2900,2845,1618,1541cm-1
mp:112.5−114.5℃
【0313】
○1−(2−シクロヘキシルエチル)−1−(2−メトキシエチル)−3−(4−ピリジル)メチルウレア(化合物1−77)
IR(neat):3350,2922,2850,1633,1603,1534cm-1
【0314】
○1−[2−(N−ベンジルオキシカルボニル−N−メチルアミノ)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−78)
IR(neat):3358,2930,1701,1633,1534cm-1
【0315】
○1−エチル−3−[3−(4−ピリジル)プロピル]−1−(3,4,5−トリメトキシフェネチル)ウレア(化合物1−79)
IR(neat):3350,2936,1626,1590,1530,1239cm-1
【0316】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジル)エチル]ウレア(化合物1−80)
IR(KBr):3346,2901,2844,1622,1538cm-1
mp:107−118℃
【0317】
○1−[2−(1H−5−イミダゾリル)エチル]−1−イソペンチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−81)
IR(neat):3117,2954,1606,1537cm-1
【0318】
○1−シクロヘキシル−1−(3,4−ジメトキシフェネチル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−82)
IR(neat):3353,2931,1621,1515,1236,1029cm-1
【0319】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(2−ピリジル)プロピル]ウレア(化合物1−83)
IR(KBr):3324,2900,2845,1622,1538cm-1
mp:84.4−85.7℃
【0320】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(3−ピリジル)プロピル]ウレア(化合物1−84)
IR(KBr):3355,2902,2845,1615,1526cm-1
mp:99.9−105.2℃
【0321】
○1−シクロプロピル−3−[3−(4−ピリジル)プロピル]−1−(3,4,5−トリメトキシフェネチル)ウレア(化合物1−85)
IR(neat):3400,2938,1644,1590,1510,1239,1128cm-1
【0322】
○1−[2−(1−アダマンチル)エチル]−3−(4−ジメチルアミノ)フェネチル−1−ペンチルウレア(化合物1−86)
IR(KBr):3341,2900,2845,1619,1526cm-1
mp:115.8−118.1℃
【0323】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[4−(4−ピリジル)ブチル]ウレア(化合物1−87)
IR(KBr):3354,2900,2844,1618,1538cm-1
mp:74.1−78.1℃
【0324】
○1−[2−(1−アダマンチル)エチル]−3−(t−ブトキシカルボニル)−1−ペンチル−3−[2−(4−ピリジル)オキシエチル]ウレア(化合物1−88)
IR(neat):2903,2847,1704,1590cm-1
【0325】
○1−[2−(1−アダマンチル)エチル]−1−[3−[N−(t−ブトキシカルボニル)−N−メチルアミノ]プロピル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−89)
IR(neat):3350,2903,2847,1694,1632,1531cm-1
【0326】
○1−シクロヘキシル(フェニル)メチル−1−[3−(4−メトキシフェノキシ)プロピル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−90)
IR(neat):3369,2930,1626,1510,1231cm-1
【0327】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−キノリル)プロピル]ウレア(化合物1−91)
IR(KBr):3354,2902,2845,1622,1534cm-1
mp:80.2−102.0℃
【0328】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(1−イミダゾリルカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−92)
IR(neat):3366,2902,2846,1695,1635,1604,1531cm-1
【0329】
○1−ジフェニルメチル−1−(3−フェニルプロピル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−93)
IR(KBr):3334,3026,2927,1621,1522cm-1
mp:123.0−124.8℃
【0330】
○1,1−ジ−(5−ヘキセニル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−94)
IR(neat):3350,3074,2930,2859,1621,1538cm-1
【0331】
○1,1−ジ−(7−オクテニル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−95)
IR(neat):3349,3074,2927,2856,1625,1537cm-1
【0332】
○4−[2−[3−[2−(1−アダマンチル)エチル]−3−ペンチル]ウレイドエチル]ベンゼンスルホン酸アミド(化合物1−96)
IR(KBr):3423,2906,2847,1598,1540,1161cm-1
mp:85.0−120.7℃
【0333】
○1−[2−(1−アダマンチル)エチル]−3−(1−イミダゾリル)プロピル−1−ペンチルウレア(化合物1−97)
IR(KBr):3340,2902,2845,1618,1534cm-1
mp:97.0−100.0℃
【0334】
○1−[2−(1−アダマンチル)エチル]−3−(4−ヒドロキシフェネチル)−1−ペンチルウレア(化合物1−98)
IR(KBr):3392,2902,2845,1614,1535,1515cm-1
mp:96.3−99.4℃
【0335】
○1−[2−(1−アダマンチル)エチル]−1−[2−(3−t−ブチル−1−メチルウレイド)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−99)
IR(neat):3310,2903,1632,1537cm-1
【0336】
○1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−100)
IR(KBr):3347,2957,2902,2846,1621,1604,1539cm-1
mp:105.3−112.3℃
【0337】
○1−[2−(1−アダマンチル)エチル]−1−[2−(1−メチル−3−プロピルウレイド)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−101)
IR(neat):3316,2902,1631,1537cm-1
【0338】
○1−ペンチル−1−(3−フェニルプロピル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−102)
IR(neat):3348,2929,1625,1537cm-1
【0339】
○1−[2−(アセチルアミノ)エチル]−1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−103)
IR(neat):3291,2902,2846,1632,1556,753cm-1
【0340】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)ブチル]ウレア(化合物1−104)
IR(KBr):3346,2901,2845,1618,1601,1539cm-1
mp:93.0−98.0℃
【0341】
○1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(4,4,4−トリフルオロブチル)ウレア(化合物1−105)
IR(KBr):3317,2901,2846,1618,1538,1255,1123cm-1
mp:142.6−145.0℃
【0342】
○1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(5,5,5−トリフルオロペンチル)ウレア(化合物1−106)
IR(KBr):3333,2900,2846,1618,1534,1259,1140cm-1
mp:116.9−118.9℃
【0343】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア(化合物1−107)
IR(neat):3350,2902,2846,1694,1672,1633,1603,1537cm-1
【0344】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジルメチル)ブチル]ウレア(化合物1−108)
IR(KBr):3347,2900,2845,1622,1538cm-1
mp:72.0−77.0℃
【0345】
○1−[2−(1−アダマンチル)エチル]−3−[2−ベンジル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−109)
IR(KBr):3329,2902,2846,1622,1544cm-1
mp:111.0−116.0℃
【0346】
○1−[2−(1−アダマンチル)エチル]−3−[2,2−ビス(4−ピリジルメチル)エチル]−1−ペンチルウレア(化合物1−110)
IR(KBr):3330,2905,2845,1619,1602,1534cm-1
mp:124.0−136.0℃
【0347】
○(Z)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア(化合物1−111)
IR(neat):3338,2901,2846,1625,1596,1530cm-1
【0348】
○(E)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア(化合物1−112)
IR(KBr):3315,2900,2845,1623,1526cm-1
mp:90−118℃
【0349】
○1−イソペンチル−3−[3−(4−ピリジル)プロピル]−1−(3,3,3−トリフルオロプロピル)ウレア(化合物1−113)
IR(neat):3342,2956,1628,1604,1539cm-1
【0350】
○1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]−1−(2,2,2−トリフルオロエチル)ウレア(化合物1−114)
IR(KBr):3346,2901,2847,1630,1604,1544,1145,1108cm-1
mp:106.2−107.3℃
【0351】
○3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチル−1−フェネチルウレア(化合物1−115)
IR(KBr):3352,2927,2858,1622,1530,1496,1453,1416,1276cm-1
mp:49.0−50.0℃
【0352】
○1,1−ジブチル−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア(化合物1−116)
IR(neat):3347,2957,2929,1624,1534cm-1
【0353】
○1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−(3,3,3−トリフルオロプロピル)ウレア(化合物1−117)
IR(KBr):3354,2901,2847,1626,1540cm-1
mp:81.1−84.1℃
【0354】
○1−(2−シクロヘキシルエチル)−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−118)
IR(neat):3346,2923,2852,1625,1533cm-1
【0355】
○1−(3−シクロヘキシルプロピル)−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−119)
IR(neat):3346,2922,1626,1537cm-1
【0356】
○(−)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−120)
IR(KBr):3337,2900,1616,1526cm-1
mp:103.0−104.0℃
[α]20 D:−4.6°(MeOH,C1.0)
【0357】
○(+)−1−[2−(1−アダマンチル)エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−121)
IR(KBr):3336,2900,1616,1526cm-1
mp:102.9−103.5℃
[α]20 D:+4.2°(MeOH,C1.0)
【0358】
○1−[3−(1−アダマンチル)プロピル]−1−ブチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−122)
IR(KBr):3323,2954,2904,2846,1624,1603,1548cm-1
mp:79.8−80.4℃
【0359】
○1−[3−(1−アダマンチル)プロピル]−3−[3−(4−ピリジル)プロピル]−1−(2,2,2−トリフルオロエチル)ウレア(化合物1−123)
IR(KBr):3355,2902,2848,1627,1605,1545,1145,1112cm-1
mp:88.9−90.0℃
【0360】
○1−[4−(1−アダマンチル)ブチル]−1−エチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−124)
IR(KBr):3352,2897,2847,1626,1604,1539cm-1
mp:92.7−93.7℃
【0361】
○1−[4−(1−アダマンチル)ブチル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−125)
IR(KBr):3343,2900,2847,1625,1604,1544cm-1
mp:110.0−110.5℃
【0362】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジルアミノ)エチル]ウレア(化合物1−126)
IR(KBr):3301,2904,2848,1628,1602,1527cm-1
mp:133.9−134.5℃
【0363】
○(+)−1−[3−(1−アダマンチル)プロピル]−3−[2−メチル−3−(4−ピリジル)プロピル]−1−プロピルウレア(化合物1−127)
IR(neat):3350,2902,2846,1625,1534cm-1[α]20 D:+4.2°(MeOH,C0.51)
【0364】
○1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−(4−ピリジル)メチルウレア(化合物1−128)
IR(KBr):3319,2902,1630,1604,1537cm-1
mp:96.0−98.0℃
【0365】
○1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−[2−(4−ピリジル)エチル]ウレア(化合物1−129)
IR(neat):3345,2901,1634,1538cm-1
【0366】
○1−[3−(1−アダマンチル)プロピル]−1−エチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−130)
IR(KBr):3345,2969,2905,2845,1622,1605,1535cm-1
mp:97.5−98.2℃
【0367】
○1−[2−(1−アダマンチルオキシ)エチル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−131)
IR(neat):3344,2911,2853,1642,1603,1534cm-1
【0368】
○1−(1−アダマンチル)アミノカルボニルメチル−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−132)
IR(KBr):3335,3261,2910,2853,1662,1622,1543cm-1
mp:132.0−132.5℃
【0369】
○1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−[4−(4−ピリジル)ブチル]ウレア(化合物1−133)
IR(neat):3350,2901,1623,1532cm-1
【0370】
○1−[3−(1−アダマンチル)プロピル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−134)
IR(neat):3347,2902,2846,1696,1632,1603,1534,1167cm-1
【0371】
○1−[2−(1−アダマンチル)エチル]−3−[2,2−ジメチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−135)
IR(KBr):3338,2905,1620,1600,1541cm-1
mp:82.5−84.9℃
【0372】
○1−[3−(1−アダマンチル)プロピル]−3−[3−(4−ピリジル)プロピル]−1−(3,3,3−トリフルオロプロピル)ウレア(化合物1−136)
IR(neat):3349,2902,1628,1538cm-1
【0373】
○1−[2−(1−アダマンチル)エチル]−3−[1−メチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−137)
IR(KBr):3338,2902,2847,1615,1533cm-1
mp:128.5−129.0℃
【0374】
○1−[2−(1−アダマンチル)エチル]−3−[3−(t−ブチルジメチルシリルオキシ)−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−138)
IR(neat):3355,2904,2849,1628,1600,1532,1099cm-1
【0375】
○(+)−1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア(化合物1−139)
IR(KBr):3345,2910,2848,1693,1622,1602,1538,1248cm-1
mp:122.7−123.7℃
[α]20 D:+2.8°(MeOH,C1.0)
【0376】
○1−[2−(1−アダマンチル)アミノエチル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−140)
IR(neat):3275,2908,2849,1636,1536cm-1
【0377】
○1−[2−(1−アダマンチル)エチル]−1−(2−ブチニル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物1−141)
IR(neat):3351,2903,2847,2290,2221,1630,1605,1538cm-1
【0378】
○1−[2−(1−アダマンチル)エチル]−3−[1,2−ジメチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−142)
IR(neat):3354,2904,2847,1623,1604,1525cm-1
【0379】
○1−[2−(1−アダマンチル)エチル]−3−[1−エチル−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−143)
IR(neat):3352,2904,2847,1622,1605,1529cm-1
【0380】
○1−[2−(1−アダマンチル)エチル]−3−[3−(t−ブチルジフェニルシリルオキシ)−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物1−144)
IR(neat):3360,3072,3050,2903,2849,1634,1602,1532,1428cm-1
【0381】
本化合物製造例2
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−プロピルアミド(化合物2−1)
中間体1−6の2−(1−アダマンチル)−N−プロピルエチルアミン(0.37g、1.7mmol)、 中間体5−1の5−(4−ピリジル)吉草酸(0.30g、1.7mmol)にN,N−ジメチルホルムアミド(8.4ml)を加え、室温で攪拌した。N−メチルモルホリン(0.27ml、2.5mmol)、次いで1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩(0.38g、2.0mmol)を加えて一夜攪拌した。反応溶液を減圧濃縮し、残留物に酢酸エチル(20ml)を加え、飽和重曹水(20ml)飽和食塩水(5ml)の順で洗浄した。硫酸ナトリウムで乾燥後酢酸エチルを減圧留去した。残留物を塩基性シリカゲルカラムクロマトグラフィーで分離精製すると、標的化合物0.21g(33%)が無色油状物として得られた。
【0382】
IR(neat):2092,2846,1644,1602cm-1
本化合物製造例2と同様の操作を行うことにより、以下の化合物が得られた。
【0383】
○5−(4−ピリジル)吉草酸 N−(1−アダマンチル)メチル−N−プロピルアミド(化合物2−2)
IR(neat):3067,2903,2847,1644,1602cm-1
【0384】
○5−(4−ピリジル)吉草酸 N−(1−アダマンチル)メチル−N−ペンチルアミド(化合物2−3)
IR(neat):2903,2847,1644,1601,1454cm-1
【0385】
○5−(4−ピリジル)吉草酸 N,N−ジブチルアミド(化合物2−4)
IR(neat):2958,2932,1641,1602cm-1
【0386】
○5−(4−ピリジル)吉草酸 N,N−ジイソペンチルアミド(化合物2−5)
IR(neat):2956,2870,1639,1603cm-1
【0387】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−(2−ブテニル)アミド(化合物2−6)
IR(neat):2903,2847,1642,1602cm-1
【0388】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−[2−[N’−(t−ブトキシカルボニル)−N’−メチルアミノ]エチル]アミド(化合物2−7)
IR(neat):2904,2847,1695,1644,1602cm-1
【0389】
○5−(4−ピリジル)吉草酸 N−[3−(1−アダマンチル)プロピル]−N−プロピルアミド(化合物2−8)
IR(neat):2902,2846,1643,1602cm-1
【0390】
○5−(4−ピリジル)吉草酸 N−ペンチル−N−フェネチルアミド(化合物2−9)
IR(neat):2930,2860,1642,1602cm-1
【0391】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−(2−ジメチルアミノエチル)アミド(化合物2−10)
IR(neat):2903,2847,1639,1605cm-1
【0392】
○5−(4−ピリジル)吉草酸 N−(2−シクロヘキシルエチル)−N−ペンチルアミド(化合物2−11)
IR(neat):2924,2853,1644,1601cm-1
【0393】
○5−(4−ピリジル)吉草酸 N,N−ビス[2−(1−アダマンチル)エチル]アミド(化合物2−12)
IR(neat):2901,2846,1643,1602cm-1
【0394】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−(3,3,3−トリフルオロプロピル)アミド(化合物2−13)
IR(neat):2904,2848,1647,1602cm-1
【0395】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−14)
IR(neat):2903,2847,1736,1643,1602cm-1
【0396】
○3−(4−ピリジルメチルチオ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−15)
IR(neat):2903,1643,1599cm-1
【0397】
○2−メチル−3−(4−ピリジルメチルチオ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−16)
IR(neat):2903,1639,1600cm-1
【0398】
○2−(t−ブトキシカルボニル)アミノ−3−(4−ピリジルメチルチオ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−17)
IR(neat):3284,2903,1705,1644cm-1
【0399】
○2−[2−(4−ピリジル)エチルチオ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−18)
IR(neat):2902,1635,1602cm-1
【0400】
○(2R)−2−(t−ブトキシカルボニル)アミノ−3−[2−(4−ピリジル)エチルチオ]プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−19)
IR(neat):3287,2903,1705,1644,1602cm-1[α]20 D:−19.0°(MeOH,C0.43)
【0401】
○ 6−(4−ピリジル)カプロン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−20)
IR(neat):2903,1644,1602cm-1
【0402】
○4−(4−ピリジル)酪酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物2−21)
IR(neat):2903,1644,1602cm-1
【0403】
本化合物製造例3
○1−[2−(1−アダマンチル)エチル]−1−(2−メチルアミノエチル)−3−[3−(4−ピリジル)プロピル]ウレア 二塩酸塩(化合物3−1)
化合物1−26の1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(0.30g、0.60mmol)にメタノール(4.4ml)を加え、塩化カルシウム管を付けて室温で攪拌した。10%塩化水素メタノール溶液(4.4ml)を加え一日攪拌後減圧濃縮すると、標的化合物0.30g(定量的)が淡黄色非結晶性粉末として得られた。
【0404】
IR(neat):3351,2904,2846,1634,1538cm-1
【0405】
本化合物製造例3と同様の操作を行うことにより、以下の化合物が得られた。
【0406】
○1−(2−シクロヘキシルエチル)−1−(2−メチルアミノエチル)−3−(4−ピリジル)メチルウレア 二塩酸塩(化合物3−2)
IR(neat):3323,2923,2850,1638,1529,1449cm-1
【0407】
○1−[2−(1−アダマンチル)エチル]−1−アミノ−3−[3−(4−ピリジル)プロピル]ウレア 二塩酸塩(化合物3−3)
IR(KBr):3410,2902,1637cm-1
mp:約100℃
【0408】
○2−アミノ−3−(4−ピリジルメチルチオ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 二塩酸塩(化合物3−4)
IR(neat):3402,2901,1638,1608,1503cm-1
【0409】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−(2−メチルアミノエチル)アミド (化合物3−5)
IR(neat):3312,2902,2846,1643,1602,1450,1416cm-1
【0410】
○(2R)−2−アミノ−3−[2−(4−ピリジル)エチルチオ]プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 二塩酸塩(化合物3−6)
IR(KBr):3423,2902,1638,1609cm-1
[α]20 D:−4.9°(H2O,C0.52)
【0411】
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジル)オキシエチル]ウレア(化合物3−7)
IR(neat):3246,2903,2846,1698,1604cm-1
【0412】
本化合物製造例4
○4−[3−[3−[2−(1−アダマンチル)エチル]−3−ペンチルウレイド]プロピル]−1−メチルピリジニウム ヨード塩(化合物4−1)
室温下、化合物1−1の1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(0.30g,0.73mmol)のアセトン(1.5ml)溶液にヨウ化メチル(90μl,1.5mmol)を加え、一晩攪拌した。反応液を減圧下溶媒留去した後、酢酸エチルで析出した結晶を濾取すると標的化合物389mg(96%)が得られた。
【0413】
IR(KBr):3374,2926,2900,1616,1526cm-1
mp:168.0−171.0℃
【0414】
本化合物製造例4と同様の操作を行うことにより、以下の化合物が得られた。
【0415】
○4−[3−[3−[2−(1−アダマンチル)エチル]−3−[2−[N−(t−ブトキシカルボニル)−N−メチルアミノ]エチル]ウレイド]プロピル]−1−メチルピリジニウム ヨード塩(化合物4−2)
IR(neat):3342,2903,2846,1682,1644,1520,1235,1166cm-1
【0416】
○4−[3−[3−[2−(1−アダマンチル)エチル]−3−[2−[N−(t−ブトキシカルボニル)アミノ]エチル]ウレイド]プロピル]−1−ベンジルピリジニウム 臭素塩(化合物4−3)
IR(KBr):3312,2907,2846,1714,1694,1625,1534,1246,1171cm-1
mp:97℃
【0417】
本化合物製造例5
○N−[2−(1−アダマンチル)エチル]−N−ペンチルカルバミン酸 3−(4−ピリジル)プロピルエステル(化合物5−1)
室温下、4−ピリジンプロパノール(528mg,3.85mmol)をアセトニトリル(20ml)に溶解し、次にトリエチルアミン(1.61ml,11.6mmol)を加えた。さらに炭酸N,N’−ジスクシンイミジルエステル(1.48g,5.87mmol)を加え、2.5時間攪拌した。反応混合物を減圧下濃縮し、残留物に酢酸エチル(100ml)、飽和炭酸水素ナトリウム水溶液(50ml)を加えて分液後、得られた有機層を飽和塩化ナトリウム水溶液(50ml)で洗浄した。無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。残留物を減圧乾燥後、無水塩化メチレン(10ml)に溶解した。次に中間体1−1の2−(1−アダマンチル)−N−ペンチルエチルアミン塩酸塩(1.32g,4.62mmol)とトリエチルアミン(0.80ml,5.7mmol)の塩化メチレン(90ml)溶液を加え、1.5時間攪拌した。反応混合物を、飽和炭酸水素ナトリウム水溶液(50ml)、飽和塩化ナトリウム水溶液(50ml)で順次洗浄し、無水硫酸ナトリウムで乾燥した。減圧下溶媒を留去し、残留物をシリカゲルカラムクロマトグラフィーで精製すると、標的化合物1.54g(97%)が油状物として得られた。
【0418】
IR(neat):2903,2847,1742,1698cm-1
【0419】
本化合物製造例5と同様の操作を行うことにより、以下の化合物が得られた。
【0420】
○1−[2−(1−アダマンチル)エチル]−1−[2−(N−シクロヘキシルオキシカルボニル−N−メチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物5−2)
IR(neat):3350,2904,2847,1682,1633,1604,1531cm-1
【0421】
○N−[3−(1−アダマンチル)プロピル]−N−プロピルカルバミン酸 3−(4−ピリジル)プロピルエステル(化合物5−3)
IR(neat):2901,2846,1740,1695,1645,1602,1451,1423cm-1
【0422】
○N−[2−(1−アダマンチル)エチル]−N−(3,3,3−トリフルオロプロピル)カルバミン酸 3−(4−ピリジル)プロピルエステル(化合物5−4)
IR(neat):2903,2847,1705,1603,1482,1451,1425cm-1
【0423】
○N−[2−(1−アダマンチル)エチル]−N−[2−[N’−(t−ブトキシカルボニル)−N’−メチルアミノ]エチル]カルバミン酸 3−(4−ピリジル)プロピルエステル(化合物5−5)
IR(neat):2903,2847,1699,1603,1480,1424cm-1
【0424】
○N−[2−(1−アダマンチル)エチル]−N−ペンチルカルバミン酸 2−メチル−3−(4−ピリジル)プロピルエステル(化合物5−6)
IR(neat):2904,2847,1701,1602,1450,1424,1381cm-1
【0425】
本化合物製造例6
○1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ヘキサヒドロ−2,4−ピリミジンジオン 塩酸塩(化合物6−1)
化合物1−69の1−[2−(1−アダマンチル)エチル]−1−[2−(t−ブトキシカルボニル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(0.23g,0.49mmol)に4N塩化水素1,4−ジオキサン溶液(2.5ml)を加え室温で一晩攪拌した。反応後減圧濃縮し、残査に1N水酸化ナトリウム水溶液(20ml)と酢酸エチル(30ml)を加え分液した。酢酸エチル層を水(20ml)、飽和塩化ナトリウム水溶液(20ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧濃縮後得られた油状物をジエチルエーテル(20ml)に溶解し4N塩化水素酢酸エチル溶液(0.50ml,2.00mol)を氷冷下加えた後減圧濃縮し、析出した固体を酢酸エチルで濾取すると、標的化合物0.17g(79%)が得られた。
【0426】
IR(KBr):2902,2437,1710,1666cm-1
mp:177.0−178.5℃
【0427】
本化合物製造例6と同様の操作を行うことにより、以下の化合物が得られた。
【0428】
○1−[2−(シクロヘキシル)エチル]−3−(4−ピリジル)メチルヘキサヒドロ−2,4−ピリミジンジオン 塩酸塩(化合物6−2)
IR(KBr):2925,2850,1718,1671,1600,1493,1450cm-1
mp:64.0−74.5℃
【0429】
○3−[2−(1−アダマンチル)エチル]−1−[3−(4−ピリジル)プロピル]ヘキサヒドロ−2,4−ピリミジンジオン 塩酸塩(化合物6−3)
IR(KBr):2906,2845,1716,1696,1658,1486cm-1
mp:170℃
【0430】
本化合物製造例7
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]チオウレア(化合物7−1)
窒素雰囲気下1,1’−チオカルボニルジイミダゾール(0.31g,1.8mmol)に中間体2−1の4−(3−アミノプロピル)ピリジン(0.24g,1.8mmol)の無水テトラヒドロフラン(10ml)溶液を加え室温で攪拌した。1時間後、中間体1−1の2−(1−アダマンチル)−N−ペンチルエチルアミン塩酸塩(0.50g,1.8mmol)の無水テトラヒドロフラン(10ml)溶液を加え2.5時間加熱還流した。放冷後反応液に酢酸エチル(50ml)と飽和炭酸水素ナトリウム水溶液(50ml)を加え分液した。酢酸エチル層を飽和塩化ナトリウム水溶液(50ml)で洗浄したのち無水硫酸マグネシウムで乾燥した。減圧濃縮後、シリカゲルカラムクロマトグラフィーにて精製を行うと標的化合物0.18g(24%)が得られた。
【0431】
IR(neat):3304,2902,2846,1603,1530,1345cm-1
【0432】
本化合物製造例7と同様の操作を行うことにより、以下の化合物が得られた。
【0433】
○1−(2−ヒドロキシエチル)−1−フェネチル−3−[3−(4−ピリジル)プロピル]チオウレア(化合物7−2)
IR(KBr):3022,2920,2876,1606,1585cm-1
mp:105.6−107.1℃
【0434】
本化合物製造例8
○1−フェネチル−3−[3−(4−ピリジル)プロピル]−2−イミダゾリジンチオン(化合物8−1)
化合物7−2の1−(2−ヒドロキシエチル)−1−フェネチル−3−[3−(4−ピリジル)プロピル]チオウレア(601mg、1.75mmol)、トリフェニルホスフィン(913mg、3.49mmol)に無水テトラヒドロフラン(2.5ml)を加え、氷/メタノール下攪拌した。アゾジカルボン酸ジイソプロピルエステル(710mg、3.49mmol)の無水テトラヒドロフラン溶液を滴下し、10分後酢酸エチル(100ml)を加えた。飽和重曹水(40ml)、飽和食塩水(40ml)の順で洗浄し、硫酸ナトリウムで乾燥後、有機層を減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで精製し、得られた固体をヘキサンで濾取すると、標的化合物107mg(19%)が結晶として得られた。
【0435】
IR(KBr):3064,3018,2926,2858,1601,1560,1498,1456cm-1
mp:99.5−104.0℃
【0436】
本化合物製造例9
○1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ヘキサヒドロピリミジン−2−オン(化合物9−1)
1−アダマンタン酢酸(1.50g,7.72mmol)の無水塩化メチレン(30.0ml)溶液に1−ヒドロキシベンゾトリアゾール(1.15g,8.49mmol)、β−アラニンエチルエステル塩酸塩(1.30g,8.49mmol)、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩(1.63g,8.49mmol)、N −メチルモルホリン(2.05ml,18.7mmol)を氷冷下加えた後、室温で一夜攪拌した。反応溶液を減圧下濃縮し、残留物に酢酸エチル(50ml)を加えた。10%クエン酸水溶液(50ml)、水(50ml)、飽和炭酸水素ナトリウム水溶液(50ml)、水(50ml)、飽和塩化ナトリウム水溶液(50ml)の順で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下濃縮すると、3−[1−(アダマンチル)メチルカルボキサミド]プロピオン酸エチルエステル2.48g(定量的)が白色個体として得られた。
【0437】
ついで、3−[(1−アダマンチル)メチルカルボキサミド]プロピオン酸エチルエステル(2.40g,8.18mmol)をエタノール(5ml)に溶解し、2N水酸化ナトリウム水溶液(4.50ml,9.00mmol)を氷冷下加えた後室温で2時間攪拌した。反応溶液に氷冷下2N塩酸(15ml)を加え弱酸性とした後、酢酸エチル(70ml)を加え抽出した。有機層を水(50ml)、飽和塩化ナトリウム水溶液(50ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下濃縮後析出する固体をジエチルエーテルを用いて濾取すると、3−[(1−アダマンチル)メチルカルボキサミド]プロピオン酸1.43g(70.1%)が得られた。
【0438】
ついで、3−[(1−アダマンチル)メチルカルボキサミド]プロピオン酸(1.4g,5.6mmol)の無水塩化メチレン(10ml)溶液に1−ヒドロキシベンゾトリアゾール(0.83g,6.2mmol)、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩(1.2g,6.2mmol)、中間体2−1の4−(3−アミノプロピル)ピリジン(0.80g,5.9mmol)、N −メチルモルホリン(0.68ml,6.2mmol)を氷冷下加えた後、室温で一夜攪拌した。反応溶液を減圧下濃縮し、残留物に酢酸エチル(50ml)を加え、飽和炭酸水素ナトリウム水溶液(30ml)、水(30ml)、飽和塩化ナトリウム水溶液(30ml)の順で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下濃縮し析出した固体をジエチルエーテルを用いて濾取すると、3−[(1−アダマンチル)メチルカルボキサミド]プロピオン酸
3−(4−ピリジル)プロピルアミド1.9g(88%)が得られた。
【0439】
水素化リチウムアルミニウム(0.45g,12mmol)に氷冷下無水ジエチルエーテル(20ml)を加えた。次いで得られた3−[(1−アダマンチル)メチルカルボキサミド]プロピオン酸 3−(4−ピリジル)プロピルアミド(0.50g,1.3mmol)の無水テトラヒドロフラン(10ml)溶液を15分間で滴下後、室温で一夜攪拌し、さらに4.5時間加熱環流後、反応溶液に氷冷下2N水酸化ナトリウム水溶液(30ml)および酢酸エチル(30ml)を注意深く加えたのち分液した。酢酸エチル層を水(30ml)および飽和塩化ナトリウム水溶液(30ml)で洗浄し無水硫酸マグネシウムで乾燥した。減圧下濃縮後、残留物をシリカゲルカラムクロマトグラフィーで精製すると、N−[2−(1−アダマンチル)エチル]−N’ −[3−(4−ピリジル)プロピル]−1,3−プロパンジアミン0.05g(10%)が得られた。
【0440】
得られたN −[2−(1−アダマンチル)エチル]−N ’−[3−(4−ピリジル)プロピル]−1,3−プロパンジアミン(80mg,0.23mmol)の無水塩化メチレン(10ml)溶液と1,1’−カルボニルジイミダゾール(40mg,0.26mmol)の無水塩化メチレン(10ml)溶液を無水塩化メチレン(50ml)に20分間かけて室温で攪拌しながら同時に滴下した。一夜攪拌した後減圧下濃縮し、残留物をシリカゲルカラムクロマトグラフィーにて精製し、標的化合物8.0mg(9.4%)を得た。
【0441】
IR(neat):3400,2902,2846,1625,1531,1451cm-1
【0442】
本化合物製造例10
○1−アセチルアミノ−1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−1)
室温下、化合物3−3の1−[2−(1−アダマンチル)エチル]−1−アミノ−3−[3−(4−ピリジル)プロピル]ウレア二塩酸塩(0.20g, 0.47mmol)にピリジン(2.0ml)と無水酢酸(1.0ml)を加え、15分攪拌した。反応液を減圧下溶媒留去後、酢酸エチル(10ml)と水(10ml)で分配した。有機層を飽和重曹水(10ml)と飽和食塩水(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下溶媒留去し、残留物をシリカゲルカラムクロマトグラフィーにより精製し、標的化合物0.11g(58%)を得た。
【0443】
IR(KBr):3374,3163,2907,1694,1638cm-1
mp:140.0−146.0℃
【0444】
本化合物製造例10と同様の操作を行うことにより、以下の化合物が得られた。なお、必要に応じて酸塩化物を用いた。
【0445】
○1−[2−(N−アセチル−N−メチルアミノ)エチル]−1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−2)
IR(neat):3337,2902,1632,1535,1492cm-1
【0446】
○1−[2−(1−アダマンチル)エチル]−1−[2−( N−イソニコチノイル−N−メチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−3)
IR(neat):3350,2902,2846,1633,1531,1450,1408cm-1
【0447】
○1−[2−(1−アダマンチル)エチル]−1−[2−[ N−メチル−N−(メチルスルホニル)アミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−4)
IR(KBr):3319,2902,2845,1616,1540,1326,1142cm-1
mp:164.9−167.2℃
【0448】
○1−[2−(1−アダマンチル)エチル]−1−[2−[ N−メチル−N−(p−トリルスルホニル)アミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−5)
IR(neat):3358,2902,2846,1633,1603,1531,1343,1161cm-1
【0449】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(3,3−ジメチルブチリル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−6)
IR(KBr):3325,2906,2845,1652,1616,1534cm-1
mp:101.4−102.4℃
【0450】
○1−[2−(1−アダマンチル)エチル]−1−[2−(N−エトキシカルボニル−N−メチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−7)
IR(neat): 3350,2902,2846,1698,1633,1532cm-1
【0451】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)アミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−8)
IR(KBr):3312,2905,2845,1710,1637,1606,1534,1269,1249,1174cm-1
mp:158.0−160.5℃
【0452】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(t−ブトキシカルボニル)−N−エチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−9)
IR(neat): 3349,2902,2846,1693,1667,1633,1603,1531,1452,1416cm-1
【0453】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(1,1−ジメチル−2,2,2−トリクロロエトキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−10)
IR(neat): 3359,2903,2846,1707,1636,1603,1534cm-1
mp:47.0−52.0℃
【0454】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(1,1−ジメチルプロポキシカルボニル)−N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−11)
IR(neat): 3349,2972,2902,2846,1695,1631,1603,1534,1226,1159cm-1
【0455】
○1−[2−(1−アダマンチル)エチル]−1−[2−(N−イソプロポキシカルボニル−N−メチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−12)
IR(neat): 3350,2903,2846,1696,1632,1603,1530cm-1
【0456】
○(−)−1−[2−(1−アダマンチル)エチル]−1−[2−(N−メントキシカルボニル−N−メチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物10−13)
IR(neat): 3350,2904,2847,1694,1633,1603,1530cm-1
[α]20 D:−27.5°(MeOH,C1.0)
【0457】
○1−[2−(1−アダマンチル)エチル]−1−[2−[N−(3,3−ジメチルブチリル)−N−メチルアミノ]エチル]−3−[2−メチル−3−(4−ピリジル)プロピル]ウレア(化合物10−14)
IR(neat): 3324,2902,2846,1633,1537cm-1
【0458】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−[2−(N’−イソプロポキシカルボニル−N’−メチルアミノ)エチル]アミド(化合物10−15)
IR(neat): 3553,2978,2903,2847,1697,1646cm-1
【0459】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−[2−(N’−ベンジルオキシカルボニル−N’−メチルアミノ)エチル]アミド(化合物10−16)
IR(neat): 3387,3030,2903,2847,1701,1646,1602,1453,1422cm-1
【0460】
○5−(4−ピリジル)吉草酸 N−[2−(1−アダマンチル)エチル]−N−[2−[N’−(3,3−ジメチルブチリル)−N’−メチルアミノ]エチル]アミド(化合物10−17)
IR(neat): 3501,2903,2847,1645,1603,1455,1417cm-1
【0461】
本化合物製造例11
○1−[2−(1−アダマンチル)エチル]−1,3−ジメチル−3−[3−(4−ピリジル)プロピル]ウレア(化合物11−1)
窒素雰囲気下、トリホスゲン(190mg,0.640mmol)のジクロロメタン(6.0ml)溶液を室温で撹拌した。中間体3−1の2−(1−アダマンチル)−N−メチルエチルアミン(330mg,1.71mmol)とジイソプロピルエチルアミン(0.357ml,2.05mmol)のジクロロメタン(6.0ml)溶液を、17分間で滴下した。8分後、中間体3−3のN−メチル−3−(4−ピリジル)プロピルアミン(264mg,1.78mmol)とジイソプロピルエチルアミン(0.357ml,2.05mmol)のジクロロメタン(5.1ml)溶液を一度に加え、20時間撹拌した。ジエチルエーテル(40ml)で希釈し、飽和炭酸水素ナトリウム水溶液(40ml)で2回、次いで飽和塩化ナトリウム水溶液(40ml)で洗浄後、硫酸マグネシウムで乾燥した。溶媒を減圧留去し、シリカゲルカラムクロマトグラフィーで精製すると、標的化合物335mg(54%)が得られた。
【0462】
IR(neat): 2903,2846,1638,1602,1492cm- 1
【0463】
本化合物製造例12
○1−[2−(1−アダマンチル)エチル]−1−ヒドロキシ−3−[3−(4−ピリジル)プロピル]ウレア(化合物12−1)
化合物1−28の1−[2−(1−アダマンチル)エチル]−1−ベンジルオキシ−3−[3−(4−ピリジル)プロピル]ウレア(438mg,0.978mmol)のメタノール(9.78ml)溶液に2N塩酸(4.0ml)を加え、窒素ガスを通気した。10%パラジウムオンカーボン(43mg)を加え、1気圧水素下3日間撹拌した。パラジウムオンカーボンを濾去し、濾液を減圧濃縮後、ジエチルエーテル(30ml)で希釈した。飽和炭酸水素ナトリウム水溶液(30ml)、飽和塩化ナトリウム水溶液(30ml)で洗浄後、硫酸マグネシウムで乾燥した。溶媒を減圧留去し、シリカゲルカラムクロマトグラフィーで精製すると、標的化合物119mg(34%)が得られた。
【0464】
IR(KBr): 3438,3152,2903,2847,1650cm-1mp:101.0−102.5℃
【0465】
本化合物製造例13
○1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア 塩酸塩(化合物13−1)
化合物1−1の1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(200mg,0.486mmol)のクロロホルム(0.3ml)溶液に、4N塩化水素酢酸エチル溶液(0.400ml,1.60mmol)を加えた。溶媒を減圧留去し、析出した固体を酢酸エチルで洗浄し濾取した。得られた粗結晶を2−ブタノン(5.0ml)から再結晶すると、標的化合物94mg(43%)が得られた。
【0466】
IR(KBr):3322,3050,2902,2496,1621,1534,1450cm-1
mp:157.0−158.0℃
【0467】
本化合物製造例13と同様の操作を行うことにより、以下の化合物が得られた。
【0468】
○1−[2−(1−アダマンチル)エチル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア 塩酸塩(化合物13−2)
IR(neat):3338,2901,2845,1620,1450cm-1
【0469】
○1−(2−シクロヘキシルエチル)−3−(4−ピリジル)メチル−1−(2−チエニル)メチルウレア 塩酸塩(化合物13−3)
IR(KBr):3296,2923,1635,1599,1518cm-1
mp:161.8−164.4℃
【0470】
○1−[2−(1−アダマンチル)エチル]−1−ブチル−3−[3−(4−ピリジル)プロピル]ウレア 塩酸塩(化合物13−4)
IR(neat):3331,2901,2845,1754,1636,1537cm-1
【0471】
○1,1−ビス[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア 塩酸塩(化合物13−5)
IR(KBr):3289,2900,2844,1637,1560cm-1
mp:120.0−122.5℃
【0472】
○1−[2−(1−アダマンチル)エチル]−1−(2−アミノエチル)−3−[3−(4−ピリジル)プロピル]ウレア 二塩酸塩(化合物13−6)
IR(neat):3358,2902,2846,1634,1538,756cm-1
【0473】
○2−[2−(4−ピリジル)エチルアミノ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 二塩酸塩(化合物13−7)
IR(KBr): 3424,2902,1651cm-1
mp:133.7−137.0℃
【0474】
○3−[N’−メチル−N’−(4−ピリジルメチル)アミノ]プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 二塩酸塩(化合物13−8)
IR(KBr): 3424,2901,2846,1641cm-1
【0475】
○1,1−ジイソペンチル−3−[3−(4−ピリジル)プロピル]ウレア 塩酸塩(化合物13−9)
IR(KBr):3082,2956,2869,2614,1626,1526cm-1
mp:120.5−131.7℃
【0476】
○1−[3−(1−アダマンチル)プロピル]−1−プロピル−3−[3−(4−ピリジル)プロピル]ウレア リン酸塩(化合物13−10)
IR(KBr):3517,3423,1642,1594,1539,1508cm-1
mp:148.0−149.0℃
【0477】
本化合物製造例14
○1−[2−(1−アダマンチル)エチル]−3−[3−ヒドロキシ−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物14−1)
化合物1−138の1−[2−(1−アダマンチル)エチル]−3−[3−(t−ブチルジメチルシリルオキシ)−3−(4−ピリジル)プロピル]−1−ペンチルウレア(136mg,0.250mmol)の10%塩化水素-メタノール溶液(2.3ml)を室温で3日間攪拌した。溶媒を減圧留去後,酢酸エチル(50ml),水(30ml),1N水酸化ナトリウム水溶液(20ml)で分配し,有機層を飽和塩化ナトリウム水溶液(40ml)で洗浄した。無水硫酸ナトリウムで乾燥後,溶媒を減圧留去してその残留物をシリカゲルカラムクロマトグラフィーで精製すると,標的化合物(59.2mg,無色非結晶性粉末,55.3%)が得られた。
【0478】
IR(neat):3339,2904,2847,1622,1605,1532cm-1
【0479】
本化合物製造例15
○cis−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[2−(4−ピリジル)シクロプロピルメチル]ウレア(化合物15−1)
窒素雰囲気氷冷下、化合物1−111の(Z)−1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)−2−プロペニル]ウレア(0.25g、0.61mmol)の無水1,2−ジクロロエタン(3ml)溶液に、ジエチル亜鉛1.0M ヘキサン溶液(3.1ml、3.1mmol)とクロロヨードメタン(0.44ml、6.1mol)を加え、1時間攪拌した。反応液に氷冷下、飽和塩化アンモニウム水溶液(10ml)を加え、20分間室温で攪拌した後、酢酸エチル(20ml)と飽和塩化アンモニウム水溶液(10ml)で分配した。有機層を飽和塩化ナトリウム水溶液(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下溶媒留去し、得られた残留物をシリカゲルカラムクロマトグラフィーで精製することにより標的化合物9.0mg(3.5%)が無色結晶として得られた。
【0480】
IR(KBr):3340,3025,2903,2847,1617,1603,1525cm-1
mp:128.0−130.0℃
【0481】
本化合物製造例16
○4−[3−[3−[2−(1−アダマンチル)エチル]−3−ペンチルウレイド]プロピル]ピリジン N−オキシド(化合物16−1)
室温窒素雰囲気下、化合物1−1の1−[2−(1−アダマンチル)エチル]−1−ペンチル−3−[3−(4−ピリジル)プロピル]ウレア(3.0g,7.3mmol)の無水ジクロロメタン(24ml)溶液にm−クロロ過安息香酸(2.5g,15mmol)を加え、一晩撹拌した。反応液をクロロホルム(20ml)と1N水酸化ナトリウム水溶液(60ml)で分配した。有機層を水(10ml)と飽和塩化ナトリウム水溶液(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下溶媒留去して得られた残留物をシリカゲルカラムクロマトグラフィーで精製することにより、標的化合物2.92g(94.2%)が得られた。
【0482】
IR(KBr):3346,2902,2845,1622,1538,1217,1178cm-1
mp:97.8−127.0℃
【0483】
本化合物製造例17
○1−[2−(1−アダマンチル)エチル]−1−[2−[ N−(2−メトキシエチル)− N−メチルアミノ]エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物17−1)
室温下、N,N−ジメチルホルムアミド(20ml)に化合物3−1のフリー塩基体である1−[2−(1−アダマンチル)エチル]−1−(2−メチルアミノエチル)−3−[3−(4−ピリジル)プロピル]ウレア(1.50g,3.76mmol)、炭酸カリウム(1.56g,11.3mmol)、ヨウ化ナトリウム(1.69g,11.3mmol)を加え、続いて2−クロロエチルメチルエーテル(412μl,4.51mmol)を加えて、80℃に加熱した。一夜攪拌の後、反応混合物にジエチルエーテル(50ml) 、水 (100ml)を加えて抽出し、得られた有機層を水 (100mL)、飽和塩化ナトリウム水溶液 (50ml)で洗浄し、無水硫酸マグネシウムで乾燥後、減圧下濃縮した。残留物をシリカゲルカラムクロマトグラフィーで精製すると、標的化合物552mg(32.1%)が淡黄色油状物として得られた。
【0484】
IR(neat):3350,2901,1643,1602,1531cm-1
【0485】
本化合物製造例18
○2−[2−(4−ピリジル)エチルアミノ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物18−1)
ブロモ酢酸(0.50g,3.6mmol)を無水テトラヒドロフラン(20ml)に溶解し、窒素雰囲気下−15℃にて攪拌した。これにN−メチルモルホリン(0.40ml,3.6mmol)、クロロ炭酸イソブチル(0.45ml,3.5mmol)を加えた。次いで中間体1−1である2−(1−アダマンチル)−N−ペンチルエチルアミン塩酸塩(1.0g,3.5mmol)のフリー塩基体の無水テトラヒドロフラン(20ml)溶液を滴下した。0℃で1.5時間攪拌した後、反応液に飽和炭酸水素ナトリウム水溶液(70ml)と酢酸エチル(70ml)を加え分配した。酢酸エチル層を水(70ml)、飽和塩化ナトリウム水溶液(70ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧濃縮すると2−ブロモ酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド1.3g(定量的)が油状物として得られた。
【0486】
つぎに、2−ブロモ酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(1.3g,3.5mmol)を無水N,N−ジメチルホルムアミド(30ml)に溶解し、炭酸カリウム(1.5g,11mmol)、ヨウ化メチル(1.6g,11mmol)、4-(2-アミノエチル)ピリジン(0.43g,3.5mmol)を加え、外温75℃で一晩撹拌した。反応液に水(100ml)、ジエチルエーテル(100ml)を加え分配し、ジエチルエーテル層を水(70ml)で2回、飽和塩化ナトリウム水溶液(120ml)で1回洗浄し、無水硫酸マグネシウムで乾燥した。減圧濃縮し、シリカゲルカラムクロマトグラフィーにて精製を行うと標的化合物0.6g(40%)が油状物として得られた。
【0487】
IR(neat):3312,2902,2846,1651,1602,1454cm-1
【0488】
本化合物製造例18と同様の操作を行うことにより、以下の化合物が得られた。
【0489】
○3−[N’−メチル−N’−(4−ピリジルメチル)]アミノプロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物18−2)
IR(neat):2902,2846,1643cm-1
【0490】
○2−[2−(4−ピリジル)エトキシ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物18−3)
IR(neat):2902,2846,1650,1602,1451,1113cm-1
【0491】
本化合物製造例19
○(R)−1−[2−(4−ピリジル)エチル]−2−ピロリジンカルボン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 塩酸塩(化合物19−1)
N−t−ブトキシカルボニル−L−プロリン(1.7g,8.0mmol)を無水テトラヒドロフラン(20ml)に溶解し、窒素雰囲気下−15℃にて攪拌した。これにN−メチルモルホリン(0.90ml,8.0mmol)、クロロ炭酸イソブチル(1.0ml,8.0mmol)を加えた。10分後中間体1−1のフリー塩基体(2.0g,8.0mmol)の無水テトラヒドロフラン(20ml)溶液を5分間かけて滴下した。0℃で45分間攪拌した後、室温に戻し一晩撹拌した。反応液に飽和炭酸水素ナトリウム水溶液(50ml)と酢酸エチル(50ml)を加え分配した。酢酸エチル層を10%クエン酸水溶液(50ml)、水(50ml)、飽和塩化ナトリウム水溶液(50ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧濃縮し、シリカゲルカラムクロマトグラフィーにて精製を行うと標的化合物の(R)−1−(t−ブトキシカルボニル)−2−ピロリジンカルボン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド1.9g(52%)が油状物として得られた。
【0492】
つぎに、(R)−1−(t−ブトキシカルボニル)−2−ピロリジンカルボン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(1.8g,4.0mmol)に氷冷下4N塩化水素/ジオキサン(20ml,81mmol)を加えた後、室温に戻し1.5時間撹拌した。減圧濃縮すると(R)−2−ピロリジンカルボン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 塩酸塩1.5g(定量的)が無晶形として得られた。
【0493】
つぎに、(R)−2−ピロリジンカルボン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 塩酸塩(1.4g,3.7mmol)を無水N,N−ジメチルホルムアミド(40ml)に溶解し、炭酸カリウム(2.6g,19mmol)、ヨウ化メチル(1.7g,11mmol)、4−(2−クロロエチル)ピリジン塩酸塩(0.70g,3.7mmol)を加えた後外温80℃で一晩撹拌した。反応液に2N水酸化ナトリウム水溶液(70ml)、ジエチルエーテル(70ml)を加え分配し、ジエチルエーテル層を水(70ml)、飽和塩化ナトリウム水溶液(70ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧濃縮し、シリカゲルカラムクロマトグラフィーにて精製を行うと標的化合物0.80g(47%)が油状物として得られた。
【0494】
IR(neat):2902,2846,1644cm-1
[α]20 D:−48.1°(MeOH,C1.0)
【0495】
本化合物製造例19と同様の操作を行うことにより、以下の化合物が得られた。
【0496】
○(S)−1−[2−(4−ピリジル)エチル]−2−ピロリジンカルボン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド 塩酸塩(化合物19−2)
IR(neat):2902,2846,1644,1601cm-1
[α]20 D:+41.6°(MeOH,C1.0)
【0497】
本化合物製造例20
○1−[2−(1−アダマンチル)エチル]−1−[2−(N−エチルアミノ)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(化合物20−1)
窒素雰囲気下,水素化リチウムアルミニウム(890mg,23.5mmol)を無水ジエチルエーテル(10ml)に懸濁させ、氷冷下、攪拌しながら化合物1−103の1−[2−(アセチルアミノ)エチル]−1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(4.86g,11.4mmol)の無水テトラヒドロフラン(60ml)溶液を2時間かけて滴下し,室温に戻して70時間攪拌した。氷冷にして酢酸エチル(25ml)を加えてから1N水酸化ナトリウム水溶液(25ml)を加え,セライト濾過で不溶物を除去した。ろ液を酢酸エチル(25ml),水(25ml)で分配し,その有機層を飽和塩化ナトリウム水溶液(20ml)で洗浄した。無水硫酸マグネシウムで乾燥後,溶媒を減圧留去して残留物をシリカゲルカラムクロマトグラフィーで精製すると,標的化合物(2.33g,無色結晶,49.8%)が得られた。
【0498】
IR(KBr):3309,2901,2845,1615,1534cm-1
mp:96.8−104.9℃
【0499】
本化合物製造例21
○3−(4−ピリジルメチリデンアミノ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物23−1)
3−(t−ブトキシカルボニルアミノ)プロピオン酸(1.0g,5.3mmol)を無水テトラヒドロフラン(15ml)に溶解しN−メチルモルホリン(0.6ml,5.5mmol)を加え−15℃で攪拌し、クロロ炭酸イソブチル(0.7ml,5.4mmol)を加えた。つぎに中間体1−1の2−(1−アダマンチル)−N−ペンチルエチルアミン塩酸塩(1.5g,5.3mmol)のフリー塩基体の無水テトラヒドロフラン(15ml)溶液を−18℃で加えた。0℃で1.5時間撹拌後、酢酸エチル(100ml)および飽和炭酸水素ナトリウム水溶液(100ml)を加え分配した。10%クエン酸水溶液(100ml)、水(100ml)、飽和塩化ナトリウム水溶液(100ml)で順に洗浄し無水硫酸マグネシウムで乾燥した。減圧濃縮しシリカゲルカラムクロマトグラフィーにて精製を行うと3−(t−ブトキシカルボニルアミノ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド1.9g(85%)が油状物質として得られた。
【0500】
3−(t−ブトキシカルボニルアミノ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(1.9g,4.4mmol)に氷冷下4.0N塩化水素/1,4-ジオキサン溶液(22ml,88mmol)を加えた後、室温に戻し1時間15分撹拌した。減圧濃縮すると目的物の塩酸塩1.4g(89%)が得られた。これに1N水酸化ナトリウム水溶液(80ml)を加えクロロホルム(80ml)で抽出した。クロロホルム層を飽和塩化ナトリウム水溶液(80ml)で洗浄し、無水硫酸マグネシウムを用い乾燥した。減圧濃縮すると3−アミノプロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミドが油状物で得られた。
【0501】
3−アミノプロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(1.3g,3.9mmol)を無水テトラヒドロフラン(10ml)に溶解し、氷冷下攪拌した。これに4−ピリジンカルボキシアルデヒド(0.42ml,4.3mmol)を加えた後室温で3時間攪拌した。減圧濃縮すると標的化合物1.7g(定量的)が油状物として得られた。
【0502】
IR(neat):2901,1713,1644,1454cm-1
【0503】
本化合物製造例22
○3−(4−ピリジルメチルアミノ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物22−1)
化合物21−1の3−(4−ピリジルメチリデンアミノ)プロピオン酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(1.6g,3.9mmol)をメタノールに溶解し、触媒量の10%パラジウムオンカーボンを加えて1気圧水素下7時間室温で攪拌した。10%パラジウムオンカーボンを濾去した後、減圧濃縮しシリカゲルカラムクロマトグラフィーにて精製を行うと標的化合物0.58g(36%)が油状物として得られた。
【0504】
IR(neat):3313,2902,2846,1636,1451cm-1
【0505】
本化合物製造例23
○1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−シアノ)ピリジル]プロピル]−1−ペンチルウレア(化合物23−1)
室温窒素雰囲気下、化合物16−1の4−[3−[3−[2−(1−アダマンチル)エチル]−3−ペンチルウレイド]プロピル]ピリジン N−オキシド(1.0g,2.3mmol)の無水アセトニトリル(1.5ml)溶液にシアン化トリメチルシリル(1.2ml,9.4mmol)とトリエチルアミン(0.65ml,4.7mmol)を加え、一晩加熱還流した。反応液をクロロホルム(40ml)と飽和炭酸水素ナトリウム水溶液(40ml)で分配した。有機層を飽和塩化ナトリウム水溶液(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下溶媒留去して得られた残留物をジイソプロピルエーテルで結晶を濾取することにより、標的化合物730mg(73.0%)が得られた。
【0506】
IR(KBr):3334,2900,2845,2234,1621,1534cm-1
mp:112.0−123.0℃
【0507】
本化合物製造例24
○1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−アミノメチル)ピリジル]プロピル]−1−ペンチルウレア(化合物24−1)
室温窒素雰囲気下、化合物23−1の1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−シアノ)ピリジル]プロピル]−1−ペンチルウレア(0.20g,0.46mmol)のメタノール(2.0ml)溶液に触媒量の10%パラジウムオンカーボンを加え、水素雰囲気下一晩攪拌した。反応液をセライト濾過後減圧下溶媒留去し、得られた残留物をジエチルエーテル(50ml)と水(50ml)で分配した。水層に2N水酸化ナトリウム水溶液(10ml)を加えた後、さらにジエチルエーテル(50ml)で抽出した。あわせた有機層を飽和塩化ナトリウム水溶液(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下溶媒留去して得られた残留物をジイソプロピルエーテルで結晶濾取することにより、標的化合物151mg(74.4%)が得られた。
【0508】
IR(KBr):3346,2901,2845,1621,1538cm-1
mp:88.0−95.0℃
【0509】
本化合物製造例25
○1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−カルボキシ)ピリジル]プロピル]−1−ペンチルウレア(化合物25−1)
室温下、化合物23−1の1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−シアノ)ピリジル]プロピル]−1−ペンチルウレア(0.20g,0.46mmol)に6N塩酸(1.5ml,9.2mmol)を加え、一晩加熱還流した。反応液を減圧下溶媒留去し、アセトンで結晶を濾取した。クロロホルム(40ml)に溶解させ、水(40ml)と飽和塩化ナトリウム水溶液(10ml)で洗浄した。有機層を無水硫酸マグネシウムで乾燥させ、減圧下溶媒留去することにより、標的化合物132mg(63.0%)が得られた。
【0510】
IR(KBr):3326,2905,2848,1704,1621,1539cm-1
mp:130℃
【0511】
本化合物製造例26
○1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−ヒドロキシメチル)ピリジル]プロピル]−1−ペンチルウレア(化合物26−1)
窒素雰囲気氷冷下、 化合物25−1の1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−カルボキシ)ピリジル]プロピル]−1−ペンチルウレア(0.10g、0.22mmol)の無水テトラヒドロフラン(0.7ml)溶液に、ボラン−テトラヒドロフラン錯体1.0Mテトラヒドロフラン溶液(0.66ml、0.66mmol)を加え、室温下4.5時間攪拌した。反応液に氷冷下、水(3ml)を加えた後、酢酸エチル(15ml)と0.1%水酸化ナトリウム水溶液(10ml)で分配した。有機層を飽和塩化ナトリウム水溶液(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下溶媒留去し、得られた残留物をシリカゲルカラムクロマトグラフィーで精製することにより標的化合物のボラン錯塩53mgが油状物として得られた。
【0512】
IR(neat):3342,2904,1630,1531cm-1
【0513】
本化合物製造例27
○1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−メチル)ピリジル]プロピル]−1−ペンチルウレア(化合物27−1)
室温下、 化合物26−1の1−[2−(1−アダマンチル)エチル]−3−[3−[4−(2−ヒドロキシメチル)ピリジル]プロピル]−1−ペンチルウレア(50mg、0.11mmol)とトリエチルアミン(20μl、0.13mmol)の無水ジクロロメタン(1.0ml)溶液に、塩化p−トルエンスルホニル(23mg、0.12mmol)を加え、室温下一晩攪拌した。反応液をクロロホルム(9ml)と水(10ml)で分配し、有機層を無水硫酸マグネシウムで乾燥した。減圧下溶媒留去し、得られた残留物をシリカゲルカラムクロマトグラフィーで精製した。得られたp−トルエンスルホニル体のメタノール(1ml)溶液に触媒量の10%パラジウムオンカーボンを加え、水素雰囲気下7日攪拌することにより標的化合物18mg(38%)が油状物として得られた。
【0514】
IR(neat):3345,2903,2847,1624,1534cm-1
【0515】
本化合物製造例28
○1−[2−(1−アダマンチル)エチル]−1−(2−アミノエチル)−3−[3−(4−ピリジル)プロピル]ウレア(化合物28−1)
氷冷下、化合物1−103の1−[2−(アセチルアミノ)エチル]−1−[2−(1−アダマンチル)エチル]−3−[3−(4−ピリジル)プロピル]ウレア(1.02g,2.39mmol)のメタノール(10ml)溶液に6N塩酸(15ml)を加えてから90℃で3日間加熱、攪拌した。反応液を1N水酸化ナトリウム水溶液(10ml)で中和し、クロロホルム(50ml)、水(10ml)を加えて分配した。有機層を飽和塩化ナトリウム水溶液(50ml)で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を減圧留去する。残渣をシリカゲルカラムクロマトグラフィーで精製すると、標的化合物200mg(21.7%)が油状物で得られた。
【0516】
IR(neat):3306,2902,2846,1629,1605,1537,753cm-1
【0517】
本化合物製造例29
○ 4−[2−[N−[2−(1−アダマンチル)エチル]−N−ペンチルカルボニルメトキシ]エトキシ]ピリジン N−オキシド(化合物29−1)
氷冷下、ジグリコリルクロライド(0.31ml、2.6mmol)とトリエチルアミン(0.70ml、5.1mmol)の無水ジクロロメタン(6ml)溶液に、中間体1−1の2−(1−アダマンチル)−N−ペンチルエチルアミン塩酸塩(0.50g、1.7mmol)を加え、室温下一晩攪拌した。反応液にメタノール(5ml)を加え3時間攪拌した。減圧下溶媒留去した後、酢酸エチルと水(各15ml)で分配し、有機層を飽和塩化ナトリウム水溶液(5ml)で洗浄し、無水硫酸マグネシウムで乾燥する。減圧下溶媒留去し、得られた残留物をシリカゲルカラムクロマトグラフィーで精製することにより2−メトキシカルボニルメトキシ酢酸 N−[2−(1−アダマンチル)エチル]−1−ペンチルアミド0.39g(60%)が油状物として得られた。
【0518】
つぎに、氷冷下、N−[2−(1−アダマンチル)エチル]−1−ペンチルアミド(0.37g、0.96mmol)のメタノール(3ml)溶液に、水素化ホウ素ナトリウム(0.18g、4.8mmol)を加え、室温下一晩攪拌した。反応液に水(10ml)を加えて10分攪拌した後、水(20ml)と酢酸エチル(30ml)を加えて分配した。有機層を飽和塩化ナトリウム水溶液(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。減圧下溶媒留去し、得られた残留物をシリカゲルカラムクロマトグラフィーで精製することにより2−(2−ヒドロキシエトキシ)酢酸 N−[2−(1−アダマンチル)エチル]−1−ペンチルアミド74mg(22%)が油状物として得られた。
【0519】
つぎに、室温下、2−(2−ヒドロキシエトキシ)酢酸 N−[2−(1−アダマンチル)エチル]−1−ペンチルアミド(60mg、0.17mmol)のN,N−ジメチルホルムアミド(0.4ml)溶液に、4−ニトロピリジン N−オキシド(24mg、0.17mmol)と炭酸カリウム(28mg、0.20mmol)を加え、60℃で2日攪拌した。反応液を減圧下溶媒留去し、得られた残留物をシリカゲルカラムクロマトグラフィーにより精製することにより標的化合物39mgが油状物として得られた。
【0520】
1H-NMR (400MHz, CDCl3) δ0.87-0.93 (m, 3H), 1.20-1.40 (m, 6H), 1.47-1.60 (m, 8H), 1.61-1.67 (m, 3H), 1.68-1.76 (m, 3H), 1.97 (brs, 3H), 3.10-3.19 (m, 2H), 3.25-3.36 (m, 2H), 3.94-3.98 (m, 2H),4.20-4.27 (m, 4H), 6.81-6.86 (m, 2H), 8.10-8.15 (m, 2H)
【0521】
本化合物製造例30
○ 2−[2−(4−ピリジルオキシ)エトキシ]酢酸 N−[2−(1−アダマンチル)エチル]−N−ペンチルアミド(化合物30−1)
窒素雰囲気室温下、化合物29−1の4−[2−[N−[2−(1−アダマンチル)エチル]−N−ペンチルカルボニルメトキシ]エトキシ]ピリジン N−オキシド(39mg、0.088mmol)と無水酢酸(20μl、0.18mmol)のメタノール(0.4ml)と酢酸(0.1ml)の混合溶液に、触媒量の10%パラジウムオンカーボンを加え、水素雰囲気下4日攪拌した。セライト濾過の後、反応液を減圧下溶媒留去し、酢酸エチル(20ml)と飽和炭酸水素ナトリウム水溶液(20ml)で分配した。有機層を飽和塩化ナトリウム水溶液(10ml)で洗浄し、無水硫酸マグネシウムで乾燥した。溶媒留去により得られた残留物をシリカゲルカラムクロマトグラフィーにより精製することにより標的化合物16mg(42%)が油状物として得られた。
【0522】
IR(neat):2903,1651,1592cm-1
【0523】
本化合物製造例31
○1−[2−(1−アダマンチル)エチル]−3−[3−オキソ−3−(4−ピリジル)プロピル]−1−ペンチルウレア(化合物31−1)
氷冷下、化合物14−11−[2−(1−アダマンチル)エチル]−3−[3−ヒドロキシ−3−(4−ピリジル)プロピル]−1−ペンチルウレア(100mg,0.234mmol)の無水ジクロロメタン(2ml)溶液に1,1,1−トリアセトキシ−1,1−ジヒドロ−1,2−ベンズヨードキソール−3(1H)−オン(221mg,0.520mmol)を加えて、室温に戻して1時間撹拌した。再び氷冷下とし、酢酸エチル(10ml)、飽和亜硫酸ナトリウム水溶液(5ml)、飽和炭酸水素ナトリウム水溶液(5ml)を加えて15分間撹拌した。反応液を酢酸エチル(50ml)、水(10ml)で分配し、有機層を飽和亜硫酸ナトリウム水溶液(5ml)、飽和炭酸水素ナトリウム水溶液(5ml)、飽和塩化ナトリウム水溶液(25ml)の順で洗浄した。有機層を無水硫酸マグネシウムで乾燥後,溶媒を減圧留去すると,標的化合物が87.3mg(87.8%)無色結晶で得られた。
【0524】
IR(KBr):3328,2901,2847,1710,1619,1540cm−1
mp:103.5−104.0℃
【0525】
[C]製剤例
本化合物の点眼剤処方の一例を以下に示す。
【0526】
処方1(100ml中)
本化合物 100mg
塩化ナトリウム 900mg
ポリソルベート80 適量
水酸化ナトリウム 適量
塩酸 適量
滅菌精製水 適量
【0527】
本化合物および添加物の混合比を適宜変更することにより、所望の点眼剤を得ることができる。
【0528】
[D]薬理試験
(1)ヒト血管内皮細胞を用いた血管新生阻害試験
in vitroにおける血管新生評価モデルとして、正常ヒトさい帯静脈血管由来血管内皮細胞 (human umbilical vein endotherial cell, HUVEC)に血管内皮増殖因子(vascular endothelial growth factor, VEGF) を処置することにより誘導される細胞増殖反応に対する薬物の阻害効果を測定するVEGF誘発HUVEC増殖反応評価系がCancer Res., 59, 99-106 (1999)に報告されている。そこで、上記文献記載の方法に準じた方法で、本化合物の血管新生評価系における効果を検討した。
【0529】
(被験化合物の調製)
本化合物をDMSOに溶解後、培地にて希釈して40μMの各被験化合物溶液を得た。
【0530】
(実験方法)
4×104 cells /mL に調製したHUVECをI型コラーゲンでコートした96穴プレートに50μLずつ播種して、2×103 cells/wellとした。1日後、被験化合物の0.8%DMSO溶液およびコントロールとして0.8%DMSO溶液を各wellに25μLずつ添加した (最終濃度として、10μMの各被験化合物および0.2%のDMSOを含有)。薬物を添加してから1時間後に、40 ng/mLのVEGF溶液を各wellに25μLずつ添加した (最終濃度として、10ng/mLのVEGFを含有)。VEGF添加3日後に、WST-8アッセイ試薬 (同仁化学)を各wellに10μL添加し、450nmによる吸光度を測定した。
【0531】
(血管新生の評価結果)
コントロールに対する細胞増殖阻害率(%)を算出したところ、多くの被験化合物の血管新生阻害率は80%以上であった。これらの結果を表1に示す。
【0532】
【表1】
【0533】
(2)高酸素負荷誘発網膜血管新生法による血管新生阻害試験
in vivo における網膜血管新生評価モデルとして新生児ラットに高酸素を負荷することにより誘発される薬物の血管新生阻害効果を測定する高酸素負荷誘発網膜血管新生評価モデルがArch Ophthalmol,114,1210-1217 (1996)に報告されている。そこで、上記文献に記載された方法に従って、本化合物の血管新生評価モデルにおける効果を検討した。
【0534】
(被験化合物の調製)
本化合物を0.4%Tween 80を含有するリン酸緩衝液(PBS)に懸濁して10mg/mlの被験化合物懸濁液を得た。
【0535】
(実験方法)
生後0日齢の新生児ラットを親ラットとともに80%酸素条件に保たれた高酸素負荷用飼育箱内にて11日間飼育し、生後11日目に通常の飼育条件に戻した(なお、高酸素負荷期間中は一日一回、30分間、通常の飼育条件に戻した。)。
【0536】
生後11日目より7日間、被験化合物(200μg/20μl/eye)をアベルチン麻酔下にて結膜下に投与した。生後18日(P18)にラットをネンブタール投与により安楽死させ、眼球を摘出した。摘出した眼球を4%パラホルムアルデヒドで固定した後、網膜を分離した。分離した網膜をADPaseで染色し、下記の血管新生評価法により、血管新生の程度を評価した。なお、モデルラットのコントロールとして、被験化合物の代わりに0.4%Tween 80を含有するPBS(2μl/eye)を結膜下に投与し、上記と同様の操作を行った。
【0537】
ADPaseで染色した網膜を4象限に分割し、光学顕微鏡下で観察し評価した。評価はつぎの評価基準に従って各象限を採点することにより行った。
【0538】
(評価基準)
0:新生血管芽および連続した血管隆起がなかった
1:5個以下の新生血管芽があった
2:6個以上の新生血管芽、または短い血管隆起があった
3:1象限の半分に満たない血管隆起があった
4:1象限の半分を超える血管隆起があった
【0539】
(血管新生の評価結果)
各象限の点数を加算した合計点から血管新生阻害率[%]を算出したところ(なお、血管新生阻害率は各9−12例の平均値とした)、多くの被験化合物の血管新生阻害率は40%以上であった。
【0540】
【発明の効果】
上記の薬理試験の結果から明らかなように、本化合物は、in vitroおよびin vivoのいずれの試験においても優れた血管新生阻害作用を有するので、血管新生が関与する疾患、特に、糖尿病性網膜症、未熟児網膜症、黄斑変性症、血管新生緑内障、網膜静脈閉塞症、網膜動脈閉塞症、翼状片、ルベオーシス、角膜新生血管症、固形腫瘍、血管腫、腫瘍の増殖・転移などの予防剤および治療剤として適用できる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an angiogenesis inhibitor comprising a novel urea compound as an active ingredient, and particularly to a drug useful for ocular diseases and cancer diseases.
[0002]
[Prior art]
Vascular homeostasis is maintained by various functions of endothelial cells. Vascular endothelial cells 1) mediate the transport of necessary components such as nutrients in the blood to the tissue and prevent unnecessary large amounts of components from passing through. 2) Smooth circulation without clotting of blood. 3) an action to prevent bleeding when the blood vessel is disconnected, and 4) a regulating action to keep the blood vessel tension constant.
[0003]
Angiogenesis occurs at the stage of degradation of the basement membrane by proteases produced by vascular endothelial cells, migration / proliferation of vascular endothelial cells, formation of lumens of vascular endothelial cells, formation of basement membranes and pericytes. Angiogenesis is various diseases, especially diabetic retinopathy, retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascular disease, solid tumor, blood vessel It is closely related to tumors, tumor growth and metastasis. Angiogenesis is thought to be caused by various growth factors, cytokines, arachidonic acid metabolites, monobutyrin, and the like. Among these, growth factors are considered to be the most important angiogenic factors (see Non-Patent Document 1).
[0004]
[Non-Patent Document 1]
History of medicine,170, 536-539 (1994).
[0005]
[Problems to be solved by the invention]
Thus, diabetic retinopathy, retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, lebeosis, corneal neovascularization, solid tumor, hemangioma, tumor It is significant to search for a compound having an angiogenesis inhibitory effect that is useful as a therapeutic agent for proliferation and metastasis.
[0006]
[Means for Solving the Problems]
The present inventors have created compounds having various chemical structures and conducted an angiogenesis inhibition test using human vascular endothelial cells and an angiogenesis inhibition test using a retinal angiogenesis method induced by high oxygen load. The novel urea compound having the structure represented by the formula [1] has an excellent angiogenesis inhibitory action in both the in vitro and in vivo tests described above, and is a disease involving angiogenesis, particularly a diabetic retina. Disease, retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascular disease, etc. and solid tumors, hemangiomas, tumor growth / metastasis The present invention has been found out as being useful as a therapeutic agent for cancer diseases such as these.
[0007]
The present invention relates to an angiogenesis inhibitor comprising a compound represented by the following general formula [1] or a salt thereof (hereinafter referred to as “the present compound” unless otherwise specified) as an active ingredient.
[0008]
[Chemical 6]
[Wherein A is-(NRFour) −Or-(CRFiveR6)−Show;
B is -O- in the chain.Or-S−Alkylene group which may be containedIndicate;
R1 Represents an alkyl group,The group is substituted with a halogen atom, a hydroxy group, an amino group, a cycloalkyl group, an adamantyl group, an aryl group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, a cyano group, or a saturated or unsaturated heterocyclic ring. May be;The hydrogen atom of each amino group, hydroxy group and aminocarbonyl group is an alkyl group, a cycloalkyl group, an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, a cycloalkyloxycarbonyl group, an arylalkoxycarbonyl group, a halogeno group. An alkyloxycarbonyl group, an imidazolylcarbonyl group, an unsaturated heterocycle or an unsaturated heterocycle may be substituted with a substituted alkyl group;
R 2 Represents an adamantylalkyl group or a cycloalkylalkyl group;
RThreeIsPyridine ringIndicates;
R Four , R Five And R 6 Are the same or different and each represents a hydrogen atom or an alkyl group;
X isIndicates O. same as below. ]
[0009]
Since this compound has an excellent angiogenesis inhibitory action, diabetic retinopathy, retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascularization It acts as an active ingredient of a therapeutic agent for diseases associated with angiogenesis such as disease, solid tumor, hemangioma, tumor growth / metastasis.
[0010]
DETAILED DESCRIPTION OF THE INVENTION
Each group defined by the general formula [1] will be described in detail.
[0011]
An alkylene group is a methylene group, ethylene group, trimethylene group, propylene group, tetramethylene group, pentamethylene group, hexamethylene group, octamethylene group, decamethylene group, dodecamethylene group, methylmethylene group, ethylethylene group, dimethylethylene group. , A straight chain or branched alkylene group having 1 to 12 carbon atoms, such as a propylethylene group, an isopropylethylene group, and a methyltrimethylene group.
[0012]
Alkenylene group has one or more double bonds such as vinylene group, propenylene group, butenylene group, pentenylene group, hexenylene group, octenylene group, butanediylidene group, methylpropenylene group, and 2 to 12 carbon atoms. A straight-chain or branched alkenylene group having the following formula:
[0013]
Alkyl groups are methyl, ethyl, propyl, butyl, hexyl, octyl, decyl, dodecyl, isopropyl, isobutyl, isopentyl, isohexyl, isooctyl, t-butyl, 3, A linear or branched alkyl group having 1 to 12 carbon atoms such as a 3-dimethylbutyl group is shown.
[0014]
The alkoxy group has 1 to 12 carbon atoms such as methoxy group, ethoxy group, propoxy group, butoxy group, hexyloxy group, octyloxy group, decyloxy group, dodecyloxy group, isopropoxy group, t-butoxy group and the like. A linear or branched alkoxy group is shown.
[0015]
The alkenyl group refers to a linear or branched alkenyl group having 2 to 12 carbon atoms such as vinyl group, allyl group, 3-butenyl group, 5-hexenyl group, isopropenyl group and the like.
[0016]
The alkynyl group refers to a straight or branched alkynyl group having 2 to 12 carbon atoms such as ethynyl group, propynyl group, butynyl group and the like.
[0017]
A cycloalkyl group refers to a cycloalkyl group having 3 to 20 carbon atoms such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclodecyl group, and a cyclododecyl group.
[0018]
The cycloalkenyl group refers to a cycloalkenyl group having 5 to 20 carbon atoms such as a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group.
[0019]
The aryl group represents an aromatic hydrocarbon ring such as a phenyl group or a naphthyl group, which may have one or more substituents. Examples of the substituent include an alkyl group, a cycloalkyl group, a carboxy group, Amino group, hydroxy group, aminoalkyl group, hydroxyalkyl group, nitro group, cyano group, halogen atom, alkyloxy group and the like can be mentioned.
[0020]
A siloxy group refers to a silicon-containing organic group such as a trialkylsilyloxy group, a dialkyl (aryl) silyloxy group, an alkyl (diaryl) oxy group, or a triarylsilyloxy group.
[0021]
The halogen atom is fluorine, chlorine, bromine or iodine.
[0022]
The heterocyclic ring is, for example, a 5- to 20-membered saturated or unsaturated monocyclic heterocyclic ring or bicyclic heterocyclic ring containing 1 to 4 nitrogen atoms, oxygen atoms, and sulfur atoms. May have one or more substituents, such as an alkyl group, a cycloalkyl group, a carboxy group, an amino group, a hydroxy group, an aminoalkyl group, a hydroxyalkyl group, a nitro group, and a cyano group. A group, a halogen atom, an alkyloxy group, an aryl group, an arylalkyl group, a saturated or unsaturated heterocyclic ring, and the like. Moreover, when said heterocyclic ring has a nitrogen atom or a sulfur atom in a ring, those atoms may be oxidized and may be in forms, such as N-oxide and S-oxide.
[0023]
Specific examples of the saturated heterocyclic ring include pyrrolidine, piperidine, homopiperidine, piperazine having a nitrogen atom in the ring, morpholine having a nitrogen atom and an oxygen atom in the ring, and thiomorpholine having a nitrogen atom and a sulfur atom in the ring. And may be condensed with a benzene ring or the like to form a bicyclic heterocycle such as tetrahydroquinoline or tetrahydroisoquinoline.
[0024]
Specific examples of the unsaturated heterocycle include monocyclic heterocycles or indoles such as pyrrole, pyridine, pyrazole, imidazole, pyrazine, pyridazine, and pyrimidine having a nitrogen atom in the ring, quinoline, isoquinoline, benzimidazole, naphthyridine, Bicyclic heterocycles such as pyrrolopyridine and imidazopyridine, monocyclic heterocycles such as furan having an oxygen atom in the ring, bicyclic heterocycles such as benzofuran, and monocycles such as thiophene having a sulfur atom in the ring A bicyclic heterocycle such as a formula heterocycle or benzothiophene, a monocyclic heterocycle such as oxazole, isoxazole, thiazole, and isothiazole having a nitrogen atom and an oxygen atom or a sulfur atom in the ring, or benzoxazole, benzothiazole, Thienopyridine, Oxazolopyridine, Thiazolo Lysine, and the like bicyclic heterocyclic ring such as furopyridine. Furthermore, the unsaturated heterocyclic ring may partially include a saturated bond.
[0025]
The salts in the present invention are not particularly limited as long as they are pharmaceutically acceptable salts, such as salts with inorganic acids such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, fumaric acid, maleic acid, succinic acid, tartaric acid and the like. Examples thereof include salts with organic acids and salts with alkali metals or alkaline earth metals such as sodium, potassium and calcium. Moreover, the quaternary ammonium salt of this compound is also included by the salts in this invention. Furthermore, when geometric isomers or optical isomers exist in the present compound, these isomers are also included in the scope of the present invention. In addition, this compound may take the form of the hydrate and the solvate.
[0026]
Preferred examples of the present invention include the following (1) to (3).
[0027]
(1) A compound or a salt thereof in which each group defined by the general formula [1] is selected from the following groups or a combination thereof:
1) RThree: A pyridine ring.
[0028]
2) R1, R2, RFour, RFiveAnd R6At least one of: an adamantylalkyl group, an adamantyloxyalkyl group, an adamantylaminoalkyl group or an adamantylaminocarbonylalkyl group.
[0029]
3) R1And R2At least one of: an adamantylalkyl group, an adamantyloxyalkyl group, an adamantylaminoalkyl group or an adamantylaminocarbonylalkyl group.
[0030]
4) R1And R2At least one of: an adamantylalkyl group.
[0031]
(2) A compound in which each group defined by the general formula [1] consists of the following groups or a salt thereof:-(NRFour)-、-(CRFiveR6)-Or -O-,
B: -O-, -S-,-(NR in the chain7)-, -CO-, -N =
Or
[Chemical 8]
An alkylene group or an alkenylene group, which may be substituted with a hydroxy group, an alkoxy group, an aryl group, a siloxy group or a saturated or unsaturated heterocyclic ring, and is bonded to A. May form a saturated heterocyclic ring,
R1: A hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom Substituted with atoms, hydroxy groups, amino groups, cycloalkyl groups, aryl groups, carboxyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups, adamantyl groups, aryloxycarbonyl groups, cyano groups or saturated or unsaturated heterocycles Well, R1The hydrogen atom of each amino group, hydroxy group and aminocarbonyl group in the alkyl group, cycloalkyl group, aryl group, arylalkyl group, acyl group, alkoxycarbonyl group, cycloalkyloxycarbonyl group, arylalkoxycarbonyl group, halogenoalkyl May be substituted with an oxycarbonyl group, an imidazolylcarbonyl group, an unsaturated heterocycle or an alkyl group substituted with an unsaturated heterocycle,
R2: Adamantylalkyl group, adamantyloxyalkyl group, adamantylaminoalkyl group or adamantylaminocarbonylalkyl group,
RThree: Unsaturated heterocycle,
RFour: Hydrogen atom, alkyl group, adamantylalkyl group, carboxyalkyl group, alkoxycarbonyl group, alkoxycarbonylalkyl group, amino group, alkylamino group, acylamino group or alkoxycarbonylamino group,
RFiveAnd R6: The same or different hydrogen atom, alkyl group, amino group or alkoxycarbonylamino group,
R7: Hydrogen atom or alkyl group,
X: = O or = S,
n: An integer of 1 to 5.
[0032]
Of these, R2Is an adamantylalkyl group and RThreeMore preferably, is a pyridine ring.
[0033]
Furthermore, a compound or a salt thereof in which each group defined by the general formula [1] is composed of the following groups is particularly preferable.
[0034]
A:-(NRFour)-、-(CRFiveR6)-Or -O-,
B: -S- in the chain or
[Chemical 9]
An alkylene group or alkenylene group, which may contain
R1: An alkyl group or an alkenyl group, wherein the alkyl group may be substituted with a halogen atom or an amino group, and the amino group is an alkyl group, an acyl group, an arylalkyloxycarbonyl group, a cycloalkyloxycarbonyl group or Optionally substituted with an alkoxycarbonyl group,
R2: Adamantylalkyl group,
RThree: Pyridine ring,
RFour: Hydrogen atom,
RFiveAnd R6: Hydrogen atom,
X: = O,
n: An integer of 1 to 5.
[0035]
(3) A compound or a salt thereof in which each group defined by the general formula [1] consists of the following groups:-(NRFour)-、-(CRFiveR6)-Or -O-,
B: -O-, -S-,-(NR in the chain7)-, -N = or
[Chemical Formula 10]
An alkylene group or an alkenylene group, which may be substituted with a hydroxy group, an alkoxy group, an aryl group or a saturated or unsaturated heterocyclic ring, A heterocyclic ring may be formed,
R1: A hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a hydroxy group or an amino group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group or cycloalkenyl group is a halogen atom May be substituted with an atom, a hydroxy group, an amino group, a cycloalkyl group, an aryl group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, a cyano group, or a saturated or unsaturated heterocyclic ring;1The hydrogen atom of each amino group, hydroxy group and aminocarbonyl group is an alkyl group, cycloalkyl group, aryl group, arylalkyl group, acyl group, alkoxycarbonyl group, cycloalkyloxycarbonyl group, arylalkoxycarbonyl group, unsaturated Optionally substituted with an alkyl group substituted with a heterocycle or an unsaturated heterocycle,
R2: Alkyl group, alkenyl group, cycloalkyl group, cycloalkylalkyl group or arylalkyl group,
RThree: Pyridine ring,
RFour: Hydrogen atom, alkyl group, adamantylalkyl group, carboxyalkyl group, alkoxycarbonylalkyl group, amino group, alkylamino group, acylamino group or alkoxycarbonylamino group,
RFiveAnd R6: The same or different hydrogen atom or alkyl group,
R7: Hydrogen atom or alkyl group,
X: = O or = S,
n: An integer of 1 to 5.
[0036]
Of these, compounds in which each group defined by the general formula [1] consists of the following groups or salts thereof are more preferable.
[0037]
A:-(NRFour)-Or-(CRFiveR6-,
B: an alkylene group or an alkenylene group,
R1: An alkyl group or an alkenyl group, wherein the alkyl group may be substituted with a halogen atom, an amino group, a cycloalkyl group, an aryl group, an imidazole group or a pyridine ring, and the amino group is an alkyl group or an acyl group , May be substituted with an alkoxycarbonyl group, a cycloalkyloxycarbonyl group or an arylalkoxycarbonyl group,
R2: Alkyl group, alkenyl group or arylalkyl group,
RThree: Pyridine ring,
RFour: Hydrogen atom,
RFiveAnd R6: Hydrogen atom,
X: = O.
[0038]
Furthermore, of these, R1Is an alkyl group having 3 or more carbon atoms, and R2Particularly preferably, is an alkyl group or an arylalkyl group.
[0039]
Moreover, the compound or its salts in which each group prescribed | regulated by General formula [1] consists of the following groups is more preferable.
[0040]
A:-(NRFour)-Or-(CRFiveR6-,
B: an alkylene group or an alkenylene group,
R1: An alkyl group, an alkenyl group or a cycloalkyl group, wherein the alkyl group is a halogen atom, a hydroxy group, an amino group, a cycloalkyl group, an aryl group, a carboxyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, an aminocarbonyl group, It may be substituted with a pyridine ring or a thiophene ring, and further R1The hydrogen atom of each amino group, hydroxy group and aminocarbonyl group therein may be substituted with an alkyl group, aryl group, arylalkyl group, acyl group, alkoxycarbonyl group, cycloalkyloxycarbonyl group or arylalkoxycarbonyl group. ,
R2: Cycloalkyl group or cycloalkylalkyl group,
RThree: Pyridine ring,
RFour: Hydrogen atom,
RFiveAnd R6: Hydrogen atom,
X: = O.
[0041]
The most preferred specific examples of the present compound include the following compounds and salts thereof.
[0042]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea
Embedded image
[0043]
○, 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea
Embedded image
[0044]
1- [2- (1-adamantyl) ethyl] -1- (2-butenyl) -3- [3- (4-pyridyl) propyl] urea
Embedded image
[0045]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) propyl] urea
Embedded image
[0046]
1- [3- (1-adamantyl) propyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea
Embedded image
[0047]
(Z) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea
Embedded image
[0048]
○ (−)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
Embedded image
[0049]
1- [2- (1-adamantyl) ethyl] -3- [1-methyl-3- (4-pyridyl) propyl] -1-pentylurea
Embedded image
[0050]
○ (+)-1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2-methyl-3- (4-Pyridyl) propyl] urea
Embedded image
[0051]
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
Embedded image
[0052]
○ 3- (4-Pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
Embedded image
[0053]
○ 2- [2- (4-Pyridyl) ethylthio] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
Embedded image
[0054]
6- (4-Pyridyl) caproic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide
Embedded image
[0055]
Cis-1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) cyclopropylmethyl] urea
Embedded image
[0056]
1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
Embedded image
[0057]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2-methyl-3- (4-pyridyl) ) Propyl] urea
Embedded image
[0058]
(E) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea
Embedded image
[0059]
(+)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
Embedded image
[0060]
○ 1,1-dibutyl-3- [3- (4-pyridyl) propyl] urea
Embedded image
[0061]
○ 3- [2-Methyl-3- (4-pyridyl) propyl] -1-pentyl-1-phenethylurea
Embedded image
[0062]
○ 5- (4-Pyridyl) valeric acid N-pentyl-N-phenethylamide
Embedded image
[0063]
1- (2-cyclohexylethyl) -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea
Embedded image
[0064]
Next, although this compound can be manufactured according to the following reaction pathways 1-3, for example, it can manufacture not only these reaction pathways but by various reaction pathways. A detailed synthesis method will be described in the examples described later.
[0065]
Reaction path 1
Embedded image
[0066]
The secondary amine (D) can be obtained by reducing the amide (A) and reacting the primary amine (B) with the compound (C) having a leaving group (the above chemistry). R in the reaction formula1And R2Can be combined. ). Similarly, the secondary amine (G) can be obtained by reacting the compound (E) having a leaving group with the primary amine (F). Reaction of primary amine (B) or secondary amine (D) with primary amine (F) or secondary amine (G) in the presence of condensing agent (H) [eg, 1,1′-carbonyldiimidazole] Then, the present compound [2] is obtained.
[0067]
Reaction path 2
Embedded image
[0068]
The primary amine (B) or the secondary amine (D) synthesized in the reaction route 1 and the carboxylic acid (I) are present in the presence of a condensing agent [for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride]. To give this compound [3].
[0069]
Reaction path 3
Embedded image
[0070]
The first amine (B) or the second amine (D) synthesized in the reaction route 1 is reacted with the alcohol (J) in the presence of a condensing agent (K) [for example, N, N′-disuccinimidyl carbonate]. Then, the present compound [4] is obtained.
[0071]
In the above synthesis method, when the reactant has a thiol group, a hydroxy group or an amino group in the molecule, these groups may be protected with an appropriate protecting group as necessary, and these protecting groups are It can also be removed by a conventional method after the reaction. When the reactant has a carboxyl group in the molecule, the carboxyl group may be esterified as necessary, and the ester can be converted to a carboxylic acid by hydrolysis or other general methods.
[0072]
The compound obtained by the above synthesis method can be converted to the salts as described above by a conventional method.
[0073]
In order to examine the usefulness of the present compound obtained by the above synthesis method, an angiogenesis inhibition test was performed. The details will be described in the pharmacological test section below, but this compound can be used for both angiogenesis using an in vitro human vascular endothelial cell, which is an angiogenesis evaluation model, and in vivo retinal angiogenesis induced by high oxygen load. It was also found that it exhibits a strong inhibitory action. This compound is an angiogenesis inhibitor and diseases involving angiogenesis, particularly diabetic retinopathy, retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis It is useful as a preventive agent, therapeutic agent and inhibitor for corneal neovascularization, solid tumor, hemangioma, tumor growth / metastasis, etc.
[0074]
This compound can be administered parenterally or orally. The dosage forms include eye drops such as eye drops, eye ointments, subconjunctival injections, conjunctival depot preparations, implantable preparations, conjunctival sac insertion agents, intravenous injections, tablets, capsules, powders, granules. And percutaneous absorption agents, and the like, and these can be prepared using known techniques including DDS preparations. For example, eye drops are prepared by appropriately adding an isotonic agent, buffer, pH adjuster, solubilizer, thickener, stabilizer, preservative, soothing agent, etc. as an additive. Can do. In addition, a stable ophthalmic solution can be obtained by adding a pH adjuster, a thickener, a dispersant, etc., and suspending the drug. The pH of the eye drop is desirably set to 4.0 to 8.0, and the osmotic pressure ratio is desirably set to around 1.0.
[0075]
Examples of isotonic agents include glycerin, propylene glycol, sodium chloride, potassium chloride, sorbitol, mannitol and the like.
[0076]
Examples of the buffer include phosphoric acid, phosphate, citric acid, acetic acid, ε-aminocaproic acid, trometamol, and the like.
[0077]
Examples of the pH regulator include hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate and the like.
[0078]
Examples of the solubilizer and dispersant include polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, purified soybean lecithin, polyoxyethylene (160) polyoxypropylene (30) glycol, and the like.
[0079]
Examples of the thickener include cellulosic polymers such as hydroxypropylmethylcellulose and hydroxypropylcellulose, polyvinyl alcohol, polyvinylpyrrolidone and the like, and examples of the stabilizer include edetic acid and sodium edetate. .
[0080]
Examples of preservatives (preservatives) include general-purpose sorbic acid, potassium sorbate, benzalkonium chloride, benzethonium chloride, methyl paraoxybenzoate, propyl paraoxybenzoate, and chlorobutanol. It can also be used.
[0081]
Examples of soothing agents include chlorobutanol, benzyl alcohol, lidocaine and the like.
[0082]
The dose of this compound can be appropriately selected depending on symptoms, age, dosage form, etc. For example, in the case of eye drops, it is usually 0.001% to 10% (w / v), preferably 0.01 to 5% (w / v). The concentration of v) may be administered once to several times a day.
[0083]
The production examples of intermediates, production examples of the present compound, formulation examples and pharmacological test results are shown below, but these examples are for better understanding of the present invention and limit the scope of the present invention. It is not a thing.
[0084]
【Example】
[A] Example of production of intermediate
Intermediate production example 1
○ 2- (1-adamantyl) -N-pentylethylamine hydrochloride (intermediate 1-1)
To a solution of methanesulfonic acid 2- (1-adamantyl) ethyl ester (2.07 g, 8.01 mmol) in ethanol (45.8 ml), pentylamine (2.69 ml, 23.2 mmol), potassium carbonate (2.14 g, 15.5 mmol) and sodium iodide (2.30 g, 15.3 mmol) were added, and the mixture was heated to reflux for 17 hours. The reaction solution was concentrated under reduced pressure and diluted with chloroform (100 ml). This was washed with 1N aqueous sodium hydroxide solution (100 ml) and saturated aqueous sodium chloride solution (100 ml), and the organic layer was dried over magnesium sulfate. The solvent was distilled off under reduced pressure and purified by silica gel column chromatography. To a solution of the obtained target compound free form (1.52 g, 6.10 mmol) in ethyl acetate (0.50 ml) was added 4N hydrogen chloride ethyl acetate solution (3.1 ml). The precipitated solid was washed with ethyl acetate and collected by filtration to obtain 1.33 g (60%) of the target compound.
[0085]
IR (KBr): 2924, 2850, 2519, 1456 cm-1
mp: 263.0-264.5 ° C
[0086]
By performing the same operations as in Intermediate Production Example 1, the following compounds were obtained. Note that the target compound may not be isolated as a hydrochloride salt.
[0087]
○ N '-[2- (1-adamantyl) ethyl] -N- (benzyloxycarbonyl) -N-methylethylenediamine (intermediate 1-2)
IR (neat): 2901, 2844, 1704 cm-1
[0088]
○ 2- (1-adamantyl) -N- (cyclopentylmethyl) ethylamine hydrochloride (intermediate 1-3)
IR (KBr): 2907, 2847, 1452 cm-1
mp: 300.0-310.0 ° C
[0089]
N '-[2- (1-adamantyl) ethyl] -N- (t-butoxycarbonyl) -N-methylethylenediamine (intermediate 1-4)
IR (neat): 3307, 2902, 2846, 1698 cm-1
[0090]
○ 2,2'-di (1-adamantyl) diethylamine hydrochloride (intermediate 1-5)
IR (KBr): 2900, 2845, 2735, 2453 cm-1
mp: 325 ° C
[0091]
○ 2- (1-adamantyl) -N-propylethylamine (intermediate 1-6)
IR (neat): 3276, 2903, 2846, 1450 cm-1
[0092]
○ N '-[2- (1-adamantyl) ethyl] -N, N-dimethylethylenediamine dihydrochloride (intermediate 1-7)
IR (KBr): 3424, 2901, 2446, 2445 cm-1
mp: 254.5-259.0 ° C
[0093]
○ 2- (1-adamantyl) -N-cyclopentylethylamine hydrochloride (intermediate 1-8)
IR (KBr): 2910, 2846, 2771, 2450 cm-1
mp: 300-312 ° C
[0094]
○ 2- (1-adamantyl) -N-cyclopropylethylamine (intermediate 1-9)
IR (neat): 3272, 2901, 2845 cm-1
[0095]
○ 2- (1-adamantyl) -N- (2-methoxyethyl) ethylamine hydrochloride (intermediate 1-10)
IR (KBr): 2909, 2846, 2792, 1451 cm-1
mp: 278.5-281.5 ° C
[0096]
○ (1-adamantyl) -N- (2-propynyl) ethylamine (intermediate 1-11)
IR (neat): 2900, 2845, 1450 cm-1
[0097]
○ N-pentyl-2- (2-pyridyl) ethylamine (intermediate 1-12)
IR (neat): 3305, 2927, 2857, 1591 cm-1
[0098]
○ 2- (1-adamantyl) -N-benzylethylamine hydrochloride (intermediate 1-13)
IR (KBr): 2900, 2846, 2750, 2528, 2468, 2372, 1585 cm-1
mp: 264.0-265.0 ° C
[0099]
○ 2- (1-adamantyl) -N-furfurylethylamine hydrochloride (intermediate 1-14)
IR (KBr): 3456, 2903, 2846, 2741, 2426 cm-1
mp: 225.0-233.0 ° C
[0100]
○ 2- (1-adamantyl) -N-butylethylamine (intermediate 1-15)
IR (neat): 2903, 1683, 1450 cm-1
[0101]
○ 2-cyclohexyl-N- (2-thienyl) methylethylamine hydrochloride (intermediate 1-16)
[0102]
○ N-pentylphenethylamine hydrochloride (intermediate 1-17)
IR (KBr): 3028, 2957, 2786, 1456 cm-1
mp: 260.0-285.0 ° C
[0103]
○ 2-cyclohexyl-N-butylethylamine hydrochloride (intermediate 1-18)
IR (KBr): 2921, 2853, 2794, 2739, 2442, 1590, 1484, 1451 cm-1
mp: 250 ° C or higher
[0104]
○ 2-cyclohexyl-N-pentylethylamine hydrochloride (intermediate 1-19)
IR (KBr): 2924, 2793, 1451 cm-1
mp: 250 ° C or higher
[0105]
○ N- (t-butoxycarbonyl) -N '-(2-cyclohexylethyl) -N-methylethylenediamine (intermediate 1-20)
IR (neat): 3350, 2923, 2850, 1697, 1481, 1449 cm-1
[0106]
○ N '-(2-cyclohexylethyl) -N, N-dimethylethylenediamine (intermediate 1-21)
IR (neat): 3310, 2921, 2850, 2815, 1448 cm-1
[0107]
○ N- [2- (1-adamantyl) ethyl] -3- (4-pyridyl) propylamine (intermediate 1-22)
IR (neat): 3291, 2902, 2845, 1602, 1450 cm-1
[0108]
○ 2- (1-adamantyl) -N-isopropylethylamine hydrochloride (intermediate 1-23)
IR (KBr): 2909, 2846, 2754, 2464, 1588, 1476, 1451 cm-1
mp: 266.0-269.5 ° C
[0109]
○ N- (2-Piperidinoethyl) pentylamine (Intermediate 1-24)
IR (neat): 2932, 2854, 1466 cm-1
[0110]
○ 2- (1-adamantyl) -N-[(2-methylthiazol-4-yl) methyl] ethylamine (intermediate 1-25)
IR (neat): 2901, 2844, 1449 cm-1
[0111]
O N- [2- (1-adamantyl) ethyl] cinnamylamine (Intermediate 1-26)
IR (neat): 2901, 2845, 1449 cm-1
[0112]
○ N- [2- (1-adamantyl) ethyl] -2-methyl-2-propenylamine (Intermediate 1-27)
IR (neat): 2902, 2845, 1450 cm-1
[0113]
N- [2- (1-adamantyl) ethyl] -3-methyl-2-butenylamine (Intermediate 1-28)
IR (neat): 2903, 2846, 1450 cm-1
[0114]
○ N- [2- (1-adamantyl) ethyl] decylamine hydrochloride (intermediate 1-29)
IR (KBr): 2926, 2849, 2778, 2469 cm-1
mp: 204.0-208.5 ° C
[0115]
○ N- [2- (1-adamantyl) ethyl] hexylamine hydrochloride (intermediate 1-30)
IR (KBr): 2909, 2848, 2766, 2446 cm-1
mp: 230.0-243.0 ° C
[0116]
○ 2- (1-adamantyl) -N- (benzyloxy) ethylamine (intermediate 1-31)
IR (neat): 2901, 2446, 1452 cm-1
[0117]
○ 2- (1-adamantyl) -N-[(2-thienyl) methyl] ethylamine hydrochloride (intermediate 1-32)
IR (KBr): 2908, 2846, 2757, 2426 cm-1
mp: 257.0-260.0 ° C
[0118]
N- [2- (1-adamantyl) ethyl] -2-butenylamine (Intermediate 1-33)
IR (neat): 2901, 1450 cm-1
[0119]
○ N- [2- (1-adamantyl) ethyl] allylamine (Intermediate 1-34)
IR (neat): 2902, 1450 cm-1
[0120]
○ N- [2- (1-adamantyl) ethyl] cyclopropylmethylamine (Intermediate 1-35)
IR (neat): 2901, 1450 cm-1
[0121]
○ N- [2- (1-adamantyl) ethyl] -3,3,3-trifluoropropylamine hydrochloride (intermediate 1-36)
IR (KBr): 2910, 2849, 2767, 2598, 2457 cm-1
mp: 300.0-310.0 ° C
[0122]
○ 1- [2- (1-adamantyl) ethyl] -2- (t-butoxycarbonyl) hydrazine (Intermediate 1-37)
IR (KBr): 3288, 2899, 1705 cm-1
mp: 73.5-81.0 ° C
[0123]
○ N- (t-butoxycarbonyl) -N-methyl-N'-phenethylethylenediamine (intermediate 1-38)
IR (neat): 3326, 3025, 2975, 2930, 1694, 1454 cm-1
[0124]
○ N- (t-butoxycarbonyl) -N-methyl-N'-pentylethylenediamine (intermediate 1-39)
IR (neat): 2958, 2929, 1694, 1457 cm-1
[0125]
O N- (benzyloxycarbonyl) -N-methyl-N'-phenethylethylenediamine (intermediate 1-40)
IR (neat): 3309, 3027, 2936, 2824, 1698, 1454 cm-1
[0126]
○ N- (benzyloxycarbonyl) -N-methyl-N'-pentylethylenediamine (intermediate 1-41)
IR (neat): 2928, 2858, 1703, 1455 cm-1
[0127]
○ 2-cyclohexyl-N- (2-methoxyethyl) ethylamine hydrochloride (intermediate 1-42)
IR (KBr): 2923, 2855, 2784, 2478, 2444 cm-1
mp: 205.0-208.0 ° C
[0128]
○ N-ethyl-3,4,5-trimethoxyphenethylamine (intermediate 1-43)
IR (neat): 3300, 2936, 2828, 1588, 1508, 1457, 1419, 1331, 1326, 1126, 1008 cm-1
[0129]
○ 5- [2- (Isopentylamino) ethyl] imidazole dihydrochloride (Intermediate 1-44)
IR (KBr): 2806, 2467, 1619, 1604, 1446, 1347, 1089, 914, 827, 735, 627, 622 cm-1
mp: 235.2-238.0 ° C
[0130]
○ N-cyclohexyl-3,4-dimethoxyphenethylamine (intermediate 1-45)
IR (neat): 2928, 2852, 1591, 1515, 1463, 1449, 1416, 1261, 1326, 1155, 1139, 1029, 802, 761 cm-1
bp: 170 ° C./210 Pa
[0131]
○ N-cyclopropyl-3,4,5-trimethoxyphenethylamine (Intermediate 1-46)
IR (neat): 3304, 2932, 2832, 1588, 1505, 1459, 1418, 1332, 1326, 1126, 1009 cm-1
[0132]
O N '-[2- (1-adamantyl) ethyl] -N- (t-butoxycarbonyl) -N-methyl-1,3-propanediamine (intermediate 1-47)
IR (neat): 3308, 2902, 2845, 1698, 1480 cm-1
[0133]
○ N-cyclohexyl (phenyl) methyl-3- (4-methoxyphenyl) propylamine hydrochloride (intermediate 1-48)
IR (KBr): 2928, 2857, 2765, 1592, 1510, 1455, 1230, 1064, 1033, 817 cm-1
mp: 187.5-189.5 ° C.
[0134]
○ N-diphenylmethyl-3-phenylpropylamine (Intermediate 1-49)
IR (neat): 3024, 2931, 1601, 1493, 1452 cm-1
[0135]
○ N-pentyl-3-phenylpropylamine hydrochloride (intermediate 1-50)
IR (KBr): 3027, 2955, 2870, 2780, 2492, 2413 cm-1
mp: 230.0-238.0 ° C
[0136]
O N-acetyl-N '-[2- (1-adamantyl) ethyl] ethylenediamine
Hydrochloride (Intermediate 1-51)
IR (neat): 2897, 2845, 2361, 1826, 1707, 1567m-1
mp: 245.0-247.0 ° C
[0137]
○ N-isopentyl-3,3,3-trifluoropropylamine hydrochloride (intermediate 1-52)
IR (KBr): 2961, 2800, 1253, 1173m-1
mp: 288 ° C or higher
[0138]
○ N- [2- (1-adamantyl) ethyl] -2,2,2-trifluoroethylamine hydrochloride (intermediate 1-53)
IR (KBr): 2904, 2849, 1273, 1233, 1176, 1145m-1
mp: 263.0-265.0 ° C
[0139]
○ 3-cyclohexyl-N-propylpropylamine hydrochloride (intermediate 1-54)
IR (KBr): 2924, 2854, 2779m-1
mp: 234.6-235.4 ° C
[0140]
○ N '-[3- (1-adamantyl) propyl] -N- (t-butoxycarbonyl) -N-methylethylenediamine (intermediate 1-55)
1H-NMR (400 MHz, CDCl3) 0.99-1.10 (m, 2H), 1.32-1.52 (m, 17H), 1.55-1.65 (m, 4H), 1.70 (d, J = 11) .8 Hz, 3H), 1.93 (s, 3H), 2.58 (t, J = 7.2 Hz, 2H), 2.77 (br, 2H), 2.91 (s, 3H), 3.33 (br, 2H)
[0141]
Intermediate production example 2
○ 4- (3-Aminopropyl) pyridine (Intermediate 2-1)
N- [3- (4-pyridyl) propyl] phthalimide (67.1 g, 252 mmol), methanol (504 ml) and hydrazine monohydrate (18.3 ml, 378 mmol) were mixed and heated to reflux for 3 hours. After standing to cool, the insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. Chloroform (1 L) and 4N aqueous sodium hydroxide solution (500 ml) were added to the residue, and after liquid separation, the organic layer was dried over sodium sulfate. After concentration under reduced pressure and distillation under reduced pressure, 20.5 g (60%) of the target compound was obtained as a colorless oil.
[0142]
IR (neat): 3362, 2933, 1603 cm-1
bp: 76.0-79.0 ° C / 40Pa
[0143]
By performing the same operations as in Intermediate Production Example 2, the following compounds were obtained.
[0144]
○ 3- (4-Pyridyl) -2-propenylamine (Intermediate 2-2)
IR (neat): 3280, 3024, 1599 cm-1
[0145]
○ 2- (4-Pyridyloxy) ethylamine (Intermediate 2-3)
IR (KBr): 3298, 3102, 1610, 1216, 1049 cm-1
mp: 108.0-111.5 ° C
[0146]
○ 3- (4-Quinolyl) -2-propenylamine (Intermediate 2-4)
IR (neat): 3270, 2944, 1585, 1568, 1508 cm-1
[0147]
Intermediate production example 3
○ 2- (1-adamantyl) -N-methylethylamine (intermediate 3-1)
To a solution of lithium aluminum hydride (569 mg, 15.0 mmol) in diethyl ether (34.0 ml) under ice-cooling, a solution of 1-adamantaneacetic acid N-methylamide (1.54 g, 7.45 mmol) in tetrahydrofuran (15.0 ml) Was added dropwise over 5 minutes. After heating under reflux for 6 hours, the mixture was again stirred under ice-cooling, ethyl acetate was added to treat excess lithium aluminum hydride, and the reaction solution was extracted twice with 1N hydrochloric acid (50 ml). The extract was made basic by the addition of 4N aqueous sodium hydroxide and extracted with diethyl ether (80 ml). The organic layer was washed with a saturated aqueous sodium chloride solution (60 ml) and then dried over magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 890 mg (66%) of the target compound.
[0148]
IR (neat): 2902, 2845, 1449 cm-1
[0149]
By performing the same operations as in Intermediate Production Example 3, the following compounds were obtained.
[0150]
The compound could be converted into a hydrochloride with 4N hydrogen chloride ethyl acetate solution.
[0151]
○ 2- (1-adamantyl) -N-ethylethylamine hydrochloride (intermediate 3-2)
IR (KBr): 2896, 2847, 2753, 2468, 1610 cm-1
mp: 230-245 ° C
[0152]
○ N-methyl-3- (4-pyridyl) propylamine (intermediate 3-3)
IR (neat): 3292, 2934, 1602 cm-1
[0153]
○ 1-adamantyl-N-propylmethylamine hydrochloride (intermediate 3-4)
IR (KBr): 2905, 1584, 1451 cm-1
mp: 340 ° C
[0154]
○ 2- (1-adamantyl) -N-methylethylamine hydrochloride (intermediate 3-5)
IR (KBr): 3422, 2900, 2846, 2676, 2450, 1630 cm-1
mp: 200-220 ° C
[0155]
○ 3- (1-adamantyl) -N-propylpropylamine hydrochloride (intermediate 3-6)
IR (KBr): 2899, 2467, 1449 cm-1
mp: 159.5-162.0 ° C
[0156]
○ 1-adamantyl-N-pentylmethylamine hydrochloride (intermediate 3-7)
IR (KBr): 2916, 2603, 2509, 2418, 1477 cm-1
mp: 170-235 ° C
[0157]
○ N- [3- (1-adamantyl) propyl] pentylamine hydrochloride (intermediate 3-8)
IR (KBr): 2901, 2847, 1466, 1453 cm-1
mp: 199-224 ° C
[0158]
○ N- [2- (1-adamantyl) ethyl] -4,4,4-trifluorobutylamine hydrochloride (intermediate 3-9)
IR (KBr): 3422, 2908, 2852, 2770, 2518, 1452, 1255, 1148 cm-1
mp: 243-274 ° C
[0159]
○ N- [2- (1-adamantyl) ethyl] -5,5,5-trifluoropentylamine (Intermediate 3-10)
IR (neat): 2903, 2846, 1450, 1255, 1142 cm-1
[0160]
○ N- [3- (1-adamantyl) propyl] butylamine hydrochloride (intermediate 3-11)
IR (KBr): 2904, 2847, 2756, 1453 cm-1
mp: 275.0-276.8 ° C
[0161]
○ 3- (1-adamantyl) -N- (2,2,2-trifluoroethyl) propylamine hydrochloride (intermediate 3-12)
IR (KBr): 2902, 2850, 2739, 1274, 1258, 1176, 1139 cm-1
mp: 262.0-268.0 ° C
[0162]
○ 4- (1-adamantyl) -N-ethylbutylamine hydrochloride (intermediate 3-13)
IR (KBr): 2901, 2847, 2457, 1451 cm-1
mp: 224-230 ° C
[0163]
○ 4- (1-adamantyl) -N-propylbutylamine hydrochloride (intermediate 3-14)
IR (KBr): 2899, 2848, 2751, 2410, 1451 cm-1
mp: 234-249 ° C.
[0164]
○ N- (1-adamantyl) -N'-propylethylenediamine dihydrochloride (intermediate 3-15)
IR (KBr): 2927, 2719, 2508, 2429, 1471 cm-1
mp: 288.5-289.5 ° C
[0165]
Intermediate production example 4
○ 3- [N- [2- (1-adamantyl) ethyl] amino] propionic acid t-butyl ester hydrochloride (intermediate 4-1)
2- (1-adamantyl) ethylamine hydrochloride (1.0 g, 4.6 mmol) was dissolved in ethanol (10 ml), and triethylamine (0.65 ml, 4.6 mmol) and acrylic acid t-butyl ester (0 .75 ml, 5.1 mmol) was added and the mixture was allowed to warm to room temperature and stirred overnight. The reaction solution was concentrated under reduced pressure, 1N aqueous sodium hydroxide solution (30 ml) and ethyl acetate (50 ml) were added to the residue, and the phases were separated. The ethyl acetate layer was washed with water (50 ml) and saturated aqueous sodium chloride solution (50 ml) and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, purification was performed by silica gel column chromatography. The obtained oil (0.50 g, 1.6 mmol) was dissolved in diethyl ether (20 ml), and a 4N hydrogen chloride ethyl acetate solution (1.0 ml, 4.0 mmol) was added under ice cooling to precipitate a solid. This was filtered with diethyl ether to obtain 0.33 g (23%) of the target compound.
[0166]
IR (KBr): 2902, 2846, 1733, 1166 cm-1
mp: 210 ° C
[0167]
By performing the same operations as in Intermediate Production Example 4, the following compounds were obtained. Note that the target compound may not be isolated as a hydrochloride salt.
[0168]
○ 3- [N- (2-cyclohexylethyl) amino] propionic acid methyl ester hydrochloride (intermediate 4-2)
IR (KBr): 2924, 2853, 2792, 1736, 1455, 1439 cm-1
mp: 185.0-187.5 ° C
[0169]
○ 3- [N- (2-cyclohexylethyl) amino] propionic acid t-butyl ester (intermediate 4-3)
IR (neat): 2777, 2922, 2850, 1728, 1449 cm-1
[0170]
○ 3- [N- [3- (4-Pyridyl) propyl] amino] propionic acid t-butyl ester hydrochloride (intermediate 4-4)
IR (neat): 3322, 2777, 2933, 1724, 1602, 1367, 1153 cm-1
[0171]
Intermediate production example 5
○ 5- (4-Pyridyl) valeric acid (intermediate 5-1)
(Benzyloxycarbonylmethyl) triphenylphosphonium bromide (4.60 g, 9.36 mmol), β- (4-pyridyl) acrolein oxalate (1.90 g, 8.51 mmol) and N, N-dimethylformamide (17 ml) ) And stirred under ice cooling. Potassium carbonate (4.70 g, 34.0 mmol) was added and the reaction solution was brought to room temperature. The mixture was stirred overnight, diluted with ethyl acetate (100 ml), and washed twice with water (100 ml) and saturated brine (50 ml) in this order. After drying over sodium sulfate, ethyl acetate was distilled off under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain 2.29 g (quantitative) of 5- (4-pyridyl) valeric acid-2,4-dienebenzyl ester as a pale yellow oil.
[0172]
Next, methanol (42 ml) and acetic acid (1.0 ml, 18 mmol) were added to 5- (4-pyridyl) valeric acid-2,4-dienebenzyl ester (2.25 g, 8.48 mmol), and nitrogen gas was added to 10%. Aerated for a minute. A catalytic amount of palladium hydroxide on carbon was added, and the mixture was stirred overnight at room temperature in a hydrogen atmosphere. Insoluble material was removed by filtration through Celite, and the filtrate was concentrated under reduced pressure. Ethyl acetate (50 ml) was added to the solidified residue, and the mixture was stirred at room temperature for 3 hours. The crystals were collected by filtration to obtain 1.00 g (66%) of the target compound as pale yellow crystals.
[0173]
IR (KBr): 2943, 1719, 1636, 1605 cm-1
mp: 155.0-180.0 ° C
[0174]
Intermediate production example 6
○ 3- [N- (2-cyclohexylethyl) amino] propionic acid amide hydrochloride (intermediate 6-1)
Under ice-cooling, trifluoroacetic acid (6 ml) was added to 3- [N- (2-cyclohexylethyl) amino] propionic acid t-butyl ester (2.0 g, 7.8 mmol) of Intermediate 4-3. After stirring overnight, the mixture was concentrated under reduced pressure. A 4N hydrogen chloride ethyl acetate solution was added to the residue, and after concentration under reduced pressure, the resulting crystals were collected by filtration with diethyl ether to give 1.5 g (96% of 96% of 3- [N- (2-cyclohexylethyl) amino] propionate hydrochloride). )was gotten.
[0175]
Next, tetrahydrofuran (8 ml) was added to 3- [N- (2-cyclohexylethyl) amino] propionate hydrochloride (1.0 g, 4.2 mmol), and the mixture was stirred at room temperature. Carbonic acid di-t-butyl ester (1.1 g, 5.1 mmol) and triethylamine (1.3 ml, 9.3 mmol) were added and stirred overnight, and then 5% aqueous citric acid solution (10 ml) was added. After extraction with chloroform (60 ml), the organic layer was washed with saturated brine (20 ml). The extract was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.79 g (62%) of 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionic acid as a colorless oil. .
[0176]
Next, anhydrous tetrahydrofuran (7 ml) was added to 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionic acid (0.59 g, 2.0 mmol), and the mixture was stirred at -78 ° C. did. N-methylmorpholine (0.22 ml, 2.0 mmol) followed by a solution of isobutyl chloroformate (0.38 ml, 2.9 mmol) in tetrahydrofuran (3 ml) was added. After 1 hour, 28% aqueous ammonia solution (6.0 ml, 9.8 mmol) was added and stirred for 1.5 hours. Chloroform (50 ml) was added to room temperature, and the mixture was washed successively with saturated aqueous sodium hydrogen carbonate (20 ml) and saturated brine (20 ml). After drying over magnesium sulfate and concentrating under reduced pressure, the residue was purified by silica gel column chromatography to give 0.34 g of 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionic acid amide (58 %) Was obtained as colorless crystals.
[0177]
Next, 3- [N- (t-butoxycarbonyl) -N- (2-cyclohexylethyl) amino] propionic acid amide (0.37 g, 1.2 mmol) was added to a 4N hydrogen chloride 1,4-dioxane solution (3. 1 ml) was added and stirred overnight at room temperature. After concentration under reduced pressure, diisopropyl ether was added to the resulting solid and collected by filtration to obtain 0.30 g (quantitative) of the target compound as colorless crystals.
[0178]
IR (KBr): 3386, 3196, 2921, 2852, 2808, 1705, 1656, 1452 cm-1
mp: 165.0 ° C
[0179]
Intermediate production example 7
○ Di-5-hexenylamine (intermediate 7-1)
N, N-dimethylformamide (28 ml) was added to 3-aminopropionitrile (0.98 g, 14 mmol), and the mixture was stirred at room temperature. 6-Bromo-1-hexene (5.0 g, 31 mmol), sodium iodide (11 g, 73 mmol) and potassium carbonate (5.8 g, 42 mmol) were added and stirred overnight. The mixture was diluted with diethyl ether (100 ml) and washed with water (100 ml, twice) and saturated brine (50 ml) in this order. After drying with sodium sulfate, the organic layer was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain 2.2 g (66%) of 3- (di-5-hexenyl) aminopropionitrile as a colorless oil.
[0180]
Next, ethanol (8.6 ml) and potassium hydroxide (0.85 g, 13 mmol) were added to 3- (di-5-hexenyl) aminopropionitrile (2.0 g, 8.6 mmol) and heated for 7.5 hours. Circulated. After cooling, water (150 ml) and chloroform (150 ml) were added and partitioned, and the organic layer was dried over sodium sulfate. After concentration under reduced pressure, the residue was separated and purified by basic silica gel column chromatography to obtain 0.32 g (21%) of the target compound as a pale yellow oil.
[0181]
IR (neat): 3076, 2976, 2928, 2856, 1679, 1640 cm-1
[0182]
By performing the same operations as in Intermediate Production Example 7, the following compounds were obtained.
[0183]
○ Di-7-octenylamine (intermediate 7-2)
IR (neat): 3075, 2976, 2926, 2854, 1640 cm-1
[0184]
Intermediate production example 8
○ N- [2- (1-adamantyloxy) ethyl] propylamine hydrochloride (intermediate 8-1)
2- (propylamino) ethanol (2.4 g, 23 mmol), 1-bromoadamantane (0.50 g, 2.3 mmol), triethylamine (0.32 ml, 2.3 mmol) were mixed, and the external temperature was 100 ° C. for 2 hours. The mixture was stirred at 130 ° C. for 5 hours and at 150 ° C. for 3 hours. After allowing to cool, ethyl acetate (50 ml) was added, and the mixture was washed with water (50 ml) twice and saturated brine (30 ml) in this order. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was separated by silica gel column chromatography, 4N hydrogen chloride ethyl acetate solution (2 ml) was added, and the mixture was concentrated under reduced pressure. The resulting crystals were collected by filtration with ethyl acetate to give 0.16 g (25%) of the target compound as colorless crystals. Obtained.
[0185]
IR (KBr): 3544, 2907, 2502, 1584 cm-1
mp: 232.0-232.7 ° C
[0186]
Intermediate production example 9
○ 2-Propylaminoacetic acid N- (1-adamantyl) amide (intermediate 9-1) Ethanol (36 ml) was added to bromoacetic acid (5.00 g, 36.0 mmol), and the mixture was stirred under ice-water cooling. Propylamine (14.8 ml, 180 mmol) was added over 1 minute, followed by stirring at an external temperature of 80 ° C. for 2.5 hours. 4N Aqueous sodium hydroxide solution (27 ml) was added, and the mixture was concentrated under reduced pressure. Water (27 ml) and tetrahydrofuran (30 ml) were added, and the mixture was stirred at room temperature. A solution of carbonic acid di-t-butyl ester (9.43 g, 43.2 mmol) in tetrahydrofuran (6 ml) was added, and after 15 minutes, citric acid monohydrate was added to make it weakly acidic. After extraction with ethyl acetate (150 ml), the mixture was washed with water (100 ml) and saturated brine (50 ml) in this order. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was separated by silica gel column chromatography to obtain 5.06 g (65%) of 2- [N- (t-butoxycarbonyl) -N-propylamino] acetic acid as a colorless solid.
[0187]
Next, 2- [N- (t-butoxycarbonyl) -N-propylamino] acetic acid (4.52 g, 20.8 mmol), 1-adamantanamine (3.46 g, 22.9 mmol) to methylene chloride (208 ml) And stirred at room temperature. N, N-diisopropylethylamine (7.25 ml, 41.6 mmol) and then O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate ( 8.71 g, 22.9 mmol) was added and stirred overnight. After the reaction solution was concentrated under reduced pressure, the residue was separated by silica gel column chromatography to give 7.88 g of 2- [N ′-(t-butoxycarbonyl) -N′-propylamino] acetic acid N- (1-adamantyl) amide ( (Quantitative) was obtained as a colorless oil. The resulting oil solidified at room temperature.
[0188]
Next, 2- [N ′-(t-butoxycarbonyl) -N′-propylamino] acetic acid N- (1-adamantyl) amide (7.68 g, 21.9 mmol) in 4N hydrogen chloride ethyl acetate solution (55 ml, 0.22 mol) was added and stirred at room temperature for 1 hour. The resulting crystals were filtered off with ethyl acetate and washed with ethyl acetate to obtain 5.97 g (95%) of the target compound as colorless crystals.
[0189]
IR (KBr): 3272, 2906, 2848, 2589, 1676, 1562 cm-1
mp: 278.0-279.2 ° C
[0190]
Intermediate production example 10
○ N- (t-butoxycarbonyl) -2- (4-pyridyloxy) ethylamine (intermediate 10-1)
Under ice cooling, di-t-butyl dicarbonate (380 mg, 1.74 mmol) and triethylamine (240 μl, 1.74 mmol) were added to a solution of intermediate 2-4 (200 g, 1.45 mmol) in tetrahydrofuran (5 ml). The mixture was stirred at room temperature for 25 minutes. The reaction mixture was evaporated under reduced pressure, and partitioned with ethyl acetate (50 ml) and saturated aqueous sodium hydrogen carbonate solution (50 ml). The aqueous layer was further extracted with chloroform (50 ml), and the combined organic layer was dried over anhydrous magnesium sulfate. The residue obtained by distilling off the solvent under reduced pressure was purified by silica gel column chromatography to obtain 70 mg (20.2%) of the target compound.
[0191]
IR (neat): 3230, 2976, 1706, 1596 cm-1
[0192]
Intermediate production example 11
○ (RS) -2-Methyl-3- (4-pyridyl) propylamine (Intermediate 11-1)
Under a nitrogen atmosphere, N, N-dimethylformamide (143 ml) was added to sodium hydride (5.36 g, 134 mmol), and the mixture was stirred under ice cooling. A solution of methylmalonic acid diethyl ester (11.7 g, 67.1 mmol) in N, N-dimethylformamide (40 ml) was added dropwise over 5 minutes, and after 10 minutes 4-picolyl chloride hydrochloride (10.0 g, 61.0 mmol) Was gradually added over 5 minutes to room temperature. After 1 hour, saturated aqueous sodium hydrogen carbonate (500 ml) was added, and the mixture was extracted with diethyl ether (400 ml). The organic layer was washed with water (100 ml) and saturated brine (50 ml), and dried over magnesium sulfate. Concentration in vacuo gave 17.2 g (quantitative, including sodium hydride oil) of 2-methyl-2- (4-pyridylmethyl) malonic acid diethyl ester as a brown oil.
[0193]
Next, 6N hydrochloric acid (96.8 ml, 581 mmol) was added to 2-methyl-2- (4-pyridylmethyl) malonic acid diethyl ester (17.2 g, 64.6 mmol), and the mixture was heated to reflux overnight. The mixture was allowed to cool and then washed with hexane (100 ml) to remove sodium hydride oil contained in 2-methyl-2- (4-pyridylmethyl) malonic acid diethyl ester and concentrated under reduced pressure. The resulting crystals were collected by filtration with ethyl acetate to obtain 10.7 g (82%) of 2-methyl-3- (4-pyridyl) propionic acid as light pink crystals.
[0194]
Next, 2-methyl-3- (4-pyridyl) propionic acid (1.69 g, 10.2 mmol) was mixed with chloroform (8 ml), thionyl chloride (2.2 ml, 30.6 mmol), N, N-dimethylformamide ( 1 drop) was added and heated to reflux with stirring for 1 hour. After concentration under reduced pressure, chloroform (8 ml) was added and slowly added to a 28% aqueous ammonia solution stirred under ice-cooling. After 10 minutes, the mixture was brought to room temperature and stirred overnight. After concentration under reduced pressure, ethyl acetate (100 ml) was added, and the resulting insoluble material was removed by filtration. The filtrate was concentrated under reduced pressure, the residue was separated and purified by silica gel column chromatography, and the resulting crystals were collected by filtration with diethyl ether to give 0.72 g (43%) of 2-methyl-3- (4-pyridyl) propionic acid amide. Was obtained as pale yellow crystals.
[0195]
Next, anhydrous diethyl ether (20 ml) was added to lithium aluminum hydride (0.45 g, 12 mmol) in a nitrogen atmosphere, and the mixture was stirred under ice cooling. A solution of 2-methyl-3- (4-pyridyl) propionic acid amide (0.68 g, 4.1 mmol) in anhydrous methylene chloride (20 ml) was added dropwise over 5 minutes, and the mixture was stirred at room temperature overnight. The mixture was again cooled on ice, ethyl acetate (5 ml) was slowly added, then 1N aqueous sodium hydroxide solution was slowly added first, and a total amount of 100 ml was added. After extraction with chloroform (100 ml), the organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain 0.56 g (90%) of the target compound as a pale yellow oil.
[0196]
IR (neat): 3293, 2957, 2925, 1602 cm-1
[0197]
By performing the same operations as in Intermediate Production Example 11, the following compounds were obtained. Moreover, an optically active substance could be obtained by optical resolution using an optically active acid.
[0198]
○ 2- (4-Pyridylmethyl) butylamine (Intermediate 11-2)
IR (neat): 3296, 3025, 2960, 2874, 1602 cm-1
[0199]
○ 2-Benzyl-3- (4-pyridyl) propylamine (Intermediate 11-3)
IR (neat): 3296, 3062, 3025, 1602 cm-1
[0200]
○ 2,2-bis (4-pyridylmethyl) ethylamine (intermediate 11-4)
IR (neat): 3290, 3026, 2924, 1602, 1557 cm-1
[0201]
○ (-)-2-Methyl-3- (4-pyridyl) propylamine (intermediate 11-5)
IR (neat): 3362, 3301, 2958, 1603 cm-1
[Α]20 D: -10.6 ° (MeOH, C1.0)
[0202]
○ (+)-2-Methyl-3- (4-pyridyl) propylamine (intermediate 11-6)
IR (neat): 3362, 3294, 2958, 1603 cm-1
[Α]20 D: + 9.9 ° (MeOH, C1.0)
[0203]
Intermediate production example 12
○ 3- (4-Quinolyl) propylamine (Intermediate 12-1)
A catalytic amount of 3- (4-quinolyl) -2-propenylamine (intermediate 2-4) (188 mg, 1.02 mmol) obtained in Intermediate Production Example 2 was added to a methanol (3 ml) solution at room temperature under a nitrogen atmosphere. 10% palladium on carbon was added and stirred overnight under a hydrogen atmosphere. The reaction mixture was filtered through Celite, and the residue obtained by evaporating the solvent under reduced pressure was partitioned between ethyl acetate (30 ml) and saturated aqueous ammonium chloride solution (30 ml). A 4N aqueous sodium hydroxide solution (30 ml) was added to the aqueous layer, followed by extraction with chloroform (100 ml), and the resulting organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 145 mg (76.3%) of the target compound.
[0204]
IR (neat): 3350, 2938, 1591, 1510 cm-1
[0205]
Intermediate production example 13
○ 3- (4-Pyridyl) butylamine (Intermediate 13-1)
N, N-dimethylformamide (33 ml) was added to 4-acetylpyridine (2.00 g, 16.5 mmol) and (benzyloxycarbonyl) triphenylphosphonium bromide (8.94 g, 18.2 mmol), followed by stirring under ice cooling. did. Potassium carbonate (9.12 g, 66.0 mmol) was added to an external temperature of 70 ° C., and the mixture was stirred overnight. After dilution with diethyl ether (100 ml), the mixture was washed with water (100 ml, twice) and saturated brine (50 ml) in this order. The extract was dried over magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to give 1.77 g of 3- (4-pyridyl) -2-butenoic acid benzyl ester (42%: mixture of E and Z forms) as a pale yellow oil. .
[0206]
Next, methanol (31 ml) and acetic acid (0.71 ml, 12.4 mmol) are added to 3- (4-pyridyl) -2-butenoic acid benzyl ester (1.75 g, 6.20 mmol), and nitrogen gas is added at room temperature for 10 minutes. Aerated. A catalytic amount of 10% -palladium on carbon was added, and the mixture was stirred overnight at room temperature in a hydrogen atmosphere. The insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting crystals were filtered with acetone to obtain 0.61 g (60%) of 3- (4-pyridyl) butyric acid as pale yellow crystals.
[0207]
Next, chloroform (5 ml), thionyl chloride (0.80 ml, 11 mmol), N, N-dimethylformamide (1 drop) were added to 3- (4-pyridyl) butyric acid (0.60 g, 3.6 mmol), and the mixture was stirred. The mixture was refluxed with heating for 1 hour. After concentration under reduced pressure, chloroform (5 ml) was added, and the mixture was slowly added to a saturated ammonia / tetrahydrofuran (5 ml) solution stirred under ice-cooling. After 2.5 hours, the insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain 0.34 g of a mixture of 3- (4-pyridyl) butyric acid amide and its olefin oxide as pale yellow crystals.
[0208]
Next, anhydrous ether (8 ml) was added to lithium aluminum hydride (0.16 g, 4.2 mmol) in a nitrogen atmosphere, and the mixture was stirred under ice cooling. A solution of 3- (4-pyridyl) butyric acid amide (0.22 g, 1.4 mmol) in anhydrous methylene chloride (8 ml) was added dropwise over 2 minutes, then brought to room temperature and stirred overnight. Ethyl acetate (1 ml) and 1N aqueous sodium hydroxide solution (20 ml) were added, followed by extraction with chloroform (50 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography to obtain 0.15 g (75%) of the target compound as a pale yellow oil.
[0209]
IR (neat): 3350, 2963, 2873, 1601 cm-1
[0210]
Intermediate production example 14
○ N- (4-pyridyl) ethylenediamine (intermediate 14-1)
Under a nitrogen atmosphere, ethylenediamine (10.4 ml, 155 mmol) was added to 4-bromopyridine hydrochloride (3.00 g, 15.5 mmol), and the mixture was heated to reflux for 1.5 hours. The mixture was brought to room temperature, potassium carbonate (8.57 g, 62.0 mmol) was added, and the mixture was stirred for 10 minutes. The solid was filtered off, and the solid was washed with toluene and 2-propanol. The filtrate was concentrated under reduced pressure, and the residue was separated and purified by basic silica gel column chromatography. The resulting solid was collected by filtration with diisopropyl ether to obtain 1.63 g (77%) of the target compound as a pale yellow solid.
[0211]
IR (KBr): 3320, 3240, 3028, 2930, 1615 cm-1
mp: 114.0-116.5 ° C.
[0212]
Intermediate production example 15
○ 4- (3-Aminobutyl) pyridine (Intermediate 15-1)
Under a nitrogen atmosphere, anhydrous N, N-dimethylformamide (41 ml) was added to sodium hydride (2.81 g, 70.3 mmol), and the mixture was stirred under ice-water cooling. A solution of acetoacetic acid t-butyl ester (6.33 g, 40.0 mmol) in N, N-dimethylformamide (20 ml) was added dropwise over 10 minutes, and further 10 minutes later under nitrogen flow, 4- (chloromethyl) pyridine hydrochloride (5.00 g, 30.5 mmol) was added in portions over 3 minutes to room temperature. Two hours later, saturated aqueous sodium hydrogen carbonate (150 ml) was added, and the mixture was extracted with ethyl acetate (100 ml). The organic layer was washed with water (100 ml) and saturated brine (50 ml), and dried over anhydrous sodium sulfate. After concentration under reduced pressure, the residue was separated and purified by silica gel column chromatography to obtain 1.34 g (18%) of 2-acetyl-3- (4-pyridyl) propionic acid ethyl ester as a pale yellow oil.
[0213]
Next, 6N hydrochloric acid (8 ml) was added to 2-acetyl-3- (4-pyridyl) propionic acid ethyl ester (1.20 g, 4.81 mmol), and the mixture was heated to reflux for 1.5 hours. After concentration under reduced pressure, 2-propanol (10 ml) was added, and the mixture was concentrated again under reduced pressure. Ethyl acetate was added to the resulting solid and collected by filtration to obtain 0.79 g (89%) of 4- (4-pyridyl) -2-butanone as a pale yellow solid.
[0214]
Next, water (12 ml) and tetrahydrofuran (1.2 ml) were added to 4- (4-pyridyl) -2-butanone (736 mg, 3.96 mmol), and the mixture was stirred at room temperature. Sodium carbonate (483 mg, 4.56 mmol) and hydroxylamine hydrochloride (358 mg, 5.15 mmol) were added, and the mixture was stirred for 1.5 hours, and diluted with ethyl acetate (50 ml). Sodium bicarbonate was added and the mixture was separated and washed with saturated brine (10 ml). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. When cyclohexane was added to the resulting crystals and collected by filtration, 584 mg (90%) of 4- (4-pyridyl) -2-butanone oxime was obtained as pale yellow crystals.
[0215]
Next, anhydrous ether (19 ml) was added to lithium aluminum hydride (257 mg, 6.77 mmol) under a nitrogen atmosphere, and the mixture was stirred under ice cooling. A solution of 4- (4-pyridyl) -2-butanone oxime (556 mg, 3.38 mmol) in ether (15 ml) was added dropwise over 7 minutes and then allowed to reach room temperature and stirred overnight. The mixture was further heated under reflux for 2 days and stirred under ice cooling. Ethyl acetate was slowly added followed by 1N aqueous sodium hydroxide solution (slowly initially, 20 ml total). Chloroform (80 ml) was added and the insoluble material was filtered off through celite. After liquid separation, chloroform was concentrated under reduced pressure. The residue and the aqueous layer were combined, tetrahydrofuran (20 ml) was added, and the mixture was stirred at room temperature. Carbonic acid di-t-butyl ester (1.48 g, 6.78 mmol) was added and stirred overnight. Chloroform (50 ml) was added and extracted, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography. To the residue were added 4N hydrogen chloride ethyl acetate solution (3 ml) and ethanol (1 ml), and the mixture was stirred at room temperature. After 3 hours, the mixture was concentrated under reduced pressure, chloroform (5 ml), methanol (5 ml) and triethylamine (1 ml) were added to the residue, and the mixture was concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography to obtain 161 mg (32%) of the target compound. ) Was obtained as a brown oil.
[0216]
IR (neat): 3354, 3280, 2958, 2925, 2866, 1602 cm-1
[0217]
By performing the same operations as in Intermediate Production Example 15, the following compounds were obtained.
[0218]
○ 1,2-Dimethyl-3- (4-pyridyl) propylamine (intermediate 15-2)
IR (neat): 3360, 3287, 2963, 2930, 2876, 1602 cm-1
[0219]
○ 1-ethyl-3- (4-pyridyl) propylamine (intermediate 15-3)
IR (neat): 3357, 2963, 2934, 2875, 1605 cm-1
[0220]
Intermediate Production Example 16
○ 2,2-Dimethyl-3- (4-pyridyl) propylamine (Intermediate 16-1) Under nitrogen atmosphere, a solution of diisopropylamine (10.0 ml, 71.5 mmol) in tetrahydrofuran (150 ml) was cooled to -78 ° C. Then, a hexane solution of butyllithium (1.6N) was added dropwise over 10 minutes. After cooling with ice-cold water for 20 minutes, it was again cooled to -78 ° C., and isobutyronitrile (3.03 ml, 33.3 mmol) was added dropwise over 5 minutes. Further, 4-pyridinecarboxaldehyde (3.18 ml, 33.3 mmol) was added dropwise over 5 minutes, and the mixture was stirred for 1 hour and 20 minutes. Water (100 ml) was added and the reaction mixture was subjected to a continuous extractor for 3 days and extracted with ethyl acetate (200 ml). The obtained organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure, and the resulting solid was collected by filtration with diethyl ether to give 3-hydroxy-2,2-dimethyl-3- (4-pyridyl) propionitrile. 4.20 g (71.6%) was obtained as a colorless solid.
[0221]
At room temperature, triethylamine (1.57 ml, 11.3 mmol) was added to a solution of 3-hydroxy-2,2-dimethyl-3- (4-pyridyl) propionitrile (1.00 g, 5.67 mmol) in dichloromethane (20 ml). added. Further, p-toluenesulfonyl chloride (1.30 g, 6.80 mmol) was added, and the mixture was stirred with heating at 50 ° C. for 3 days. After allowing to cool, the reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography to obtain 699 mg (37.4%) of 2,2-dimethyl-3- (4-pyridyl) -3- (p-tolylsulfonyloxy) propionitrile. ) Was obtained as a pale yellow solid.
[0222]
Under a nitrogen atmosphere, lithium aluminum hydride (345 mg, 9.10 mmol) was added, and anhydrous diethyl ether (10 ml) was added dropwise under ice water cooling. Subsequently, a solution of 2,2-dimethyl-3- (4-pyridyl) -3- (p-tolylsulfonyloxy) propionitrile (600 mg, 1.82 mmol) in tetrahydrofuran (10 ml) was added dropwise. The mixture was stirred overnight at room temperature, and water (324 μl), a 15% aqueous sodium hydroxide solution (324 μl), and water (972 μl) were sequentially added while vigorously stirring the reaction mixture under cooling with ice water. The extract was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain the target compound (83.0 mg, 0.505 mmol, 28%) as a pale yellow oil.
[0223]
IR (neat): 3290, 3074, 2960, 1652, 1602, 1417 cm-1
[0224]
Intermediate Production Example 17
○ (RS) -2-methyl-3- (4-pyridyl) propanol (intermediate 17-1)
2-Methyl-3- (4-pyridyl) propionic acid (136 g, 0.676 mol) obtained in the synthesis process of Intermediate Production Example 11 was dissolved in tetrahydrofuran (1500 ml), and sodium borohydride ( 56.2 g, 1.49 mol) was added. After 30 minutes, a mixed solution of iodine (85.8 g, 0.338 mol) and tetrahydrofuran (500 ml) was added dropwise under ice water cooling to room temperature. After 2 hours, the mixture was cooled with ice water, and a saturated aqueous sodium hydrogen carbonate solution (100 ml) was added dropwise. A saturated aqueous sodium chloride solution (900 ml) and water (400 ml) were added, and the mixture was extracted with chloroform (1 L × 2). The organic layer was washed sequentially with 0.01% aqueous sodium thiosulfate solution (1 L) and saturated aqueous sodium chloride solution (500 ml), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to yield 127.1 g (quantitative) of the target compound as yellow. Obtained as an oil.
[0225]
IR (neat): 3292, 2928, 1606, 1558, 1419 cm-1
[0226]
Intermediate Production Example 18
○ 3- (t-butyldiphenylsilyloxy) -3- (4-pyridyl) propylamine (intermediate 18-1)
Diisopropylamine (1.98 g, 19.6 mmol) was added dropwise over 5 minutes to a solution of butyllithium hexane (10.5 ml, 16.8 mmol) in anhydrous tetrahydrofuran (20 ml) at −80 ° C., and the temperature was raised to 0 ° C. And stirred for 30 minutes. After cooling again to −80 ° C., acetonitrile (573 mg, 14.0 mmol) was added dropwise over 7 minutes, and further 20 minutes later, 4-pyridinecarboxaldehyde (758 mg, 7.08 mmol) was added dropwise over 10 minutes. After 50 minutes, a saturated aqueous ammonium chloride solution (20 ml) was added and the temperature was returned to room temperature. The reaction solution was extracted continuously for 4 days (ethyl acetate, water). The organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography. 3-hydroxy-3- (4-pyridyl) propionitrile (666 mg, colorless crystals, 63.5%) was gotten.
[0227]
Next, the resulting 3-hydroxy-3- (4-pyridyl) propionitrile (1.00 g, 6.75 mmol) was added to imidazole (4.60 g, 67.5 mmol), N, N-dimethylformamide (30 ml). And stirred at room temperature. t-Butyldiphenylchlorosilane (2.23 g, 8.10 mmol) was added and stirred for one day, and further stirred at an external temperature of 50 ° C. for 3 hours. Ethyl acetate (50 ml) ether (50 ml) was added, washed with water (20 ml) three times and saturated brine (30 ml) in this order, and the organic layer was dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the residue was separated and purified by silica gel column chromatography to obtain 2.58 g (98.9%) of 3- (t-butyldiphenylsiloxy) -3- (4-pyridyl) propionitrile as a colorless oil. Obtained.
[0228]
Under a nitrogen atmosphere, lithium aluminum hydride (299 mg, 7.87 mmol) was suspended in anhydrous diethyl ether (10 ml), and the resulting 3- (t-butyldiphenylsiloxy) -3- ( A solution of 4-pyridyl) propionitrile (1.00 g, 2.59 mmol) in anhydrous diethyl ether (15 ml) was added dropwise over 8 minutes, and the mixture was returned to room temperature and stirred for 75 minutes. After cooling with ice and adding ethyl acetate (15 ml), water (0.28 ml), 15% aqueous sodium hydroxide solution (0.28 ml) and water (0.85 ml) were added in this order, and the mixture was warmed to room temperature for 10 minutes. Stir. After adding anhydrous magnesium sulfate to the reaction solution and drying, the solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography to obtain the target compound (180.0 mg, yellow oil, 17.8%).
[0229]
IR (neat): 3286, 3071, 9322, 2858, 1601, 1428 cm-1
[0230]
The following compounds were obtained by performing the same operation as in Intermediate Production Example 18.
[0231]
○ 3- (t-butyldimethylsilyloxy) -3- (4-pyridyl) propylamine (intermediate 18-2)
[0232]
Intermediate Production Example 19
○ N- [2- (1-adamantyl) ethyl] -2-butynylamine (Intermediate 19-1)
Dimethyl sulfoxide (60 ml) and triethylamine (8.4 ml, 60 mmol) were added to 2-butyn-1-ol (3.0 ml, 40 mmol), and the mixture was stirred under ice-water cooling. Sulfur trioxide pyridine complex (4.2 g, 26 mmol) was added and 15 minutes later, further sulfur trioxide pyridine complex (5.1 g, 32 mmol) was added and stirred for 1.5 hours. Water (40 ml) was added to the reaction solution, extracted twice with methylene chloride (40 ml), washed twice with 1N hydrochloric acid (30 ml) and twice with water (40 ml), and then the organic layer was dried over anhydrous magnesium sulfate. . The solvent was distilled off under reduced pressure to obtain 1.0 g (37%) of 2-butynal as a brown oil.
[0233]
Then, 2- (1-adamantyl) ethylamine hydrochloride (2.0 g, 9.3 mmol) was partitioned between chloroform (30 ml) and 1N aqueous sodium hydroxide solution (40 ml), and the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Methanol (15 ml) and triethylamine (2.6 ml, 19 mmol) were added to 2- (1-adamantyl) ethylamine thus obtained, and the mixture was stirred at room temperature. Next, a solution of 2-butynal (0.80 g, 12 mmol) obtained in the previous reaction in methanol (10 ml) was added, and after 3 hours, sodium borohydride (1.9 g, 50 mmol) was added under ice water cooling. After 1 hour, water (40 ml) was added, extracted with chloroform (60 ml), washed with saturated brine (40 ml), and the organic layer was dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the residue was separated and purified by silica gel column chromatography to obtain 0.48 g (22%) of the target compound as a brown oil.
[0234]
IR (neat): 3302, 2902, 2846, 2279, 2244 cm-1
[0235]
[B] Production example of this compound
This compound production example 1
○ 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-1)
1,1′-carbonyldiimidazole (427 mg, 2.63 mmol) was added to a solution of intermediate 2-1 in 4- (3-aminopropyl) pyridine (285 mg, 2.09 mmol) in tetrahydrofuran (10 ml), and the mixture was stirred at room temperature for 20 minutes. Stir for minutes. Intermediate 1-1 (2- (1-adamantyl) -N-pentylethylamine hydrochloride (571 mg, 2.00 mmol) was added, and the mixture was heated to reflux for 1 hour. The mixture was diluted with ethyl acetate (50 ml), washed with saturated aqueous sodium hydrogen carbonate solution (50 ml) and saturated aqueous sodium chloride solution (50 ml), dried over magnesium sulfate. The solvent was distilled off under reduced pressure, and the precipitated solid was washed with diisopropyl ether and collected by filtration to obtain 606 mg (73%) of the target compound.
[0236]
IR (KBr): 2900, 2845, 1618, 1534 cm-1
mp: 124.0-124.7 ° C
[0237]
The following compounds were obtained by carrying out the same operations as in Production Example 1 of this compound.
[0238]
○ 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea (Compound 1-2)
IR (neat): 3339, 2902, 2846, 1626, 1530 cm-1
[0239]
○ N- [3- (4-Pyridyl) propyl] -1-piperidinecarboxamide (Compound 1-3)
IR (neat): 3339, 2934, 2854, 1621, 1538 cm-1
[0240]
O N- [3- (4-Pyridyl) propyl] -1,2,3,6-tetrahydropyridine-1-carboxamide (Compound 1-4)
IR (neat): 3337, 2922, 2858, 1624, 1537, 1414 cm-1
[0241]
○ N- [3- (4-Pyridyl) propyl] -1,2,3,4-tetrahydroisoquinoline-2-carboxamide (Compound 1-5)
IR (KBr): 3342, 2925, 1614, 1543, 1489 cm-1
mp: 76.0-79.0 ° C
[0242]
○ N- [3- (4-Pyridyl) propyl] -4-morpholinecarboxamide (Compound 1-6)
IR (KBr): 3347, 2968, 1626, 1546, 1115 cm-1
mp: 94.0-98.0 ° C
[0243]
O N- [3- (4-Pyridyl) propyl] -1-homopiperidinecarboxamide (Compound 1-7)
IR (neat): 3343, 2927, 1625, 1537 cm-1
[0244]
○ 1,1-diallyl-3- [3- (4-pyridyl) propyl] urea (compound 1-8)
IR (neat): 3350, 2928, 1628, 1603, 1535 cm-1
[0245]
O N- [3- (4-Pyridyl) propyl] -2-decahydroisoquinolinecarboxamide (Compound 1-9)
IR (neat): 3343, 2855, 2622, 1621, 1539 cm-1
[0246]
○ 1,1-Dibutyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-10)
IR (neat): 3347, 2957, 2872, 1626, 1537 cm-1
[0247]
○ 1,1-Dihexyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-11)
IR (neat): 3348, 2928, 2857, 1626, 1532 cm-1
[0248]
○ 1,1-Diisopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-12)
IR (neat): 3344, 2955, 2869, 1626, 1533 cm-1
[0249]
○ 1,1-didecyl-3- [3- (4-pyridyl) propyl] urea (compound 1-13)
IR (neat): 3346, 2925, 2854, 1626, 1537 cm-1
[0250]
1- [2- (1-adamantyl) ethyl] -1- [2- (N-benzyloxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1 -14)
IR (neat): 3360, 2902, 2846, 1772, 1699, 1634, 1532 cm-1
[0251]
1- [2- (1-adamantyl) ethyl] -1- [2- (dimethylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-15)
IR (KBr): 3322, 2900, 2845, 1621, 1526 cm-1
mp: 104.0-106.5 ° C
[0252]
○ 1- [2- (1-adamantyl) ethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-16)
IR (KBr): 3331, 2901, 2846, 1622, 1602, 1534 cm-1
mp: 99.0-103.0 ° C
[0253]
1- [2- (1-adamantyl) ethyl] -1- (2-propynyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-17)
IR (KBr): 3322, 3204, 2899, 2845, 2112, 1626, 1605, 1543, 1444 cm-1
mp: 152.0-154.0 ° C
[0254]
1- [2- (1-adamantyl) ethyl] -1- (2-methoxyethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-18)
IR (KBr): 3321, 2900, 2846, 1625, 1602, 1534, 1451 cm-1
mp: 101.5-104.5 ° C
[0255]
1- [2- (1-adamantyl) ethyl] -1-cyclopropyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-19)
IR (KBr): 3365, 2900, 1633 cm-1
mp: 108.0-115.5 ° C.
[0256]
1- [2- (1-Adamantyl) ethyl] -1-cyanomethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-20)
IR (neat): 3350, 2903, 2247, 1644 cm-1
[0257]
1- [2- (1-adamantyl) ethyl] -1-cyclopentylmethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-21)
IR (KBr): 3328, 2906, 2845, 1615, 1450 cm-1
mp: 155.0-158.0 ° C
[0258]
1- [2- (1-adamantyl) ethyl] -1-cyclopropylmethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-22)
IR (KBr): 3328, 2900, 2845, 1618, 1534 cm-1
mp: 123.0-125.0 ° C
[0259]
○ 1- [2- (1-adamantyl) ethyl] -1-allyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-23)
IR (KBr): 3329, 2900, 1625, 1538 cm-1
mp: 99.0-102.0 ° C
[0260]
1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea (Compound 1-24)
IR (KBr): 3310, 2900, 2847, 1622, 1543 cm-1
mp: 107.5-109.0 ° C
[0261]
1- [2- (1-adamantyl) ethyl] -1- (2-butenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-25)
IR (KBr): 3328, 2900, 1619 cm-1
mp: 89.5-93.5 ° C
[0262]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-26)
IR (neat): 3350, 2903, 2846, 1694, 1633, 1537 cm-1
[0263]
1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (2-thienyl) methylurea (Compound 1-27)
IR (KBr): 3328, 2900, 2845, 1626, 1544 cm-1
mp: 142.5-144.5 ° C
[0264]
1- [2- (1-Adamantyl) ethyl] -1-benzyloxy-3- [3- (4-pyridyl) propyl] urea (Compound 1-28)
IR (neat): 3444, 3350, 2902, 2846, 1666, 1517 cm-1
[0265]
1- [2- (1-adamantyl) ethyl] -1-hexyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-29)
IR (KBr): 3354, 2901, 2845, 1619, 1538 cm-1
mp: 119.5-121.5 ° C
[0266]
1- (1-adamantyl) methyl-1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-30)
IR (neat): 3350, 2902, 1626 cm-1
[0267]
1- [2- (1-adamantyl) ethyl] -1- (3-methyl-2-butenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-31)
IR (KBr): 3358, 2900, 2845, 1622, 1526 cm-1
mp: 93.0-96.0 ° C
[0268]
○ 1- [2- (1-adamantyl) ethyl] -1-decyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-32)
IR (KBr): 3340, 2924, 2846, 1626, 1602, 1534 cm-1
mp: 75.0-76.0 ° C
[0269]
1- [2- (1-adamantyl) ethyl] -1- (2-methyl-2-propenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-33)
IR (KBr): 3336, 2905, 2846, 1624, 1544 cm-1
mp: 108.0-109.0 ° C
[0270]
1- [2- (1-adamantyl) ethyl] -1-cinnamyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-34)
IR (KBr): 3374, 2899, 2844, 1619, 1534 cm-1
mp: 130.0-134.5 ° C
[0271]
○ 1- [3- (1-adamantyl) propyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-35)
IR (neat): 3349, 2901, 1626, 1536 cm-1
[0272]
1- (1-adamantyl) methyl-1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-36)
IR (neat): 3349, 2903, 1625, 1531 cm-1
[0273]
1- [2- (1-adamantyl) ethyl] -1- (2-methylthiazol-4-yl) methyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-37)
IR (neat): 3337, 2901, 1632, 1536 cm-1
[0274]
○ 1,1-dipentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-38)
IR (neat): 3347, 2929, 2859, 1626, 1537 cm-1
[0275]
1-pentyl-1- (2-piperidinoethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-39)
IR (neat): 3350, 2933, 2856, 1640, 1533 cm-1
[0276]
1- [2- (1-Adamantyl) ethyl] -1-methyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-40)
IR (KBr): 3334, 2901, 2446, 1626, 1604, 1534 cm-1
mp: 99.0-109.0 ° C
[0277]
1- [2- (1-adamantyl) ethyl] -1-ethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-41)
IR (KBr): 3324, 2901, 2845, 1622, 1540 cm-1
mp: 106.0-115.0 ° C
[0278]
1- [2- (1-adamantyl) ethyl] -1-furfuryl-3- [3- (4-pyridyl) propyl] urea (Compound 1-42)
IR (KBr): 3331, 2900, 2846, 1618, 1538 cm-1
mp: 128.0-130.0 ° C
[0279]
1- [2- (1-adamantyl) ethyl] -1-benzyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-43)
IR (KBr): 3335, 2901, 2847, 1619, 1538 cm-1
mp: 130.5-135.0 ° C
[0280]
○ 1- (2-Cyclohexylethyl) -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-44)
IR (neat): 3345, 2923, 1625, 1603, 1531 cm-1
[0281]
1-pentyl-1-phenethyl-3- [3- (4-pyridyl) propyl] urea (compound 1-45)
IR (neat): 3345, 3063, 2929, 1625, 1533 cm-1
[0282]
○ 1-Butyl-1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1-46)
IR (neat): 3342, 2922, 2851, 1629, 1602, 1563, 1530, 1448 cm-1
[0283]
○ 1- (2-Cyclohexylethyl) -1,3-bis [(4-pyridyl) methyl] urea (Compound 1-47)
IR (neat): 3337, 3029, 2922, 2850, 1633, 1602, 1534, 1445 cm-1
[0284]
1- (2-cyclohexylethyl) -3- (4-pyridyl) methyl-1- (2-thienyl) methylurea (Compound 1-48)
IR (neat): 3342, 2921, 2850, 1631, 1602, 1562, 1536, 1415, 1267, 1227 cm-1
[0285]
1- [2- (t-Butoxycarbonyl) ethyl] -1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1-49)
IR (neat): 3347, 2977, 2923, 2851, 1727, 1633, 1602, 1563, 1531, 1449 cm-1
[0286]
1- (2-Cyclohexylethyl) -1- [2- (methoxycarbonyl) ethyl] -3- (4-pyridyl) methylurea (Compound 1-50)
IR (neat): 3348, 2923, 2850, 1737, 1633, 1603, 1563, 1532, 1437 cm-1
[0287]
○ 1- (2-carbamoylethyl) -1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1-51)
IR (neat): 3324, 2922, 2850, 1673, 1632, 1606, 1563, 1530, 1448 cm-1
[0288]
1- (2-Cyclohexylethyl) -1-pentyl-3- (4-pyridyl) methylurea (Compound 1-52)
IR (KBr): 3313, 2925, 1627, 1602, 1527, 1410 cm-1
mp: 64.7-65.8 ° C
[0289]
○ 1- (2-cyclohexylethyl) -1- (2-dimethylaminoethyl) -3- (4-pyridyl) methylurea (Compound 1-53)
IR (KBr): 3346, 2922, 2850, 2778, 1635, 1562, 1533, 1448 cm-1
[0290]
1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -1- (2-cyclohexylethyl) -3- (4-pyridyl) methylurea (Compound 1-54)
IR (neat): 3338, 2976, 2924, 2851, 1694, 1633, 1602, 1563, 1531, 1484, 1450 cm-1
[0291]
1-pentyl-1- [2- (2-pyridyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-55)
IR (neat): 3350, 2929, 2859, 1633, 1602, 1537 cm-1
[0292]
○ 1,1-bis [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-56)
IR (neat): 3358, 2901, 2845, 1625, 1530 cm-1mp: 80 ° C
[0293]
1- [2- (1-adamantyl) ethyl] -1-butyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-57)
IR (KBr): 3315, 2901, 1618, 1534 cm-1
mp: 109.5-118.0 ° C.
[0294]
○ 1,1-bis (2-hydroxypropyl) -3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 1-58)
IR (neat): 3350, 1688, 1638, 1538 cm-1
[0295]
1- [Bis (t-butoxycarbonylaminomethyl)] methyl-1-isopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-59)
IR (neat): 3326, 2960, 1698, 1631, 1525 cm-1
[0296]
1-Cyclohexyl (phenyl) methyl-1- (3-phenylpropyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-60)
IR (KBr): 3352, 2931, 1619, 1522 cm-1
mp: 107.0-112.0 ° C
[0297]
○ 1,1-Dicyclohexyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-61)
IR (KBr): 3304, 2930, 2848, 1638, 1602, 1533 cm-1
mp: 143.0-145.5 ° C.
[0298]
1- [2- [N- (t-Butoxycarbonyl) -N-methylamino] ethyl] -1-phenethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-62)
IR (neat): 3350, 1694, 1633, 1532, 1166 cm-1
[0299]
1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-63)
IR (neat): 3350, 1694, 1632, 1537, 1167 cm-1
[0300]
1- [2- (N-Benzyloxycarbonyl-N-methylamino) ethyl] -1-phenethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-64)
IR (neat): 3350, 1698, 1632, 1531 cm-1
[0301]
1- [3- (1-adamantyl) propyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-65)
IR (KBr): 3333, 2901, 2844, 1623, 1602, 1543 cm-1
[0302]
1- [2- (1-adamantyl) ethyl] -3-pentyl-1- [3- (4-pyridyl) propyl] urea (Compound 1-66)
IR (KBr): 3370, 3322, 2903, 2846, 1618, 1534 cm-1
mp: 47.0-50.0 ° C
[0303]
○ 3- [2- (1-adamantyl) ethyl] -1- [2- (t-butoxycarbonyl) ethyl] -1- [3- (4-pyridyl) propyl] urea (Compound 1-67)
IR (neat): 3348, 2902, 2846, 1726, 1627, 1538, 1367, 1152 cm-1
[0304]
1- [2- (1-adamantyl) ethyl] -1-isopropyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-68)
IR (KBr): 3330, 2903, 2845, 1614, 1533 cm-1
mp: 132.0-134.0 ° C
[0305]
1- [2- (1-adamantyl) ethyl] -1- [2- (t-butoxycarbonyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-69)
IR (KBr): 3356, 2903, 1720, 1622, 1538, 1156 cm-1
mp: 124.5-127.0 ° C
[0306]
1- [2- (1-adamantyl) ethyl] -1-cyclopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-70)
IR (KBr): 3297, 2906, 2844, 1618, 1544 cm-1
mp: 135.5-137.5 ° C
[0307]
1- [2- (1-adamantyl) ethyl] -1- (t-butoxycarbonylamino) -3- [3- (4-pyridyl) propyl] urea (Compound 1-71)
IR (neat): 3231, 2903, 1732, 1650 cm-1
[0308]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- (2-pyridyl) methylurea (Compound 1-72)
IR (KBr): 3333, 2900, 2844, 1625, 1535 cm-1
mp: 87.5-92.0 ° C
[0309]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- (3-pyridyl) methylurea (Compound 1-73)
IR (KBr): 3328, 2901, 846, 1622, 1530 cm-1
mp: 88.5-101.5 ° C.
[0310]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- (4-pyridyl) methylurea (Compound 1-74)
IR (KBr): 3331, 2900, 2845, 1626, 1538 cm-1
mp: 96.5-108.0 ° C
[0311]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (2-pyridyl) ethyl] urea (Compound 1-75)
IR (KBr): 3346, 2904, 2845, 1622, 1539 cm-1
mp: 80.0-100.0 ° C
[0312]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (3-pyridyl) ethyl] urea (Compound 1-76)
IR (KBr): 3334, 2900, 2845, 1618, 1541 cm-1
mp: 112.5-114.5 ° C.
[0313]
○ 1- (2-cyclohexylethyl) -1- (2-methoxyethyl) -3- (4-pyridyl) methylurea (Compound 1-77)
IR (neat): 3350, 2922, 2850, 1633, 1603, 1534 cm-1
[0314]
1- [2- (N-benzyloxycarbonyl-N-methylamino) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-78)
IR (neat): 3358, 2930, 1701, 1633, 1534 cm-1
[0315]
1-ethyl-3- [3- (4-pyridyl) propyl] -1- (3,4,5-trimethoxyphenethyl) urea (Compound 1-79)
IR (neat): 3350, 2936, 1626, 1590, 1530, 1239 cm-1
[0316]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) ethyl] urea (Compound 1-80)
IR (KBr): 3346, 2901, 2844, 1622, 1538 cm-1
mp: 107-118 ° C
[0317]
1- [2- (1H-5-imidazolyl) ethyl] -1-isopentyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-81)
IR (neat): 3117, 2954, 1606, 1537 cm-1
[0318]
1-Cyclohexyl-1- (3,4-dimethoxyphenethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-82)
IR (neat): 3353, 2931, 1621, 1515, 1236, 1029 cm-1
[0319]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (2-pyridyl) propyl] urea (Compound 1-83)
IR (KBr): 3324, 2900, 2845, 1622, 1538 cm-1
mp: 84.4-85.7 ° C
[0320]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (3-pyridyl) propyl] urea (Compound 1-84)
IR (KBr): 3355, 2902, 2845, 1615, 1526 cm-1
mp: 99.9-105.2 ° C
[0321]
1-cyclopropyl-3- [3- (4-pyridyl) propyl] -1- (3,4,5-trimethoxyphenethyl) urea (Compound 1-85)
IR (neat): 3400, 2938, 1644, 1590, 1510, 1239, 1128 cm-1
[0322]
1- [2- (1-adamantyl) ethyl] -3- (4-dimethylamino) phenethyl-1-pentylurea (Compound 1-86)
IR (KBr): 3341, 2900, 2845, 1619, 1526 cm-1
mp: 115.8-118.1 ° C.
[0323]
1- [2- (1-Adamantyl) ethyl] -1-pentyl-3- [4- (4-pyridyl) butyl] urea (Compound 1-87)
IR (KBr): 3354, 2900, 2844, 1618, 1538 cm-1
mp: 74.1-78.1 ° C.
[0324]
1- [2- (1-adamantyl) ethyl] -3- (t-butoxycarbonyl) -1-pentyl-3- [2- (4-pyridyl) oxyethyl] urea (Compound 1-88)
IR (neat): 2903, 2847, 1704, 1590 cm-1
[0325]
1- [2- (1-adamantyl) ethyl] -1- [3- [N- (t-butoxycarbonyl) -N-methylamino] propyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-89)
IR (neat): 3350, 2903, 2847, 1694, 1632, 1531 cm-1
[0326]
1-Cyclohexyl (phenyl) methyl-1- [3- (4-methoxyphenoxy) propyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-90)
IR (neat): 3369, 2930, 1626, 1510, 1231 cm-1
[0327]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-quinolyl) propyl] urea (Compound 1-91)
IR (KBr): 3354, 2902, 2845, 1622, 1534 cm-1
mp: 80.2-102.0 ° C
[0328]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (1-imidazolylcarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-92)
IR (neat): 3366, 2902, 2846, 1695, 1635, 1604, 1531 cm-1
[0329]
1-Diphenylmethyl-1- (3-phenylpropyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-93)
IR (KBr): 3334, 3026, 2927, 1621, 1522 cm-1
mp: 123.0-124.8 ° C
[0330]
○ 1,1-Di- (5-hexenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-94)
IR (neat): 3350, 3074, 2930, 2859, 1621, 1538 cm-1
[0331]
O 1,1-Di- (7-octenyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-95)
IR (neat): 3349, 3074, 2927, 2856, 1625, 1537 cm-1
[0332]
○ 4- [2- [3- [2- (1-adamantyl) ethyl] -3-pentyl] ureidoethyl] benzenesulfonic acid amide (Compound 1-96)
IR (KBr): 3423, 2906, 2847, 1598, 1540, 1161 cm-1
mp: 85.0-120.7 ° C
[0333]
1- [2- (1-adamantyl) ethyl] -3- (1-imidazolyl) propyl-1-pentylurea (Compound 1-97)
IR (KBr): 3340, 2902, 2845, 1618, 1534 cm-1
mp: 97.0-100.0 ° C
[0334]
1- [2- (1-adamantyl) ethyl] -3- (4-hydroxyphenethyl) -1-pentylurea (Compound 1-98)
IR (KBr): 3392, 2902, 2845, 1614, 1535, 1515 cm-1
mp: 96.3-99.4 ° C
[0335]
1- [2- (1-adamantyl) ethyl] -1- [2- (3-tert-butyl-1-methylureido) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1 -99)
IR (neat): 3310, 2903, 1632, 1537 cm-1
[0336]
1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-100)
IR (KBr): 3347, 2957, 2902, 2846, 1621, 1604, 1539 cm-1
mp: 105.3-112.3 ° C
[0337]
1- [2- (1-adamantyl) ethyl] -1- [2- (1-methyl-3-propylureido) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-101 )
IR (neat): 3316, 2902, 1631, 1537 cm-1
[0338]
1-pentyl-1- (3-phenylpropyl) -3- [3- (4-pyridyl) propyl] urea (compound 1-102)
IR (neat): 3348, 2929, 1625, 1537 cm-1
[0339]
1- [2- (acetylamino) ethyl] -1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-103)
IR (neat): 3291, 2902, 2846, 1632, 1556, 753 cm-1
[0340]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) butyl] urea (Compound 1-104)
IR (KBr): 3346, 2901, 2845, 1618, 1601, 1539 cm-1
mp: 93.0-98.0 ° C
[0341]
○ 1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (4,4,4-trifluorobutyl) urea (Compound 1-105)
IR (KBr): 3317, 2901, 2446, 1618, 1538, 1255, 1123 cm-1
mp: 142.6-145.0 ° C
[0342]
1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (5,5,5-trifluoropentyl) urea (Compound 1-106)
IR (KBr): 3333, 2900, 2846, 1618, 1534, 1259, 1140 cm-1
mp: 116.9-118.9 ° C.
[0343]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2-methyl-3- (4-pyridyl) ) Propyl] urea (compound 1-107)
IR (neat): 3350, 2902, 2846, 1694, 1672, 1633, 1603, 1537 cm-1
[0344]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridylmethyl) butyl] urea (Compound 1-108)
IR (KBr): 3347, 2900, 2845, 1622, 1538 cm-1
mp: 72.0-77.0 ° C
[0345]
1- [2- (1-adamantyl) ethyl] -3- [2-benzyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-109)
IR (KBr): 3329, 2902, 2846, 1622, 1544 cm-1
mp: 111.0-116.0 ° C
[0346]
1- [2- (1-adamantyl) ethyl] -3- [2,2-bis (4-pyridylmethyl) ethyl] -1-pentylurea (Compound 1-110)
IR (KBr): 3330, 2905, 2845, 1619, 1602, 1534 cm-1
mp: 124.0-136.0 ° C
[0347]
○ (Z) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea (Compound 1-111)
IR (neat): 3338, 2901, 846, 1625, 1596, 1530 cm-1
[0348]
○ (E) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea (Compound 1-112)
IR (KBr): 3315, 2900, 2845, 1623, 1526 cm-1
mp: 90-118 ° C
[0349]
1-Isopentyl-3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea (Compound 1-113)
IR (neat): 3342, 2956, 1628, 1604, 1539 cm-1
[0350]
1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] -1- (2,2,2-trifluoroethyl) urea (Compound 1-114)
IR (KBr): 3346, 2901, 2847, 1630, 1604, 1544, 1145, 1108 cm-1
mp: 106.2-107.3 ° C
[0351]
○ 3- [2-Methyl-3- (4-pyridyl) propyl] -1-pentyl-1-phenethylurea (Compound 1-115)
IR (KBr): 3352, 2927, 2858, 1622, 1530, 1496, 1453, 1416, 1276 cm-1
mp: 49.0-50.0 ° C
[0352]
○ 1,1-Dibutyl-3- [2-methyl-3- (4-pyridyl) propyl] urea (Compound 1-116)
IR (neat): 3347, 2957, 2929, 1624, 1534 cm-1
[0353]
1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea (Compound 1-117) )
IR (KBr): 3354, 2901, 2847, 1626, 1540 cm-1
mp: 81.1-84.1 ° C
[0354]
1- (2-Cyclohexylethyl) -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-118)
IR (neat): 3346, 2923, 2852, 1625, 1533 cm-1
[0355]
1- (3-Cyclohexylpropyl) -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-119)
IR (neat): 3346, 2922, 1626, 1537 cm-1
[0356]
○ (−)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-120)
IR (KBr): 3337, 2900, 1616, 1526 cm-1
mp: 103.0-104.0 ° C
[Α]20 D: -4.6 ° (MeOH, C1.0)
[0357]
○ (+)-1- [2- (1-adamantyl) ethyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-121)
IR (KBr): 3336, 2900, 1616, 1526 cm-1
mp: 102.9-103.5 ° C
[Α]20 D: + 4.2 ° (MeOH, C1.0)
[0358]
1- [3- (1-Adamantyl) propyl] -1-butyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-122)
IR (KBr): 3323, 2954, 2904, 2846, 1624, 1603, 1548 cm-1
mp: 79.8-80.4 ° C
[0359]
1- [3- (1-adamantyl) propyl] -3- [3- (4-pyridyl) propyl] -1- (2,2,2-trifluoroethyl) urea (Compound 1-123)
IR (KBr): 3355, 2902, 2848, 1627, 1605, 1545, 1145, 1112 cm-1
mp: 88.9-90.0 ° C
[0360]
1- [4- (1-adamantyl) butyl] -1-ethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-124)
IR (KBr): 3352, 2897, 2847, 1626, 1604, 1539 cm-1
mp: 92.7-93.7 ° C
[0361]
1- [4- (1-adamantyl) butyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-125)
IR (KBr): 3343, 2900, 2847, 1625, 1604, 1544 cm-1
mp: 110.0-110.5 ° C
[0362]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridylamino) ethyl] urea (Compound 1-126)
IR (KBr): 3301, 2904, 2848, 1628, 1602, 1527 cm-1
mp: 133.9-134.5 ° C
[0363]
○ (+)-1- [3- (1-adamantyl) propyl] -3- [2-methyl-3- (4-pyridyl) propyl] -1-propylurea (Compound 1-127)
IR (neat): 3350, 2902, 2846, 1625, 1534 cm-1[Α]20 D: + 4.2 ° (MeOH, C0.51)
[0364]
1- [3- (1-adamantyl) propyl] -1-propyl-3- (4-pyridyl) methylurea (Compound 1-128)
IR (KBr): 3319, 2902, 1630, 1604, 1537 cm-1
mp: 96.0-98.0 ° C
[0365]
○ 1- [3- (1-adamantyl) propyl] -1-propyl-3- [2- (4-pyridyl) ethyl] urea (Compound 1-129)
IR (neat): 3345, 2901, 1634, 1538 cm-1
[0366]
○ 1- [3- (1-adamantyl) propyl] -1-ethyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-130)
IR (KBr): 3345, 2969, 2905, 2845, 1622, 1605, 1535 cm-1
mp: 97.5-98.2 ° C
[0367]
1- [2- (1-adamantyloxy) ethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-131)
IR (neat): 3344, 2911, 2853, 1642, 1603, 1534 cm-1
[0368]
○ 1- (1-adamantyl) aminocarbonylmethyl-1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-132)
IR (KBr): 3335, 3261, 2910, 2853, 1662, 1622, 1543 cm-1
mp: 132.0-132.5 ° C
[0369]
1- [3- (1-adamantyl) propyl] -1-propyl-3- [4- (4-pyridyl) butyl] urea (Compound 1-133)
IR (neat): 3350, 2901, 1623, 1532 cm-1
[0370]
1- [3- (1-adamantyl) propyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 1-134)
IR (neat): 3347, 2902, 2846, 1696, 1632, 1603, 1534, 1167 cm-1
[0371]
1- [2- (1-adamantyl) ethyl] -3- [2,2-dimethyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-135)
IR (KBr): 3338, 2905, 1620, 1600, 1541 cm-1
mp: 82.5-84.9 ° C.
[0372]
○ 1- [3- (1-adamantyl) propyl] -3- [3- (4-pyridyl) propyl] -1- (3,3,3-trifluoropropyl) urea (Compound 1-136)
IR (neat): 3349, 2902, 1628, 1538 cm-1
[0373]
1- [2- (1-adamantyl) ethyl] -3- [1-methyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-137)
IR (KBr): 3338, 2902, 2847, 1615, 1533 cm-1
mp: 128.5-129.0 ° C.
[0374]
1- [2- (1-adamantyl) ethyl] -3- [3- (t-butyldimethylsilyloxy) -3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-138)
IR (neat): 3355, 2904, 2849, 1628, 1600, 1532, 1099 cm @ -1
[0375]
○ (+)-1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [2-methyl-3- (4-Pyridyl) propyl] urea (Compound 1-139)
IR (KBr): 3345, 2910, 2848, 1693, 1622, 1602, 1538, 1248 cm @ -1.
mp: 122.7-123.7 ° C
[Α]20 D: + 2.8 ° (MeOH, C1.0)
[0376]
○ 1- [2- (1-adamantyl) aminoethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea (Compound 1-140)
IR (neat): 3275, 2908, 2849, 1636, 1536 cm @ -1.
[0377]
1- [2- (1-adamantyl) ethyl] -1- (2-butynyl) -3- [3- (4-pyridyl) propyl] urea (Compound 1-141)
IR (neat): 3351, 2903, 2847, 2290, 2221, 1630, 1605, 1538 cm <-1>
[0378]
1- [2- (1-adamantyl) ethyl] -3- [1,2-dimethyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-142)
IR (neat): 3354, 2904, 2847, 1623, 1604, 1525 cm @ -1.
[0379]
1- [2- (1-adamantyl) ethyl] -3- [1-ethyl-3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-143)
IR (neat): 3352, 2904, 2847, 1622, 1605, 1529 cm @ -1
[0380]
1- [2- (1-adamantyl) ethyl] -3- [3- (t-butyldiphenylsilyloxy) -3- (4-pyridyl) propyl] -1-pentylurea (Compound 1-144)
IR (neat): 3360, 3072, 3050, 2903, 2849, 1634, 1602, 1532, 1428 cm @ -1.
[0381]
This compound production example 2
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N-propylamide (Compound 2-1)
Intermediate 1-6 2- (1-adamantyl) -N-propylethylamine (0.37 g, 1.7 mmol), Intermediate 5-1 5- (4-pyridyl) valeric acid (0.30 g, 1. 7 mmol) was added N, N-dimethylformamide (8.4 ml) and stirred at room temperature. N-methylmorpholine (0.27 ml, 2.5 mmol) was added followed by 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (0.38 g, 2.0 mmol) and stirred overnight. The reaction solution was concentrated under reduced pressure, ethyl acetate (20 ml) was added to the residue, and the mixture was washed successively with saturated aqueous sodium hydrogen carbonate (20 ml) and saturated brine (5 ml). After drying over sodium sulfate, ethyl acetate was distilled off under reduced pressure. The residue was separated and purified by basic silica gel column chromatography to obtain 0.21 g (33%) of the target compound as a colorless oil.
[0382]
IR (neat): 2092, 2846, 1644, 1602 cm-1
The following compounds were obtained by carrying out the same operations as in Production Example 2 of this compound.
[0383]
○ 5- (4-Pyridyl) valeric acid N- (1-adamantyl) methyl-N-propylamide (Compound 2-2)
IR (neat): 3067, 2903, 2847, 1644, 1602 cm-1
[0384]
○ 5- (4-Pyridyl) valeric acid N- (1-adamantyl) methyl-N-pentylamide (Compound 2-3)
IR (neat): 2903, 2847, 1644, 1601, 1454 cm-1
[0385]
○ 5- (4-Pyridyl) valeric acid N, N-dibutyramide (Compound 2-4)
IR (neat): 2958, 2932, 1641, 1602 cm-1
[0386]
○ 5- (4-Pyridyl) valeric acid N, N-diisopentylamide (Compound 2-5)
IR (neat): 2956, 2870, 1639, 1603 cm-1
[0387]
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- (2-butenyl) amide (Compound 2-6)
IR (neat): 2903, 2847, 1642, 1602 cm-1
[0388]
O 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- [N '-(t-butoxycarbonyl) -N'-methylamino] ethyl] amide (compound 2-7)
IR (neat): 2904, 2847, 1695, 1644, 1602 cm-1
[0389]
○ 5- (4-Pyridyl) valeric acid N- [3- (1-adamantyl) propyl] -N-propylamide (Compound 2-8)
IR (neat): 2902, 2846, 1643, 1602 cm-1
[0390]
○ 5- (4-Pyridyl) valeric acid N-pentyl-N-phenethylamide (Compound 2-9)
IR (neat): 2930, 2860, 1642, 1602 cm-1
[0390]
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- (2-dimethylaminoethyl) amide (Compound 2-10)
IR (neat): 2903, 2847, 1639, 1605 cm-1
[0392]
○ 5- (4-Pyridyl) valeric acid N- (2-cyclohexylethyl) -N-pentylamide (Compound 2-11)
IR (neat): 2924, 2853, 1644, 1601 cm-1
[0393]
○ 5- (4-Pyridyl) valeric acid N, N-bis [2- (1-adamantyl) ethyl] amide (Compound 2-12)
IR (neat): 2901, 846, 1643, 1602 cm-1
[0394]
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- (3,3,3-trifluoropropyl) amide (Compound 2-13)
IR (neat): 2904, 2848, 1647, 1602 cm-1
[0395]
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-14)
IR (neat): 2903, 2847, 1736, 1643, 1602 cm-1
[0396]
○ 3- (4-Pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-15)
IR (neat): 2903, 1643, 1599 cm-1
[0397]
○ 2-methyl-3- (4-pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-16)
IR (neat): 2903, 1639, 1600 cm-1
[0398]
○ 2- (t-Butoxycarbonyl) amino-3- (4-pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-17)
IR (neat): 3284, 2903, 1705, 1644 cm-1
[0399]
○ 2- [2- (4-Pyridyl) ethylthio] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-18)
IR (neat): 2902, 1635, 1602 cm-1
[0400]
(2R) -2- (t-butoxycarbonyl) amino-3- [2- (4-pyridyl) ethylthio] propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2- 19)
IR (neat): 3287, 2903, 1705, 1644, 1602 cm-1[Α]20 D: -19.0 ° (MeOH, C0.43)
[0401]
○ 6- (4-Pyridyl) caproic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-20)
IR (neat): 2903, 1644, 1602 cm-1
[0402]
○ 4- (4-Pyridyl) butyric acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 2-21)
IR (neat): 2903, 1644, 1602 cm-1
[0403]
This compound production example 3
1- [2- (1-adamantyl) ethyl] -1- (2-methylaminoethyl) -3- [3- (4-pyridyl) propyl] urea dihydrochloride (Compound 3-1)
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) of compound 1-26 ) Propyl] urea (0.30 g, 0.60 mmol) was added with methanol (4.4 ml), and a calcium chloride tube was attached and stirred at room temperature. A 10% hydrogen chloride methanol solution (4.4 ml) was added, and the mixture was stirred for one day and concentrated under reduced pressure to obtain 0.30 g (quantitative) of the target compound as a pale yellow amorphous powder.
[0404]
IR (neat): 3351, 2904, 2846, 1634, 1538 cm-1
[0405]
The following compounds were obtained by carrying out the same operations as in Production Example 3 of this compound.
[0406]
1- (2-Cyclohexylethyl) -1- (2-methylaminoethyl) -3- (4-pyridyl) methylurea dihydrochloride (Compound 3-2)
IR (neat): 3323, 2923, 2850, 1638, 1529, 1449 cm-1
[0407]
1- [2- (1-adamantyl) ethyl] -1-amino-3- [3- (4-pyridyl) propyl] urea dihydrochloride (Compound 3-3)
IR (KBr): 3410, 2902, 1637 cm-1
mp: about 100 ° C
[0408]
○ 2-amino-3- (4-pyridylmethylthio) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (compound 3-4)
IR (neat): 3402, 2901, 1638, 1608, 1503 cm-1
[0409]
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- (2-methylaminoethyl) amide (Compound 3-5)
IR (neat): 3312, 2902, 2846, 1643, 1602, 1450, 1416 cm-1
[0410]
(2R) -2-amino-3- [2- (4-pyridyl) ethylthio] propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (compound 3-6)
IR (KBr): 3423, 2902, 1638, 1609 cm-1
[Α]20 D: -4.9 ° (H2O, C0.52)
[0411]
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) oxyethyl] urea (Compound 3-7)
IR (neat): 3246, 2903, 2846, 1698, 1604 cm-1
[0412]
This compound manufacture example 4
○ 4- [3- [3- [2- (1-adamantyl) ethyl] -3-pentylureido] propyl] -1-methylpyridinium iodo salt (Compound 4-1)
At room temperature, 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (0.30 g, 0.73 mmol) of acetone (0.31 g) of compound 1-1 was used. 1.5 ml) solution was added methyl iodide (90 μl, 1.5 mmol) and stirred overnight. After the solvent of the reaction solution was distilled off under reduced pressure, the crystals precipitated with ethyl acetate were collected by filtration to obtain 389 mg (96%) of the target compound.
[0413]
IR (KBr): 3374, 2926, 2900, 1616, 1526 cm-1
mp: 168.0-171.0 ° C
[0414]
The following compounds were obtained by carrying out the same operations as in Production Example 4 of this compound.
[0415]
4- [3- [3- [2- (1-adamantyl) ethyl] -3- [2- [N- (t-butoxycarbonyl) -N-methylamino] ethyl] ureido] propyl] -1-methyl Pyridinium iodo salt (Compound 4-2)
IR (neat): 3342, 2903, 2846, 1682, 1644, 1520, 1235, 1166 cm-1
[0416]
O 4- [3- [3- [2- (1-adamantyl) ethyl] -3- [2- [N- (t-butoxycarbonyl) amino] ethyl] ureido] propyl] -1-benzylpyridinium bromine salt ( Compound 4-3)
IR (KBr): 3312, 2907, 2846, 1714, 1694, 1625, 1534, 1246, 1171 cm-1
mp: 97 ° C
[0417]
This compound manufacture example 5
○ N- [2- (1-adamantyl) ethyl] -N-pentylcarbamic acid 3- (4-pyridyl) propyl ester (Compound 5-1)
At room temperature, 4-pyridinepropanol (528 mg, 3.85 mmol) was dissolved in acetonitrile (20 ml), and then triethylamine (1.61 ml, 11.6 mmol) was added. Further, carbonic acid N, N′-disuccinimidyl ester (1.48 g, 5.87 mmol) was added and stirred for 2.5 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate solution (50 ml) were added to the residue, and the mixture was partitioned. The resulting organic layer was washed with saturated aqueous sodium chloride solution (50 ml). It dried with the anhydrous sodium sulfate and the solvent was depressurizingly distilled. The residue was dried under reduced pressure and then dissolved in anhydrous methylene chloride (10 ml). Next, a solution of intermediate 1-1 in 2- (1-adamantyl) -N-pentylethylamine hydrochloride (1.32 g, 4.62 mmol) and triethylamine (0.80 ml, 5.7 mmol) in methylene chloride (90 ml) was added. The mixture was further stirred for 1.5 hours. The reaction mixture was washed successively with saturated aqueous sodium hydrogen carbonate solution (50 ml) and saturated aqueous sodium chloride solution (50 ml), and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 1.54 g (97%) of the target compound as an oil.
[0418]
IR (neat): 2903, 2847, 1742, 1698 cm-1
[0419]
The following compounds were obtained by carrying out the same operations as in Production Example 5 of this compound.
[0420]
1- [2- (1-adamantyl) ethyl] -1- [2- (N-cyclohexyloxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 5 -2)
IR (neat): 3350, 2904, 2847, 1682, 1633, 1604, 1531 cm-1
[0421]
N- [3- (1-adamantyl) propyl] -N-propylcarbamic acid 3- (4-pyridyl) propyl ester (Compound 5-3)
IR (neat): 2901, 2846, 1740, 1695, 1645, 1602, 1451, 1423 cm-1
[0422]
O N- [2- (1-adamantyl) ethyl] -N- (3,3,3-trifluoropropyl) carbamic acid 3- (4-pyridyl) propyl ester (Compound 5-4)
IR (neat): 2903, 2847, 1705, 1603, 1482, 1451, 1425 cm-1
[0423]
O N- [2- (1-adamantyl) ethyl] -N- [2- [N ′-(t-butoxycarbonyl) -N′-methylamino] ethyl] carbamic acid 3- (4-pyridyl) propyl ester ( Compound 5-5)
IR (neat): 2903, 2847, 1699, 1603, 1480, 1424 cm-1
[0424]
O N- [2- (1-adamantyl) ethyl] -N-pentylcarbamic acid 2-methyl-3- (4-pyridyl) propyl ester (Compound 5-6)
IR (neat): 2904, 2847, 1701, 1602, 1450, 1424, 1381 cm-1
[0425]
This compound manufacture example 6
1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] hexahydro-2,4-pyrimidinedione hydrochloride (Compound 6-1)
1- [2- (1-adamantyl) ethyl] -1- [2- (t-butoxycarbonyl) ethyl] -3- [3- (4-pyridyl) propyl] urea of compound 1-69 (0.23 g, 0.49 mmol) was added 4N hydrogen chloride 1,4-dioxane solution (2.5 ml) and stirred at room temperature overnight. After the reaction, the mixture was concentrated under reduced pressure, and 1N aqueous sodium hydroxide solution (20 ml) and ethyl acetate (30 ml) were added to the residue to separate the layers. The ethyl acetate layer was washed with water (20 ml) and saturated aqueous sodium chloride solution (20 ml), and dried over anhydrous magnesium sulfate. The oily substance obtained after concentration under reduced pressure was dissolved in diethyl ether (20 ml), a 4N hydrogen chloride ethyl acetate solution (0.50 ml, 2.00 mol) was added under ice-cooling, and the mixture was concentrated under reduced pressure. Filtration yielded 0.17 g (79%) of the target compound.
[0426]
IR (KBr): 2902, 2437, 1710, 1666 cm-1
mp: 177.0-178.5 ° C
[0427]
The following compounds were obtained by carrying out the same operations as in Production Example 6 of this compound.
[0428]
○ 1- [2- (Cyclohexyl) ethyl] -3- (4-pyridyl) methylhexahydro-2,4-pyrimidinedione hydrochloride (Compound 6-2)
IR (KBr): 2925, 2850, 1718, 1671, 1600, 1493, 1450 cm-1
mp: 64.0-74.5 ° C
[0429]
○ 3- [2- (1-adamantyl) ethyl] -1- [3- (4-pyridyl) propyl] hexahydro-2,4-pyrimidinedione hydrochloride (Compound 6-3)
IR (KBr): 2906, 2845, 1716, 1696, 1658, 1486cm-1
mp: 170 ° C
[0430]
This compound manufacture example 7
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] thiourea (Compound 7-1)
In a nitrogen atmosphere, 1,1′-thiocarbonyldiimidazole (0.31 g, 1.8 mmol) was added to intermediate 2-1 4- (3-aminopropyl) pyridine (0.24 g, 1.8 mmol) in anhydrous tetrahydrofuran (0.24 g, 1.8 mmol). 10 ml) solution was added and stirred at room temperature. After 1 hour, a solution of intermediate 1-1 in 2- (1-adamantyl) -N-pentylethylamine hydrochloride (0.50 g, 1.8 mmol) in anhydrous tetrahydrofuran (10 ml) was added and heated to reflux for 2.5 hours. After allowing to cool, ethyl acetate (50 ml) and saturated aqueous sodium hydrogen carbonate solution (50 ml) were added to the reaction solution, and the phases were separated. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution (50 ml) and then dried over anhydrous magnesium sulfate. After concentration under reduced pressure, purification by silica gel column chromatography gave 0.18 g (24%) of the target compound.
[0431]
IR (neat): 3304, 2902, 2846, 1603, 1530, 1345 cm-1
[0432]
The following compounds were obtained by carrying out the same operations as in Production Example 7 of this compound.
[0433]
1- (2-hydroxyethyl) -1-phenethyl-3- [3- (4-pyridyl) propyl] thiourea (Compound 7-2)
IR (KBr): 3022, 2920, 2876, 1606, 1585 cm-1
mp: 105.6-107.1 ° C
[0434]
This compound manufacture example 8
1-phenethyl-3- [3- (4-pyridyl) propyl] -2-imidazolidinethione (Compound 8-1)
To compound 7-2 1- (2-hydroxyethyl) -1-phenethyl-3- [3- (4-pyridyl) propyl] thiourea (601 mg, 1.75 mmol), triphenylphosphine (913 mg, 3.49 mmol). Anhydrous tetrahydrofuran (2.5 ml) was added, and the mixture was stirred under ice / methanol. An anhydrous tetrahydrofuran solution of azodicarboxylic acid diisopropyl ester (710 mg, 3.49 mmol) was added dropwise, and after 10 minutes, ethyl acetate (100 ml) was added. Saturated aqueous sodium hydrogen carbonate (40 ml) and saturated brine (40 ml) were washed in this order, dried over sodium sulfate, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, and the obtained solid was collected by filtration with hexane to obtain 107 mg (19%) of the target compound as crystals.
[0435]
IR (KBr): 3064, 3018, 2926, 2858, 1601, 1560, 1498, 1456 cm-1
mp: 99.5-104.0 ° C
[0436]
This compound manufacture example 9
1- [2- (1-Adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] hexahydropyrimidin-2-one (Compound 9-1)
To a solution of 1-adamantaneacetic acid (1.50 g, 7.72 mmol) in anhydrous methylene chloride (30.0 ml) was added 1-hydroxybenzotriazole (1.15 g, 8.49 mmol), β-alanine ethyl ester hydrochloride (1.30 g). , 8.49 mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (1.63 g, 8.49 mmol) and N-methylmorpholine (2.05 ml, 18.7 mmol) were added under ice cooling. Then, the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, and ethyl acetate (50 ml) was added to the residue. 10% aqueous citric acid solution (50 ml), water (50 ml), saturated aqueous sodium hydrogen carbonate solution (50 ml), water (50 ml) and saturated aqueous sodium chloride solution (50 ml) were washed in this order and dried over anhydrous magnesium sulfate. Concentration under reduced pressure gave 2.48 g (quantitative) of 3- [1- (adamantyl) methylcarboxamide] propionic acid ethyl ester as a white solid.
[0437]
Subsequently, 3-[(1-adamantyl) methylcarboxamide] propionic acid ethyl ester (2.40 g, 8.18 mmol) was dissolved in ethanol (5 ml), and 2N aqueous sodium hydroxide solution (4.50 ml, 9.00 mmol) was dissolved. After adding under ice cooling, the mixture was stirred at room temperature for 2 hours. The reaction solution was made weakly acidic by adding 2N hydrochloric acid (15 ml) under ice cooling, followed by extraction with ethyl acetate (70 ml). The organic layer was washed with water (50 ml) and saturated aqueous sodium chloride solution (50 ml) and dried over anhydrous magnesium sulfate. The solid precipitated after concentration under reduced pressure was collected by filtration using diethyl ether to obtain 1.43 g (70.1%) of 3-[(1-adamantyl) methylcarboxamide] propionic acid.
[0438]
Subsequently, 1-hydroxybenzotriazole (0.83 g, 6.2 mmol), 1-hydroxybenzotriazole (0.83 g, 6.2 mmol), 3-[(1-adamantyl) methylcarboxamide] propionic acid (1.4 g, 5.6 mmol) in anhydrous methylene chloride (10 ml), 1- Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (1.2 g, 6.2 mmol), intermediate 2-1 4- (3-aminopropyl) pyridine (0.80 g, 5.9 mmol), N -Methylmorpholine (0.68 ml, 6.2 mmol) was added under ice cooling, followed by stirring overnight at room temperature. The reaction solution was concentrated under reduced pressure, ethyl acetate (50 ml) was added to the residue, and the mixture was washed with a saturated aqueous sodium hydrogen carbonate solution (30 ml), water (30 ml) and a saturated aqueous sodium chloride solution (30 ml) in that order. Dried. The solid precipitated after concentration under reduced pressure was collected by filtration using diethyl ether to give 3-[(1-adamantyl) methylcarboxamide] propionic acid.
1.9 g (88%) of 3- (4-pyridyl) propylamide was obtained.
[0439]
Anhydrous diethyl ether (20 ml) was added to lithium aluminum hydride (0.45 g, 12 mmol) under ice cooling. Subsequently, a solution of 3-[(1-adamantyl) methylcarboxamide] propionic acid 3- (4-pyridyl) propylamide (0.50 g, 1.3 mmol) obtained in anhydrous tetrahydrofuran (10 ml) was added dropwise over 15 minutes, followed by room temperature. The mixture was stirred at rt overnight, heated under reflux for 4.5 hours, and then carefully added with 2N aqueous sodium hydroxide solution (30 ml) and ethyl acetate (30 ml) under ice-cooling, followed by liquid separation. The ethyl acetate layer was washed with water (30 ml) and saturated aqueous sodium chloride solution (30 ml) and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the residue was purified by silica gel column chromatography. N- [2- (1-adamantyl) ethyl] -N ′-[3- (4-pyridyl) propyl] -1,3-propanediamine 0 .05 g (10%) was obtained.
[0440]
Obtained N- [2- (1-adamantyl) ethyl] -N ′-[3- (4-pyridyl) propyl] -1,3-propanediamine (80 mg, 0.23 mmol) in anhydrous methylene chloride (10 ml) A solution and a solution of 1,1′-carbonyldiimidazole (40 mg, 0.26 mmol) in anhydrous methylene chloride (10 ml) were simultaneously added dropwise to anhydrous methylene chloride (50 ml) with stirring at room temperature over 20 minutes. After stirring overnight, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 8.0 mg (9.4%) of the target compound.
[0441]
IR (neat): 3400, 2902, 2846, 1625, 1531, 1451 cm-1
[0442]
This compound manufacture example 10
1-acetylamino-1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10-1)
1- [2- (1-adamantyl) ethyl] -1-amino-3- [3- (4-pyridyl) propyl] urea dihydrochloride of Compound 3-3 (0.20 g, 0.47 mmol) at room temperature To the solution were added pyridine (2.0 ml) and acetic anhydride (1.0 ml), and the mixture was stirred for 15 minutes. The reaction mixture was evaporated under reduced pressure, and partitioned with ethyl acetate (10 ml) and water (10 ml). The organic layer was washed with saturated aqueous sodium hydrogen carbonate (10 ml) and saturated brine (10 ml), and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 0.11 g (58%) of the target compound.
[0443]
IR (KBr): 3374, 3163, 2907, 1694, 1638 cm-1
mp: 140.0-146.0 ° C
[0444]
The following compounds were obtained by carrying out the same operations as in Production Example 10 of this compound. In addition, acid chloride was used as needed.
[0445]
1- [2- (N-acetyl-N-methylamino) ethyl] -1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10-2 )
IR (neat): 3337, 2902, 1632, 1535, 1492 cm-1
[0446]
1- [2- (1-adamantyl) ethyl] -1- [2- (N-isonicotinoyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10-3 )
IR (neat): 3350, 2902, 2846, 1633, 1531, 1450, 1408 cm-1
[0447]
1- [2- (1-adamantyl) ethyl] -1- [2- [N-methyl-N- (methylsulfonyl) amino] ethyl] -3- [3- (4-pyridyl) propyl] urea (compound 10-4)
IR (KBr): 3319, 2902, 2845, 1616, 1540, 1326, 1142 cm-1
mp: 164.9-167.2 ° C
[0448]
1- [2- (1-adamantyl) ethyl] -1- [2- [N-methyl-N- (p-tolylsulfonyl) amino] ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10-5)
IR (neat): 3358, 2902, 2846, 1633, 1603, 1531, 1343, 1161 cm-1
[0449]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (3,3-dimethylbutyryl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) Propyl] urea (Compound 10-6)
IR (KBr): 3325, 2906, 2845, 1652, 1616, 1534 cm-1
mp: 101.4-102.4 ° C
[0450]
1- [2- (1-adamantyl) ethyl] -1- [2- (N-ethoxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10- 7)
IR (neat): 3350, 2902, 2846, 1698, 1633, 1532 cm-1
[0451]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) amino] ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10- 8)
IR (KBr): 3312, 2905, 2845, 1710, 1637, 1606, 1534, 1269, 1249, 1174 cm-1
mp: 158.0-160.5 ° C
[0452]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (t-butoxycarbonyl) -N-ethylamino] ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10-9)
IR (neat): 3349, 2902, 2846, 1693, 1667, 1633, 1603, 1531, 1452, 1416 cm-1
[0453]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (1,1-dimethyl-2,2,2-trichloroethoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-Pyridyl) propyl] urea (Compound 10-10)
IR (neat): 3359, 2903, 2846, 1707, 1636, 1603, 1534 cm-1
mp: 47.0-52.0 ° C
[0454]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (1,1-dimethylpropoxycarbonyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) Propyl] urea (Compound 10-11)
IR (neat): 3349, 2972, 2902, 2846, 1695, 1631, 1603, 1534, 1226, 1159 cm-1
[0455]
1- [2- (1-adamantyl) ethyl] -1- [2- (N-isopropoxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 10 -12)
IR (neat): 3350, 2903, 2846, 1696, 1632, 1603, 1530 cm-1
[0456]
○ (−)-1- [2- (1-adamantyl) ethyl] -1- [2- (N-menthoxycarbonyl-N-methylamino) ethyl] -3- [3- (4-pyridyl) propyl] Urea (Compound 10-13)
IR (neat): 3350, 2904, 2847, 1694, 1633, 1603, 1530 cm-1
[Α]20 D: -27.5 ° (MeOH, C1.0)
[0457]
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (3,3-dimethylbutyryl) -N-methylamino] ethyl] -3- [2-methyl-3- ( 4-pyridyl) propyl] urea (compound 10-14)
IR (neat): 3324, 2902, 2846, 1633, 1537 cm-1
[0458]
O 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- (N′-isopropoxycarbonyl-N′-methylamino) ethyl] amide (Compound 10-15 )
IR (neat): 3553, 2978, 2903, 2847, 1697, 1646 cm-1
[0459]
O 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- (N'-benzyloxycarbonyl-N'-methylamino) ethyl] amide (Compound 10-16 )
IR (neat): 3387, 3030, 2903, 2847, 1701, 1646, 1602, 1453, 1422 cm-1
[0460]
○ 5- (4-Pyridyl) valeric acid N- [2- (1-adamantyl) ethyl] -N- [2- [N ′-(3,3-dimethylbutyryl) -N′-methylamino] ethyl] Amide (Compound 10-17)
IR (neat): 3501, 2903, 2847, 1645, 1603, 1455, 1417 cm-1
[0461]
This compound manufacture example 11
○ 1- [2- (1-adamantyl) ethyl] -1,3-dimethyl-3- [3- (4-pyridyl) propyl] urea (Compound 11-1)
Under a nitrogen atmosphere, a solution of triphosgene (190 mg, 0.640 mmol) in dichloromethane (6.0 ml) was stirred at room temperature. A solution of intermediate 3-1 in 2- (1-adamantyl) -N-methylethylamine (330 mg, 1.71 mmol) and diisopropylethylamine (0.357 ml, 2.05 mmol) in dichloromethane (6.0 ml) was added over 17 minutes. It was dripped. After 8 minutes, Intermediate 3-3 in N-methyl-3- (4-pyridyl) propylamine (264 mg, 1.78 mmol) and diisopropylethylamine (0.357 ml, 2.05 mmol) in dichloromethane (5.1 ml) Were added in one portion and stirred for 20 hours. The mixture was diluted with diethyl ether (40 ml), washed twice with a saturated aqueous sodium hydrogen carbonate solution (40 ml), then with a saturated aqueous sodium chloride solution (40 ml), and dried over magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography to obtain 335 mg (54%) of the target compound.
[0462]
IR (neat): 2903, 2846, 1638, 1602, 1492 cm- 1
[0463]
This compound manufacture example 12
○ 1- [2- (1-adamantyl) ethyl] -1-hydroxy-3- [3- (4-pyridyl) propyl] urea (Compound 12-1)
Compound 1-28 1- [2- (1-adamantyl) ethyl] -1-benzyloxy-3- [3- (4-pyridyl) propyl] urea (438 mg, 0.978 mmol) in methanol (9.78 ml) To the solution was added 2N hydrochloric acid (4.0 ml), and nitrogen gas was bubbled through. 10% Palladium on carbon (43 mg) was added, and the mixture was stirred under 1 atmosphere of hydrogen for 3 days. Palladium on carbon was removed by filtration, and the filtrate was concentrated under reduced pressure and diluted with diethyl ether (30 ml). The extract was washed with a saturated aqueous sodium hydrogen carbonate solution (30 ml) and a saturated aqueous sodium chloride solution (30 ml) and then dried over magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography to obtain 119 mg (34%) of the target compound.
[0464]
IR (KBr): 3438, 3152, 2903, 2847, 1650 cm-1mp: 101.0-102.5 ° C
[0465]
This compound manufacture example 13
1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-1)
A solution of compound 1-1 in 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (200 mg, 0.486 mmol) in chloroform (0.3 ml). To the solution was added 4N hydrogen chloride ethyl acetate solution (0.400 ml, 1.60 mmol). The solvent was distilled off under reduced pressure, and the precipitated solid was washed with ethyl acetate and collected by filtration. The obtained crude crystals were recrystallized from 2-butanone (5.0 ml) to obtain 94 mg (43%) of the target compound.
[0466]
IR (KBr): 3322, 3050, 2902, 2496, 1621, 1534, 1450 cm-1
mp: 157.0-158.0 ° C
[0467]
The following compounds were obtained by carrying out the same operations as in Production Example 13 of this compound.
[0468]
○ 1- [2- (1-adamantyl) ethyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-2)
IR (neat): 3338, 2901, 2845, 1620, 1450 cm-1
[0469]
○ 1- (2-cyclohexylethyl) -3- (4-pyridyl) methyl-1- (2-thienyl) methylurea hydrochloride (Compound 13-3)
IR (KBr): 3296, 2923, 1635, 1599, 1518 cm-1
mp: 161.8-164.4 ° C
[0470]
1- [2- (1-adamantyl) ethyl] -1-butyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-4)
IR (neat): 3331, 2901, 2845, 1754, 1636, 1537 cm-1
[0471]
○ 1,1-bis [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-5)
IR (KBr): 3289, 2900, 2844, 1637, 1560 cm-1
mp: 120.0-122.5 ° C
[0472]
1- [2- (1-adamantyl) ethyl] -1- (2-aminoethyl) -3- [3- (4-pyridyl) propyl] urea dihydrochloride (Compound 13-6)
IR (neat): 3358, 2902, 2846, 1634, 1538, 756 cm-1
[0473]
○ 2- [2- (4-Pyridyl) ethylamino] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (Compound 13-7)
IR (KBr): 3424, 2902, 1651 cm-1
mp: 133.7-137.0 ° C
[0474]
O 3- [N'-methyl-N '-(4-pyridylmethyl) amino] propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide dihydrochloride (compound 13-8)
IR (KBr): 3424, 2901, 2446, 1641 cm-1
[0475]
○ 1,1-Diisopentyl-3- [3- (4-pyridyl) propyl] urea hydrochloride (Compound 13-9)
IR (KBr): 3082, 2956, 2869, 2614, 1626, 1526 cm-1
mp: 120.5-131.7 ° C
[0476]
○ 1- [3- (1-adamantyl) propyl] -1-propyl-3- [3- (4-pyridyl) propyl] urea phosphate (Compound 13-10)
IR (KBr): 3517, 3423, 1642, 1594, 1539, 1508 cm-1
mp: 148.0-149.0 ° C
[0477]
This compound manufacture example 14
1- [2- (1-adamantyl) ethyl] -3- [3-hydroxy-3- (4-pyridyl) propyl] -1-pentylurea (Compound 14-1)
1- [2- (1-adamantyl) ethyl] -3- [3- (t-butyldimethylsilyloxy) -3- (4-pyridyl) propyl] -1-pentylurea (136 mg, 0) of compound 1-138 .250 mmol) in 10% hydrogen chloride-methanol (2.3 ml) was stirred at room temperature for 3 days. The solvent was distilled off under reduced pressure, and the residue was partitioned with ethyl acetate (50 ml), water (30 ml), 1N aqueous sodium hydroxide solution (20 ml), and the organic layer was washed with saturated aqueous sodium chloride solution (40 ml). After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the target compound (59.2 mg, colorless amorphous powder, 55.3%).
[0478]
IR (neat): 3339, 2904, 2847, 1622, 1605, 1532 cm-1
[0479]
This compound manufacture example 15
Cis-1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [2- (4-pyridyl) cyclopropylmethyl] urea (Compound 15-1)
Under cooling with nitrogen under ice cooling, (Z) -1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) -2-propenyl] urea of compound 1-111 (0 .25 g, 0.61 mmol) in anhydrous 1,2-dichloroethane (3 ml) with diethylzinc 1.0M hexane solution (3.1 ml, 3.1 mmol) and chloroiodomethane (0.44 ml, 6.1 mol). Added and stirred for 1 hour. A saturated aqueous ammonium chloride solution (10 ml) was added to the reaction mixture under ice cooling, and the mixture was stirred at room temperature for 20 minutes, and then partitioned between ethyl acetate (20 ml) and saturated aqueous ammonium chloride solution (10 ml). The organic layer was washed with a saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain 9.0 mg (3.5%) of the target compound as colorless crystals.
[0480]
IR (KBr): 3340, 3025, 2903, 2847, 1617, 1603, 1525 cm-1
mp: 128.0-130.0 ° C
[0481]
This compound manufacture example 16
○ 4- [3- [3- [2- (1-adamantyl) ethyl] -3-pentylureido] propyl] pyridine N-oxide (Compound 16-1)
Of 1- [2- (1-adamantyl) ethyl] -1-pentyl-3- [3- (4-pyridyl) propyl] urea (3.0 g, 7.3 mmol) of Compound 1-1 under a nitrogen atmosphere at room temperature. M-Chloroperbenzoic acid (2.5 g, 15 mmol) was added to an anhydrous dichloromethane (24 ml) solution and stirred overnight. The reaction mixture was partitioned between chloroform (20 ml) and 1N aqueous sodium hydroxide solution (60 ml). The organic layer was washed with water (10 ml) and saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The residue obtained by evaporating the solvent under reduced pressure was purified by silica gel column chromatography to obtain 2.92 g (94.2%) of the target compound.
[0482]
IR (KBr): 3346, 2902, 2845, 1622, 1538, 1217, 1178 cm-1
mp: 97.8-127.0 ° C
[0483]
This compound manufacture example 17
1- [2- (1-adamantyl) ethyl] -1- [2- [N- (2-methoxyethyl) -N-methylamino] ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 17-1)
At room temperature, 1- [2- (1-adamantyl) ethyl] -1- (2-methylaminoethyl) -3- [3 which is the free base of compound 3-1 was added to N, N-dimethylformamide (20 ml). -(4-pyridyl) propyl] urea (1.50 g, 3.76 mmol), potassium carbonate (1.56 g, 11.3 mmol), sodium iodide (1.69 g, 11.3 mmol) were added, followed by 2- Chloroethyl methyl ether (412 μl, 4.51 mmol) was added and heated to 80 ° C. After stirring overnight, diethyl ether (50 ml) and water (100 ml) were added to the reaction mixture for extraction, and the resulting organic layer was washed with water (100 ml) and saturated aqueous sodium chloride solution (50 ml), and anhydrous magnesium sulfate. After drying, it was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 552 mg (32.1%) of the target compound as a pale yellow oil.
[0484]
IR (neat): 3350, 2901, 1643, 1602, 1531 cm-1
[0485]
This compound manufacture example 18
○ 2- [2- (4-Pyridyl) ethylamino] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 18-1)
Bromoacetic acid (0.50 g, 3.6 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml) and stirred at −15 ° C. under a nitrogen atmosphere. To this, N-methylmorpholine (0.40 ml, 3.6 mmol) and isobutyl chlorocarbonate (0.45 ml, 3.5 mmol) were added. Next, a solution of 2- (1-adamantyl) -N-pentylethylamine hydrochloride (1.0 g, 3.5 mmol) as an intermediate 1-1 in anhydrous tetrahydrofuran (20 ml) was added dropwise. After stirring at 0 ° C. for 1.5 hours, a saturated aqueous sodium hydrogen carbonate solution (70 ml) and ethyl acetate (70 ml) were added to the reaction solution and partitioned. The ethyl acetate layer was washed with water (70 ml) and saturated aqueous sodium chloride solution (70 ml) and dried over anhydrous magnesium sulfate. Concentration in vacuo gave 1.3 g (quantitative) of 2-bromoacetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide as an oil.
[0486]
Next, 2-bromoacetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.3 g, 3.5 mmol) was dissolved in anhydrous N, N-dimethylformamide (30 ml) to obtain potassium carbonate. (1.5 g, 11 mmol), methyl iodide (1.6 g, 11 mmol), 4- (2-aminoethyl) pyridine (0.43 g, 3.5 mmol) were added, and the mixture was stirred overnight at an external temperature of 75 ° C. Water (100 ml) and diethyl ether (100 ml) were added to the reaction solution for partitioning, and the diethyl ether layer was washed twice with water (70 ml) and once with a saturated aqueous sodium chloride solution (120 ml) and dried over anhydrous magnesium sulfate. After concentration under reduced pressure and purification by silica gel column chromatography, 0.6 g (40%) of the target compound was obtained as an oil.
[0487]
IR (neat): 3312, 2902, 2846, 1651, 1602, 1454 cm-1
[0488]
The following compounds were obtained by carrying out the same operations as in Production Example 18 of this compound.
[0489]
○ 3- [N'-methyl-N '-(4-pyridylmethyl)] aminopropionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 18-2)
IR (neat): 2902, 2846, 1643 cm-1
[0490]
○ 2- [2- (4-Pyridyl) ethoxy] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 18-3)
IR (neat): 2902, 2846, 1650, 1602, 1451, 1113 cm-1
[0491]
This compound manufacture example 19
○ (R) -1- [2- (4-Pyridyl) ethyl] -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride (Compound 19-1)
Nt-butoxycarbonyl-L-proline (1.7 g, 8.0 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml) and stirred at −15 ° C. under a nitrogen atmosphere. N-methylmorpholine (0.90 ml, 8.0 mmol) and isobutyl chlorocarbonate (1.0 ml, 8.0 mmol) were added thereto. After 10 minutes, a solution of the intermediate 1-1 free base (2.0 g, 8.0 mmol) in anhydrous tetrahydrofuran (20 ml) was added dropwise over 5 minutes. After stirring at 0 ° C. for 45 minutes, the mixture was returned to room temperature and stirred overnight. Saturated aqueous sodium hydrogen carbonate solution (50 ml) and ethyl acetate (50 ml) were added to the reaction solution and partitioned. The ethyl acetate layer was washed with 10% aqueous citric acid solution (50 ml), water (50 ml) and saturated aqueous sodium chloride solution (50 ml), and dried over anhydrous magnesium sulfate. After concentration under reduced pressure and purification by silica gel column chromatography, the target compound (R) -1- (t-butoxycarbonyl) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N— 1.9 g (52%) of pentylamide was obtained as an oil.
[0492]
Next, (R) -1- (t-butoxycarbonyl) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.8 g, 4.0 mmol) was ice-cooled. After 4N hydrogen chloride / dioxane (20 ml, 81 mmol) was added, the mixture was returned to room temperature and stirred for 1.5 hours. Concentration under reduced pressure gave 1.5 g (quantitative) of (R) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride as an amorphous form.
[0493]
Next, (R) -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride (1.4 g, 3.7 mmol) was added to anhydrous N, N-dimethylformamide (40 ml). ), Potassium carbonate (2.6 g, 19 mmol), methyl iodide (1.7 g, 11 mmol), 4- (2-chloroethyl) pyridine hydrochloride (0.70 g, 3.7 mmol) was added to the outside. Stir overnight at a temperature of 80 ° C. A 2N aqueous sodium hydroxide solution (70 ml) and diethyl ether (70 ml) were added to the reaction solution for partitioning, and the diethyl ether layer was washed with water (70 ml) and a saturated aqueous sodium chloride solution (70 ml), and dried over anhydrous magnesium sulfate. Concentration under reduced pressure and purification by silica gel column chromatography gave 0.80 g (47%) of the target compound as an oil.
[0494]
IR (neat): 2902, 2846, 1644 cm-1
[Α]20 D: -48.1 ° (MeOH, C1.0)
[0495]
The following compounds were obtained by carrying out the same operations as in Production Example 19 of this compound.
[0496]
○ (S) -1- [2- (4-Pyridyl) ethyl] -2-pyrrolidinecarboxylic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide hydrochloride (Compound 19-2)
IR (neat): 2902, 2846, 1644, 1601 cm-1
[Α]20 D: + 41.6 ° (MeOH, C1.0)
[0497]
This compound manufacture example 20
1- [2- (1-adamantyl) ethyl] -1- [2- (N-ethylamino) ethyl] -3- [3- (4-pyridyl) propyl] urea (Compound 20-1)
Under a nitrogen atmosphere, lithium aluminum hydride (890 mg, 23.5 mmol) was suspended in anhydrous diethyl ether (10 ml), and 1- [2- (acetylamino) ethyl of compound 1-103 was stirred with ice-cooling while stirring. A solution of -1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea (4.86 g, 11.4 mmol) in anhydrous tetrahydrofuran (60 ml) was added dropwise over 2 hours. The mixture was returned to room temperature and stirred for 70 hours. The mixture was ice-cooled, ethyl acetate (25 ml) was added, 1N aqueous sodium hydroxide solution (25 ml) was added, and the insoluble material was removed by Celite filtration. The filtrate was partitioned with ethyl acetate (25 ml) and water (25 ml), and the organic layer was washed with saturated aqueous sodium chloride solution (20 ml). After drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the target compound (2.33 g, colorless crystals, 49.8%).
[0498]
IR (KBr): 3309, 2901, 2845, 1615, 1534 cm-1
mp: 96.8-104.9 ° C
[0499]
This compound manufacture example 21
○ 3- (4-Pyridylmethylideneamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 23-1)
3- (t-Butoxycarbonylamino) propionic acid (1.0 g, 5.3 mmol) was dissolved in anhydrous tetrahydrofuran (15 ml), N-methylmorpholine (0.6 ml, 5.5 mmol) was added, and the mixture was stirred at -15 ° C. , Isobutyl chlorocarbonate (0.7 ml, 5.4 mmol) was added. Next, a solution of intermediate 1-1 in 2- (1-adamantyl) -N-pentylethylamine hydrochloride (1.5 g, 5.3 mmol) in free tetrahydrofuran (15 ml) was added at -18 ° C. After stirring at 0 ° C. for 1.5 hours, ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate solution (100 ml) were added and partitioned. The extract was washed successively with a 10% aqueous citric acid solution (100 ml), water (100 ml), and a saturated aqueous sodium chloride solution (100 ml) and dried over anhydrous magnesium sulfate. After concentration under reduced pressure and purification by silica gel column chromatography, 1.9 g (85%) of 3- (t-butoxycarbonylamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide was obtained as an oil. Obtained as material.
[0500]
3- (t-Butoxycarbonylamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.9 g, 4.4 mmol) was added with 4.0 N hydrogen chloride / 1,4 under ice cooling. -After adding a dioxane solution (22 ml, 88 mmol), the mixture was returned to room temperature and stirred for 1 hour and 15 minutes. Concentration under reduced pressure yielded 1.4 g (89%) of the desired hydrochloride salt. To this was added 1N aqueous sodium hydroxide solution (80 ml), and the mixture was extracted with chloroform (80 ml). The chloroform layer was washed with a saturated aqueous sodium chloride solution (80 ml) and dried using anhydrous magnesium sulfate. Upon concentration under reduced pressure, 3-aminopropionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide was obtained as an oil.
[0501]
3-Aminopropionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.3 g, 3.9 mmol) was dissolved in anhydrous tetrahydrofuran (10 ml) and stirred under ice cooling. 4-Pyridinecarboxaldehyde (0.42 ml, 4.3 mmol) was added thereto, followed by stirring at room temperature for 3 hours. Concentration under reduced pressure gave 1.7 g (quantitative) of the target compound as an oil.
[0502]
IR (neat): 2901, 1713, 1644, 1454 cm-1
[0503]
This compound manufacture example 22
○ 3- (4-Pyridylmethylamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 22-1)
3- (4-Pyridylmethylideneamino) propionic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (1.6 g, 3.9 mmol) of Compound 21-1 was dissolved in methanol to obtain a catalyst. An amount of 10% palladium on carbon was added, and the mixture was stirred at room temperature for 7 hours under 1 atmosphere of hydrogen. 10% Palladium on carbon was filtered off, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain 0.58 g (36%) of the target compound as an oil.
[0504]
IR (neat): 3313, 2902, 2846, 1636, 1451 cm-1
[0505]
This compound manufacture example 23
1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-cyano) pyridyl] propyl] -1-pentylurea (Compound 23-1)
Of 4- [3- [3- [2- (1-adamantyl) ethyl] -3-pentylureido] propyl] pyridine N-oxide (1.0 g, 2.3 mmol) of Compound 16-1 under nitrogen atmosphere at room temperature. Trimethylsilyl cyanide (1.2 ml, 9.4 mmol) and triethylamine (0.65 ml, 4.7 mmol) were added to an anhydrous acetonitrile (1.5 ml) solution, and the mixture was heated to reflux overnight. The reaction solution was partitioned between chloroform (40 ml) and saturated aqueous sodium hydrogen carbonate solution (40 ml). The organic layer was washed with a saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The residue obtained by evaporating the solvent under reduced pressure was collected by filtration of the crystals with diisopropyl ether to obtain 730 mg (73.0%) of the target compound.
[0506]
IR (KBr): 3334, 2900, 2845, 2234, 1621, 1534 cm-1
mp: 112.0-123.0 ° C
[0507]
This compound manufacture example 24
1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-aminomethyl) pyridyl] propyl] -1-pentylurea (Compound 24-1)
1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-cyano) pyridyl] propyl] -1-pentylurea of compound 23-1 (0.20 g, A catalytic amount of 10% palladium on carbon was added to a methanol (2.0 ml) solution of 0.46 mmol) and stirred overnight in a hydrogen atmosphere. The reaction mixture was filtered through celite, and the solvent was evaporated under reduced pressure. The obtained residue was partitioned between diethyl ether (50 ml) and water (50 ml). A 2N aqueous sodium hydroxide solution (10 ml) was added to the aqueous layer, and the mixture was further extracted with diethyl ether (50 ml). The combined organic layers were washed with a saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The residue obtained by evaporating the solvent under reduced pressure was crystallized with diisopropyl ether to obtain 151 mg (74.4%) of the target compound.
[0508]
IR (KBr): 3346, 2901, 2845, 1621, 1538 cm-1
mp: 88.0-95.0 ° C
[0509]
This compound manufacture example 25
1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-carboxy) pyridyl] propyl] -1-pentylurea (Compound 25-1)
At room temperature, 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-cyano) pyridyl] propyl] -1-pentylurea (0.20 g,. 46 mmol) was added 6N hydrochloric acid (1.5 ml, 9.2 mmol), and the mixture was refluxed overnight. The reaction mixture was evaporated under reduced pressure, and the crystals were collected by filtration with acetone. It was dissolved in chloroform (40 ml) and washed with water (40 ml) and saturated aqueous sodium chloride solution (10 ml). The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure to obtain 132 mg (63.0%) of the target compound.
[0510]
IR (KBr): 3326, 2905, 2848, 1704, 1621, 1539 cm-1
mp: 130 ° C
[0511]
This compound manufacture example 26
1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-hydroxymethyl) pyridyl] propyl] -1-pentylurea (Compound 26-1)
Under ice-cooling in a nitrogen atmosphere, 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-carboxy) pyridyl] propyl] -1-pentylurea of compound 25-1 (0.10 g) Borane-tetrahydrofuran complex 1.0 M tetrahydrofuran solution (0.66 ml, 0.66 mmol) was added to a solution of anhydrous tetrahydrofuran (0.7 ml) in 0.22 mmol) and stirred at room temperature for 4.5 hours. Water (3 ml) was added to the reaction mixture under ice-cooling, and the mixture was partitioned between ethyl acetate (15 ml) and 0.1% aqueous sodium hydroxide solution (10 ml). The organic layer was washed with a saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain 53 mg of a borane complex salt of the target compound as an oil.
[0512]
IR (neat): 3342, 2904, 1630, 1531 cm-1
[0513]
This compound production example 27
1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-methyl) pyridyl] propyl] -1-pentylurea (Compound 27-1)
At room temperature, 1- [2- (1-adamantyl) ethyl] -3- [3- [4- (2-hydroxymethyl) pyridyl] propyl] -1-pentylurea (50 mg, 0.11 mmol) of compound 26-1. ) And triethylamine (20 μl, 0.13 mmol) in anhydrous dichloromethane (1.0 ml) were added p-toluenesulfonyl chloride (23 mg, 0.12 mmol) and stirred overnight at room temperature. The reaction solution was partitioned between chloroform (9 ml) and water (10 ml), and the organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography. A catalytic amount of 10% palladium-on-carbon was added to a solution of the obtained p-toluenesulfonyl compound in methanol (1 ml), and the mixture was stirred for 7 days in a hydrogen atmosphere to obtain 18 mg (38%) of the target compound as an oil.
[0514]
IR (neat): 3345, 2903, 2847, 1624, 1534 cm-1
[0515]
This compound production example 28
1- [2- (1-adamantyl) ethyl] -1- (2-aminoethyl) -3- [3- (4-pyridyl) propyl] urea (Compound 28-1)
Under ice cooling, 1- [2- (acetylamino) ethyl] -1- [2- (1-adamantyl) ethyl] -3- [3- (4-pyridyl) propyl] urea of compound 1-103 (1. (02 g, 2.39 mmol) in methanol (10 ml) was added 6N hydrochloric acid (15 ml), and the mixture was heated and stirred at 90 ° C. for 3 days. The reaction solution was neutralized with 1N aqueous sodium hydroxide solution (10 ml), and partitioned by adding chloroform (50 ml) and water (10 ml). The organic layer is washed with a saturated aqueous sodium chloride solution (50 ml), dried over anhydrous magnesium sulfate, and the solvent is distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 200 mg (21.7%) of the target compound as an oil.
[0516]
IR (neat): 3306, 2902, 2846, 1629, 1605, 1537, 753 cm-1
[0517]
This compound production example 29
O 4- [2- [N- [2- (1-adamantyl) ethyl] -N-pentylcarbonylmethoxy] ethoxy] pyridine N-oxide (Compound 29-1)
Under ice cooling, a solution of diglycolyl chloride (0.31 ml, 2.6 mmol) and triethylamine (0.70 ml, 5.1 mmol) in anhydrous dichloromethane (6 ml) was added 2- (1-adamantyl)-of intermediate 1-1. N-pentylethylamine hydrochloride (0.50 g, 1.7 mmol) was added, and the mixture was stirred overnight at room temperature. Methanol (5 ml) was added to the reaction solution and stirred for 3 hours. After evaporating the solvent under reduced pressure, the residue is partitioned with ethyl acetate and water (15 ml each), and the organic layer is washed with a saturated aqueous sodium chloride solution (5 ml) and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography to give 0.39 g of 2-methoxycarbonylmethoxyacetic acid N- [2- (1-adamantyl) ethyl] -1-pentylamide (60 %) Was obtained as an oil.
[0518]
Next, to a solution of N- [2- (1-adamantyl) ethyl] -1-pentylamide (0.37 g, 0.96 mmol) in methanol (3 ml) under ice cooling, sodium borohydride (0.18 g, (4.8 mmol) was added, and the mixture was stirred overnight at room temperature. Water (10 ml) was added to the reaction mixture and stirred for 10 minutes, and then water (20 ml) and ethyl acetate (30 ml) were added and partitioned. The organic layer was washed with a saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography to give 74 mg of 2- (2-hydroxyethoxy) acetic acid N- [2- (1-adamantyl) ethyl] -1-pentylamide ( 22%) was obtained as an oil.
[0519]
Then, 2- (2-hydroxyethoxy) acetic acid N- [2- (1-adamantyl) ethyl] -1-pentylamide (60 mg, 0.17 mmol) N, N-dimethylformamide (0.4 ml) at room temperature. ) 4-Nitropyridine N-oxide (24 mg, 0.17 mmol) and potassium carbonate (28 mg, 0.20 mmol) were added to the solution and stirred at 60 ° C. for 2 days. The reaction solution was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain 39 mg of the target compound as an oil.
[0520]
1H-NMR (400MHz, CDCl3) δ 0.87-0.93 (m, 3H), 1.20-1.40 (m, 6H), 1.47-1.60 (m, 8H), 1.61-1.67 (m, 3H), 1.68-1.76 (m, 3H), 1.97 (brs, 3H), 3.10-3.19 (m, 2H), 3.25-3.36 (m, 2H) , 3.94-3.98 (m, 2H), 4.20-4.27 (m, 4H), 6.81-6.86 (m, 2H), 8.10-8.15 (m, 2H)
[0521]
Compound Preparation Example 30
○ 2- [2- (4-Pyridyloxy) ethoxy] acetic acid N- [2- (1-adamantyl) ethyl] -N-pentylamide (Compound 30-1)
Under nitrogen atmosphere at room temperature, Compound 29-1 4- [2- [N- [2- (1-adamantyl) ethyl] -N-pentylcarbonylmethoxy] ethoxy] pyridine N-oxide (39 mg, 0.088 mmol) and anhydrous To a mixed solution of acetic acid (20 μl, 0.18 mmol) in methanol (0.4 ml) and acetic acid (0.1 ml), a catalytic amount of 10% palladium-on-carbon was added and stirred for 4 days in a hydrogen atmosphere. After celite filtration, the reaction mixture was evaporated under reduced pressure, and partitioned with ethyl acetate (20 ml) and saturated aqueous sodium hydrogen carbonate solution (20 ml). The organic layer was washed with a saturated aqueous sodium chloride solution (10 ml) and dried over anhydrous magnesium sulfate. The residue obtained by distilling off the solvent was purified by silica gel column chromatography to obtain 16 mg (42%) of the target compound as an oil.
[0522]
IR (neat): 2903, 1651, 1592 cm-1
[0523]
This compound manufacture example 31
1- [2- (1-adamantyl) ethyl] -3- [3-oxo-3- (4-pyridyl) propyl] -1-pentylurea (Compound 31-1)
Under ice cooling, anhydrous compound 14-11- [2- (1-adamantyl) ethyl] -3- [3-hydroxy-3- (4-pyridyl) propyl] -1-pentylurea (100 mg, 0.234 mmol) Add 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3 (1H) -one (221 mg, 0.520 mmol) to a dichloromethane (2 ml) solution, and return to room temperature. And stirred for 1 hour. The mixture was again cooled on ice, ethyl acetate (10 ml), saturated aqueous sodium sulfite solution (5 ml) and saturated aqueous sodium hydrogen carbonate solution (5 ml) were added, and the mixture was stirred for 15 minutes. The reaction solution was partitioned with ethyl acetate (50 ml) and water (10 ml), and the organic layer was washed with a saturated aqueous sodium sulfite solution (5 ml), a saturated aqueous sodium hydrogen carbonate solution (5 ml) and a saturated aqueous sodium chloride solution (25 ml) in this order. After drying the organic layer over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure to obtain 87.3 mg (87.8%) of the target compound as colorless crystals.
[0524]
IR (KBr): 3328, 2901, 2847, 1710, 1619, 1540 cm-1
mp: 103.5-104.0 ° C
[0525]
[C] Formulation example
An example of an eye drop formulation of this compound is shown below.
[0526]
Formula 1 (in 100ml)
100 mg of this compound
Sodium chloride 900mg
Polysorbate 80 appropriate amount
Sodium hydroxide
Hydrochloric acid
Sterilized purified water
[0527]
Desired eye drops can be obtained by appropriately changing the mixing ratio of the present compound and additives.
[0528]
[D] Pharmacological test
(1) Angiogenesis inhibition test using human vascular endothelial cells
Cell growth induced by treatment of normal human umbilical vein endotherial cells (HUVEC) with vascular endothelial growth factor (VEGF) as an in vitro angiogenesis evaluation model Cancer Res., 59, 99-106 (1999) has reported a VEGF-induced HUVEC proliferation response evaluation system that measures the inhibitory effect of drugs on response. Therefore, the effect of the present compound in the angiogenesis evaluation system was examined by a method according to the method described in the above literature.
[0529]
(Preparation of test compound)
This compound was dissolved in DMSO and then diluted with a medium to obtain 40 μM of each test compound solution.
[0530]
(experimental method)
4x104 50μL each of HUVEC prepared to cells / mL is seeded in 96-well plate coated with type I collagen, 2 × 103 Cells / well. One day later, 25 μL of 0.8% DMSO solution of the test compound and 0.8% DMSO solution as a control were added to each well (containing 10 μM of each test compound and 0.2% DMSO as the final concentration). One hour after the drug was added, 25 μL of a 40 ng / mL VEGF solution was added to each well (containing 10 ng / mL VEGF as the final concentration). Three days after the addition of VEGF, 10 μL of WST-8 assay reagent (Dojin Chemical) was added to each well, and the absorbance at 450 nm was measured.
[0531]
(Angiogenesis evaluation results)
When the cell growth inhibition rate (%) relative to the control was calculated, the angiogenesis inhibition rate of many test compounds was 80% or more. These results are shown in Table 1.
[0532]
[Table 1]
[0533]
(2) Angiogenesis inhibition test by high oxygen load induced retinal neovascularization
As a model for evaluating retinal neovascularization in vivo, Arch Ophthalmol, a model for evaluating retinal neovascularization induced by hyperoxia, which measures the angiogenesis inhibitory effect of drugs induced by hyperoxia on neonatal rats,1141210-1217 (1996). Therefore, the effect of this compound in an angiogenesis evaluation model was examined according to the method described in the above literature.
[0534]
(Preparation of test compound)
This compound was suspended in a phosphate buffer (PBS) containing 0.4% Tween 80 to obtain a 10 mg / ml test compound suspension.
[0535]
(experimental method)
A 0-day-old newborn rat was reared together with the parent rat for 11 days in a high oxygen load breeding box maintained at 80% oxygen, and returned to normal breeding conditions on the 11th day after birth (high oxygen During the loading period, the animals were returned to normal breeding conditions once a day for 30 minutes.)
[0536]
The test compound (200 μg / 20 μl / eye) was administered subconjunctivally under avertin anesthesia for 7 days from the 11th day after birth. On the 18th day after birth (P18), the rats were euthanized by administration of Nembutal, and the eyeballs were removed. The removed eyeball was fixed with 4% paraformaldehyde, and then the retina was separated. The separated retina was stained with ADPase, and the degree of angiogenesis was evaluated by the following angiogenesis evaluation method. As a model rat control, PBS (2 μl / eye) containing 0.4% Tween 80 was administered subconjunctivally instead of the test compound, and the same operation as described above was performed.
[0537]
The retina stained with ADPase was divided into four quadrants and observed and evaluated under an optical microscope. Evaluation was performed by scoring each quadrant according to the following evaluation criteria.
[0538]
(Evaluation criteria)
0: There was no neovascular bud and no continuous vascular protuberance
1: There were less than 5 neovascular buds
2: There were 6 or more neovascular buds or short vascular protuberances
There was less than half of the 3: 1 quadrant
There was a vascular protuberance that exceeded half of the 4: 1 quadrant
[0539]
(Angiogenesis evaluation results)
When the angiogenesis inhibition rate [%] was calculated from the total points obtained by adding the scores of each quadrant (the angiogenesis inhibition rate was the average value of 9 to 12 cases each), the angiogenesis inhibition rate of many test compounds Was 40% or more.
[0540]
【The invention's effect】
As is apparent from the results of the above pharmacological tests, since this compound has an excellent angiogenesis inhibitory effect in both in vitro and in vivo tests, diseases involving angiogenesis, particularly diabetic retinopathy. Retinopathy of prematurity, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascular disease, solid tumor, hemangioma, tumor growth / metastasis and It can be applied as a therapeutic agent.
Claims (4)
Bは鎖中に、−O−または−S−を含有してもよいアルキレン基を示し;
R1 はアルキル基を示し、該アルキル基は、ハロゲン原子、ヒドロキシ基、アミノ基、シクロアルキル基、アダマンチル基、アリール基、カルボキシル基、アルコキシカルボニル基、アリールオキシカルボニル基、アミノカルボニル基、シアノ基または飽和若しくは不飽和の複素環で置換されていてもよく;上記された各アミノ基、ヒドロキシ基およびアミノカルボニル基の水素原子はアルキル基、シクロアルキル基、アリール基、アリールアルキル基、アシル基、アルコキシカルボニル基、シクロアルキルオキシカルボニル基、アリールアルコキシカルボニル基、ハロゲノアルキルオキシカルボニル基、イミダゾリルカルボニル基、不飽和の複素環または不飽和の複素環が置換したアルキル基で置換されていてもよく;
R 2 は、アダマンチルアルキル基またはシクロアルキルアルキル基を示し;
R3はピリジン環を示し;
R 4 、R 5 およびR 6 は、同一または異なって水素原子またはアルキル基を示し;
XはOを示す。]An angiogenesis inhibitor comprising a compound represented by the following general formula [1] or a salt thereof as an active ingredient.
B is in the chain, -O- or -S - indicates alkylene group which may contain;
R 1 represents an alkyl group, and the alkyl group is a halogen atom, hydroxy group, amino group, cycloalkyl group, adamantyl group, aryl group, carboxyl group, alkoxycarbonyl group, aryloxycarbonyl group, aminocarbonyl group, cyano group. Or may be substituted with a saturated or unsaturated heterocyclic ring; the hydrogen atom of each amino group, hydroxy group and aminocarbonyl group described above is an alkyl group, a cycloalkyl group, an aryl group, an arylalkyl group, an acyl group, An alkoxycarbonyl group, a cycloalkyloxycarbonyl group, an arylalkoxycarbonyl group, a halogenoalkyloxycarbonyl group, an imidazolylcarbonyl group, an unsaturated heterocycle or an unsaturated heterocycle may be substituted with a substituted alkyl group;
R 2 represents an adamantylalkyl group or a cycloalkylalkyl group;
R 3 represents a pyridine ring ;
R 4 , R 5 and R 6 are the same or different and each represents a hydrogen atom or an alkyl group;
X represents O. ]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002346601A JP4304364B2 (en) | 2001-11-30 | 2002-11-29 | Angiogenesis inhibitor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-366088 | 2001-11-30 | ||
JP2001366088 | 2001-11-30 | ||
JP2002346601A JP4304364B2 (en) | 2001-11-30 | 2002-11-29 | Angiogenesis inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003226686A JP2003226686A (en) | 2003-08-12 |
JP4304364B2 true JP4304364B2 (en) | 2009-07-29 |
Family
ID=27759526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002346601A Expired - Fee Related JP4304364B2 (en) | 2001-11-30 | 2002-11-29 | Angiogenesis inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4304364B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2666767A1 (en) | 2007-10-16 | 2013-11-27 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for TRPV1-mediated disease |
JP2010024219A (en) * | 2008-06-18 | 2010-02-04 | Santen Pharmaceut Co Ltd | Therapeutic agent for optic nerve disorder |
CN102196810B (en) * | 2008-10-22 | 2013-11-06 | 参天制药株式会社 | Pharmaceutical composition improved in absorption through intestinal tract |
MX2013005479A (en) * | 2010-11-15 | 2013-06-12 | Abbvie Inc | Nampt inhibitors. |
-
2002
- 2002-11-29 JP JP2002346601A patent/JP4304364B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2003226686A (en) | 2003-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4482735B2 (en) | TNF-α production inhibitor | |
US20080161270A1 (en) | Angiogenesis inhibitors | |
JP5753927B2 (en) | Organic compounds | |
CA2737739C (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
US6878707B2 (en) | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | |
JP4304364B2 (en) | Angiogenesis inhibitor | |
AU766824B2 (en) | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090317 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090413 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120515 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |